

Ipas

Clinical Updates in Reproductive Health 2026



© 2026 Ipas.

Cover photo by Sophoto Studios for Ipas

Suggested citation:

Ipas. (2026). *Clinical Updates in Reproductive Health*. E. Jackson (Ed.). Ipas

Ipas works to advance reproductive justice by expanding access to abortion and contraception, using a comprehensive approach that addresses health, legal and social systems. We believe every person should have the right to bodily autonomy and be able to determine their own future. Across Africa, Asia and the Americas, we work with partners to ensure that reproductive health services, including abortion and contraception, are available and accessible to all.

Ipas is a registered 501(c)(3) nonprofit organization. All contributions to Ipas are tax deductible to the full extent allowed by law.

For more information or to donate to Ipas:

info@ipas.org
www.ipas.org
P.O. Box 9990
Chapel Hill, NC 27515 USA

Ipas Network
11 Holland Avenue, Suite 300, Ottawa ON K1Y 4S, Canada

Clinical Updates in Reproductive Health 2026

Medical Editor:

Emily Jackson

Lead Librarian:

Allison Campbell

Clinical advisory team:

Sangeeta Batra, India

Abiyot Belai, Ethiopia

Deeb Shrestha Dangol, Nepal

Ernest Nyamato, Kenya

Guillermo Ortiz, United States

Bill Powell, United States

Marcela Masabanda, Latin America and Mexico

Mike Mpoyi, Democratic Republic of Congo

Henry Flores, Bolivia

Edward Ngoga, Kenya

Acknowledgements

Thanks to those who contributed to this and previous versions of Clinical Updates in Reproductive Health:

Babatunde Adelekan

Rebecca Allen

Lynn Borgatta

Dalia Brahmi

Anne Burke

Catherine Casino

Talemoh Dah

Gillian Dean

Alison Edelman

Courtney Firestine

Mary Fjerstad

Bela Ganatra

Vinita Goyal

Joan Healy

Emily Jackson

Nathalie Kapp

Bliss Kaneshiro

Ann Leonard

Radha Lewis

Patricia Lohr

Claudia Martinez Lopez

Steve Luboya

Alice Mark (Founding Editor)

Lisa Memmel

Karen Padilla

Regina Renner

Cristião Rosas

Laura Schoedler

Clinical Updates topics are determined through queries gathered from Ipas-supported trainings and programs in the public and private health sectors. For their technical expertise and contributions, we are grateful to Ipas's clinical trainers and country program staff in Africa, Asia, and Latin America, as well as the India Development Foundation.

List of abbreviations

ACOG	American College of Obstetricians and Gynecologists
CI	confidence interval
D&E	dilatation and evacuation
FIGO	International Federation of Gynecology and Obstetrics
GRADE	Grading of Recommendations Assessment, Development and Evaluation
hCG	human chorionic gonadatropin
IM	intramuscular
IU	international units
IUD	intrauterine device
IV	intravenous
Kg	kilogram
LMP	last menstrual period
Mcg	microgram
Mg	milligram
MVA	manual vacuum aspirator
mL	milliliter
MOOSE	Meta-analysis of Observational Studies in Epidemiology
NSAID	Nonsteroidal anti-inflammatory drug
PRISMA	Preferred Reporting Items for Systematic Reviews and Meta-Analyses
RCOG	Royal College of Obstetricians and Gynaecologists
RR	relative risk
SC	subcutaneous
WHO	World Health Organization

Table of Contents

Introduction	8
Making Ipas recommendations	8
1. General recommendations for abortion care	11
1.1 Summary of recommended medical abortion regimens	11
1.2 Uterine evacuation: Replace sharp curettage with aspiration or medications	13
1.3 Prophylactic antibiotics for vacuum aspiration and dilatation and evacuation	15
1.4 Prophylactic antibiotics for medical abortion	19
1.5 Medical abortion contraindications and precautions	21
1.6 Misoprostol product quality	25
2. Pain management	28
2.1 Pain management for medical abortion before 13 weeks gestation	28
2.2 Pain management for medical abortion after 13 weeks gestation	31
2.3 Pain management for vacuum aspiration	34
2.4 Pain management for dilatation and evacuation	40
2.5 Paracervical block	44
3. Recommendations for abortion before 13 weeks gestation	48
3.1 Adolescents: Safety and effectiveness	48
3.2 Gestational dating	52
3.3 Screening for ectopic pregnancy	57
3.4 Vacuum Aspiration	61
3.4.1. Safety and effectiveness	61
3.4.2. Cervical preparation	65
3.4.3. Bimanual examination	68
3.4.4. Examining products of conception	70
3.4.5. Processing Ipas MVA Plus® and Ipas Single-Valve aspirators	72
3.5 Medical abortion	75
3.5.1. Self-management	75
3.5.2. Risk of fetal malformations	80
3.5.3. Mifepristone and misoprostol: Recommended regimen	82
3.5.4. Misoprostol only: Recommended regimen	88
3.5.5. Home use of medications up to 12 weeks gestation	94
3.5.6. Confirmation of success	98
3.5.7. Ultrasound findings at follow-up	103

4.	Recommendations for abortion at or after 13 weeks gestation	106
4.1	Who has abortions at 13 weeks or later?	106
4.2	Comparing methods	111
4.3	Gestational dating	114
4.4	Induced fetal demise	116
4.5	Follow-up	119
4.6	Dilatation and evacuation	120
	4.6.1. Cervical preparation	120
4.7	Medical abortion	126
	4.7.1. Mifepristone and misoprostol: Recommended regimen	126
	4.7.2. Misoprostol only: Recommended regimen	131
	4.7.3. Presence of uterine scar: Recommended regimen	135
5.	Postabortion care	138
5.1	Treatment of incomplete and missed abortion for less than 13 weeks uterine size	138
5.2	Treatment of incomplete abortion and intrauterine fetal demise for 13 weeks or larger uterine size	142
5.3	Postabortion contraception: When and what type	145
5.4	Postabortion IUD use: Safety and timing	151
5.5	Postabortion hemorrhage: Prevention and management	155
5.6	Managing uterine perforation	159
	Appendices	163
A.	Pain medication table	163
B.	Continuum of depth of sedation: Definition of general anesthesia and levels of sedation/analgesia	167
C.	World Health Organization recommendations for health worker roles in abortion care	169

Introduction

Ipas's *Clinical Updates in Reproductive Health* contain up-to-date, evidence-based clinical recommendations on comprehensive abortion care, with new topics and resources added regularly. *The Clinical Updates in Reproductive Health* provide concise, easy-to-read information about abortion care, combining the latest evidence with lessons learned from health professionals globally to produce relevant clinical recommendations.

Who should use this resource

First published in 2013, the Clinical Updates in Reproductive Health were designed originally as an up-to-date, evidence-based clinical resource for Ipas staff. Over time, the publication has also been of use to:

- **clinicians** providing abortion care
- **clinical and public health professionals** working on patient care protocols in public health systems and the private sector
- **safe abortion advocates and policymakers** creating laws and policies that fulfill women's, girls', and pregnant people's right to health

What's new in this revision

In this edition of the *Clinical Updates in Reproductive Health*, you will find updated, evidence-based recommendations on more than 40 abortion care topics. During the 2026 update, we reviewed newly published literature related to all of the topics contained in this document, and we updated our recommendations, "In practice" tips, evidence summaries, and clinical tools and resources to reflect the latest clinical data relating to comprehensive abortion care.

The online Clinical Updates (www.ipas.org/clinicalupdates) contains the recommendations included in this manual along with easy-to-use drop-down menus to help readers navigate quickly to the information they need. Both online and print/PDF editions are also available in Spanish, French and Portuguese.

Finally, in recognition that people who identify as transgender, non-binary, gender-fluid, and additional gender identities can experience pregnancy and abortion, we have attempted to incorporate gender inclusive language in this revision of the *Clinical Updates in Reproductive Health*. Most available evidence about abortion care has been conducted in populations of cisgender women; where specific studies included in the *Clinical Updates in Reproductive Health* describe study participants as "women," we also use the term "women" to be consistent with what is reported. In our discussions of abortion generally, and when referring to all the gender diverse individuals requiring abortion care, we use the terms "people," "individuals," "abortion seeker," or other gender inclusive language.

Making Ipas recommendations

Ipas strives to integrate the best scientific evidence into our clinical programs. This section documents the methodology Ipas uses to make its clinical recommendations.

Using evidence to support recommendations

Clinical recommendations are based on relevant published, peer-reviewed evidence. For each clinical topic contained in the Clinical Updates in Reproductive Health, we conduct systematic searches of the literature using a methodology drawn from the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines (Page et al., 2021; Stroup, Berlin, & Morton, 2000).

Process for making recommendations

Ipas applies the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system to its recommendation formation (Schunemann et al., 2013). The GRADE system provides a framework to evaluate the quality of the available evidence, and to translate that evidence into a context-appropriate recommendation. For every recommendation in the Clinical Updates, both the quality of evidence and the strength of the recommendation based on that evidence are reported.

Quality of evidence

Sources of clinical evidence range from well-designed large clinical studies that have minimized bias to uncontrolled clinical observations, case series or reports. When there is no available evidence, expert opinion may be used. In the GRADE system, the quality of evidence related to a specific clinical outcome is defined as both the extent to which one can be confident that an estimate of effect is correct, and the extent to which the available evidence relates to the specific context in which it is being applied. When assessing the quality of evidence, the following criteria are considered:

- study design
- study limitations and the risk of bias
- consistency of the results across available studies
- precision of the results (wide or narrow confidence intervals)
- applicability with respect to populations, interventions and settings where the proposed intervention may be used
- likelihood of publication bias

Quality of evidence determinations are reported as follows (Balslem et al., 2011):

- A **high** grade: we are very confident that the true effect lies close to the estimate of the effect.
- A **moderate** grade: we are moderately confident in the effect estimate. The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
- A **low** grade: confidence in the effect estimate is limited. The true effect may be substantially different from the estimate.
- A **very low** grade: we have very little confidence in the estimate of the effect. The true effect is likely to be substantially different from the estimate.

For example, randomized trials are initially given a high grade, while observational studies are initially labeled as low-quality.

Strength of recommendation

Strength of recommendation is defined as the extent to which one can be confident that the desirable consequences of a recommendation outweigh its undesirable consequences (Andrews et al., 2013). Desirable effects include improved health outcomes, less burden for providers and health systems, and cost savings. Undesirable effects include harm to patients, inconvenience or hassle, and increased resource use.

- **Strong** recommendations are made when the desirable effects of a recommended intervention clearly outweigh the undesirable effects (Schunemann et al., 2013). Most informed people would make the recommended choice for an intervention (Andrews et al., 2013).
- **Weak** recommendations are made when evidence suggests that desirable effects of a recommended intervention probably outweigh the undesirable effects, but there are small benefits or benefits that may not be worth the costs (Schunemann et al., 2013). While most informed people would choose the recommended course of action, a substantial number would not (Andrews et al., 2013).

Can you have a strong recommendation based on low-quality evidence?

Answer: Yes. There are many factors that influence the strength of a recommendation.

For example, although there is limited evidence about bimanual examination prior to uterine aspiration, several factors increase the strength of the recommendation that bimanual examination should be performed by the clinician who will perform the procedure: 1) the potential benefit to patients, 2) the low risk of harm associated with bimanual examination, and 3) its low cost as well as potential savings when complications are avoided. All or almost all providers and women, when informed of the balance between desirable and undesirable effects, would choose to include a bimanual examination before uterine procedures.

Maintaining the *Clinical Updates*

The *Clinical Updates* are revised regularly. The “last reviewed” date for each topic indicates all relevant published literature up to that date has been considered and included where appropriate. New topics and proposed revisions to the document come from end-users, a regionally representative *Clinical Updates* Advisory Group, and observations made during routine quality monitoring of clinical services in Ipas-supported programs. The regionally representative Clinical Advisory Group reviews all updates proposed by the medical editor. New recommendations or substantially revised recommendations may undergo an internal peer review process. The revision process—including systematic search and review of literature, documentation of the body of evidence, generation and revision of recommendations and resultant changes to the Clinical Updates in Reproductive Health—is documented and archived.

References

Andrews, J., Guyatt, G., Oxman, A., Alderson, P., Dahm, P., Falck-Ytter, Y., ... Schunemann, H. J. (2013). GRADE Guidelines: 14. Going from evidence to recommendations: The significance and presentation of recommendations. *Journal of Clinical Epidemiology*, 66, 719-725.

Balshem, H., Helfand, M., Schunemann, H. J., Oxman, A. D., Kunz, R., Brozek, J., ... Guyatt, G. H. (2011). GRADE Guidelines: 3. Rating the quality of the evidence. *Journal of Clinical Epidemiology*, 64, 401-406.

Page, M.J., McKenzie, J.E., Bossuyt, P.M., Boutron, I., Hoffman, T.C., Mulrow, C.D., Shamseer, L., Tetzlaff, J.M., Akl, E.A., Brennan, S.E., Chou, R., Glanville, J., Grimshaw, J.M., Hrobjartsson, A., Lalu, M.M., Li, T., Loder, E.W., Mayo-Wilson, E., McDonald, S., McGuinness, L.A., Stewart, L.A., Thomas, J., Tricco, A.C., Welch, V.A., Whiting, P., & Moher, D. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. *BMJ*, 372, n71.

Schunemann, H., Brozek, J., Guyatt, G., & Oxman, A. (2013). GRADE Handbook. Available at: <https://gdt.gradepro.org/app/handbook/handbook.html#hged5uqebmir9>. Accessed April 15, 2023.

Stroup, D. F., Berlin, J. A., Morton, S. C., Olkin, I., Williamson, G. D., Rennie, D. ... for the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) Group. (2000). Meta-analysis of Observational Studies in Epidemiology: A proposal for reporting. *JAMA*, 283(15), DOI:10.1001/jama.283.15.2008.

World Health Organization. (2024). *Abortion care guideline, 2nd ed.* Geneva: World Health Organization.

1. General recommendations for abortion care

Summary of recommended medical abortion regimens

Medical abortion with mifepristone and misoprostol

Before 13 weeks gestation:

- Mifepristone 200mg orally
- Misoprostol 800mcg buccally, sublingually or vaginally 1-2 days after mifepristone. The dose of misoprostol can be repeated to achieve abortion success. After 9 weeks gestation, routinely using at least two doses of misoprostol, administered 3-4 hours apart, improves abortion success rates.

At or after 13 weeks gestation (13-24 weeks):

- Mifepristone 200mg orally
- Misoprostol 400mcg buccally, sublingually or vaginally 1-2 days after mifepristone, then every three hours until fetal and placental expulsion
- The median time to abortion is 6-10 hours after beginning misoprostol, although some individuals will require more time to successfully abort.

Medical abortion with misoprostol only

Before 13 weeks gestation:

- Misoprostol 800mcg buccally, sublingually or vaginally every three hours until expulsion
- Individuals undergoing misoprostol-only medical abortion outside of a health facility should be provided with 3-4 doses of misoprostol depending on the scenario.

At or after 13 weeks gestation (13-24 weeks):

- Misoprostol 400mcg buccally, sublingually or vaginally every three hours until fetal and placental expulsion. Vaginal dosing is more effective than other routes.
- The average time to abortion is 10-15 hours after beginning misoprostol, although some individuals will require multiple days to successfully abort.

Medical treatment for incomplete abortion, missed abortion or intrauterine fetal demise (postabortion care)

Less than 13 weeks uterine size:

- **Incomplete abortion:**
 - Individuals undergoing misoprostol-only medical abortion outside of a health facility should be provided with 3-4 doses of misoprostol depending on the scenario.
- **Missed abortion:**
 - Misoprostol 800mcg buccally, sublingually or, in the absence of vaginal bleeding, vaginally every 3 hours until expulsion (generally 1-3 doses)
 - Where available, add pretreatment with mifepristone 200mg orally 1-2 days before misoprostol

13 weeks or larger uterine size:

- **Incomplete abortion:**
 - Misoprostol 400mcg buccally, sublingually or, in the absence of vaginal bleeding, vaginally every three hours until expulsion
- **Intrauterine fetal demise (up to 24 weeks):**
 - Misoprostol 400mcg buccally, sublingually or, in the absence of vaginal bleeding, vaginally every 4-6 hours until expulsion.
 - Where available, add pretreatment with mifepristone 200mg orally 1-2 days before misoprostol.

Resources

www.ipas.org/ClinicalResources

Protocols for medical
abortion (dosage card)

Mifepristone/Misoprostol
Gestational Dating Wheels

Misoprostol Only
Gestational Dating Wheels



1.2

1. General recommendations for abortion care

Uterine evacuation: Replace sharp curettage with aspiration or medications

Recommendation:

- Vacuum aspiration or medical abortion should replace sharp curettage (also known as dilatation and curettage [D&C]) for the treatment of abortion and postabortion care.

Strength of recommendation:

Strong

Quality of evidence:

Moderate

Last reviewed:

September 29, 2025

The World Health Organization (WHO) and the International Federation of Gynecology and Obstetrics (FIGO) recommend against the use of sharp curettage—including sharp curette ‘checks’ to complete the abortion—and state that vacuum aspiration or medication regimens should replace sharp curettage for uterine evacuation (FIGO, 2011; WHO, 2024). In places where no uterine evacuation services exist, vacuum aspiration and medical abortion should be introduced.

Multiple systematic reviews have shown that vacuum aspiration is as effective as sharp curettage in treating early incomplete and missed abortions, while reducing procedure time, blood loss and pain (Ghosh et al., 2021; Tuncalp, Gulmezoglu, & Souza, 2010), and it is feasible to introduce in settings using D&C (Kakinuma, et al 2020). In a retrospective case series of 80,437 women seeking induced abortion, vacuum aspiration was associated with less than half the rate of major and minor complications compared to sharp curettage (Grimes, Schulz, Cates Jr, & Tyler Jr., 1976). A more recent series, including more than 100,000 abortion procedures, found that sharp curettage performed alone or in combination with vacuum aspiration was significantly more likely to be associated with complications, particularly incomplete abortion, than vacuum aspiration without curettage (Sekiguchi et al., 2015).

Multiple studies on induced abortion and postabortion care have shown that because vacuum aspiration can be performed in an outpatient setting by many kinds of health care workers without general anaesthesia, the costs to both the health system and individuals are significantly less than sharp curettage (Benson, Okoh, KrennHrubec, Lazzarino, & Johnston, 2012; Choobun, Khanuengkitkong, & Pinjaroen, 2012; Farooq, Javed, Mumtaz, & Naveed, 2011; Johnston, Akhter, & Oliveras, 2012).

A 2021 network meta-analysis compared surgical uterine evacuation methods, including D&C, to medical management of early pregnancy loss, finding similar effectiveness for vacuum aspiration, D&C, and medical management (Ghosh et al., 2021). The safety and tolerability of medical regimens for uterine evacuation are well documented (Kulier et al., 2011; Neilson, Gyte, Hickey, Vazquez, & Dou, 2013).

The use of sharp curettage to manage incomplete or missed abortion may be associated with Asherman's syndrome (intrauterine adhesions). A retrospective review from one tertiary care center reported on 884 women who underwent sharp curettage, manual vacuum aspiration or misoprostol for early pregnancy failure (Gilman Barber, Rhone, & Fluker, 2014). In follow-up, 1.2% of women managed with sharp curettage were found to have Asherman's syndrome (6 out of 483 women), while no cases were found in the 401 women managed by manual vacuum aspiration or misoprostol.

References

- Benson, J., Okoh, M., KrennHrubec, K., Lazzarino, M. A., & Johnston, H. B. (2012). Public hospital costs of treatment of abortion complications in Nigeria. *International Journal of Gynecology & Obstetrics*, 118(2), 60012-60015.
- Choobun, T., Khanuengkitkong, S., & Pinjaroen, S. (2012). A comparative study of cost of care and duration of management for first-trimester abortion with manual vacuum aspiration (MVA) and sharp curettage. *Archives of Gynecology and Obstetrics*, 286(5), 1161-1164.
- Farooq, F., Javed, L., Mumtaz, A., & Naveed, N. (2011). Comparison of manual vacuum aspiration, and dilatation and curettage in the treatment of early pregnancy failure. *Journal of Ayub Medical College Abbottabad*, 23(3), 28-31.
- FIGO. (2011). Consensus statement on uterine evacuation. Retrieved from <https://www.figo.org/news/new-download-uterine-evacuation-figo-consensus-statement-0014150>
- Ghosh, J., Papadopoulou, A., Devall, A.J., Jeffery, H.C., Beeson, L.E., ... & Gallos, I.D. (2021). Methods for managing miscarriage: A network meta-analysis. *Cochrane Database of Systematic Reviews*, 6(6):CD012602
- Gilman Barber, A. R., Rhone, S. A., & Fluker, M. R. (2014). Curettage and Asherman's syndrome-lessons to (re-) learn? *Journal of Obstetrics and Gynaecology Canada*, 36(11), 997-1001.
- Grimes, D. A., Schulz, K. F., Cates Jr, W., & Tyler, C. W., Jr. (1976). *The Joint Program for the Study of Abortion/CDC: A Preliminary Report*. Paper presented at the Abortion in the Seventies: Proceeding of the Western Regional Conference on Abortion, Denver, Colorado.
- Johnston, H. B., Akhter, S., & Oliveras, E. (2012). Quality and efficiency of care for complications of unsafe abortion: A case study from Bangladesh. *International Journal of Gynecology & Obstetrics*, 118(2), 60013-60017.
- Kakinuma, T., Kakinuma, K., Sakamoto, Y., Kawarai, Y., Saito, K., Ihara, M., Matsuda, Y., Sato, I., Ohwada, M., Yanagida, K., & Tanaka, H. (2020). Safety and efficacy of manual vacuum suction compared with conventional dilatation and sharp curettage and electric vacuum aspiration in surgical treatment of miscarriage: a randomized controlled trial. *BMC Pregnancy Childbirth*, 16;20(1), 695.
- Kulier, R., Kapp, N., Gulmezoglu, A. M., Hofmeyr, G. J., Cheng, L., & Campana, A. (2011). Medical methods for first trimester abortion. *Cochrane Database of Systematic Reviews*, 9(11).
- Neilson, J. P., Gyte, G. M., Hickey, M., Vazquez, J. C., & Dou, L. (2013). Medical treatments for incomplete miscarriage. *Cochrane Database of Systematic Reviews*, 28(3).
- Sekiguchi, A., Ikeda, T., Okamura, K., & Nakai, A. (2015). Safety of induced abortions at less than 12 weeks of pregnancy in Japan. *International Journal of Gynecology & Obstetrics*, 129(1), 54-57.
- Tuncalp, O., Gulmezoglu, A. M., & Souza, J. P. (2010). Surgical procedures for evacuating incomplete miscarriage. *Cochrane Database of Systematic Reviews*, 8(9).
- World Health Organization. (2024). Abortion Care Guideline, 2nd ed. Geneva: World Health Organization.

1.3

1. General recommendations for abortion care

Prophylactic antibiotics for vacuum aspiration and dilatation and evacuation

Recommendation:

- Administer prophylactic antibiotics prior to vacuum aspiration and dilatation and evacuation (D&E).
- Where antibiotics are unavailable, uterine evacuation procedures should still be offered.
- Administer treatment doses of antibiotics to those with signs or symptoms of sexually transmitted infection; partners of individuals with sexually transmitted infections also require treatment. Treatment should not delay uterine evacuation.

In practice:

- When antibiotic prophylaxis is needed, a single dose of doxycycline (a tetracycline antibiotic) or metronidazole (a nitroimidazole antibiotic) are commonly used because of their efficacy, ease of oral administration, low cost, and low risk of allergic reaction.

Strength of recommendation:

Strong

Quality of evidence:

- Vacuum aspiration: High
- D&E: Very low
- Incomplete or missed abortion: Moderate

Last reviewed:

September 30, 2025

Risk of infection

When objective measures are used to diagnose postabortion infection following vacuum aspiration performed before 13 weeks gestation, the infection rate ranges from 0.01-2.44% (Achilles & Reeves, 2011). In studies performed in the United States before routine use of antibiotic prophylaxis, reported rates of infection following D&E ranged from 0.8-1.6% (Achilles & Reeves, 2011).

Evidence for antibiotic prophylaxis

A Cochrane meta-analysis of 19 randomized controlled clinical trials showed that administration of prophylactic antibiotics at the time of vacuum aspiration for induced abortion before 13 weeks gestation significantly reduces the risk of infection (Low et al., 2012). Evidence to support use of prophylactic antibiotics before D&E is limited; however, because of the demonstrated benefit of prophylactic antibiotics before vacuum aspiration, the World Health Organization (WHO, 2024), Society of Family Planning (Cheng et al., 2025), American College of Obstetricians and Gynecologists (ACOG, 2018 reaffirmed 2022) and Royal College of Obstetricians and Gynaecologists (RCOG, 2022) recommend prophylactic antibiotics for all people undergoing vacuum aspiration or D&E.

A Cochrane meta-analysis of six randomized controlled trials found that prophylactic antibiotics administered before uterine evacuation for incomplete or missed abortion (postabortion care) up to 22 weeks gestation significantly reduced the risk of uterine infection when analysis was restricted to high-quality studies (Ahmed et al., 2025).. The largest of the included studies, a multicountry randomized trial that examined currently recommended prophylactic antibiotics administered as part of postabortion care up to 22 weeks, found that fewer women in the prophylactic antibiotic group developed postabortion infection than those in the placebo group when strict, international diagnostic criteria for pelvic infection were used (Lissauer et al., 2019; Serwadda, 2019). A secondary analysis of this study found that antibiotic prophylaxis is cost-effective, estimating that routine prophylaxis could save \$8.5 million across the two regions of sub-Saharan Africa and South Asia (Goranitis et al., 2019).

Giving prophylactic antibiotics is more effective and less costly than screening everyone presenting for abortion care and treating only those with evidence of infection (Levallois & Rioux, 1988; Low et al., 2012). The inability to provide antibiotics should not limit access to abortion (WHO, 2024), as the overall risk of infection with abortion procedures is very low.

Regimen

Multiple antibiotic regimens are effective for prophylaxis before abortion (Cheng et al., 2025; Low et al., 2012). Tetracyclines (doxycycline) and nitroimidazoles (metronidazole and tinidazole) are commonly used because of their efficacy, ease of oral administration, low cost and low risk of allergic reactions; penicillins have also been shown to be effective but have more risk of allergy (Achilles & Reeves, 2011; O’Connell et al., 2008; WHO, 2024). Although studies of abortion are limited (Caruso et al., 2008), evidence from the obstetric (Costantine et al., 2008), gynecologic (Mittendorf et al., 1993) and general surgery (Classen et al., 1992) literature supports the practice of giving antibiotics before the procedure to decrease the risk of infection. Antibiotic regimens do not need to be continued after the abortion procedure (Cheng et al., 2025; Caruso, et al., 2008; Levallois & Rioux, 1988; Lichtenberg & Shott, 2003).

The following table lists regimens recommended by professional organizations based on clinical evidence and expert opinion.

Common Regimens	Recommender
Doxycycline 200mg orally before the procedure <i>or</i> Azithromycin 500mg orally before the procedure <i>or</i> Metronidazole 500mg orally before the procedure	Society of Family Planning (Cheng et al., 2025)
Doxycycline 200mg orally within 1 hour before procedure	American College of Obstetricians and Gynecologists (ACOG, 2018 reaffirmed 2022)

Antibiotics with osmotic dilators

Although not well studied, cervical preparation with osmotic dilators does not appear to increase the risk of infection (Fox & Krajewski, 2014; Jonasson et al., 1989). Some providers start antibiotics at the time of osmotic dilator placement, but there are no studies evaluating the benefit of this practice (White et al., 2018). Antibiotic prophylaxis with dilator placement should not replace antibiotic prophylaxis at the time of the uterine evacuation procedure (Cheng et al., 2025).

Therapeutic antibiotics

Those at high risk should be screened for sexually transmitted infections in addition to receiving prophylactic antibiotics. Individuals who have signs and symptoms of sexually transmitted infection should receive abortion services without delay and appropriate antibiotic treatment according to evidence-based regimens (Cheng et al., 2025; WHO, 2024; WHO, 2021). Partners of individuals with sexually transmitted infections also require treatment (WHO, 2025; WHO, 2021).

References

- Achilles, S. L., & Reeves, M. F. (2011). Society of Family Planning Clinical Guideline 20102: Prevention of infection after induced abortion. *Contraception*, 83(4), 295-309.
- Ahmed, S. I., Ammerdorffer, A., Moakes, C. A., Cheshire, J., Gülmezoglu, A. M., Coomarasamy, A., Lissauer, D., & Wilson, A. (2025). Prophylactic antibiotics for uterine evacuation procedures to manage miscarriage. *The Cochrane Database of Systematic Reviews*, 4(4), CD014844.
- American College of Obstetrics and Gynecology. (2018, reaffirmed 2022). Practice Bulletin No. 195: Prevention of infection after gynecologic procedures. *Obstetrics & Gynecology*, 131(6), e172-e189.
- Caruso, S., Di Mari, L., Cacciatore, A., Mammana, G., Agnello, C., & Cianci, A. (2008). [Antibiotic prophylaxis with prulifloxacin in women undergoing induced abortion: A randomized controlled trial]. *Minerva Ginecologica*, 60(1), 1-5.
- Cheng, T., Kumar, N., Laursen, L., Achilles, S. L., & Reeves, M. F. (2025). Society of Family Planning Clinical Recommendation: Prevention of infection after abortion and pregnancy loss. *Contraception*, 148.
- Classen, D. C., Evans, R. S., Pestotnik, S. L., Horn, S. D., Menlove, R. L., & Burke, J. P. (1992). The timing of prophylactic administration of antibiotics and the risk of surgical-wound infection. *The New England Journal of Medicine*, 326(5), 281-286.
- Costantine, M. M., Rahman, M., Ghulmiyah, L., Byers, B. D., Longo, M., Wen, T., & Saade, G. R. (2008). Timing of perioperative antibiotics for cesarean delivery: A metanalysis. *American Journal of Obstetrics & Gynecology*, 199(3), 301-306.
- Fox, M. C., & Krajewski, C. M. (2014). Society of Family Planning Clinical Guideline 20134: Cervical preparation for second-trimester surgical abortion prior to 20 weeks' gestation. *Contraception*, 89(2), 75-82.
- Goranitis, I., Lissauer, D. M., Coomarasamy, A., Wilson, A., Daniels, J., Middleton, L., ... & Roberts, T. E. (2019). Antibiotic prophylaxis in the surgical management of miscarriage in low-income countries: a cost-effectiveness analysis of the AIMS trial. *The Lancet Global Health*, 7(9), e1280-e1286.
- Jonasson, A., Larsson, B., Bygdeman, S., & Forsum, U. (1989). The influence of cervical dilatation by laminaria tent and with Hegar dilators on the intrauterine microflora and the rate of postabortal pelvic inflammatory disease. *Acta Obstetrica et Gynecologica Scandinavica*, 68(5), 405-410.
- Levallois, P., & Rioux, J. E. (1988). Prophylactic antibiotics for suction curettage abortion: Results of a clinical controlled trial. *American Journal of Obstetrics & Gynecology*, 158(1), 100-105.
- Lichtenberg, E. S., & Shott, S. (2003). A randomized clinical trial of prophylaxis for vacuum abortion: 3 versus 7 days of doxycycline. *Obstetrics & Gynecology*, 101(4), 726-731.
- Lissauer, D., Wilson, A., Hewitt, C.A., Middleton, L., Bishop, J.R.B., Daniels, J., ... Coomarasamy, A. (2019). A randomized trial of prophylactic antibiotics for miscarriage surgery. *The New England Journal of Medicine*, 380(11), 1012-1021.
- Low, N., Mueller, M., Van Vliet, H., & Kapp, N. (2012). Perioperative antibiotics to prevent infection after first-trimester abortion. *The Cochrane Database of Systematic Reviews*, (3), CD005217.

Resources

www.ipas.org/ClinicalResources

Recommendations for use of prophylactic antibiotics in safe abortion care (card)



References continued

Mittendorf, R., Aronson, M. P., Berry, R. E., Williams, M. A., Kupelnick, B., Klickstein, A., & Chalmers, T. C. (1993). Avoiding serious infections associated with abdominal hysterectomy: A meta-analysis of antibiotic prophylaxis. *American Journal of Obstetrics & Gynecology*, 169(5), 1119-1124.

Royal College of Obstetricians and Gynaecologists. (2022). Best practice in abortion care. London: Royal College of Obstetricians and Gynaecologists.

Serwadda, D. M. (2019). To give or not to give prophylactic antibiotics for miscarriage surgery? *The New England Journal of Medicine*, 380(11), 1075-1076.

White, K. O., Jones, H. E., Shorter, J., Norman, W. V., Guilbert, E., Lichtenberg, E. S., & Paul, M. (2018). Second-trimester surgical abortion practices in the United States. *Contraception*, 98, 95-99.

World Health Organization. (2024). *Abortion Care Guideline, 2nd ed.* Geneva: World Health Organization.

World Health Organization. (2025). *Guidelines for the management of asymptomatic sexually transmitted infections.* Geneva: World Health Organization.

World Health Organization. (2021). *Guidelines for the management of symptomatic sexually transmitted infections.* Geneva: World Health Organization.

1.4

1. General recommendations for abortion care

Prophylactic antibiotics for medical abortion

Recommendation:

- Routine use of antibiotics is not recommended for medical abortion.
- Administer treatment doses of antibiotics to those with signs or symptoms of sexually transmitted infection. Partners of individuals with sexually transmitted infections also require treatment. Treatment should not delay medical abortion.

Strength of recommendation:

Strong

Quality of evidence:

Very low

Last reviewed:

September 30, 2025

Risk of infection

The overall risk of infection found in prospective studies of medical abortion using mifepristone and misoprostol or misoprostol only before 13 weeks gestation is approximately 0.01-0.5% (Cheng et al., 2025; Chen & Creinin, 2015; Upadhyay et al., 2015). Retrospective studies indicate similar rates of infection following self-managed medical abortion (Cheng et al., 2025). Serious infections requiring hospitalization are very uncommon, with rates in large retrospective studies from the United States ranging from 0.03% to 0.09% (Fjerstad et al., 2009; Henderson et al., 2005).

Infection rates for medical abortion at or after 13 weeks gestation are more difficult to determine as fever is a common side effect of repeated doses of prostaglandin. Available data report infection rates of 1-3% following medical abortion at or after 13 weeks gestation (Achilles & Reeves, 2011).

Infectious mortality

Nine cases of fatal *Clostridium* sepsis occurred in North America following mifepristone and misoprostol medical abortion before 13 weeks gestation (Cohen et al., 2007; Fischer et al., 2005; Meites, Zane, & Gould, 2010; Sinave et al., 2002). One death from group A streptococcus has been reported in Australia and one death from *Clostridium sordelli* has been reported in Portugal (Reis et al., 2011) in women who used mifepristone and misoprostol. The overall mortality rate from infection related to medical abortion remains very low at 0.58 per 100,000 medical abortions (Meites et al., 2010).

Prophylactic antibiotics

There have been no randomized controlled trials examining the effect of antibiotic prophylaxis on medical abortion outcomes (Cheng et al., 2025; Low et al., 2012). Given the large number of people who would need to take antibiotics to prevent a single infection, coupled with the expense and side effects of antibiotics, the American College of Obstetricians and Gynecologists (2020), the Society of Family Planning (Cheng et al., 2025), the Royal College of Obstetricians and Gynaecologists (2022) and the World Health Organization (WHO, 2024) do not recommend routine antibiotic use prior to medical abortion.

Therapeutic antibiotics

Those at high risk should be screened for sexually transmitted infections. Individuals who have signs and symptoms of sexually transmitted infection should be provided abortion services without delay and receive appropriate antibiotic treatment according to evidence-based regimens (Cheng et al., 2025; WHO, 2024; WHO, 2021). Partners of individuals with sexually transmitted infections also require treatment (WHO 2025; WHO, 2021).

References

Achilles, S. L., & Reeves, M. F. (2011). Society of Family Planning Clinical Guideline 20102: Prevention of infection after induced abortion. *Contraception*, 83(4), 295-309.

American College of Obstetricians and Gynecologists. (2020). Practice Bulletin No. 225: Medication abortion up to 70 days of gestation. *Obstetrics & Gynecology*, 136:e31-47.

Chen, M. J., & Creinin, M. D. (2015). Mifepristone with buccal misoprostol for medical abortion: A systematic review. *Obstetrics & Gynecology*, 126(1), 12-21.

Cheng, T., Kumar, N., Laursen, L., Achilles, S. L., & Reeves, M. F. (2025). Society of Family Planning Clinical Recommendation: Prevention of infection after abortion and pregnancy loss. *Contraception*, 148.

Cohen, A. L., Bhatnagar, J., Reagan, S., Zane, S. B., D'Angeli, M. A., Fischer, M., ... McDonald, L. C. (2007). Toxic shock associated with *Clostridium sordellii* and *Clostridium perfringens* after medical and spontaneous abortion. *Obstetrics & Gynecology*, 110(5), 1027-1033.

Fischer, M., Bhatnagar, J., Guarner, J., Reagan, S., Hacker, J. K., Van Meter, S. H., & Zaki, S. R. (2005). Fatal toxic shock syndrome associated with *Clostridium sordellii* after medical abortion. *New England Journal of Medicine*, 353(22), 2352-2360.

Fjerstad M., Trussell J., Sivin I., Lichtenberg E.S., & Cullins V. (2009). Rates of serious infection after changes in regimens for medical abortion. *New England Journal of Medicine*, 361(2), 145-51.

Henderson, J. T., Hwang, A. C., Harper, C. C., & Stewart, F. H. (2005). Safety of mifepristone abortions in clinical use. *Contraception*, 72(3), 175-178.

Low, N., Mueller, M., Van Vliet, H., & Kapp, N. (2012). Perioperative antibiotics to prevent infection after first-trimester abortion. *The Cochrane Database of Systematic Reviews* (3), CD005217.

Resources

www.ipas.org/ClinicalResources

Recommendations for use of prophylactic antibiotics in safe abortion care (card)



Meites, E., Zane, S., & Gould, C. (2010). Fatal *Clostridium sordellii* infections after medical abortions. *New England Journal of Medicine*, 363(14), 1382-1383.

Reis, T., Chaves, C., Soares, A., Moreira, M., Boaventura, L., & Ribiero, G. (2011). A *Clostridium sordellii* fatal toxic shock syndrome post-medical-abortion in Portugal. Paper presented at the 21st *European Congress of Clinical Microbiology and Infectious Diseases* (ECCMID).

Royal College of Obstetricians and Gynaecologists. (2022). *Best practice in abortion care*. London: Royal College of Obstetricians and Gynaecologists Press.

Sinave, C., Le Templier, G., Blouin, D., Leveille, F., & Deland, E. (2002). Toxic shock syndrome due to *Clostridium sordellii*: A dramatic postpartum and postabortion disease. *Clinical Infectious Diseases*, 35(11), 1441-1443.

Upadhyay, U. D., Desai, S., Zlidar, V., Weitz, T. A., Grossman, D., Anderson, P., & Taylor, D. (2015). Incidence of emergency department visits and complications after abortion. *Obstetrics & Gynecology*, 125(1), 175-83.

World Health Organization. (2024). *Abortion Care Guideline, 2nd ed.* Geneva: World Health Organization.

World Health Organization. (2025). *Guidelines for the management of asymptomatic sexually transmitted infections*. Geneva: World Health Organization.

World Health Organization. (2021). *Guidelines for the management of symptomatic sexually transmitted infections*. Geneva: World Health Organization Press.

Medical abortion contraindications and precautions

Recommendation:

	Mifepristone and misoprostol regimen	Misoprostol-only regimen
Contraindications	• Previous allergic reaction to mifepristone or misoprostol • Known or suspected ectopic pregnancy • Inherited porphyria • Chronic adrenal failure	• Previous allergic reaction to misoprostol • Known or suspected ectopic pregnancy
Precautions	• Intrauterine device (IUD) in place • Serious/unstable health problems, including but not limited to hemorrhagic disorders, heart disease and severe anemia • Severe uncontrolled asthma or long-term corticosteroid therapy	• IUD in place • Serious/unstable health problems, including but not limited to hemorrhagic disorders, heart disease and severe anemia

Strength of recommendation:

Strong

Quality of evidence:

Very low

Last reviewed:

September 30, 2025

Definitions

Contraindications: People with any of these specific conditions should not be offered medical abortion with the specified regimen. Vacuum aspiration, dilatation and evacuation or treatment for ectopic pregnancy should be offered, as appropriate.

Precautions: For people with any of these specific conditions, medical abortion with the specified regimen may incur higher risks than normal. The risks, benefits and alternatives to medical abortion must be considered. Medical abortion provision to individuals with these conditions may require a higher degree of clinical judgment, skill and monitoring. Referral to a higher-level facility or alternative treatment may be appropriate.

Contraindications

Previous allergic reaction to one of the drugs involved: Allergic reactions have been reported after use of mifepristone and misoprostol (Bene et al., 2014; Cruz et al., 2009; Das et al., 2022; Hauseknecht, 2003; Tupek et al., 2022; Sahraei, Mirabzadeh, & Eshraghi, 2016; Schoen et al., 2014; Zhang et al., 2019). *Quality of evidence: High*

Known or suspected ectopic pregnancy: Mifepristone and misoprostol do not treat ectopic pregnancy and use of the medications may delay diagnosis and treatment of this life-threatening condition. *Quality of evidence: High*

Inherited porphyria: Porphyrias are rare metabolic disorders in which genetic mutations alter the body's generation of heme. Theoretically, mifepristone could exacerbate the manifestation of porphyria (Ventura, Cappellini, & Rochi, 2009). *Quality of evidence: Very low.* No human studies exist, but animal models exhibit the effect of mifepristone (Cable et al., 1994).

Chronic adrenal failure: Mifepristone is a glucocorticoid receptor antagonist (Spitz & Bardin, 1993). Mifepristone blocks negative feedback mechanisms that control cortisol secretion. For those with adrenal insufficiency on long-term corticosteroid therapy, mifepristone exposure may exacerbate the underlying condition (Sitruk-Ware & Spitz, 2003). *Quality of evidence: Very low.* There are no data on mifepristone use in pregnant people with adrenal insufficiency, but there is experimental and animal data to support the recommendation.

Precautions

IUD in place: A person who is pregnant with an IUD is at significantly elevated risk of ectopic pregnancy (Barnhart, 2009) and must be evaluated for the presence of ectopic pregnancy. If the pregnancy is found to be intrauterine, the IUD should be removed before starting medical abortion due to the theoretical risk of uterine perforation from contractions during medical abortion and the potential risk of infection (Danco, 2016; Davey, 2006). *Quality of evidence: Very low.* There are no studies to verify whether having an IUD in place poses actual risks during medical abortion.

Serious medical problems: Medical abortion studies generally exclude those with severe anemia or serious medical problems (Christin-Maitre, Bouchard, & Spitz, 2000; Sitruk-Ware & Spitz, 2003). Available studies estimate a decrease in hemoglobin of 0.1 to 0.7 g/dL during medical abortion before 13 weeks (Rose, Putnam, & Espey, 2025). One case report (Hou, 2016) documents successful medical abortion in a patient with mild hemophilia; this patient received specialized, additional medication to minimize bleeding risk. Three case reports document misoprostol-induced acute coronary artery vasospasm, which in one case required coronary artery stent placement (Illa et al., 2010; Mazhar, Sultana, & Akram, 2018; Munoz-Franco et al., 2019). One case report documents a spontaneous coronary artery dissection which may have been associated with misoprostol use (Motaweihi et al., 2025). Whether to provide medical abortion to individuals with medical conditions will depend on clinical judgment, monitoring and options available for safe abortion care. *Quality of evidence: Very low.*

Severe uncontrolled asthma or long-term corticosteroid therapy: Mifepristone is a glucocorticoid receptor antagonist (Spitz & Bardin, 1993). Mifepristone blocks negative endocrine feedback mechanisms that control cortisol secretion. For those on long-term corticosteroid therapy for severe or uncontrolled asthma, mifepristone may exacerbate the underlying condition (Sitruk-Ware & Spitz, 2003). There are no direct studies of medical abortion among people on corticosteroid treatment, but one review suggested that increasing the dose of the steroid medications can counteract the cortisol blunting effect of mifepristone (Davey, 2006).

Medical abortion in asthmatic people requiring systemic corticosteroids has not been studied as giving

mifepristone risks asthma exacerbation. One review suggests using a high level of caution when giving mifepristone to such people and only doing so if the asthma is well-controlled (Davey, 2006). The glucocorticoid dose should be increased for several days before and after mifepristone. Other experts recommend that those with severe, poorly controlled asthma who are on long-term corticosteroids not take mifepristone due to the life-threatening nature of acute asthma exacerbation (Christin-Maitre et al., 2000; Creinin & Gemzell Danielsson, 2009; Sitruk-Ware, 2006).

Inhaled corticosteroids for asthma are not systemically absorbed and are not a contraindication to mifepristone. Some experts recommend that mifepristone and misoprostol should be available to individuals with asthma who are not on long-term systemic steroids (Creinin & Gemzell Danielsson, 2009). *Quality of evidence: Very low*

References

- Barnhart, K. T. (2009). Clinical practice. Ectopic pregnancy. *New England Journal of Medicine*, 361(4), 379-387.
- Bene, J., Alarcon, P., Faucon, M., Auffret, M., Delfosse, F., Becker, T., ... Gautier, S. (2014). Anaphylactic shock after misoprostol in voluntary termination pregnancy-a case report. *European Journal of Obstetrics, Gynecology and Reproductive Biology*, 182, 260-261.
- Cable, E. E., Pepe, J. A., Donohue, S. E., Lambrecht, R. W., & Bonkovsky, H. L. (1994). Effects of mifepristone (RU-486) on heme metabolism and cytochromes P-450 in cultured chick embryo liver cells, possible implications for acute porphyria. *European Journal of Biochemistry*, 225(2), 651-657.
- Christin-Maitre, S., Bouchard, P., & Spitz, I. M. (2000). Medical termination of pregnancy. *New England Journal of Medicine*, 342(13), 946-956.
- Creinin, M. & Gemzell Danielsson K. (2009). Medical abortion in early pregnancy. In M. Paul, E. S. Lichtenberg, L. Borgatta, D. A. Grimes, P. G. Stubblefield & M. D. Creinin (Eds.), *Management of unintended and abnormal pregnancy*. West Sussex UK: Wiley-Blackwell.
- Cruz, M. J., Duarte, A. F., Baudrier, T., Cunha, A. P., Barreto, F., & Azevedo, F. (2009). Lichenoid drug eruption induced by misoprostol. *Contact Dermatitis*, 61, 240-242.
- Danco Laboratories, LLC. (2016). Mifeprex® Prescribing Information. Retrieved from: www.earlyoptionpill.com
- Das, R., Panda, S., Sharma, N., & Deb, P. (2022). A rare case of misoprostol hypersensitivity. *Journal of Family Medicine and Primary Care*, 11(5):2226-7.
- Davey, A. (2006). Mifepristone and prostaglandin for termination of pregnancy: Contraindications for use, reasons, and rationale. *Contraception*, 74(1), 16-20.
- Hausknecht, R. (2003). Mifepristone and misoprostol for early medical abortion: 18 months experience in the United States. *Contraception*, 67(6), 463-465.

References continued

- Hou, M. Y. (2016). Uncomplicated abortion with mifepristone and misoprostol in hemophilia A carrier. *Contraception*, 94(2), 187-189.
- Illa, M., Bennasar, M., Berge, R., Font, C., & Palacio, M. (2010). Acute coronary artery vasospasm associated with misoprostol for termination of pregnancy. *Fetal Diagnosis and Therapy*, 27, 174-177.
- Mazhar, F., Sultana, J., & Akram, S. (2018). Misoprostol-induced acute coronary syndrome in a premenopausal woman: A case report with literature review. *Current Drug Safety*, 13(1), epub ahead of print.
- Motaweihi, M. A., Baraskar, B., Shin, Y. B., & Iantorno, M. (2025). A Rare Cause of an Acute Myocardial Infarction in a Young Pregnant Woman After Misoprostol-Induced Abortion. *Cureus*, 17(8), e90655.
- Munoz-Franco, F. M., Lacunza-Ruiz, F. J., Vazquez-Andres, D. J., & Rodriguez-Hernandez, J. R. (2019). Coronary artery vasospasm after misoprostol treatment for incomplete abortion: A case report. *Contraception*, 100(6), 498-501.
- Rose, L., Putnam, S., & Espey, E. (2025). First-trimester medication abortion: anemia and blood loss. *Current Opinion in Obstetrics and Gynecology*, 37(6), 387-396.
- Sahraei, Z., Mirabzadeh, M., & Eshraghi, A. (2016). *Erythema multiforme associated with misoprostol: A case report*. *American Journal of Therapeutics*, 23(5), e1230-1233.
- Schoen, C., Campbell, C., Maratas, A., & Cheung, K. (2014). Anaphylaxis to buccal misoprostol for labor induction. *Obstetrics & Gynecology*, 124(2, Part 2, Supplement 1), 466-468.
- Sitruk-Ware, R. (2006). Mifepristone and misoprostol sequential regimen side effects, complications and safety. *Contraception*, 74(1), 48-55.
- Sitruk-Ware, R. & Spitz, I. M. (2003). Pharmacological properties of mifepristone: Toxicology and safety in animal and human studies. *Contraception*, 68(6), 409-20.
- Spitz, I. M. & Bardin, C. W. (1993). Mifepristone (RU-486)—A modulator of progestin and glucocorticoid action. *New England Journal of Medicine*, 329(6), 404-12.
- Tupek, T., Gregoric, A., Pavokovic, D., Cerovac, A., & Habek, D. (2022). Severe, protracted anaphylaxis with hypovolemic shock after sublingual misoprostol administration. *Journal of Obstetrics and Gynaecology*, 42(1):169-170.
- Ventura, P., Cappellini M. D., & Rochi, E. (2009). The acute porphyrias: A diagnostic and therapeutic challenge in internal and emergency medicine. *Internal and Emergency Medicine*, 4(4), 297-308.
- Zhang, L., Qian, M., Hong, L., & Wu, Q. (2020). First case report of acute generalized exanthematous pustulosis (AGEP) caused by mifepristone. *Contact Dermatitis*, 82(3): 177-179.

1. General recommendations for abortion care

Misoprostol product quality

Recommendation:

- Providers should track medical abortion success rates to help ensure they are using an effective misoprostol product.
- Purchase misoprostol in double-aluminum blister packs and keep the misoprostol in its original packaging; check the integrity of packaging before use. Avoid purchasing polyvinyl chloride (PVC) or polyvinylidene chloride (PVDC)/aluminum blister packs.
- Store misoprostol in a cool, dry place.

Strength of recommendation:

Strong

Quality of evidence:

Low

Last reviewed:

September 30, 2025

Manufacture and quality of misoprostol

Good Manufacturing Practice is a system for ensuring medications are consistently produced according to quality standards (World Health Organization [WHO], 2014). There are at least 30-40 manufacturers of misoprostol worldwide, and some manufacturers subcontract production of the drug, which makes the enforcement of Good Manufacturing Practice and the assurance of quality across all brands difficult (Hall & Tagontong, 2016). Misoprostol brands approved by stringent regulatory agencies (such as the European Medicines Agency or the United States Food and Drug Administration) or prequalified by WHO (WHO-PQ) conform to Good Manufacturing Practice and are of high quality (Hagen et al., 2020a).

Exposure to heat and humidity during manufacturing, packaging, shipping or storage may compromise the stability and quality of misoprostol (Cayman Chemical, 2012; Hagen et al., 2020a). Degradation decreases the effectiveness of misoprostol, leading to decreased success rates of medical abortion and unsuccessful treatment of incomplete abortion and postpartum hemorrhage.

Four studies have examined the quality of misoprostol products obtained from low- and middle-income countries. A 2016 study analyzed 215 misoprostol samples from countries all over the world (Hall & Tagontong, 2016). When samples were tested for content and purity, 5% contained more misoprostol than expected (110-121% of labeled content, to allow for degradation), 55% were within specification per the International Pharmacopeia, meaning they contained between 90-100% of labeled content, and 40% were below specification, containing less than 90% of labeled content. Of the 85 samples that were below specification, 14 contained no misoprostol at all. A 2018 study tested the quality of 166 misoprostol samples obtained from a variety of health care providers across Nigeria, ranging from federal medical centers and state hospitals to patent and proprietary medicine vendors (Anyakora et al., 2018). Although all samples passed a visual inspection, 34% did not meet specification as defined above. A similar study in Malawi found 23 of 30 samples from health centers and pharmacies around the country met specification for misoprostol; all samples meeting specification were packaged in aluminum-aluminum blister packs (Hagen, Khuluza & Heide, 2020b). A systematic review and meta-analysis of the quality of medicines, including oxytocics, in low- and middle-in-

come countries included these three studies and found that 39% of all misoprostol samples failed to meet specification (Torloni et al., 2020). Since the publication of the systematic review, two additional studies have been published. Onestudy assessed quality of misoprostol from health facilities in Rwanda (Bizimana et al., 2021), finding that 10 of the 25 misoprostol samples assessed (40%) did not meet specification. A 2023 study assessed quality of misoprostol, mifepristone, and combipacks from 11 low- and middle-income countries (Bower et al., 2023). Of the 56 misoprostol samples tested, 57% did not meet specification; 9 of the 38 mifepristone samples (24%) did not meet specification.

Three factors influence misoprostol integrity:

- impact of moisture at all stages from production to patient
- manufacture and quality of the active pharmaceutical ingredient
- packaging

Clinic use and storage

Even misoprostol manufactured in high-quality conditions and packaged well can degrade if it is shipped or stored in conditions that expose it to heat or humidity for prolonged periods of time. Quality misoprostol is stable when stored properly in room temperature conditions (25°C and 60% humidity). There have not been large field studies on the stability of misoprostol when stored in tropical climates, but laboratory studies have shown that misoprostol is less stable when exposed to moisture or heat (Chu et al., 2007; WHO, 2009).

Misoprostol packaged in double-aluminum blister packs (aluminum on top and bottom) retains the most active ingredient; after one year, 100% of pills packaged in plastic and single-aluminum blister packs will degrade, compared to 28% of misoprostol packaged in double-aluminum blister packs (Hall & Tagontong, 2016). The integrity of the double-aluminum blister packs must be preserved to maintain drug potency (Hagen et al., 2020a). If the packaging is inadvertently opened or perforated, even in normal room-temperature conditions, the tablets' potency degrades within 48 hours and continues to degrade over time (Berard et al., 2014; Hagen et al., 2020a).

Quality assurance

If providers notice a decrease in medical abortion success rates from expected baseline, they should stop using the current lot of misoprostol and start a new lot. Providers should contact the pill vendor or manufacturer to ensure that there are no recalls of the affected lot. Providers should consult the Medical Abortion Commodities Database (www.medab.org) to assess the quality of products available in their setting (Hagen et al., 2020b). In some cases, providers may need to consult with one another to determine which local misoprostol brands are most effective.

References

- Anyakora, C., Oni, Y., Ezedinachi, U., Adekoya, A., Ali, I., Nwachukwu, C., ... Nwokike, J. (2018). Quality medicines in maternal health: Results of oxytocin, misoprostol, magnesium sulfate and calcium gluconate quality audits. *BMC Pregnancy and Childbirth*, 18, 44.
- Berard, V., Fiala, C., Cameron, S., Bombas, T., Parachini, M., & Gemzell-Danielsson, K. (2014). Instability of misoprostol tablets stored outside the blister: A potential serious concern for clinical outcome in medical abortion. *PLoS ONE*, 9(12), e112401.
- Bizimana, T., Hagen, N., Gnegel, G., Kayumba, P.C., & Heide, L. (2020). Quality of oxytocin and misoprostol in health facilities of Rwanda. *PLoS One*, 16(1):e0245054.
- Bower, J., Chinery, L., Fleurent, A., Gülmezoglu, A. M., Im-Amornphong, W., Kilfedder, C., Procter, P., & Tomazzini, A. (2024). Quality testing of mifepristone and misoprostol in 11 countries. *International Journal of Gynaecology and Obstetrics: The Official Organ of the International Federation of Gynaecology and Obstetrics*, 165(2), 405–415.
- Cayman Chemical. (2012). Product Information: Misoprostol. Retrieved November 14, 2012, from <https://www.caymanchem.com/pdfs/13820.pdf>
- Chu, K. O., Wang, C. C., Pang, C. P., & Rogers, M. S. (2007). Method to determine stability and recovery of carboprost and misoprostol in infusion preparations. *Journal of Chromatography B*, 857(1), 83-91.
- Hall, P. E., & Tagontong, N. (2016). Quality of misoprostol products. *WHO Drug Information*, 30(1), 35-39.
- Hagen, N., Bizimana, T., Kayumba, P.C., Khuluza, F., & Heide, L. (2020a). Stability of misoprostol tablets collected in Malawi and Rwanda: Importance of intact primary packaging. *PLoS ONE* 15(9), e0238628.
- Hagen, N., Khuluza, F., & Heide, L. (2020b). Quality, availability and storage conditions of oxytocin and misoprostol in Malawi. *BMC Pregnancy and Childbirth*, 20, 184.
- Torloni, M.R., Bonet, M., Betra n, A.P., Ribeiro-do-Valle, C.C., & Widmer, M. (2020). Quality of medicines for life-threatening pregnancy complications in low- and middle-income countries: A systematic review. *PLoS ONE* 15(7), e0236060.
- World Health Organization. (2009). *Application to include Misoprostol for prevention of postpartum hemorrhage in WHO Model List of Essential Medicines: comments from Departments of Making Pregnancy Safer & Reproductive Health and Research*. Retrieved from http://www.who.int/selection_medicines/committees/expert/17/application/WHO_Misoprostol.pdf
- World Health Organization. (2014). *WHO good manufacturing practices for pharmaceutical products: Main principles* (Annex 2, WHO Technical Report Series 986). Geneva, Switzerland: WHO Press.

2.1

2. Pain management

Pain management for medical abortion before 13 weeks gestation

Recommendation:

- Offer pain medication to all people undergoing medical abortion.
- Nonsteroidal anti-inflammatory drugs (NSAIDs) are recommended either prophylactically or at the time cramping begins.
- Non-pharmacologic pain management measures may be helpful.
- Narcotic analgesics have not been demonstrated to be effective in relieving pain during the medical abortion process and are not recommended for routine use.
- Paracetamol should not be used unless an allergy or contraindication to NSAIDs exists.

Strength of recommendation:

Strong

Quality of evidence:

Low

Last reviewed:

October 2, 2025

Pain during medical abortion before 13 weeks gestation

Pain is the most commonly reported side effect of medical abortion (Fiala et al., 2014). In one study of 6,755 women using medical abortion up to 63 days gestation, 78.4% reported moderate or severe pain and cramping (Goldstone, Michelson, & Williamson, 2012). Similarly, a 2006 systematic review of five large British and American case series of analgesia use during medical abortion concluded that 75% of women experience pain severe enough to require narcotic analgesia (Penney, 2006). A qualitative study of women's experience with medical abortion pain in Nepal, South Africa and Vietnam found that women described pain as stronger than what they experienced during menstruation and manifested in four distinct patterns: minimal or no pain; brief intense pain, typically right before expulsion; intermittent pain, similar to contractions; and constant pain for one or several hours (Grossman et al., 2019). Pain typically peaks 2.5 to 4 hours after misoprostol use and lasts around one hour (Colwill et al., 2019). More than 75% of patients report resolution of pain by 12 hours after taking misoprostol, with reports increasing to 90% by 24 hours (Friedlander et al., 2022). Patient characteristics associated with more pain include increasing gestational age, younger patient age, nulliparity, no previous vaginal deliveries, and history of dysmenorrhea (Dragoman et al., 2021; Kemppainen et al., 2020; Suhonen et al., 2011; Teal, Dempsey-Fanning, & Westhoff, 2007; Westhoff et al., 2000).

There are few trials assessing effectiveness of pain management strategies during medical abortion before 13 weeks gestation. Neither pain nor its treatment are systematically reported in clinical trials of medical abortion; where these data are reported, multiple regimens and treatment protocols have been used, rendering them difficult to compare (Fiala et al., 2014; Fiala et al., 2019; Jackson & Kapp, 2011; Reynolds-Wright, 2022).

Medications for pain management

Two small randomized controlled trials indicate that ibuprofen is more effective than placebo (Avraham et al., 2012) or acetaminophen (Livshits et al., 2009) in relieving medical abortion pain in women with pregnancies of less than seven weeks gestation. Pre-treatment with ibuprofen is no better for pain management than treatment once cramping starts (Raymond et al., 2013). A three-armed randomized trial compared ibuprofen plus metoclopramide, tramadol, or placebo taken at the time of misoprostol administration and again 4 hours later; finding that ibuprofen plus metoclopramide and tramadol alleviated pain more effectively than the placebo, but did not result in clinically significant differences in participants' reported pain (Dragoman et al., 2021). In women with pregnancies up to 10 weeks gestation, one randomized controlled trial found that pregabalin (a gamma-aminobutyric acid analog) did not decrease maximum pain scores when taken at the time of misoprostol administration; however, women who received pregabalin were less likely to require ibuprofen or narcotic pain medication and more likely to report satisfaction with analgesia than women who received the placebo (Friedlander et al., 2018).

One randomized trial found no difference in the amount or duration of pain experienced by women receiving an oral opioid medication (oxycodone) to manage medical abortion pain, compared to placebo (Colwill et al., 2019). Study authors concluded that while providing routine opioid medications is unnecessary, it is reasonable to provide four or fewer oxycodone tablets to those who request them. One hospital-based study randomized women undergoing medical abortion into two groups: intravenous patient-controlled-analgesia for pain, or on-demand oral, intramuscular, or intravenous administration of oxycodone for pain (Kemppainen et al., 2022). Results show that most participants in both groups utilized opioid medication; those in the patient-controlled-analgesia group were more likely to characterize pain as mild or tolerable (21% compared to 6% in the on-demand group), although maximum reported pain was the same in both groups.

Non-pharmacologic pain management

In one randomized trial, high frequency transcutaneous electrical nerve stimulation (80Hz TENS) applied to the abdomen and back when cramping began reduced women's abortion pain compared to placebo (Goldman et al., 2020). Another randomized trial found no benefit of auricular acupuncture or acupressure in improving medical abortion pain, when compared to placebo (Westhoff et al., 2021). Other non-pharmacologic pain management strategies for medical abortion before 13 weeks gestation have not been the subject of comparative trials. However, experts recommend adjunctive non-pharmacologic measures to improve individual's comfort during a medical abortion, including thorough education about expected pain and bleeding (Teal, Dempsey-Fanning, & Westhoff, 2007), a supportive environment and application of a heating pad or hot water bottle to the lower abdomen (Akin, et al., 2001). These modalities are to be employed in addition to—not as substitutes for—pain medications.

Resources

www.ipas.org/ClinicalResources

Pain Medication Table

Continuum of depth of sedation: Definition of general anesthesia and levels of sedation/analgesia



References

- Rose, L., Putnam, S., & Espey, E. (2025). First-trimester medication abortion: anemia and blood loss. *Current Opinion in Obstetrics and Gynecology*, 37(6), 387-396.
- Sahraei, Z., Mirabzadeh, M., & Eshraghi, A. (2016). *Erythema multiforme associated with misoprostol: A case report. American Journal of Therapeutics*, 23(5), e1230-1233.
- Schoen, C., Campbell, C., Maratas, A., & Cheung, K. (2014). Anaphylaxis to buccal misoprostol for labor induction. *Obstetrics & Gynecology*, 124(2, Part 2, Supplement 1), 466-468.
- Sitruk-Ware, R. (2006). Mifepristone and misoprostol sequential regimen side effects, complications and safety. *Contraception*, 74(1), 48-55.
- Sitruk-Ware, R. & Spitz, I. M. (2003). Pharmacological properties of mifepristone: Toxicology and safety in animal and human studies. *Contraception*, 68(6), 409-20.
- Spitz, I. M. & Bardin, C. W. (1993). Mifepristone (RU-486)—A modulator of progestin and glucocorticoid action. *New England Journal of Medicine*, 329(6), 404-12.
- Tupek, T., Gregoric, A., Pavokovic, D., Cerovac, A., & Habek, D. (2022). Severe, protracted anaphylaxis with hypovolemic shock after sublingual misoprostol administration. *Journal of Obstetrics and Gynaecology*, 42(1):169-170.
- Ventura, P., Cappellini M. D., & Rochi, E. (2009). The acute porphyrias: A diagnostic and therapeutic challenge in internal and emergency medicine. *Internal and Emergency Medicine*, 4(4), 297-308.
- Zhang, L., Qian, M., Hong, L., & Wu, Q. (2020). First case report of acute generalized exanthematous pustulosis (AGEP) caused by mifepristone. *Contact Dermatitis*, 82(3): 177-179.

2.2

2. Pain management

Pain management for medical abortion after 13 weeks gestation

Recommendation:

- Offer pain medication to everyone undergoing medical abortion.
- Nonsteroidal anti-inflammatory drugs (NSAIDs) are recommended and should be initiated with misoprostol.
- Narcotic analgesics and anxiolytics should be offered in addition to NSAIDs.
- Non-pharmacologic pain management measures may be helpful.
- Regional anesthesia and patient-controlled anesthesia may be offered where available.

Strength of recommendation:

Strong

Quality of evidence:

Very Low

Last reviewed:

October 2, 2025

Pain during medical abortion at or after 13 weeks gestation

In multiple cohort studies of medical abortion using prostaglandin E1 analogues (misoprostol, gemeprost) at or after 13 weeks gestation, most people required pain medication (Ashok et al., 2004; Gemzell-Danielsson & Östlund, 2000; Hamoda et al., 2004; Rose, Shand, & Simmons, 2006). Nulliparity, advanced gestational age, higher number of misoprostol doses and longer induction-to-abortion interval are associated with increased pain during medical abortion (Hamoda et al., 2004; Louie et al., 2017; Rydelius et al., 2025). Pain rarely starts after taking mifepristone; cramping pain generally starts after initiating misoprostol and typically peaks with expulsion (Mentula, Kalso, & Heikinheimo, 2014).

Medications for pain management

Limited evidence exists regarding the optimal pain medication regimen for medical abortion at or after 13 weeks gestation (Jackson & Kapp, 2020). One randomized trial of 74 women at or after 13 weeks gestation undergoing abortion with mifepristone and misoprostol prophylactically treated patients with either an NSAID (diclofenac) or with paracetamol plus codeine at the time of misoprostol administration. There was no difference in reported pain between the two groups, but NSAID pretreatment reduced the need for subsequent intravenous opiates (Fiala et al., 2005). A second trial randomized 54 women undergoing abortion between 14-24 weeks gestation to receive the NSAID celecoxib or a placebo at the time of misoprostol administration. Those in the NSAID group had significantly lower pain scores at the time of abortion; however, nearly half of participants in both groups reported severe pain and there was no difference in use of additional analgesia between the two groups (Tintara, Voradithi, & Choobun, 2018). A small nonrandomized trial including 40 participants compared pain management with piritramide patient-controlled analgesia to a nurse-admin-

istered stepwise protocol that included acetaminophen, ibuprofen, tramadol, metamizole, and meptazinol/hyoscine butylbromide (Tascon Padron et al., 2023). The study found higher rates of pain and nausea in the piritramide group, although satisfaction with pain management in both groups was similar.

In the largest available cohort study, 1,002 women at or after 13 weeks gestation undergoing abortion with mifepristone and misoprostol were offered a combination of oral and parenteral narcotic analgesics and NSAIDs to manage pain (Ashok et al., 2004). Study authors reported the proportion of women who used no analgesia (18%), and those who used paracetamol plus dihydrocodone (70%), parenteral morphine (7%) or NSAIDs (5%) for pain relief; women's pain or satisfaction with pain management was not reported. In a smaller cohort study, 425 participants who received prophylactic and ongoing acetaminophen and NSAIDs chose from several different pain management modalities for breakthrough pain during mifepristone and misoprostol medical abortion. Women's pain score (on a 100-point visual analog scale) decreased by about 15 points after opioid medication, by 35 points after paracervical block, and by 50 to 60 points when paracervical block was administered after opioid medications (Rydellius et al., 2026). Two small comparative studies examining use of paracervical block during medical abortion at or after 13 weeks gestation found no improvement in pain with this modality (Andersson et al., 2016; Winkler et al., 1997).

Ipas recommends a combination regimen involving prophylactic NSAIDs given at the time of misoprostol, plus oral and/or parenteral narcotic analgesics (Edelman & Mark, 2017). Regional (epidural) and patient-controlled anesthesia are safe and effective methods of pain management. They may be offered if the requisite personnel, monitoring and equipment are available, (Maggiore et al., 2016; Smith et al., 2016; World Health Organization [WHO], 2024).

Non-pharmacologic pain management

There are no comparative trials evaluating the benefit of non-pharmacologic pain management strategies for medical abortion at or after 13 weeks gestation. However, experts recommend adjunctive non-pharmacologic measures to improve women's comfort during a medical abortion, including thorough education about expected pain and bleeding, a supportive environment and application of a heating pad or hot water bottle to the lower abdomen (Akin et al., 2001). These modalities are to be employed in addition to—not as substitutes for—pain medications.

Resources

www.ipas.org/ClinicalResources

Pain Medication Table

Continuum of depth of sedation: Definition of general anesthesia and levels of sedation/analgesia



References

- Akin, M. D., Weingard, K. W., Hengehold, D. A., Goodale, M. B., Hinkle, R. T., & Smith, R. P. (2001). Continuous low-level topical heat in the treatment of dysmenorrhea. *Obstetrics & Gynecology*, 97, 343-349.
- Andersson, I. M., Benson, L., Christensson, K., & Gemzell-Danielsson, K. (2016). Paracervical block as pain treatment during second-trimester medical termination of pregnancy: An RCT with bupivacaine versus sodium chloride. *Human Reproduction*, 31(1), 67-74.
- Ashok, P., Templeton, A., Wagaarachchi, P., & Flett, G. (2004). Midtrimester medical termination of pregnancy: A review of 1002 consecutive cases. *Contraception*, 69(1), 51-58.
- Edelman, A., & Mark, A. (2017). *Medical abortion reference guide: Induced abortion and postabortion care at or after 13 weeks gestation*. Chapel Hill, NC: Ipas.
- Fiala, C., Swahn, M., Stephansson, O., & Gemzell-Danielsson, K. (2005). The effect of non-steroidal anti-inflammatory drugs on medical abortion with mifepristone and misoprostol at 13–22 weeks gestation. *Human Reproduction*, 20(11), 3072-3077.
- Gemzell-Danielsson, K., & Östlund, E. (2000). Termination of second trimester pregnancy with mifepristone and gemeprost. *Acta Obstetrica et Gynecologica Scandinavica*, 79(8), 702-706.
- Hamoda, H., Ashok, P., Flett, G., & Templeton, A. (2004). Analgesia requirements and predictors of analgesia use for women undergoing medical abortion up to 22 weeks of gestation. *BJOG: An International Journal of Obstetrics & Gynaecology*, 111(9), 996-1000.
- Jackson, E., & Kapp, N. (2020). Pain management for medical and surgical termination of pregnancy between 13 and 24 weeks of gestation: a systematic review. *BJOG: An International Journal of Obstetrics & Gynaecology*, 127, 1348-1357.
- Louie, K. S., Chong, E., Tsereteli, T., Avagyan, G., Abrahamyan, R., & Winikoff, B. (2017). Second trimester medical abortion with mifepristone followed by unlimited dosing of buccal misoprostol in Armenia. *European Journal of Contraception & Reproductive Health Care*, 22(1), 76-80.
- Maggiore, U. L. R., Silanos, R., Carlevaro, S., Gratarola, A., Venturini, P.L., Ferrero, S., & Pelosi, P. (2016). Programmed intermittent epidural bolus versus continuous epidural infusion for pain relief during termination of pregnancy: A prospective, double-blind, randomized trial. *International Journal of Obstetric Anesthesia*, 25, 37-44.
- Mentula, M., Kalso, E., & Heikinheimo, O. (2014). Same-day and delayed reports of pain intensity in second-trimester medical termination of pregnancy: A brief report. *Contraception*, 90(6), 609-11.
- Rose, S. B., Shand, C., & Simmons, A. (2006). Mifepristone- and misoprostol-induced mid-trimester termination of pregnancy: A review of 272 cases. *Australian and New Zealand Journal of Obstetrics and Gynaecology*, 46(6), 479-485.
- Rydellius, J., Kallner, H. K., Karlsson, O., Hognert, H., & Gemzell-Danielsson, K. (2026). Pain management for medical abortion beyond 12 weeks of gestation: a cross-sectional study in Sweden. *BMJ Sexual & Reproductive Health*, 52, 19-25.
- Smith, R. L., Siddiqui, N., Henderson, T., Teresi, J., Downey, K., & Carvalho, J. C. (2016). Analgesia for medically induced second trimester termination of pregnancy: A randomized trial. *Journal of Obstetrics and Gynaecology Canada*, 38(2), 147-153.
- Tascón Padrón, L., Emrich, N. L. A., Strizek, B., Gass, A., Link, C., Hilbert, T., Klaschik, S., Meissner, W., Gembruch, U., & Jiménez Cruz, J. (2023). Implementation of a piritramide based patient-controlled analgesia (PCA) as a standard of care for pain control in late abortion induction: A prospective cohort study from a patient perspective. *European Journal of Obstetrics & Gynecology and Reproductive Biology: X*, 20, 100251.
- Tintara, H., Voradithi, P., & Choobun, T. (2018). Effectiveness of celecoxib for pain relief and antipyresis in second trimester medical abortions with misoprostol: a randomized controlled trial. *Archives of Gynecology and Obstetrics*, 297(3), 709-715.
- Winkler, M., Wolters, S., Funk, A., & Rath, W. (1997). Second trimester abortion with vaginal gemeprost-improvement by paracervical anesthesia? *Zentralblatt für Gynäkologie*, 119, 621-624.
- World Health Organization. (2024). *Abortion care guideline, 2nd ed.* Geneva: World Health Organization.

2.3

2. Pain management

Pain management for vacuum aspiration

Recommendation:

- A combination of paracervical block and preprocedure nonsteroidal anti-inflammatory drugs (NSAIDs) for pain management is recommended for all people.
- Additional measures such as narcotic analgesics, anxiolytics and non-pharmacologic pain management measures may be helpful.
- Intravenous sedation, where available, may be offered.
- Paracetamol is not effective for vacuum aspiration pain management.
- General anesthesia is not recommended for pain management for routine vacuum aspiration procedures.

In practice:

- Pain management is recommended for all vacuum aspiration procedures, whether they are performed to induce abortion or for postabortion care.
- Clinicians consistently underestimate the amount of pain people experience during vacuum aspiration.

Strength of recommendation:

Strong

Quality of evidence:

High

Last reviewed:

October 2, 2025

Pain during vacuum aspiration

Most people undergoing vacuum aspiration—whether for induced abortion (Borgatta & Nickinovich, 1997) or for postabortion care (Crouthamel et al., 2022; Gomez et al., 2004)—will experience pain. Preprocedure depression or emotional distress, or gestational age beyond 10 weeks, are associated with more pain during uterine aspiration (Allen et al., 2006; Belanger, Melzack, & Lauzon, 1989; Duros et al., 2018), while having a prior vaginal delivery is associated with less pain (Borgatta & Nickinovich, 1997). Clinicians consistently underestimate the amount of pain people experience during abortion (Oviedo et al., 2018; Singh et al., 2008; Tschann et al., 2018).

Methods of pain management

For vacuum aspiration before 13 weeks gestation, a combination of paracervical block with local anesthesia, analgesics, and non-pharmacologic measures typically provides pain relief for most people (Renner et al., 2010; Royal College of Obstetricians and Gynaecologists [RCOG], 2022; World Health Organization [WHO], 2024). Intravenous sedation may also be offered (RCOG, 2022; WHO, 2024). **Local anesthesia**

A paracervical block given before dilating the cervix has been shown to decrease pain with dilation and uterine aspiration (Renner et al., 2024). Two studies comparing paracervical block to NSAIDs found that paracervical block was more effective at managing pain during the procedure (Acmaaz et al., 2013; Sarker et al., 2024) and that participants who received paracervical block were more satisfied with their pain management (Sarker et al., 2024). Paracervical block is a low-risk procedure that can be safely performed by many types of healthcare workers, including physicians, associate/advanced associate clinicians, nurses, traditional and complementary medicine professionals, and health workers who provide basic emergency obstetric care (Warriner et al., 2006; WHO, 2024). For further information, see section 2.5 Paracervical block.

Medications

Two small studies examining use of oral NSAIDs alone for vacuum aspiration pain found no benefit (Acmaaz et al., 2013; Li et al., 2003). However, pre-procedure treatment with NSAIDs was found to decrease pain during and after the procedure in studies where participants also received paracervical block for pain relief (Renner et al., 2010; Romero, Turok, & Gilliam, 2008; Suprpto & Reed, 1984; Wiebe & Rawling, 1995); both oral and intramuscular NSAIDs are effective (Braaten et al., 2013). There are no studies assessing the additional benefit of NSAIDs when moderate intravenous sedation is used for pain relief; based on findings from three small randomized trials, it is unclear if NSAIDs provide additional benefit when deeper levels of intravenous sedation are used (Khazin et al., 2011; Lowenstein et al., 2006; Roche et al., 2012).

The benefit of narcotic analgesics in alleviating vacuum aspiration pain is unclear. In one randomized controlled trial, the addition of oral hydrocodone-acetaminophen to a pain management regimen of paracervical block, ibuprofen and lorazepam did not improve pain during uterine aspiration when compared to placebo (Micks et al., 2012), while in another randomized trial, the addition of intravenous fentanyl to the same pain management regimen significantly improved procedural pain (Rawling & Weibe, 2001). Intranasal fentanyl, however, when added to ibuprofen and paracervical block, did not improve pain when compared to placebo (Moayedi et al., 2022). Two randomized trials showed that oral and rectal NSAIDs are more effective than tramadol in alleviating postprocedure pain (Lowenstein et al., 2006; Romero et al., 2008); however, a third randomized trial showed that rectal tramadol was more effective than NSAIDs (Khazin et al., 2011).

Anxiolytics such as lorazepam or midazolam decrease anxiety related to the procedure and cause amnesia for some, but do not affect pain scores (Allen et al., 2006; Bayer et al., 2015; Wiebe, Podhradsky, & Dijak, 2003).

Only one study has assessed effectiveness of pretreatment with paracetamol on pain during uterine aspiration performed without paracervical block, finding no difference between the paracetamol group and control group (Acmaaz et al., 2013). In two studies where women also received deep sedation or general anesthesia, paracetamol did not improve post-procedure pain (Cade & Ashley, 1993; Lowenstein et al., 2006).

One randomized trial compared the effect of preprocedure gabapentin to placebo in women who also received oral lorazepam, ibuprofen, oxycodone and acetaminophen and found no difference in pain scores between the two groups (Gray et al., 2019). A subsequent trial compared preprocedure gabapentin to placebo amongst women having uterine aspiration under local anesthesia with paracervical block and oral ibuprofen and found no differences in intra-operative or postoperative pain scores (Hailstorks et al., 2020).

Intravenous sedation

Intravenous sedation using a combination of narcotics and anxiolytics is an effective means of pain control and improves satisfaction with the abortion procedure (Allen et al., 2009; Allen et al., 2006; Cansino et al., 2021; Wells, 1992; Wong et al., 2002). Intravenous administration of narcotics and anxiolytics is more effective than oral administration for pain during uterine aspiration (Allen et al., 2009). One randomized non-inferiority study found that patients were equally satisfied with intravenous sedation using a combination of ketamine and anxiolytics as sedation with fentanyl and anxiolytics, although patients in the ketamine group experienced a higher incidence of hallucinations (Chin et al., 2022). In people who receive sedation for pain management,

it is unclear if there is additional benefit in administering a paracervical block (Kan, Ng, & Ho, 2004; Renner et al., 2010; Wong et al., 2002). When delivered by trained staff and with appropriate monitoring, intravenous sedation is safe. A 2017 retrospective cohort study which included more than 20,000 normal weight, overweight and obese women who received intravenous sedation for vacuum aspiration found that the rate of any anesthesia-related adverse event was very low (0.2%) (Horwitz et al., 2018). However, providing intravenous sedation increases the expense, complexity and potential risks of an abortion procedure and requires a trained provider with equipment for patient monitoring (Cansino et al., 2021). The increased monitoring necessary to deliver intravenous sedation safely requires facility investments in training and equipment. For further information regarding the definition of levels of sedation, including general anesthesia, see Appendix B: Continuum of depth of sedation: Definition of general anesthesia and levels of sedation/analgesia.

General anesthesia

Although effective for pain control, general anesthesia increases the expense, complexity and potential risks associated with abortion and is not recommended for routine procedures (Atrash, Cheek, & Hogue, 1988; Bartlett et al., 2004; RCOG, 2022; WHO, 2024). When using general anesthesia it is unclear whether preprocedure administration of pain medication affects postprocedure pain (Ali, Shamim, & Chughtai, 2015; Liu et al., 2005; Mustafa-Mikhail et al., 2017), and there is no additional benefit to using a paracervical block (Hall et al. 1997; Renner et al., 2010). For further information regarding the definition of levels of sedation, including general anesthesia, see Appendix B: Continuum of depth of sedation: Definition of general anesthesia and levels of sedation/analgesia.

Non-pharmacologic pain management

Medications and paracervical block should be supplemented with supportive techniques to decrease pain and anxiety (Allen & Singh, 2018). Helpful approaches include educating the patient about what to expect during the procedure; conducting the procedure in a clean and private setting with supportive staff; providing verbal support; using gentle and efficient technique; and applying a heating pad or hot water bottle to the lower abdomen in the recovery room (Akin et al., 2001; Qian et al., 2023). A 2016 systematic review of non-pharmacological adjunctive therapies to manage pain included studies of hypnosis, aromatherapy, music, relaxation and imagery exercises and use of doulas. While the review found that none of the interventions showed a statistically significant reduction in pain or anxiety, women rated non-pharmacological interventions highly and recommend their use, particularly those that include dedicated support people (Tschann, Salcedo, & Kane-shiro, 2016; Wilson et al., 2016).

Three subsequent randomized trials found no difference in reported pain between those receiving preprocedure music therapy (Belloeil et al., 2020), aromatherapy (Free, Sheeder & Cohen, 2024) or an adjunctive, nonpharmacologic pain management strategy of their choosing (ambient music, guided imagery meditation or focused breathing, among others), and women receiving standard care (Tschann et al., 2018). Two studies examining the use of auricular acupuncture, in combination with paracervical block and preprocedure NSAIDs, had conflicting results (Ndubisi et al., 2019; Oviedo et al., 2021). Additionally, a third trial combining auricular acupuncture with deep sedation did not find a clinically meaningful improvement in postprocedure pain in the intervention group (Zhu et al., 2022). The use of transcutaneous acupoint electrical stimulation (TEAS) as a means to modulate abortion pain is an area of active research, but no recommendations can be drawn from existing studies (Feng et al., 2016; Wang et al., 2018). Data regarding the effectiveness of transcutaneous electrical nerve stimulation (TENS) are conflicting. A single well designed randomized controlled trial found TENS to be non-inferior to intravenous sedation for aspiration pain relief up to 12 weeks gestation (Lerma et al., 2021), while a second well-designed randomized controlled trial found no difference in pain relief between TENS and a sham treatment (Henkel et al., 2025).

Resources

www.ipas.org/ClinicalResources

Pain Medication Table

Continuum of depth of sedation: Definition of general anesthesia and levels of sedation/analgesia



References

- Acmaaz, G., Aksoy, H., Ozoglu, N., Aksoy, U., & Albayrak, E. (2013). Effect of paracetamol, dexketoprofen trometamol, lidocaine spray, and paracervical block application for pain relief during suction termination of first-trimester pregnancy. *BioMed Research International*, 2013, 869275.
- Akin, M. D., Weingard, K. W., Hengehold, D. A., Goodale, M. B., Hinkle, R. T., & Smith, R. P. (2001). Continuous low-level topical heat in the treatment of dysmenorrhea. *Obstetrics & Gynecology*, 97, 343-349.
- Allen, R. H., & Singh, R. (2018). Society of Family Planning clinical guidelines pain control in surgical abortion part 1 - local anesthesia and minimal sedation. *Contraception*, 97(6), 471-477.
- Allen, R.H., Fitzmaurice, G., Lifford, K. L., Lasic, M., & Goldberg, A. (2009). Oral compared with intravenous sedation for first-trimester surgical abortion: A randomized controlled trial. *Obstetrics & Gynecology*, 113(2Pt1), 276-283.
- Allen, R. H., Kumar, D., Fitzmaurice, G., Lifford, K. L., & Goldberg, A. B. (2006). Pain management of first-trimester surgical abortion: Effects of selection of local anesthesia with and without lorazepam or intravenous sedation. *Contraception*, 74(5), 407-413.
- Ali, M. A., Shamim, F., & Chughtai, S. (2015). Comparison between intravenous paracetamol and fentanyl for intraoperative and postoperative pain relief in dilatation and evacuation: Prospective, randomized interventional trial. *Journal of Anaesthesiology and Clinical Pharmacology*, 31(1), 54-58.
- Atrash, H. K., Cheek, T. G., & Hogue, C. J. (1988). Legal abortion mortality and general anesthesia. *American Journal of Obstetrics & Gynecology*, 158(2), 420-424.
- Bartlett, L. A., Berg, C. J., Shulman, H. B., Zane, S. B., Green, C. A., Whitehead, S., & Atrash, H. K. (2004). Risk factors for legal induced abortion-related mortality in the United States. *Obstetrics & Gynecology*, 103, 729-739.
- Bayer, L. L., Edelman, A. B., Fu, R., Lambert, W. E., Nichols, M. D., Bednarek, P. H., ... Jensen, J. T. (2015). An evaluation of oral midazolam for anxiety and pain in first-trimester surgical abortion: A randomized controlled trial. *Obstetrics & Gynecology*, 126(1), 37-46.
- Belanger, E., Melzack, R., & Lauzon, P. (1989). Pain of first-trimester abortion: A study of psychosocial and medical predictors. *Pain*, 36(3), 339-350.
- Belloeil, V., Cazeneuve, C.T., Leclercq, A., Mercier, M.B., Legendre, G., & Corroenne, R. (2020). Impact of music therapy before first-trimester instrumental termination of pregnancy: a randomized controlled trial. *BJOG: An International Journal of Obstetrics & Gynaecology*, 127, 738-745.
- Borgatta, L., & Nickinovich, D. (1997). Pain during early abortion. *Journal of Reproductive Medicine*, 42(5), 287-293.
- Braaten, K.P., Hurwitz, S., Fortin, J., & Goldberg, A.B. (2014). Intramuscular ketorolac versus oral ibuprofen for pain relief in first-trimester surgical abortion: A randomized clinical trial. *Contraception*, 89(2), 116-121.
- Cade, L., & Ashley, J. (1993). Prophylactic paracetamol for analgesia after vaginal termination of pregnancy. *Anaesthesia and Intensive Care*, 21(1), 93.
- Cansino, C., Denny, C., Carlisle, A.S., & Stubblefield, P. (2021). Society of Family Planning clinical recommendations: Pain control in surgical abortion part 2-Moderate sedation, deep sedation, and general anesthesia. *Contraception*, 104(6), 583-592.
- Chin, J., McGrath, M., Lokken, E., Upegui, C. D., Prager, S., & Micks, E. (2022). Ketamine Compared With Fentanyl for Surgical Abortion: A Randomized Controlled Trial. *Obstetrics & Gynecology*, 140(3), 461.
- Crouthamel, B., Economou, N., Averbach, S., Rible, R., Kully, G., Meckstroth, K., & Mody, S. (2022). Effect of paracervical block volume on pain control for dilation and aspiration: A randomized controlled trial. *Obstetrics & Gynecology*, 140(2), 234-242.
- Duros, S., Joueidi, Y., Nyangoh Timoh, K., Boyer, L., Lemeut, P., Tavenard, A., ... Lavoue, V. (2018). A prospective study of the frequency of severe pain and predictive factors in women undergoing first-trimester surgical abortion under local anaesthesia. *European Journal of Obstetrics, Gynecology and Reproductive Biology*, 221, 123-128.

References continued

- Feng, X., Ye, T., Wang, Z., Chen, X., Cong, W., Chen, Y., ... Xie, W. (2016). Transcutaneous acupoint electrical stimulation pain management after surgical abortion: a cohort study. *International Journal of Surgery*, 30, 104-108.
- Free, L. L., Sheeder, J., & Cohen, R. H. (2024). Effects of aromatherapy on patient satisfaction with procedural abortion at less than 10 weeks' gestation: A randomized controlled trial. *Contraception*, 130.
- Gray, B. A., Hagey, J. M., Crabtree, D., Wynn, C., Weber, J. M., Pieper, C. F., & Haddad, L. B. (2019). Gabapentin for perioperative pain management for uterine aspiration: A randomized controlled trial. *Obstetrics and Gynecology*, 134(3), 611-619.
- Gomez, P.I., Gaitan, H., Nova, C., & Paradas, A. (2004). Paracervical block in incomplete abortion using manual vacuum aspiration: Randomized clinical trial. *Obstetrics & Gynecology*, 103 (5 pt 1), 943-51.
- Hailstorks, T.P., Cordes, S.M.D., Cwiak, C.A., Gray, B.A., Ge, L.M.A., Moore, R.H., & Haddad, L.B., (2020). Gabapentin as an adjunct to paracervical block for perioperative pain management for first-trimester uterine aspiration: a randomized controlled trial. *American Journal of Obstetrics and Gynecology*, 223, 884.e1-10.
- Hall, G., Ekblom, A., Persson, E., & Irestedt, L. (1997). Effects of prostaglandin treatment and paracervical blockade on postoperative pain in patients undergoing first trimester abortion in general anesthesia. *Acta Obstetrica et Gynecologica Scandinavica*, 76, 868-872.
- Henkel, A., Cahill, E. P., Chavez, S., Shorter, J. M., Liu, S. M., Amaya, S. I., Kaur, S., & Shaw, K. A. (2025). Transcutaneous electrical nerve stimulation (TENS) for pain control during first-trimester procedural abortion: A blinded randomized controlled trial. *Contraception*, 149.
- Horwitz, G., Roncari, D., Braaten, K. P., Maurer, R., Fortin, J., & Goldberg, A. (2018). Moderate intravenous sedation for first trimester surgical abortion: A comparison of adverse outcomes between obese and normal-weight women. *Contraception*, 97(1), 48-53.
- Kan, A. S. Y., Ng, E. H. Y., & Ho, P. C. (2004). The role and comparison of two techniques of paracervical block for pain relief during suction evacuation for first-trimester pregnancy termination. *Contraception*, 70, 159-163.
- Khazin, V., Weitzman, S., Rozenzvit-Podles, E., Ezri, T., Debby, A., Golan, A., & Evron, S. (2011). Postoperative analgesia with tramadol and indomethacin for diagnostic curettage and early termination of pregnancy. *International Journal of Obstetric Anesthesia*, 20(3), 236-239.
- Lerma, K., Goldthwaite, L.M., Blumenthal, P.D., & Shaw, K.A. (2021). Transcutaneous electrical nerve stimulation for pain management of aspiration abortion up to 83 days of gestation: A randomized controlled trial. *Obstetrics & Gynecology*, 138(3), 417-425.
- Li, C. F. I., Wong, C. Y. G., Chan, C. P. B., & Ho, P. C. (2003). A study of co-treatment of nonsteroidal anti-inflammatory drugs (NSAIDs) with misoprostol for cervical priming before suction termination of first trimester pregnancy. *Contraception*, 67, 101-105.
- Liu, W., Loo, C. C., Chiu, J. W., Tan, H. M., Ren, H. Z., & Lim, Y. (2005). Analgesic efficacy of pre-operative etoricoxib for termination of pregnancy in an ambulatory centre. *Singapore Medical Journal*, 46(8), 397-400.
- Lowenstein, L., Granot, M., Tamir, A., Glik, A., Deutsch, M., Jakobi, P., & Zimmer, E. Z. (2006). Efficacy of suppository analgesia in postabortion pain reduction. *Contraception*, 74(4), 345-348.
- Oviedo, J. D., Ohly, N. T., Guerrero, J. M., & Castano, P. M. (2018). Factors associated with participant and provider pain rating during office-based first-trimester vacuum aspiration. *Contraception*, 97(6), 497-499.
- Micks, E. A., Edelman, A. B., Renner, R. M., Fu, R., Lambert, W. E., Bednarek, P. H., ... Jensen, J. T. (2012). Hydrocodone-acetaminophen for pain control in first-trimester surgical abortion: A randomized controlled trial. *Obstetrics & Gynecology*, 120(5), 1060-1069.
- Moayed, G., Stevens, K., Fontanilla, T., Tschann, M., Bednarek, P.H., Salcedo, J., Kaneshiro, B. & Soon, R. (2022). Intranasal fentanyl for first-trimester uterine aspiration pain: A randomized controlled trial. *Contraception*, 113, 101-107.
- Ndubisi, C., Danvers, A., Gold, M. A., Morrow, L., & Westhoff, C. L. (2018). Auricular acupuncture as an adjunct for pain management during first trimester abortion: A randomized, double-blinded, three arm trial. *Contraception*, 99(3), 143-147.
- Oviedo, J.D., Marquez, E., Gold, M.A., & Westhoff, C.L. (2021). Auricular acupressure and auricular acupuncture as an adjunct for pain management during first trimester aspiration abortion: A randomized, double-blinded, three-arm trial. *Contraception* 103(5), 342-347.

References continued

- Qian, J., Sun, S., Wang, M., & Yu, X. (2023). Nonpharmacological pain management interventions in medical and surgical abortion: A scoping review. *International Journal of Nursing Practice*, 29(2), e13056.
- Rawling, M. J., & Wiebe, E. R. (2001). A randomized controlled trial of fentanyl for abortion pain. *American Journal of Obstetrics & Gynecology*, 185, 103-107.
- Renner, R.M., Jensen, J.T., Nichols, M.D., & Edelman, A.B. (2010). Pain control in first-trimester surgical abortion: A systematic review of randomized controlled trials. *Contraception*, 81, 372-388.
- Renner, R.-M., Ennis, M., McKercher, A. E., Henderson, J. T., & Edelman, A. (2024). Local anaesthesia for pain control in first trimester surgical abortion. *The Cochrane Database of Systematic Reviews*, 2024(2), CD006712.
- Roche, N. E., Li, D., James, D., Fechner, A., & Tilak, V. (2012). The effect of perioperative ketorolac on pain control in pregnancy termination. *Contraception*, 85(3), 299-303.
- Romero, I., Turok, D., & Gilliam, M. (2008). A randomized trial of tramadol versus ibuprofen as an adjunct to pain control during vacuum aspiration abortion. *Contraception*, 77(1), 56-59.
- Royal College of Obstetricians and Gynaecologists. (2022). Best practice in abortion care. London: Royal College of Obstetricians and Gynaecologists.
- Sarker, R. R., Begum, S. A., Mahmud, T., Sultana, Z., Parvin, P. A., Faruq, M., & Khanom, A. (2024). Comparative Study between Paracervical Block and Non-Steroidal Anti Inflammatory Drug for Relief of Pain during Manual Vacuum Aspiration Procedure. *Mymensingh Medical Journal: MMJ*, 33(2), 440-445.
- Singh, R. H., Ghanem, K. G., Burke, A. E., Nichols, M. D., Rogers, K., & Blumenthal, P. D. (2008). Predictors and perception of pain in women undergoing first trimester surgical abortion. *Contraception*, 78(2), 155-161.
- Suprpto, K., & Reed, S. (1984). Naproxen sodium for pain relief in first-trimester abortion. *American Journal of Obstetrics & Gynecology*, 150(8), 1000-1001.
- Tschann, M., Salcedo, J., & Kaneshiro, B. (2016). Nonpharmacological pain control adjuncts during first-trimester aspiration abortion: A review. *Journal of Midwifery Women's Health*, 61(3), 331-338.
- Tschann, M., Salcedo, J., Soon, R., & Kaneshiro, B. (2018). Patient choice of adjunctive nonpharmacologic pain management during first-trimester abortion: A randomized controlled trial. *Contraception*, 98(3), 205-209.
- Wang, Z., Chen, Y., Chen, C., Zhao, L., Chen, P., Zeng, L., & Xie, W. (2018). Pain management of surgical abortion using transcutaneous acupoint electrical stimulation: An orthogonal prospective study. *Journal of Obstetrics and Gynaecology Research*, 44(7), 1235-1242.
- Warriner, I. K., Meirik, O., Hoffman, M., Morroni, C., Harries, J., My Huong, N. T., & Seuc, A. H. (2006). Rates of complication in first-trimester manual vacuum aspiration abortion done by doctors and midlevel providers in South Africa and Vietnam: A randomised controlled equivalence trial. *The Lancet*, 368(9551), 1965-1972.
- Wells, N. (1992). Reducing distress during abortion: A test of sensory information. *Journal of Advanced Nursing*, 17, 1050-1056.
- Wiebe, E., Podhradsky, L., & Diyak, V. (2003). The effect of lorazepam on pain and anxiety in abortion. *Contraception*, 67(3), 219-221.
- Wiebe, E. R., & Rawling, M. (1995). Pain control in abortion. *International Journal of Gynecology & Obstetrics*, 50(1), 41-46.
- Wilson, S. F., Gurney, E. P., Sammel, M. D., & Schreiber, C. A. (2016). Doulas for surgical management of miscarriage and abortion: a randomized controlled trial. *American Journal of Obstetrics & Gynecology*, 216(1), 44.e1-44.e6.
- Wong, C. Y., Ng, E. H., Ngai, S. W., & Ho, P. C. (2002). A randomized, double blind, placebo-controlled study to investigate the use of conscious sedation in conjunction with paracervical block for reducing pain in termination of first trimester pregnancy by suction evacuation. *Human Reproduction*, 17(5), 1222-1225.
- World Health Organization. (2024). *Abortion care guideline, 2nd ed.* Geneva: World Health Organization
- Zhu, X., He, X., Fan, B., Liu, J., Wu, S., Wang, H., & Chen, C. (2022). Effect of propofol intravenous anesthesia combined with press-needle therapy on analgesic effect during painless abortion. *Computational and mathematical methods in medicine*, 6543211.

2.4

2. Pain management

Pain management for dilatation and evacuation

Recommendation:

- A combination of paracervical block, nonsteroidal anti-inflammatory drugs (NSAIDs) and narcotic analgesics, with or without anxiolytics, is recommended.
- Intravenous sedation, where available, should be offered.
- The increased risks of general anesthesia must be weighed against the benefits.

Strength of recommendation:

Strong

Quality of evidence:

Very Low

Last reviewed:

October 2, 2025

Pain during dilatation and evacuation

A longer duration of pregnancy at the time of abortion is associated with higher reported pain scores during dilatation and evacuation (D&E) (Dzuba et al., 2022). At later gestations, D&E requires more preoperative and operative cervical dilation, longer procedure times and deeper uterine manipulation.

Methods of pain management

Comparative studies of pain management during D&E are largely lacking. Existing studies examine pain management during osmotic dilator placement before a D&E, the effect of adjuvant medications on post-procedure pain amongst people receiving general anesthesia or deep intravenous sedation, or focus instead on safety of pain management strategies during D&E. International consensus statements generally focus on the minimum amount of anesthesia at which a D&E can be performed to ensure access at lower-level facilities (Royal College of Obstetricians and Gynaecologists [RCOG], 2022; World Health Organization [WHO], 2024).

Local anesthesia

See section 2.5 Paracervical block.

Medications

No studies assess the effectiveness of oral, intramuscular or intravenous pain medications during the D&E procedure. One study found that participants who received the intravenous NSAID ketorolac in combination with deep intravenous sedation or general anesthesia during their D&E procedure reported significantly lower pain post-procedure than those who did not receive the medication (Liu & Flink-Bochacki, 2021). These data must be interpreted with caution as the study was not designed to address this comparison, however, studies of vacuum aspiration have consistently found that pre-procedure administration of oral or intramuscular NSAIDs decreases pain during and after the procedure (Braaten et al., 2013; Renner et al., 2010; Romero, Turok, & Gilliam, 2008; Suprpto & Reed, 1984; Wiebe & Rawling, 1995).

Intravenous sedation

Only one randomized trial has assessed the effectiveness of intravenous moderate sedation during D&E, finding that moderate sedation with fentanyl and midazolam was significantly more effective than inhaled nitrous oxide for pain management in women between 12-16 gestational weeks who also received preprocedure ibuprofen and paracervical block (Thaxton et al., 2018). Additional data from studies of vacuum aspiration have found that intravenous sedation using a combination of narcotics and anxiolytics is an effective means of pain control and improves satisfaction with the abortion procedure (Allen et al., 2009; Allen et al., 2006; Wells, 1992; Wong et al., 2002). Studies that have assessed safety of intravenous sedation with fentanyl and midazolam in combination with paracervical block during D&E have found rates of major procedure-related complications of less than 1% (Racek, Chen, & Creinin, 2010), and no additional anesthesia-related adverse events (Gokhale et al., 2016; Wilson, Chen, & Creinin, 2009; Wiebe et al., 2013). One study randomized 126 participants receiving fentanyl and midazolam for D&E between 14 and 19 weeks gestation to additional treatment with either gabapentin or placebo. The study found no difference in maximum recalled pain between the two groups, however gabapentin recipients experienced less intraoperative pain and reported higher satisfaction (Brant et al., 2022). Intravenous deep sedation with propofol and without intubation is safe and has few complications in the outpatient setting, without risk of pulmonary aspiration (Aksel et al., 2018; Dean et al., 2011; Gokhale et al., 2016; Mancuso et al., 2017).

Providing intravenous sedation increases the expense, complexity and potential risks of an abortion procedure, and it requires a trained provider with equipment for patient monitoring (Cansino et al., 2021). The increased monitoring necessary to deliver intravenous sedation safely requires facility investments in personnel, training and equipment. For further information regarding the definition of levels of sedation, including general anesthesia, see Appendix B: Continuum of depth of sedation: Definition of general anesthesia and levels of sedation/analgesia.

Intravenous sedation

Although effective for pain control during the procedure, general anesthesia increases the expense, complexity and potential risks associated with abortion and is not recommended for routine procedures (Atrash, Cheek, & Hogue, 1988; Bartlett et al., 2004; MacKay, Schulz, & Grimes, 1985; RCOG, 2022; WHO, 2024). For further information regarding the definition of levels of sedation, including general anesthesia, see Appendix B: Continuum of depth of sedation: Definition of general anesthesia and levels of sedation/analgesia.

Non-pharmacologic pain management

Pain medications and paracervical block should be supplemented with supportive techniques to decrease pain and anxiety. Helpful approaches may include educating the patient about what to expect during the procedure; conducting the procedure in a clean and private setting with supportive staff; providing verbal support; using gentle and efficient technique; and applying a heating pad or hot water bottle to the lower abdomen in the recovery room (Akin et al., 2001).

Resources

www.ipas.org/ClinicalResources

Pain Medication Table

Continuum of depth of sedation: Definition of general anesthesia and levels of sedation/analgesia



References

- Akin, M. D., Weingard, K. W., Henghold, D. A., Goodale, M. B., Hinkle, R. T., & Smith, R. P. (2001). Continuous low-level topical heat in the treatment of dysmenorrhea. *Obstetrics & Gynecology*, 97, 343-349.
- Aksel, S., Lang, L., Steinauer, J. E., Drey, E. A., Lederle, L., Sokoloff, A., & Carlisle, A. S. (2018). Safety of Deep Sedation Without Intubation for Second-Trimester Dilation and Evacuation. *Obstetrics & Gynecology*, 132(1), 171-178.
- Allen, R.H., Fitzmaurice, G., Lifford, K. L., Lasic, M., & Goldberg, A. (2009). Oral compared with intravenous sedation for first-trimester surgical abortion: A randomized controlled trial. *Obstetrics & Gynecology*, 113(2Pt1), 276-283.
- Allen, R. H., Kumar, D., Fitzmaurice, G., Lifford, K. L., & Goldberg, A. B. (2006). Pain management of first-trimester surgical abortion: Effects of selection of local anesthesia with and without lorazepam or intravenous sedation. *Contraception*, 74(5), 407-413.
- Altman, A. M., Stubblefield, P. G., Schlam, J. F., Loberfeld, R., & Osathanondh, R. (1985). Midtrimester abortion with laminaria and vacuum evacuation on a teaching service. *The Journal of Reproductive Medicine*, 30(8), 601-606.
- Atrash, H., Cheek, T., & Hogue, C. (1988). Legal abortion mortality and general anesthesia. *American Journal of Obstetrics & Gynecology*, 158(2), 420.
- Bartlett, L. A., Berg, C. J., Shulman, H. B., Zane, S. B., Green, C. A., Whitehead, S., & Atrash, H. K. (2004). Risk factors for legal induced abortion-related mortality in the United States. *Obstetrics & Gynecology*, 103, 729-739.
- Braaten, K.P., Hurwitz, S., Fortin, J., & Goldberg, A.B. (2014). Intramuscular ketorolac versus oral ibuprofen for pain relief in first-trimester surgical abortion: A randomized clinical trial. *Contraception*, 89(2), 116-121.
- Brant, A. R., Reeves, M. F., Ye, P. P., Scott, R. K., Floyd, S., Tefera, E., & Lotke, P. S. (2023). Gabapentin as an adjunct for pain management during dilation and evacuation: A double-blind randomized controlled trial. *Contraception*, 118.
- Cansino, C., Denny, C., Carlisle, A.S., & Stubblefield, P. (2021). Society of Family Planning clinical recommendations: Pain control in surgical abortion part 2-Moderate sedation, deep sedation, and general anesthesia. *Contraception*, 104(6), 583-592.
- Castleman, L. D., Oanh, K. T. H., Hyman, A. G., Thuy, L. T., & Blumenthal, P. D. (2006). Introduction of the dilation and evacuation procedure for second-trimester abortion in Vietnam using manual vacuum aspiration and buccal misoprostol. *Contraception*, 74, 272-276.
- Dean, G., Jacobs, A. R., Goldstein, R. C., Gevirtz, C. M., & Paul, M. E. (2011). The safety of deep sedation without intubation for abortion in the outpatient setting. *Journal of Clinical Anesthesia*, 23437-442.
- Dzuba, I.G., Chandrasekaran, S., Fix, L., Blanchard, K., & King, E. (2022). Pain, side effects, and abortion experience among people seeking abortion care in the second trimester. *Women's Health Reports*, 3.1, 533-542.
- Edelman, A., & Kapp, N. (2017). Dilatation and evacuation (D&E) reference guide: *Induced abortion and postabortion care at or after 13 weeks gestation*. Chapel Hill, NC: Ipas.
- Gokhale, P., Lappen, J. R., Waters, J. H., & Perriera, L. K. (2016). Intravenous Sedation Without Intubation and the Risk of Anesthesia Complications for Obese and Non-Obese Women Undergoing Surgical Abortion: A Retrospective Cohort Study. *Anesthesia and Analgesia*, 122(6), 1957-1962.
- Jacot, F. R. M., Poulin, C., Bilodeau, A. P., Morin, M., Moreau, S., Gendron, F., & Mercier, D. (1993). A five-year experience with second-trimester induced abortions: No increase in complication rate as compared to the first trimester. *American Journal of Obstetrics & Gynecology*, 168(2), 633-637.
- Jackson, E., & Kapp, N. (2020). Pain management for medical and surgical termination of pregnancy between 13 and 24 weeks of gestation: a systematic review. *BJOG: An International Journal of Obstetrics & Gynaecology*, 127,1348-1357.
- Liu, S.M, & Flink-Bochacki, R. (2021). A single-blinded randomized controlled trial evaluating pain and opioid use after dilator placement for second-trimester abortion. *Contraception*, 103(3), 171-177 .
- MacKay, H. T., Schulz, K. F., & Grimes, D. A. (1985). Safety of local versus general anesthesia for second-trimester dilatation and evacuation abortion. *Obstetrics & Gynecology*, 66, 661-665.
- Mancuso, A. C., Lee, K., Zhang, R., Hoover, E. A., Stockdale, C., & Hardy-Fairbanks, A. J. (2017). Deep sedation without intubation during second trimester surgical termination in an inpatient hospital setting. *Contraception*, 95, 288-291.

References continued

- Racek, C. M., Chen, B. A., & Creinin, M. D. (2010). Complication rates and utility of intravenous access for surgical abortion procedures from 12 to 18 weeks of gestation. *Contraception*, 82, 286-290.
- Renner, R.M., Jensen, J.T., Nichols, M.D., & Edelman, A.B. (2010). Pain control in first-trimester surgical abortion: A systematic review of randomized controlled trials. *Contraception*, 81, 372-388.
- Romero, I., Turok, D., & Gilliam, M. (2008). A randomized trial of tramadol versus ibuprofen as an adjunct to pain control during vacuum aspiration abortion. *Contraception*, 77(1), 56-59.
- Royal College of Obstetricians and Gynaecologists. (2022). *Best practice in abortion care*. London: Royal College of Obstetricians and Gynaecologists.
- Siddiqui, K. M., & Chohan, U. (2007). Tramadol versus nalbuphine in total intravenous anaesthesia for dilatation and evacuation. *Journal of the Pakistani Medical Association*, 57(2), 67-70.
- Suprpto, K., & Reed, S. (1984). Naproxen sodium for pain relief in first-trimester abortion. *American Journal of Obstetrics & Gynecology*, 150(8), 1000-1001.
- Thaxton, L., Pitotti, J., Espey, E., Teal, S., Sheeder, J., & Singh, R.H. (2018). Nitrous oxide compared with intravenous sedation for second-trimester abortion: a randomized controlled trial. *Obstetrics & Gynecology*, 132, 1182-7.
- Wells, N. (1992). Reducing distress during abortion: A test of sensory information. *Journal of Advanced Nursing*, 17, 1050-1056.
- Wiebe, E. R., Byczko, B., Kaczorowski, J., & McLane, A. L. (2013). Can we safely avoid fasting before abortions with low-dose procedural sedation? A retrospective cohort chart review of anesthesia-related complications in 47,748 abortions. *Contraception*, 87, 51-54.
- Wiebe, E. R., & Rawling, M. (1995). Pain control in abortion. *International Journal of Gynecology & Obstetrics*, 50(1), 41-46.
- Wilson, L. C., Chen, B. A., & Creinin, M. D. (2009). Low-dose fentanyl and midazolam in outpatient surgical abortion up to 18 weeks of gestation. *Contraception*, 79, 122-128.
- Wong, C. Y., Ng, E. H., Ngai, S. W., & Ho, P. C. (2002). A randomized, double blind, placebo-controlled study to investigate the use of conscious sedation in conjunction with paracervical block for reducing pain in termination of first trimester pregnancy by suction evacuation. *Human Reproduction*, 17(5), 1222-1225.
- World Health Organization. (2024). *Abortion care guideline, 2nd ed*. Geneva: World Health Organization.

Paracervical block

Recommendation:

- Paracervical block with local anesthetic is an effective method of pain management and should be a part of all vacuum aspiration, osmotic dilator placement and dilatation and evacuation (D&E) procedures.
- Many types of health care workers—including associate and advanced associate clinicians, nurses, midwives, traditional and complementary medicine professionals, auxiliary nurses and auxiliary nurse midwives—can safely and effectively provide paracervical anesthesia.
- Paracervical block is not effective for managing pain associated with fetal expulsion during medical abortion at or after 13 weeks gestation.
- A paracervical block composed of 20mL of 1% lidocaine, injected to a depth of 3cm is recommended. If 1% lidocaine is unavailable, 10mL of 2% lidocaine may be substituted, although evidence supporting the use of 2% lidocaine is sparse. Either a two-point or a four-point paracervical injection technique should be used.

In practice:

- Paracervical block should be used for uterine evacuation procedures performed for both induced abortion and postabortion care.

Strength of recommendation:

Strong

Quality of evidence:

High

Last reviewed:

October 2, 2025

Local anesthesia for pain management

A longer duration of pregnancy at the time of abortion is associated with higher reported pain scores during dilatation and evacuation (D&E) (Dzuba et al., 2022). At later gestations, D&E requires more preoperative and operative cervical dilation, longer procedure times and deeper uterine manipulation.

Methods of pain management

Vacuum aspiration

A 2024 systematic review evaluating paracervical block for abortion procedures found that paracervical block reduced pain during cervical dilation and uterine aspiration, although not post-procedure pain, when compared to placebo or no anesthesia (Renner et al., 2024). In the highest-quality study available on the use of paracervical block during vacuum aspiration, 120 women undergoing abortion before 11 weeks gestation were randomized to receive either a paracervical block—containing 20mL of 1% lidocaine buffered with sodium bicarbonate and injected to a depth of three centimeters at four paracervical points—or a sham injection where a capped needle was touched to the cervicovaginal junction to mimic administration of paracervical

block. Participants who received the paracervical block had less pain during dilation and aspiration compared to those who received the sham injection (Renner et al., 2012). Deeper injection of anesthetic (3cm) improves pain management compared to superficial (1.5cm) injection (Cetin, & Cetin, 1997; Renner et al., 2010). A subsequent randomized controlled trial found the addition of sodium bicarbonate (1mL of 8.4% sodium bicarbonate for every 10mL of anesthetic solution) to a paracervical block containing 1% lidocaine did not decrease pain scores at the time of injection or at cervical dilation when compared to lidocaine only (Chin et al., 2020). It is unclear whether a four-point injection technique is superior to a two-point injection technique. In one randomized trial, a four-point technique was superior to a two-point technique, however differences in pain were small (Renner et al., 2016). In a different randomized trial, no differences in pain were found between two- and four-point techniques (Glantz & Shomento, 2001). A waiting period between injection and cervical dilation is not necessary, as it does not improve pain control (Phair, Jensen, & Nichols, 2002; Renner et al., 2016; Wiebe & Rawling, 1995).

It is unclear if the volume of anesthetic administered influences pain relief; a randomized trial including 114 people having uterine aspiration found no difference in reported pain when people received a 40mL 0.5% lidocaine or a 20mL 1% lidocaine paracervical block (Crouthamel et al., 2022), while two observational studies with significant confounders showed that people who received a 20mL block reported lower pain scores than those who received a 10mL block (Allen et al. 2006; Wiebe, 1992). Providers should avoid inadvertent intravascular injection to limit potential dose-related lidocaine toxicity (Lau et al., 1999), and may prefer a two-point injection technique when using a smaller volume of anesthetic.

For people receiving deep sedation for pain management, it is unclear if there is additional benefit to administering paracervical block (Kan, Ng, & Ho, 2004; Renner et al., 2010; Wells, 1992; Wong et al., 2002). When using general anesthesia, there is no additional benefit to administering paracervical block (Hall et al., 1997; Renner et al., 2010).

Dilatation and evacuation

No studies have evaluated paracervical block for pain management during D&E procedures without concomitant sedation or anesthesia. One randomized trial has examined paracervical block use during D&E when women also received deep sedation or general anesthesia; the addition of paracervical block did not improve postoperative pain (Lazenby, Fogelson, & Aeby, 2009). The recommendation to perform paracervical block for D&E has been extrapolated from data from vacuum aspiration studies and two randomized controlled trials assessing pain control during osmotic dilator placement before a D&E. One included 41 people and found significantly decreased pain during osmotic dilator placement when paracervical block was used (Soon et al., 2017). The other trial included 91 people and found that a smaller volume of anesthetic (12mL of 1% lidocaine) was noninferior to a larger volume (20mL of 1% lidocaine) in managing pain related to osmotic dilator placement (Shaw et al., 2021).

Medical abortion

No studies evaluate use of paracervical block for pain management during medical abortion before 13 weeks gestation. Two studies examining use of paracervical block during medical abortion at or after 13 weeks found no improvement in pain (Andersson et al., 2016; Winkler et al., 1997).

Who can perform paracervical block

The World Health Organization (WHO) makes service delivery recommendations for the provision of uterine aspiration, which includes routine administration of paracervical block (WHO, 2024). Health workers with the skills to perform a transcervical procedure, and a bimanual pelvic examination to diagnose pregnancy and determine gestational age based on uterine size, can be trained to provide vacuum aspiration with paracervical block. WHO advises that uterine aspiration is within the scope of practice for specialty and general medical practitioners; and recommends the provision of vacuum aspiration by associate and advanced associate clinicians, midwives, and nurses based on moderate certainty evidence of safety and effectiveness. Traditional and complementary medical professionals are recommended to provide uterine aspiration based on low certainty evidence of safety and effectiveness, and WHO suggests that auxiliary nurses and auxiliary nurse midwives

may be able to perform aspiration in settings where they provide basic emergency obstetric care (WHO, 2024). For more information about who can perform specific tasks related to abortion care, see Appendix C: World Health Organization recommendations for health worker roles in abortion care.

Technique

More information on paracervical block technique can be found in the Paracervical block technique job aid, linked opposite.

References

Allen, R. H., Kumar, D., Fitzmaurice, G., Lifford, K. L., & Goldberg, A. B. (2006). Pain management of first-trimester surgical abortion: Effects of selection of local anesthesia with and without lorazepam or intravenous sedation. *Contraception*, 74(5), 407-413.

Andersson, I. M., Benson, L., Christensson, K., & Gemzell-Danielsson, K. (2016). Paracervical block as pain treatment during second-trimester medical termination of pregnancy: An RCT with bupivacaine versus sodium chloride. *Human Reproduction*, 31(1), 67-74.

Cetin, A., & Cetin, M. (1997). Effect of deep injections on local anesthetics and basal dilatation of cervix in management of pain during legal abortions. A randomized, controlled study. *Contraception*, 56, 85-87.

Chin, J., Kaneshiro, B., Elia, J., Raidoo, S., Savala, M. & Soon R. (2020). Buffered lidocaine for paracervical blocks in first-trimester abortions: a randomized controlled trial. *Contraception X*, 18(2), 100044.

Crouthamel, B., Economou, N., Averbach, S., Rible, R., Kully, G., Meckstroth, K., & Mody, S. (2022). Effect of paracervical block volume on pain control for dilation and aspiration: A randomized controlled trial. *Obstetrics & Gynecology*, 140(2), 234-242.

Glantz, J. C., & Shomento, S. (2001). Comparison of paracervical block techniques during first trimester pregnancy termination. *International Journal of Gynecology & Obstetrics*, 72, 171-8.

Hall, G., Ekblom, A., Persson, E., & Irestedt, L. (1997). Effects of prostaglandin treatment and paracervical blockade on postoperative pain in patients undergoing first trimester abortion in general anesthesia. *Acta Obstetrica et Gynecologica Scandinavica*, 76, 868-872.

Resources

www.ipas.org/ClinicalResources

Pain Medication Table

Continuum of depth of sedation: Definition of general anesthesia and levels of sedation/analgesia

Paracervical Block Technique Job Aid

Abortion Care Videos—*Ipas: How to do a Paracervical Block*



Kan, A. S., Ng E. H., & Ho, P. C. (2004). The role and comparison of two techniques of paracervical block for pain relief during suction evacuation for first-trimester pregnancy termination. *Contraception*, 70, 159-163.

Lau, W. C., Lo, W. K., Tam, W. H., & Yuen, P. M. (1999). Paracervical anesthesia in outpatient hysteroscopy: A randomized double-blind placebo-controlled trial. *BJOG: An International Journal of Obstetrics & Gynaecology*, 106(4), 356-9.

Lazenby, G. B., Fogelson, N. S., & Aeby, T. (2009). Impact of paracervical block on postabortion pain in patients undergoing abortion under general anesthesia. *Contraception*, 80(6), 578-582.

O'Connell, K., Jones, H. E., Simon, M., Saporta, V., Paul, M., & Lichtenberg, E. S. (2009). First-trimester surgical abortion practices: A survey of National Abortion Federation members. *Contraception*, 79: 385-392.

Phair, N., Jensen, J. T., & Nichols, M. (2002). Paracervical block and elective abortion: The effect on pain of waiting between injection and procedure. *American Journal of Obstetrics & Gynecology*, 186, 1304-1307.

Renner, R.M., Jensen, J.T., Nichols, M.D., & Edelman, A. (2010). Pain control in first trimester surgical abortion: A systematic review of randomized controlled trials. *Contraception*, 81, 372-388.

Renner, R. M., Nichols, M. D., Jensen, J. T., Li, H., & Edelman, A. B. (2012). Paracervical block for pain control in first-trimester surgical abortion: A randomized controlled trial. *Obstetrics & Gynecology*, 119(5), 1030-1037.

References continued

Renner, R. M., Edelman, A. B., Nichols, M. D., Jensen, J. T., Lim J. Y., & Bednarek, P. H. (2016). Refining paracervical block techniques for pain control in first trimester surgical abortion: A randomized controlled noninferiority trial. *Contraception*, 95(5), 461-466.

Renner, R.-M., Ennis, M., McKercher, A. E., Henderson, J.T., & Edelman, A. (2024). Local anaesthesia for pain control in first trimester surgical abortion. *The Cochrane Database of Systematic Reviews*, 2024(2), CD006712.

Shaw, K.A., Lerma, K., Hughes, T., Hastings, C., Fok, W.K., & Blumenthal, P.D. (2021). A comparison of paracervical block volumes before osmotic dilator placement: A randomized controlled trial. *Obstetrics & Gynecology*, 138(3), 443-448.

Soon, R., Tschann, M., Salcedo, J., Stevens, K., Ahn, H. J., & Kaneshiro, B. (2017). Paracervical block for laminaria insertion before second-trimester abortion: A randomized controlled trial. *Obstetrics & Gynecology*, 130, 387-392.

Wiebe, E. R. (1992). Comparison of the efficacy of different local anesthetics and techniques of local anesthesia in therapeutic abortion. *American Journal of Obstetrics & Gynecology*, 167, 131-4.

Winkler, M., Wolters, S., Funk, A., & Rath, W. (1997). Second trimester abortion with vaginal gemeprost-improvement by paracervical anesthesia? *Zentralblatt fur Gynakologie*, 119, 621-624.

Wells, N. (1992). Reducing distress during abortion: A test of sensory information. *Journal of Advanced Nursing*, 17(9), 1050-1056.

Wong, C. Y., Ng, E. H., Ngai, S. W., & Ho, P. C. (2002). A randomized, double-blind, placebo-controlled study to investigate the use of conscious sedation in conjunction with paracervical block for reducing pain in termination of first trimester pregnancy by suction evacuation. *Human Reproduction*, 17, 1222-1225.

World Health Organization. (2024). *Abortion care guideline, 2nd ed.* Geneva: World Health Organization.

3.1

3. Recommendations for abortion before 13 weeks gestation

Adolescents: Safety and effectiveness

Recommendation:

- Vacuum aspiration and medical abortion are safe and effective for adolescents and should be offered as methods of induced abortion.
- Cervical preparation before vacuum aspiration should be considered for adolescents.
- Adolescents should be able to access safe abortion services without delay.

Strength of recommendation:

Strong

Quality of evidence:

Moderate

Last reviewed:

October 6, 2025

Adolescents and abortion

The World Health Organization (WHO) defines adolescents as individuals 10-19 years of age, and young people as 20-24 years of age. Adolescents face barriers to accessing safe abortion care and present for abortions at later gestational ages than adults (Jatlaoui et al., 2017; Sowmini, 2013). Adolescents are at increased risk of complications of unsafe abortion due to delays in seeking and receiving care, seeking care from unskilled providers and not accessing services when complications arise (Espinoza, Samandari, & Andersen, 2020; Fatusi et al., 2021; Keogh et al., 2021; Olukoya et al., 2001). The Guttmacher Institute estimates that in 2019, 5.7 million adolescents aged 15-19 living in low- and middle-income countries experienced pregnancies that ended in abortion, the majority of which were unsafe (Sully et al., 2020). Decreasing barriers to abortion services may particularly benefit adolescents and young people.

When adolescents receive safe abortion services, they experience fewer complications than do older people. In a large United States-based retrospective cohort study which captured all complications within six weeks of 54,911 surgical and medical abortions, adolescents experienced the lowest rate of abortion-related complications—1.5%—of any age group (Upadhyay et al., 2015). Results were not stratified by method of uterine evacuation, trimester or type of complication.

Vacuum aspiration

Effectiveness

Success rates for vacuum aspiration have not been disaggregated by age. In studies reporting data for adolescent and older women together, rates of incomplete and failed abortion were less than 1% (Upadhyay et al., 2015; Warriner et al., 2006; Weitz et al., 2013). A 2014 systematic review, which included 25 randomized and observational trials documenting abortion care for adolescent and young people concluded that abortion,

including vacuum aspiration, is safe and effective although specific effectiveness rates were not reported (Renner, de Guzman, & Brahmi, 2014).

Safety

A large, prospective, United States multi-center cohort study of 164,000 women undergoing legal abortion, 50,000 of whom were adolescents, found that mortality and major morbidity were lower in adolescents compared to older women (Cates Jr., Schulz, & Grimes, 1983). The mortality rate was 1.3 per 100,000 in women under 20 years old compared to 2.2 per 100,000 in women age 20 and older. Serious adverse events including major surgery, hemorrhage requiring transfusion, and uterine perforation were less common in those under age 20. However, age of 17 years or younger was associated with higher rates of cervical injury, even after controlling for nulliparity (5.5 per 1000 compared to 1.7 per 1000 in women aged 30 years and older, relative risk 1.9, 95% CI 1.2, 2.9) (Cates et al., 1983; Renner et al., 2014; Schulz, Grimes, & Cates, 1983). To reduce this risk, cervical preparation before vacuum aspiration should be considered for adolescents (Allen & Goldberg, 2016; WHO, 2024).

Acceptability

Age-stratified data on acceptability of vacuum aspiration among adolescents are lacking (Renner et al., 2014).

Medical abortion

Effectiveness

Clinical trials and cohort studies have shown that young women have similar (Haimov-Kochman et al., 2007; Heikinheimo, Leminen, & Suhonen, 2007) or increased (Niinimäki et al., 2011; Shannon et al., 2006) success rates when using mifepristone and misoprostol for medical abortion compared to older women. A large Finnish population-based retrospective cohort study that compared 3,024 adolescents to 24,006 adult women up to 20 weeks gestational age found the risk of surgical evacuation following medical abortion was significantly lower in adolescents (Niinimäki et al., 2011).

In a prospective cohort that included young women, the success rate of misoprostol-only medical abortion was the same for young and older women (Bugalho et al., 1996). Two prospective cohort studies of misoprostol-only abortion have enrolled only adolescents; efficacy in both studies was equivalent to that reported in trials of adult women (Carbonell et al., 2001; Velazco et al., 2000).

Safety

The Finnish population-based retrospective cohort study referenced above found that complication rates after medical abortion among adolescents were similar to or lower than those of older women, even when controlling for nulliparity. In this study, adolescents had a significantly lower incidence of hemorrhage, incomplete abortion, and need for surgical evacuation. Postabortion infection occurred at similar rates among adolescents and older women, despite adolescents' higher rates of chlamydia infection in the population (Niinimäki, et al., 2011). In studies of misoprostol-only medical abortion that include adolescents, adolescents do not experience higher rates of adverse outcomes than adult women (Carbonell et al., 2001; Velazco et al., 2000).

Acceptability

A Finnish study compared the pain experience of 56 adolescents undergoing medical abortion to that of 76 adult women, finding that the pain experienced in both groups was similar, and that more than half of all participants experienced severe pain (Kemppainen et al., 2020). Despite this, satisfaction with care was high in both the adolescent and adult groups, with 90% of participants stating they would choose medical abortion again. In one small, non-comparative study of 28 adolescents aged 14-17 using mifepristone and misoprostol medical abortion, 96% found medical abortion acceptable and 79% reported satisfaction with the procedure by four weeks of follow-up (Phelps, Schaff, & Fielding, 2001).

Subsequent perinatal outcomes

Three studies have examined perinatal outcomes in pregnancies in adolescent and young women who have had a previous abortion—a United States-based retrospective cohort study comparing 654 nulliparous adolescent deliveries to 102 adolescent deliveries with a prior abortion (van Veen, Haeri, & Baker, 2015), a German retrospective cohort including 7,845 nulliparous adolescent deliveries and 211 adolescent deliveries with one prior induced abortion (Reime, Schucking, & Wenzlaff, 2008) and a Hong Kong case-control study comparing 118 adolescent deliveries with one or more prior abortions to 118 age- and parity-matched controls (Lao & Ho, 1998). The American and Hong Kong studies found no difference in adverse perinatal outcomes between study groups. After adjusting for confounding factors, the German study found an increased risk of very low birth-weight infants among adolescents who had a previous abortion. Method of abortion and whether preoperative cervical preparation was undertaken was not specified in any of these studies.

References

- Allen, R., & Goldberg, A. (2016). Society of Family Planning Clinical Guideline 20071: Cervical dilation before first trimester surgical abortion (< 14 weeks gestation). *Contraception*, 93(4), 277-291.
- Bugalho, A., Faundes, A., Jamisse, L., Usfa, M., Maria, E., & Bique, C. (1996). Evaluation of the effectiveness of vaginal misoprostol to induce first trimester abortion. *Contraception*, 53(4), 243-246.
- Cates Jr, W., Schulz, K. F., & Grimes, D. A. (1983). The risks associated with teenage abortion. *New England Journal of Medicine*, 309(11), 621-624.
- Carbonell, J. L., Velazco, A., Varela, L., Tanda, R., Sanchez, C., Barambio, S., & Mari, J. (2001). Misoprostol for abortion at 9-12 weeks' gestation in adolescents. *The European Journal of Contraception and Reproductive Health Care*, 6(1), 39-45.
- Espinoza, C., Samandari, G., & Andersen, K. (2020). Abortion knowledge, attitudes and experiences among adolescent girls: A review of the literature. *Sexual and Reproductive Health Matters*, 28(1), 175-195.
- Fatusi, A., Riley, T., Kayembe, P.K., & Mabika, C. (2021). Unintended pregnancy, induced abortion and abortion care-seeking experiences among adolescents in Kinshasa, Democratic Republic of Congo: A cross-sectional review. *BMJ Open*, 11(9), e044682.
- Haimov-Kochman, R., Arbel, R., Sciaky-Tamir, Y., Brzezinski, A., Laufer, N., & Yagel, S. (2007). Risk factors for unsuccessful medical abortion with mifepristone and misoprostol. *Acta Obstetrica et Gynecologica Scandinavica*, 86(4), 462-466.
- Heikinheimo, O., Leminen, R., & Suhonen, S. (2007). Termination of early pregnancy using flexible, low-dose mifepristone-misoprostol regimens. *Contraception*, 76(6), 456-460.
- Jatloui, T. C., Shah, J., Mandel, M. G., Krashin, J. W., Suchdev, D. B., Jamieson, D. J., & Pazol, K. (2017). Abortion surveillance-United States, 2014. *MMWR Surveillance Summaries*, 66(24), 1-48.
- Kemppainen, V., Mentula, M., Palkama, V., & Heikinheimo, O. (2020). Pain during medical abortion in early pregnancy in teenage and adult women. *Acta Obstetrica et Gynecologica Scandinavica*, 99(12), 1603-1610.
- Keogh, S.C., Otupiri, E., Castillo, P.W., Li, N.W., Apenkwa, J., & Polis, C.B. (2021). Contraceptive and abortion practices of young Ghanaian women aged 15-24: Evidence from a nationally representative sample. *Reproductive Health*, 18(1), 150.
- Lao, T. T., & Ho, L. F. (1998). Induced abortion is not a cause of subsequent preterm delivery in teenage pregnancies. *Human Reproduction*, 13(3), 758-761.
- Niinimäki, M., Suhonen, S., Mentula, M., Hemminki, E., Heikinheimo, O., & Gissler, M. (2011). Comparison of rates of adverse events in adolescent and adult women undergoing medical abortion: A population register based study. *BMJ: British Medical Journal*, 342, d2111.
- Olukoya, A., Kaya, A., Ferguson, B., & AbouZahr, C. (2001). Unsafe abortion in adolescents. *International Journal of Gynecology & Obstetrics*, 75(2), 137-147.
- Phelps, R. H., Schaff, E. A., & Fielding, S. L. (2001). Mifepristone abortion in minors. *Contraception*, 64(6), 339-343.
- Reime, B., Schucking, B. A., & Wenzlaff, P. (2008). Reproductive outcomes in adolescents who had a previous birth or an induced abortion compared to adolescents' first pregnancies. *BioMed Central Pregnancy and Childbirth*, 8(4).

References continued

- Renner, R. M., de Guzman, A., & Brahmi, D. (2014). Abortion care for adolescent and young women. *International Journal of Gynecology & Obstetrics*, 126, 1-7.
- Schulz, K., Grimes, D., & Cates, W. (1983). Measures to prevent cervical injury during suction curettage abortion. *The Lancet*, 321(8335), 1182-1185.
- Shannon, C., Wiebe, E., Jacot, F., Guilbert, E., Dunn, S., Sheldon, W., & Winikoff, B. (2006). Regimens of misoprostol with mifepristone for early medical abortion: A randomized trial. *BJOG: An International Journal of Obstetrics & Gynaecology*, 113(6), 621-628.
- Sowmini, S.V. (2013). Delay in termination of pregnancy among unmarried adolescents and young women attending a tertiary hospital abortion clinic in Trivandrum, Kerala, India. *Reproductive Health Matters*, 21(41), 243-250.
- Sully, E.A., Biddlecom, A., Darroch, J.E., Riley, T., Ashford, L.S., Lince-Deroche, N., Firestein, L., & Murro, R. (2020). *Adding it up: Investing in Sexual and Reproductive Health 2019*. New York: Guttmacher Institute.
- Upadhyay, U. D., Desai, S., Zlidar, V., Weitz, T. A., Grossman, D., Anderson, P., & Taylor, D. (2015). Incidence of emergency department visits and complications after abortion. *Obstetrics & Gynecology*, 125(1), 175-83.
- Van Veen, T. R., Haeri, S., & Baker, A. M. (2015). Teen pregnancy: Are pregnancies following an elective termination associated with increased risk for adverse perinatal outcomes? *Journal of Pediatric and Adolescent Gynecology*, 28, 530-532.
- Velazco, A., Varela, L., Tanda, R., Sanchez, C., Barambio, S., Chami, S., ... Carbonell, J. L. L. (2000). Misoprostol for abortion up to 9 weeks' gestation in adolescents. *The European Journal of Contraception and Reproductive Health Care*, 5, 227-233.
- Warriner, I. K., Meirik, O., Hoffman, M., Morroni, C., Harries, J., My Huong, N., & Seuc, A. H. (2006). Rates of complication in first-trimester manual vacuum aspiration abortion done by doctors and midlevel providers in South Africa and Vietnam: A randomized controlled equivalence trial. *The Lancet*, 368(9551), 1965-1972.
- Weitz, T. A., Taylor, D., Desai, S., Upadhyay, U. D., Waldman, J., Battistelli, M. F., & Drey, E. A. (2013). Safety of aspiration abortion performed by nurse practitioners, certified nurse midwives, and physician assistants under a California legal waiver. *American Journal of Public Health*, 103(3), 454-461.
- World Health Organization. (2024). *Abortion care guideline, 2nd ed.* Geneva: World Health Organization.

3.2

3. Abortion before 13 weeks gestation

Gestational dating

Recommendation:

- Gestational age must be assessed before provision of abortion services.
- For individuals confident of the dates of their last menstrual period (LMP), gestational age may be calculated using LMP alone.
- When there is clinically relevant uncertainty about pregnancy duration using LMP alone, gestational age should be assessed using estimated LMP combined with bimanual examination; ultrasound may be useful when gestational age is unclear or there is a discrepancy between the two estimates.
- Routine use of ultrasound for gestational age determination is not necessary.

In practice:

- Bimanual examination is a routine step before intrauterine procedures and must be performed before all vacuum aspiration procedures, even when not indicated for gestational dating.

Strength of recommendation:

Strong

Quality of evidence:

Moderate

Last reviewed:

October 7, 2025

Importance of gestational dating

The gestational age of the pregnancy will influence the method of abortion and whether the abortion can take place at home or should take place in a facility. There are multiple ways to assess gestational age, including LMP, clinical examination of uterine size, and ultrasound. The use of LMP, alone or in combination with a validated tool such as a pregnancy dating wheel or checklist, enables individuals to self-assess gestational age (World Health Organization [WHO], 2024). Ultrasound screening for ectopic pregnancy in symptom-free individuals without risk factors is not necessary before a medical abortion (WHO, 2024); the incidence of ectopic pregnancy is lower in abortion seekers than the general population (Duncan, Reynolds-Wright, & Cameron, 2022). See 3.3: *Recommendations for abortion before 13 weeks gestation: Screening for ectopic pregnancy* for more information.

LMP alone

Clinician assessment of gestational age using LMP

Most people can recall their LMP reasonably well regardless of their education and whether they usually record their LMP dates (Averbach et al., 2018; Harper, Ellertson & Winikoff, 2002; Wegienka & Baird, 2005). Several studies report the accuracy of LMP alone to determine gestational age compared to ultrasound prior to medical abortion (Blanchard et al., 2007; Bracken et al., 2011; Constant et al., 2017; Schonberg et al., 2014). Two studies included a combined total of 833 women; both found that 12% of women eligible for medical abortion

based on their LMP were beyond gestational age limits as determined by ultrasound dating (Blanchard et al., 2007; Constant et al., 2017). However, in the largest available study only 3.3% of 4,257 women fell into this group when a 63-day cut off value for medical abortion eligibility was used; even fewer women (1.2%) determined to be eligible by LMP were beyond 70 days gestation (Bracken et al., 2011). This study also examined the accuracy of provider assessment of pregnancy duration using LMP combined with bimanual examination and found that, when this method of gestational dating was used, the rate of women who were incorrectly determined to be eligible for medical abortion decreased from 3.3% to 1.6%. A study of 660 women seeking medical abortion in Nepal compared gestational age determined by LMP to LMP plus bimanual examination without comparison to ultrasound (Averbach et al., 2018). Investigators found high agreement (99%) between the two gestational age measurements.

Two prospective cohort studies reporting on the effectiveness of telemedicine for the provision of medical abortion during the COVID-19 pandemic utilized reported LMP alone to determine gestational age and medical abortion eligibility (Aiken et al., 2021; Reynolds-Wright et al., 2021). One study, from England, compared a cohort of 22,158 individuals who received a traditional medical abortion pre-pandemic, which included in-person assessment and routine ultrasound, to a cohort who received either a telemedicine abortion (if they had a low risk of ectopic pregnancy and their self-reported LMP was consistent with a gestational age of less than 10 weeks (n=18435) or a traditional medical abortion if they did not meet these criteria (n=11549) (Aiken et al., 2021). Treatment success, serious adverse events and incidence of ectopic pregnancy did not differ between the two cohorts; 11 people (0.04%) in the telemedicine cohort were found to have a gestational age of greater than the expected 10 weeks; all were able to complete their abortion at home without incident. A smaller Scottish cohort study followed a similar telemedicine protocol but included participants who were up to 12 weeks gestation by self-reported LMP (Reynolds-Wright et al., 2021). Of the 663 people included in the cohort, gestational age was determined using LMP alone in 79%; ultrasound was performed for uncertain gestational age in 14% and to confirm intrauterine pregnancy in 5%. Complete abortion occurred in 98% of cases, and ongoing pregnancy occurred in less than 1% of women; 2.4% of women sought additional care but no serious adverse events were reported.

Self-assessment of gestational age using LMP

When asked to determine gestational age or medical abortion eligibility based on LMP, a minority of women's assessments disagree with those of their providers. In the earliest study (Ellertson et al., 2000), 10% of the 173 women in India who used a worksheet and their LMP to determine gestational age believed they were eligible for medical abortion, while providers determined that their pregnancies were beyond the 56-day cut off. In Nepal, 13% of 3,091 women who used their LMP and a modified gestational dating wheel to determine their medical abortion eligibility, using a 63-day cut off, were incorrect when compared to providers' assessments (Andersen et al., 2017). In Ghana, 770 women used a modified gestational dating wheel and LMP to determine if their pregnancy was before or after 13 weeks gestation (Shellenberg et al., 2017); when compared to provider assessment, 3.6% of women incorrectly believed their pregnancies were less than 13 weeks. Of these women, one pregnancy was 13 weeks (0.1% of 770), 15 were 14 weeks (1.9%), seven were 16 weeks (0.9%), two were 18 weeks and 22 weeks (0.3% each) and one was 28 weeks (0.1%). A US based study compared self-assessment of pregnancy duration to ultrasound measurements in a cohort of 1089 participants seeking abortion (Ralph et al., 2022). Using their LMP, 84% of participants who were ineligible for medical abortion (using a 70-day cut off) accurately identified themselves as such; when asked instead if they were more than 10 weeks pregnant, the sensitivity rose to 91%. Accuracy was consistent across adolescent, young adult, and adult age groups (Ralph et al., 2023). Two prospective US studies assessed self-administered tools that queried factors that could lead to misdating, such as irregular menses or contraception use, or indicate a possible ectopic pregnancy, such as unexplained pain or bleeding, in addition to using LMP to establish medical abortion eligibility (Kerstes et al., 2024; Ralph et al., 2025). In both studies, less than 2% of participants would have been incorrectly identified as eligible for medical abortion using the tool when ultrasound or additional clinical assessment identified them as ineligible.

LMP combined with bimanual examination

Provider assessment based on reported LMP, combined with bimanual examination, is an accurate means of determining gestational age prior to abortion (Bracken et al., 2011; Fielding, Schaff, & Nam, 2002; Kaneshiro et al., 2011). The two largest trials comparing use of LMP and bimanual examination to ultrasound prior to medical abortion up to 9 weeks gestation found that fewer than 2% of the nearly 5,000 women included would have been inappropriately offered medical abortion beyond gestational age limits if LMP and bimanual examination were relied upon to determine pregnancy duration (Bracken et al., 2011; Fielding et al., 2002).

Two small cohort studies have examined the accuracy of bimanual examination compared to ultrasound for gestational dating before vacuum aspiration (Kulier & Kapp, 2011). In one study of 120 women, 81% of gestational age determinations made with provider assessment were concordant with ultrasound, and an additional 13% were within two weeks of ultrasound estimates (Fakih et al., 1986). A second study included 245 women and found that experienced providers using only bimanual examination to assess gestational age were within two weeks of ultrasound estimates 92% of the time, while inexperienced providers were within two weeks only 75% of the time (Nichols, Morgan, & Jensen, 2002).

Ultrasound

Ultrasound has an inherent margin of error of 3-5 days before 12 weeks gestation; this margin of error increases as the pregnancy advances (Hadlock et al., 1992). In studies conducted in low-resource settings—such as India, Nepal, Vietnam and Tunisia—lack of ultrasound availability has not had an impact on the success or safety of abortion (Coyaji et al., 2001; Mundle et al., 2007; Ngoc et al., 1999; Warriner et al., 2011). Ultrasound can be helpful to establish pregnancy duration when it cannot be estimated by other methods, to confirm an intrauterine pregnancy and to identify uterine malformations (Clark et al., 2007; Kulier & Kapp, 2011). Dependence on routine ultrasound for gestational age determination can limit access to safe abortion services and is not necessary for accurate assessment of pregnancy duration (American College of Obstetricians and Gynecologists & the Society of Family Planning, 2020; Kaneshiro et al., 2011; Royal College of Obstetricians and Gynaecologists, 2022; WHO, 2024).

Resources

www.ipas.org/ClinicalResources

Abortion Care Videos —
Ipas: Dating a Pregnancy



References

- Aiken, A., Lohr, P.A., Lord, J., Ghosh, N., & Starling, J. (2021). Effectiveness, safety and acceptability of no-test medical abortion provided via telemedicine: a national cohort study. *BJOG: An International Journal of Obstetrics & Gynaecology*, 128(9), 1464-1474.
- American College of Obstetricians and Gynecologists & Society of Family Planning. (2020). Medication abortion up to 70 days of gestation. *Contraception*, 102, 225-236.
- Andersen, K., Fjerstad, M., Basnett, I., Neupane, S., Acre, V., Sharma, S. K., & Jackson, E. (2017). Determination of medical abortion eligibility by women and community health volunteers in Nepal: A toolkit evaluation. *PLoS ONE*, 12(9), e0178248.
- Averbach, S., Puri, M., Blum, M., & Rocca, C. (2018). Gestational dating using last menstrual period and bimanual exam for medication abortion in pharmacies and health centers in Nepal. *Contraception*, 98(4), 296-300.
- Blanchard, K., Cooper, D., Dickson, K., Cullingworth, L., Mavimbela, N., Von Mollendorf, C., & Winikoff, B. (2007). A comparison of women's, providers' and ultrasound assessments of pregnancy duration among termination of pregnancy clients in South Africa. *BJOG: An International Journal of Obstetrics & Gynaecology*, 114(5), 569-575.
- Bracken, H., Clark, W., Lichtenberg, E., Schweikert, S., Tanenhaus, J., Barajas, A., & Winikoff, B. (2011). Alternatives to routine ultrasound for eligibility assessment prior to early termination of pregnancy with mifepristone-misoprostol. *BJOG: An International Journal of Obstetrics & Gynaecology*, 118(1), 17-23.
- Clark, W. H., Gold, M., Grossman, D., & Winikoff, B. (2007). Can mifepristone medical abortion be simplified? A review of the evidence and questions for future research. *Contraception*, 75(4), 245-250.
- Constant, D., Harries, J., Moodley, J., & Myer, L. (2017). Accuracy of gestational age estimation from last menstrual period among women seeking abortion in South Africa, with a view to task sharing: A mixed methods study. *Reproductive Health*, 14(100).
- Coyaji, K., Elul, B., Krishna, U., Oti, S., Ambardekar, S., Bopardikar, A., & Winikoff, B. (2001). Mifepristone abortion outside the urban research hospital setting in India. *The Lancet*, 357(9250), 120-122.
- Duncan, C.I., Reynolds-Wright, J.J., & Cameron, S.T. (2022). Utility of a routine ultrasound for detection of ectopic pregnancies among women requesting abortion: A retrospective review. *BMJ Sexual and Reproductive Health*, 48(1), 22-27.
- Ellertson, C., Elul, B., Ambardekar, S., Wood, L., Carroll, J., & Coyaji, K. (2000). Accuracy of assessment of pregnancy duration by women seeking early abortions. *The Lancet*, 355(9207), 877-881.
- Fakih, M. H., Barnea, E. R., Yarkoni, S., & DeCherney, A. H. (1986). The value of real time ultrasonography in first trimester termination. *Contraception*, 33(6), 533-538.
- Fielding, S. L., Schaff, E. A., & Nam, N. (2002). Clinicians' perception of sonogram indication for mifepristone abortion up to 63 days. *Contraception*, 66(1), 27-31.
- Hadlock, F., Shah, Y., Kanon, D., & Lindsey, J. (1992). Fetal crown-rump length: Reevaluation of relation to menstrual age (5-18 weeks) with high-resolution real-time US. *Radiology*, 182(2), 501-505.
- Hamoda, H., Ashok, P. W., Flett, G. M. M., & Templeton, A. (2005). Medical abortion at 9-13 weeks' gestation: A review of 1076 consecutive cases. *Contraception*, 71(5), 327-332.
- Harper, C., Ellertson, C., & Winikoff, B. (2002). Could American women use mifepristone-misoprostol pills safely with less medical supervision? *Contraception*, 65(2), 133-142.
- Kaneshiro, B., Edelman, A., Sneeringer, R. K., & Gómez Ponce de León, R. (2011). Expanding medical abortion: Can medical abortion be effectively provided without the routine use of ultrasound? *Contraception*, 83(3), 194-201.
- Kerestes, C., Tschann, M., Pearlman Shapiro, M., Berry, E., Gawron, L., Soon, R., & Kaneshiro, B. (2024). Self-Determination of Eligibility for Medication Abortion Without Ultrasonography Using a History-Based Tool: LMP-SURE. *Obstetrics & Gynecology*, 144(4), 457.
- Kulier, R., & Kapp, N. (2011). Comprehensive analysis of the use of pre-procedure ultrasound for first- and second-trimester abortion. *Contraception*, 83, 30-33.
- Mundle, S., Elul, B., Anand, A., Kalyanwala, S., & Ughade, S. (2007). Increasing access to safe abortion services in rural India: Experiences with medical abortion in a primary health center. *Contraception*, 76, 66-70.

References continued

- Nichols, M., Morgan, E., & Jensen, J. T. (2002). Comparing bimanual examination to ultrasound measurement for assessment of gestational age in the first trimester of pregnancy. *Journal of Reproductive Medicine*, 47(10), 825-828.
- Ngoc, N. T. N., Winikoff, B., Clark, S., Ellertson, C., Am, K. N., Hieu, D. T., & Elul, B. (1999). Safety, efficacy and acceptability of mifepristone-misoprostol medical abortion in Vietnam. *International Family Planning Perspectives*, 25(1), 10-14, 33.
- Ralph, L.J., Ehrenreich, K., Barar, R., Biggs, M.A., Morris, N., Blanchard, K., Kapp, N., Moayedi, G., Perrit, J., Raymond, E.G., White, K., & Grossman, D. (2022). Accuracy of self-assessment of gestational duration among people seeking abortion. *American Journal of Obstetrics and Gynecology*, 226(5), 710.e1-710.e.21.
- Ralph, L., Biggs, M. A., Ehrenreich, K., & Grossman, D. (2023). Accuracy of Self-assessment of Gestational Duration Among Adolescents Seeking Abortion Using Information in Addition to Date of Last Menstrual Period. *JAMA Pediatrics*, 177(6), 642-644.
- Ralph, L. J., Ehrenreich, K., Kaller, S., Gurazada, T., Biggs, M. A., Blanchard, K., Hauser, D., Kapp, N., Kromenaker, T., Moayedi, G., Gil, J. P., Peritt, J. B., Raymond, E., Taylor, D., White, K., Valladares, E. S., Williams, S., & Grossman, D. (2025). Accuracy of survey-based assessment of eligibility for medication abortion compared with clinician assessment. *American Journal of Obstetrics & Gynecology*, 233(1), 44.e1-44.e15.
- Reynolds-Wright, J.J., Johnstone, A., McCabe, K., Evans, E., & Cameron, S. (2021). Telemedicine medical abortion at home under 12 weeks gestation: A prospective observational cohort study during the COVID-19 pandemic. *BMJ Sexual & Reproductive Health*, 47(4), 246-251.
- Royal College of Obstetricians and Gynaecologists. (2022). *Best practice in abortion care*. London: Royal College of Obstetricians and Gynaecologists.
- Schonberg, D., Wang, L.F., Bennett, A.H., Gold, M., & Jackson, E. (2014). The accuracy of using last menstrual period to determine gestational age for first trimester medication abortion: A systematic review. *Contraception*, 90(5), 480-487.
- Shellenberg, K. M., Antobam, S. K, Griffin, R., Edelman, A., & Voetagbe, G. (2017). Determining the accuracy of pregnancy-length dating among women presenting for induced abortions in Ghana. *International Journal of Gynecology & Obstetrics*, 139, 71-77.
- Warriner, I., Wang, D., Huong, N., Thapa, K., Tamang, A., Shah, I., & Meirik, O. (2011). Can midlevel health-care providers administer early medical abortion as safely and effectively as doctors? A randomised controlled equivalence trial in Nepal. *The Lancet*, 377(9772), 1155-1161.
- Wegienka, G., & Baird, D. D. (2005). A comparison of recalled date of last menstrual period with prospectively recorded dates. *Journal of Women's Health*, 14(3), 248-252.
- World Health Organization. (2024). *Abortion Care Guideline, 2nd ed*. Geneva: World Health Organization.

3.3

3. Abortion before 13 weeks gestation

Screening for ectopic pregnancy

Recommendation:

- Diagnosis of an ectopic pregnancy should be excluded in individuals who have a concerning history or examination.

Strength of recommendation:

Strong

Quality of evidence:

Low

Last reviewed:

October 12, 2025

Epidemiology

In both high and low resource settings, ectopic pregnancy rates range from less than 1% to 2% of pregnancies (Al Naimi et al., 2021; Anyanwu & Titilope, 2021; Berhe et al., 2021; Ghimire, 2020; Stulberg et al., 2013; Tao, Patel, & Hoover, 2016; Trabert et al., 2011; Webster et al., 2019), and are even lower in pregnant people seeking abortion (Aiken et al., 2021; Cleland et al., 2013; Duncan, Reynolds-Wright, & Cameron, 2022). Rare variants include cervical, cesarean scar and intramural ectopic pregnancy; precise incidence of these variants is not known (Hu et al., 2025; Nijjar, Jauniaux, & Jurkovic, 2023; Ntafam, Sanusi-Musa, & Harris, 2023; Rayamajhi et al., 2023). Ectopic pregnancy accounts for 2.7% of pregnancy-related deaths in the United States (Creanga et al., 2017). Ectopic pregnancy accounts for approximately 1% of pregnancy-related deaths in low resource settings where other causes of maternal death are more prevalent (Khan et al., 2006).

Risk factors

Factors with the highest associated risk of ectopic pregnancy in a pregnant person are:

Risk factor	Risk of ectopic in the current pregnancy
Previous ectopic pregnancy	10-25%
History of tubal surgery, including sterilization	25-50%
Intrauterine device (IUD) in place	25-50%

(American College of Obstetricians and Gynecologists [ACOG], 2018; Ankum et al., 1996; Barnhart, 2009; Gaskins et al., 2018; Jacob, Kalder, & Kostev, 2017)

Other risk factors include a history of infertility and assisted reproductive technology use, a history of pelvic infections, multiple partners, early age at first intercourse, age over 30 years, and smoking (ACOG, 2018; Ankum et al., 1996; Barnhart, 2009; Gaskins et al., 2018; Brim et al., 2024; Olamijulo et al., 2020). Oral contraceptive use reduces risk of ectopic pregnancy (Brim et al., 2024).

Screening

Half of all ectopic pregnancies occur in people with no risk factors and with a benign clinical presentation in high-income countries (Stovall et al., 1990), whereas in low- and middle-income countries, people are more likely to present with acute clinical features, including hemodynamic instability (Olamijulo et al., 2020). In addition to gathering information about last menstrual period and regularity of menses, providers should screen for ectopic pregnancy risk factors during the history and physical examination, such as previous ectopic pregnancy, tubal ligation, tubal surgery or an IUD in place. Screening should also include symptoms and signs of ectopic pregnancy found during history taking and physical examination, such as an adnexal mass, pain on examination or vaginal bleeding (Kaislasuo & Heikinheimo, 2025).

Some people present for abortion care very early in pregnancy, before there is definitive ultrasound evidence of an intrauterine gestation. A 2020 systematic review, including three retrospective comparative cohort studies of 5,315 people seeking early medical or aspiration abortion, found that there was no increase in incidence of missed diagnosis of ectopic pregnancy or incomplete abortion when abortion was initiated prior to ultrasound evidence of intrauterine pregnancy in women who did not have signs or symptoms of an ectopic pregnancy (Schmidt-Hansen et al., 2020). Two subsequent small, retrospective cohort studies have confirmed that among people with very early pregnancies and no major ectopic pregnancy risk factors, there is no increase in the diagnosis of a missed ectopic pregnancy when medical abortion was initiated before ultrasound evidence of pregnancy (Goldberg, et al., 2022; Jar-Allah et al., 2022).

Treatment for high-risk people

Ultrasound and serial hCG testing are often used to help assess pregnancy location (Fields & Hathaway, 2017; Nijjar, Jauniaux, & Jurkovic, 2023). In some cases, the most expeditious way to confirm an intrauterine pregnancy is to perform vacuum aspiration; presence of products of conception in the uterine aspirate confirms that the pregnancy was intrauterine. Individuals with suspicious signs and symptoms or a concerning physical exam should be diagnosed and treated as soon as possible or transferred immediately to a facility that can manage ectopic pregnancy. Early diagnosis and treatment of ectopic pregnancy can help preserve fertility and save lives.

Post-procedure screening

For those undergoing vacuum aspiration, the aspirate should be strained and examined to confirm the presence of products of conception (see 3.4.4 Examining products of conception). If products of conception are not seen, a diagnosis of ectopic pregnancy should be considered.

References

- Aiken, A., Lohr, P.A., Lord, J., Ghosh, N., & Starling, J. (2021). *BJOG: An International Journal of Obstetrics & Gynaecology*, 128(9), 1464-1474.
- Al Naimi, A., Moore, P., Bruggmann, D., Krysa, L., Louwen, F., & Bahlmann, F. (2021). Ectopic pregnancy: A single-center experience over ten years. *Reproductive Biology and Endocrinology*, 19(1), 79
- American College of Obstetricians and Gynecologists. (2018). Practice bulletin No 193: Tubal ectopic pregnancy. *Obstetrics & Gynecology* 131, e91-e103.
- Ankum, W. M., Mol, B. W. J., Van der Veen, F., & Bossuyt, P. M. M. (1996). Risk factors for ectopic pregnancy: A meta-analysis. *Fertility and Sterility*, 60(6), 1093-9.
- Anyanwu, M., & Titilope, G. (2021). Ectopic pregnancy at the Gambian tertiary hospital. *African Health Sciences*, 21(1), 295-303.
- Barnhart, K. T. (2009). Clinical practice. Ectopic pregnancy. *New England Journal of Medicine*, 361(4), 379-387.
- Berhe, E.T., Kiros, K., Hagos, M.G., Gesesew, H.A., Ward, P.R., & Gebremeskel, T.G. (2021). Ectopic pregnancy in Tigray, Ethiopia: A cross-sectional survey of prevalence, management, outcomes, and associated factors. *Journal of Pregnancy*, 4443117. Doi: 10.1155/2021/4443117.
- Brim, A. C. S., Barretto, V. R. D., Reis-Oliveira, J. G., da Silveira de Araújo, R. B., & Romeo, A. C. D. C. B. (2025). Risk factors for ectopic pregnancy occurrence: Systematic review and meta-analysis. *International Journal of Gynecology & Obstetrics*, 168(3), 919–932.
- Cleland, K., Creinin, M. D., Nucatola, D., Nshom, M., & Trussell, J. (2013). Significant adverse events and outcomes after medical abortion. *Obstetrics & Gynecology*, 121(1), 166-171.
- Creanga, A. A., Syverson, C., Seed, K., & Callaghan, W. M. (2017). Pregnancy-related mortality in the United States, 2011-2013. *Obstetrics & Gynecology*, 130(2), 366-373.
- Duncan, C.I., Reynolds-Wright, J.J., & Cameron, S.T. (2022). Utility of a routine ultrasound for detection of ectopic pregnancies among women requesting abortion: A retrospective review. *BMJ Sexual and Reproductive Health*, 48(1), 22-27.
- Fields, L., & Hathaway, A. (2017). Key concepts in pregnancy of unknown location: Identifying ectopic pregnancy and providing patient-centered care. *Journal of Midwifery and Womens Health*, 62(2), 172-179.
- Gaskins, A. J., Missmer, S. A., Rich-Edwards, J. W., Williams, P. L., Souter, I., & Chavarro, J. E. (2018). Demographic, lifestyle, and reproductive risk factors for ectopic pregnancy. *Fertility and Sterility*, 110(7), 1328-1337.
- Ghimire, S.P. (2021). Study of ectopic pregnancy at tertiary care hospital in Province 1 of Nepal. *Journal of Nepal Health Research Council*, 18(4), 698-701.
- Goldberg, A.B., Fulcher, I.R., Fortin, J., Hofer, R.K., Cottrill, A., Dethier, D., Gilbert, A., Janiak, E., & Roncari, D. (2022). Mifepristone and misoprostol for undesired pregnancy of unknown location. *Obstetrics & Gynecology*, 139(5), 771-780.
- Hu, C., Chawla, K., Hostetter, K., & Mark, K. (2025). Cesarean delivery scar ectopic pregnancy diagnosed after no-test abortion: A case report. *Contraception*, 152, 111206.
- Jacob, L., Kalder, M., & Kostev, K. (2017). Risk factors for ectopic pregnancy in Germany: a retrospective study of 100,197 patients. *German Medical Science*, 15, Doc19.
- Jar-Allah, T., Hognert, H., Kocher, L., Berggren, L., Fiala, C., Milsom, I., & Gemzell-Danielsson, K. (2022). Detection of ectopic pregnancy and serum beta hCG level in women undergoing very early medical abortion: A retrospective study. *European Journal of Contraception and Reproductive Health Care*, 27(3), 240-246.
- Kaislasuo, J., & Heikinheimo, O. (2025). Safety and accuracy of dating unwanted pregnancies and detecting ectopic pregnancy with the RCOG decision aid without routine ultrasound—a retrospective analysis from a large abortion service. *The European Journal of Contraception & Reproductive Health Care*, 30(2), 93–96.
- Khan, K. S., Wojdyla, D., Say, L., Gulmezoglu, A. M., & Van Look, P. F. (2006). WHO analysis of causes of maternal death: A systematic review. *The Lancet*, 367(9516), 1066-1074.
- Nijjar, S., Jauniaux, E., & Jurkovic, D. (2023). Definition and diagnosis of cesarean scar ectopic pregnancies. *Best Practice & Research Clinical Obstetrics & Gynaecology*, 89, 102360.
- Ntafam, C. N., Sanusi-Musa, I., & Harris, R. D. (2023). Intramural ectopic pregnancy: An individual patient data systematic review. *European Journal of Obstetrics & Gynecology and Reproductive Biology: X*, 21, 100272.

References continued

Olamijulo, J.A., Okusanya, B.O., Adenekan, M.A., Ugwu, A.O., Olorunfemi, G., & Okojie, O. (2020). Ectopic pregnancy at the Lagos University Teaching Hospital, Lagos, South-Western Nigeria: Temporal trends, clinical presentation and management outcomes from 2005 to 2014. *Nigerian Postgraduate Medical Journal*, 27, 177-83.

Rayamajhi, A., Rayamajhi, A. K., Adhikari, A., Basnet, P., & Tiwari, A. (2023). Cervical Ectopic Pregnancy with Unsupervised Intake of Medications for Abortion: A Case Report. *JNMA: Journal of the Nepal Medical Association*, 61(267), 897-900.

Schmidt-Hansen, M., Cameron, S., Lord, J., & Hasler, E. (2020). Initiation of abortion before there is definitive ultrasound evidence of intrauterine pregnancy: A systematic review with meta-analyses. *Acta Obstetrica et Gynecologica Scandinavica* 99, 451-458.

Stovall, T. G., Kellerman, A. L., Ling, F. W., & Buster, J. E. (1990). Emergency department diagnosis of ectopic pregnancy. *Annals of Emergency Medicine*, 19(10), 1098-

1103.

Stulberg, D., Cain, L. R., Dahlquist, I., & Lauderdale, D. S. (2013). Ectopic pregnancy rates in the Medicaid population. *American Journal of Obstetrics & Gynecology*, 208(4), 274.e1-7.

Tao, G., Patel, C., & Hoover, K. W. (2016). Updated estimates of ectopic pregnancy among commercially and Medicaid-insured women in the United States, 2002-2013. *Southern Medical Journal*, 110(1), 18-24.

Trabert, B., Holt, V. L., Yu, O., Ven Den Eeden, S. K., & Scholes, D. (2011). Population-based ectopic trends, 1993-2007. *American Journal of Preventative Medicine*, 40(5), 556-560.

Webster, K., Eadon, H., Fishburn, S., & Kumar, G. (2019). Ectopic pregnancy and miscarriage: diagnosis and initial management: summary of updated NICE guidance. *British Medical Journal*, 367, 16283.

3.4

3. Abortion before 13 weeks gestation

Vacuum Aspiration

3.4.1. Safety and effectiveness

Key information:

- Vacuum aspiration is effective and safe, with success rates over 98% and major complication rates under 1%.

Quality of evidence:

High

Last reviewed:

October 7, 2025

Effectiveness

A successful vacuum aspiration requires no further intervention to evacuate the uterus. In a large United States-based observational study of 11,487 first-trimester aspiration abortions done by physicians, nurse practitioners, certified nurse midwives and physicians assistants, the need for repeat aspiration due to incomplete abortion was 0.28% and ongoing pregnancy was 0.16% (Weitz et al., 2013).

Safety

A 2015 systematic review analyzed 57 studies reporting data for 337,460 aspiration abortions performed before 14 weeks gestation in North America, Western Europe, Scandinavia and Australia/New Zealand (White, Carroll, & Grossman, 2015). Major complications requiring intervention (such as hemorrhage requiring transfusion or perforation necessitating repair) occurred in $\leq 0.1\%$ of procedures; hospitalization was necessary in $\leq 0.5\%$ of cases. Studies looking at different cadres of providers (physician assistants, nurses, nurse midwives, etc.) in other settings have had similar results (Hakim-Elahi, Tovell, & Burnhill, 1990; Jejeebhoy et al., 2011; Warriner et al., 2006; Weitz et al., 2013). In two studies that compared newly trained advanced practice clinicians to experienced physician providers (Jejeebhoy et al., 2011; Weitz et al., 2013), there were no observed differences in abortion success or complication rates.

A retrospective cohort study conducted in the United States compared rates of procedural complications during outpatient aspiration abortion through 13 weeks and six days gestation in women with at least one medical comorbidity (diabetes, hypertension, obesity, HIV, epilepsy, asthma, thyroid disease and bleeding/clotting disorders) to women without comorbidities. The overall rate of complications—which included uterine perforation, blood loss greater than 100mL, cervical laceration and retained products of conception that required reaspiration—was 2.9%; there was no difference between the two groups (Guiahi et al., 2015). Two retrospective cohort studies, that together included 5,288 aspiration abortion procedures performed before 13 weeks gestation, found no differences in complication rates between obese, overweight, and normal weight women (Benson et al., 2016; Mark et al., 2017).

A 2025 retrospective population-based cohort study from Canada compared rates of adverse events occurring within 42 days of either a procedural abortion (type of procedure not specified) or dispensing of a medical abortion prescription for mifepristone and misoprostol (Liu & Ray, 2025). Investigators found that serious adverse events (e.g., end-organ damage, intensive care unit admission, death) occurred in 114 out of 65,176 patients (0.2%) who had an outpatient procedural abortion up to 14 weeks gestation, and in 27 out of 8,861

patients (0.3%) of patients who had an ambulatory hospital based procedure up to 9 weeks gestation. Adverse events (e.g., hemorrhage, retained products of conception, transfusion) occurred in about 3% of patients in both groups.

Mortality

In the United States, the mortality rate from all legal induced abortion between 2013-2018 was 0.41 deaths per 100,000 reported abortions; mortality rates disaggregated by abortion type or length of pregnancy are not available (Kortsmit et al., 2021). In comparison, during the period from 2007-2016 the mortality rate from live birth in the United States was 17 deaths per 100,000 live births (Creanga et al., 2017; Petersen et al., 2019). A secondary data analysis that compared mortality rates associated with live birth to those from legal induced abortion in the United States found that the risk of death from childbirth was 14-fold higher than the risk of death from abortion (Raymond & Grimes, 2012). In the 2015 systematic review about the safety of vacuum aspiration in multiple countries referenced above, no deaths were reported (White et al., 2015).

	Upadhyay, 2015	Weitz, 2013	Jejeebhoy, 2011	Warriner, 2006	Hakim-Elahi, 1990
Number of women included	34,744	11,487	897	2,789	170,000
Location	USA	USA	India	South Africa and Vietnam	USA
Provider type	Not specified	Experienced physicians and newly trained nurse practitioners, certified nurse midwives and physician assistants	Newly trained physicians and nurses	Experienced physicians, midwives and doctor-assistants	Experienced physicians
Time period	2009-2010	2007- 2011	2009-2010	2003-2004	1971-1987
Total minor complication rate	1.1%	1.3%	1% (all reported as incomplete abortion)	1%	0.85%
Incomplete abortion	0.33%	0.3%	1%	0.9%	0.85%
Ongoing pregnancy	0.04%	0.16%	Not reported	Not reported	0%
Minor infection	0.27%	0.12%	Not reported	0.1%	0.5%
Total major complication rate	0.16%	0.05% (6 complications: 2 perforations, 3 infections and \ 1 hemorrhage)	0.12% (1 complication: 1 high fever)	0%	0.07% (hospitalizations for perforation, ectopic pregnancy, hemorrhage, sepsis or incomplete abortion)
Death	0%	0%	0%	0%	0%

Who can perform vacuum aspiration?

The World Health Organization (WHO) makes service delivery recommendations for the provision of uterine aspiration, which includes assessment of gestational age, cervical preparation if needed, the procedure itself, pain management including the provision of a paracervical block, and the assessment of procedure completeness through visual examination of the products of conception (WHO, 2024). Health workers with the skills to perform transcervical procedures and bimanual examinations to diagnose pregnancy and determine gestational age based on uterine size can be trained to perform vacuum aspiration. WHO advises that uterine aspiration is within the scope of practice for specialty and general medical practitioners and recommends the provision of vacuum aspiration by associate and advanced associate clinicians, midwives, and nurses based on moderate certainty evidence of safety and effectiveness. Traditional and complementary medicine professionals are recommended to provide uterine aspiration based on low certainty evidence of safety and effectiveness, and WHO suggests that auxiliary nurses and auxiliary nurse midwives may be able to perform aspiration in settings where they provide basic emergency obstetric care (WHO, 2024). For further information about health worker roles in abortion care, see Appendix C: World Health Organization recommendations for health worker roles in abortion care.

References

- Benson, L. S., Micks, E. A., Ingalls, C., & Prager, S. W. (2016). Safety of outpatient surgical abortion for obese patients in the first and second trimesters. *Obstetrics & Gynecology*, 128(5), 1065-1070.
- Cates Jr, W., Schulz, K. F., & Grimes, D. A. (1983). The risks associated with teenage abortion. *New England Journal of Medicine*, 309(11), 621-624.
- Creanga, A., Syverson, C., Seed, K., & Callaghan, W. (2017). Pregnancy-related mortality in the United States, 2011-2013. *Obstetrics & Gynecology*, 130, 366-373.
- Guiahi, M., Schiller, G., Sheeder, J., & Teal, S. (2015). Safety of first-trimester uterine evacuation in the outpatient setting for women with common chronic conditions. *Contraception*, 92(5), 453-457.
- Hakim-Elahi, E., Tovell, H., & Burnhill, M. (1990). Complications of first-trimester abortion: A report of 170,000 cases. *Obstetrics & Gynecology*, 76(1), 129-135.
- Jejeebhoy, S. J., Kalyanwala, S., Zavier, A., Kumar, R., Mundle, S., Tank, J., & Jha, N. (2011). Can nurses perform manual vacuum aspiration (MVA) as safely and effectively as physicians? Evidence from India. *Contraception*, 84(6), 615-621.
- Kortsmi, K., Mandel, M.G., Reeves, J.A., Clark, E., Pagano, H.P., Nguyen, A., Petersen, E.E., & Whiteman, M.K. (2021). Abortion surveillance-United States, 2019. *Morbidity and Mortality Weekly Report Surveillance Summaries*, 70(9), 1-29.
- Liu, N., & Ray, J. G. (2023). Short-Term Adverse Outcomes After Mifepristone–Misoprostol Versus Procedural Induced Abortion. *Annals of Internal Medicine*, 176(2), 145–153.
- Mark, K. S., Bragg, B., Talaie, T., Chawla, K., Murphy, L., & Terplan, M. (2017). Risk of complication during surgical abortion in obese women. *American Journal of Obstetrics & Gynecology*, DOI: 10.1016/j.ajog.2017.10.018. Epub ahead of print.
- Petersen, E.E., Davis, N.L., Goodman, D., Cox, S., Syverson, C., Seed, K., Shapiro-Mendoza, C., Callaghan, W.M., & Barfield, W. (2019). Racial/ethnic disparities in pregnancy-related deaths-United States, 2007-2016. *Morbidity and Mortality Weekly Report Surveillance Summaries*, 68(35), 762-765.
- Raymond, E. G & Grimes, D. A. (2012). The comparative safety of legal induced abortion and childbirth in the United States. *Obstetrics & Gynecology*, 119, 215-219.
- Upadhyay, U. D., Desai, S., Zlidar, V., Weitz, T. A., Grossman, D., Anderson, P., & Taylor, D. (2015). Incidence of emergency department visits and complications after abortion. *Obstetrics & Gynecology*, 125(1), 175-83.
- Warriner, I. K., Meirik, O., Hoffman, M., Morroni, C., Harries, J., My Huong, N., & Seuc, A. H. (2006). Rates of complication in first-trimester manual vacuum aspiration abortion done by doctors and midlevel providers in South Africa and Vietnam: A randomised controlled equivalence trial. *The Lancet*, 368(9551), 1965-1972.
- Weitz, T. A., Taylor, D., Desai, S., Upadhyay, U. D., Waldman, J., Battistelli, M. F., & Drey, E. A. (2013). Safety of aspiration abortion performed by nurse practitioners, certified nurse midwives, and physician assistants under a California legal waiver. *American Journal of Public Health*, 103(3), 454-461.

References continued

White, K., Carroll, E., & Grossman, D. (2015). Complications from first-trimester aspiration abortion: A systematic review of the literature. *Contraception*, 92, 422-438.

World Health Organization. (2024). *Abortion care guideline, 2nd ed.* Geneva: World Health Organization.

3.4

3. Abortion before 13 weeks gestation

Vacuum Aspiration

3.4.2. Cervical preparation

Recommendation:

- Cervical preparation is recommended routinely after 12 weeks gestation. Before 12 weeks gestation, cervical preparation may be considered, but should not be routinely used.
- Recommended methods for cervical preparation include:
 - Misoprostol 400mcg sublingually 1-3 hours before the procedure;
 - Misoprostol 400mcg vaginally or buccally 3 hours before the procedure;
 - Or mifepristone 200mg orally 1-2 days before the procedure.

Strength of recommendation:

Strong

Quality of evidence:

Moderate

Last reviewed:

October 8, 2025

Benefits of cervical preparation

A meta-analysis of 51 randomized controlled clinical trials of cervical preparation through 13 weeks gestation found that procedure time was shorter with cervical preparation but there were no differences in serious complications, such as cervical laceration or uterine perforation, in people given cervical preparation compared to those given placebo (Kapp et al., 2010). In the largest multicenter randomized controlled trial, which included 4,972 women given either misoprostol 400mcg vaginally or placebo three hours before a vacuum aspiration, there was no difference in the rates of cervical laceration, perforation or infection between the two groups (Meirik et al., 2012). However, a significant decrease in the risk of incomplete abortion was observed in those who received misoprostol for cervical preparation (<1%) compared to the placebo group (2%), but side effects were more frequent for those who were given misoprostol (O'Shea et al., 2020). For people at higher risk of complications during cervical dilation (young people, people with cervical abnormalities or prior cervical surgery) or for inexperienced providers, there may be a benefit from cervical preparation before 12-14 weeks gestation (Allen & Goldberg, 2016; Grimes, Schulz, & Cates, 1984; Kaunitz et al., 1985).

Side effects of cervical preparation

In the largest randomized controlled trial of misoprostol for cervical preparation, 55% of participants who took misoprostol complained of pre-procedure abdominal pain and 37% had vaginal bleeding, compared to 22% and 7% in the placebo group (Meirik et al., 2012). In addition, cervical preparation adds cost, complexity and time to an abortion, as individuals must visit the clinic a day before the procedure to receive mifepristone, or must wait in the health center for misoprostol to take effect. Because abortion before 13 weeks gestation is very safe, the gestational age at which the benefit of routine cervical preparation outweighs the side-effects is not known (Kapp et al., 2010). Patient satisfaction with cervical preparation has not been systematically studied in randomized controlled trials but is an important consideration for quality of care and service delivery (Kapp et al., 2010).

Choice of methods

The choice of misoprostol or mifepristone for cervical preparation depends on availability, expense, convenience and preference. Sublingual misoprostol has superior effectiveness but more gastrointestinal side effects than vaginal misoprostol (Kapp et al., 2010; Saav et al., 2015; Saxena et al., 2008). Mifepristone given 24 hours prior to the abortion results in greater cervical dilation and less aspiration associated pain than misoprostol, but adds time and expense to the abortion procedure (Ashok, Flett, & Templeton, 2000; Hamdaoui et al., 2021; Kapp et al., 2010). Misoprostol and osmotic dilators have similar effectiveness, however the World Health Organization (WHO) recommends against the use of osmotic dilators for cervical priming before 12 weeks gestation due to the longer time to complete the procedure and reduced satisfaction among participants compared to misoprostol (Bartz, et al., 2013; Burnett, Corbett, & Gertenstein, 2005; MacIsaac et al., 1999; WHO, 2024).

Young people

Adolescents may benefit from cervical preparation due to their increased risk of cervical injury during abortion (Allen & Goldberg, 2016; Schulz et al., 1983). This risk is independent of nulliparity (Meirik et al., 2014); adolescents have physiologically immature cervices that may be more difficult to dilate regardless of obstetric history (Allen & Goldberg, 2016; Schulz et al., 1983). There are no clinical trials examining the use of cervical preparation in this patient population.

Who can perform cervical preparation with medications?

WHO makes service delivery recommendations for the provision of uterine aspiration, which includes assessment of gestational age, cervical preparation if needed, the procedure itself, pain management including the provision of a paracervical block, and the assessment of procedure completeness through visual examination of the products of conception (WHO, 2024). WHO advises that provision of medication for cervical preparation is within the scope of practice for specialty and general medical practitioners, and recommends the provision of cervical preparation medications by associate and advanced associate clinicians, midwives, nurses, auxiliary nurses and auxiliary nurse midwives, and traditional and complementary medicine professionals based on expected competencies for these roles and low-certainty evidence of safety and effectiveness. Although there is no direct evidence, WHO suggests that community health workers, pharmacists and pharmacy workers can safely and effectively provide medications for cervical preparation based on expected competencies for these roles, adding that these health workers need to ensure continuity of care for the individual obtaining the medications prior to an abortion procedure (WHO, 2024). For further information about health worker roles in abortion care, see Appendix C: *World Health Organization recommendations for health worker roles in abortion care*.

Resources

www.ipas.org/ClinicalResources

Steps for performing manual vacuum aspiration using the Ipas MVA Plus® and EasyGrip® cannulae—Ipas



References

- Allen, R., & Goldberg, A. (2016). Society of Family Planning Clinical Guideline 20071: Cervical dilation before first trimester surgical abortion (< 14 weeks gestation). *Contraception*, 93(4), 277-291.
- Ashok, P. W., Flett, G. M., & Templeton, A. (2000). Mifepristone versus vaginally administered misoprostol for cervical priming before first-trimester termination of pregnancy: A randomized, controlled study. *American Journal of Obstetrics & Gynecology*, 183(4), 998-1002.
- Bartz, D., Maurer, R., Allen, R., Fortin, J., Kuang, B., & Goldberg, A. (2013). Buccal misoprostol compared with synthetic osmotic cervical dilator before surgical abortion: A randomized controlled trial. *Obstetrics & Gynecology*, 122, 57-63.
- Burnett, M. A., Corbett, C. A., & Gertenstein, R. J. (2005). A randomized trial of laminaria tents versus vaginal misoprostol for cervical ripening in first trimester surgical abortion. *Journal of Obstetrics and Gynaecology Canada*, 27(1), 38-42.
- Grimes, D. A., Schulz, K. F., & Cates, W. J., Jr. (1984). Prevention of uterine perforation during curettage abortion. *Journal of American Medical Association*, 251(16), 2108-2111.
- Hamdaoui, N., Cardinale, C., Fabre, C., Baumstarck, K., & Agostini, A. (2021). Pain associated with cervical priming for first-trimester surgical abortion: A randomized controlled trial. *Obstetrics & Gynecology*, 137(6), 1055-1060.
- Kapp, N., Lohr, P. A., Ngo, T. D., & Hayes, J. L. (2010). Cervical preparation for first trimester surgical abortion. *The Cochrane Database of Systematic Reviews* (2), CD007207.
- Kaunitz, A. M., Rovira, E. Z., Grimes, D. A., & Schulz, K. F. (1985). Abortions that fail. *Obstetrics & Gynecology*, 66(4), 533-537.
- MacIsaac, L., Grossman, D., Balistreri, E., & Darney, P. (1999). A randomized controlled trial of laminaria, oral misoprostol, and vaginal misoprostol before abortion. *Obstetrics & Gynecology*, 93(5 Pt 1), 766-770.
- Meirik, O., Huong, N. T., Piaggio, G., Bergel, E., & von Hertzen, H. (2012). Complications of first-trimester abortion by vacuum aspiration after cervical preparation with and without misoprostol: A multicentre randomised trial. *The Lancet*, 379(9828), 1817-1824.
- O'Shea, L.E., Lord, J., Fletcher, J., Hasler, E., & Cameron, S. (2020). Cervical priming before surgical abortion up to 13+6 weeks' gestation: A systematic review and metaanalyses for the National Institute for Health and Care Excellence-new clinical guidelines for England. *American Journal of Obstetrics and Gynecology MFM*, 2(4), 100220.
- Saav, I., Kopp Kallner, H., Fiala, C., & Gemzell-Danielsson, K. (2015). Sublingual versus vaginal misoprostol for cervical dilatation 1 or 3 h prior to surgical abortion: A double blinded RCT. *Human Reproduction*, 30(6), 1314-1322.
- Saxena P., Sarda, N., Salhan, S., & Nandan, D. (2008). A randomised comparison between sublingual, oral and vaginal route of misoprostol for pre-abortion cervical ripening in first-trimester pregnancy termination under local anesthesia. *Australian and New Zealand Journal of Obstetrics and Gynaecology*, 48(1), 101-6.
- Schulz, K. F., Grimes, D. A., & Cates, W., Jr. (1983). Measures to prevent cervical injury during suction curettage abortion. *The Lancet*, 1(8335), 1182-1185.
- World Health Organization. (2024). *Abortion care guideline, 2nd ed.* Geneva: World Health Organization.

3.4

3. Abortion before 13 weeks gestation

Vacuum Aspiration

3.4.3. Bimanual examination

Recommendation:

- Bimanual examination must be performed before any procedure in which instruments are being placed in the uterus, such as vacuum aspiration or intrauterine device insertion.
- The bimanual examination must be performed by the clinician doing the procedure.

Strength of recommendation:

Strong

Quality of evidence:

Very Low

Last reviewed:

October 8, 2025

Importance of bimanual examination

Bimanual examination is a routine step before intrauterine procedures recommended by the World Health Organization (WHO, 2024). It provides information about the client's comfort, pregnancy status, gestational age, presence of infection, anatomic abnormalities and uterine position, all of which affect management of intrauterine procedures. Ultrasound can additionally be performed but is not a replacement for bimanual examination before intrauterine procedures.

Determining uterine size

Uterine size can be assessed using bimanual examination. In cases where last menstrual period (LMP) is known, bimanual examination can confirm gestational age assessment based on LMP. When LMP is not certain, bimanual examination can offer an estimate of gestational age based on uterine size (See section 3.2 Recommendations for abortion before 13 weeks: Gestational dating). In cases of postabortion care, where some or all pregnancy tissue may have been expelled from the uterus, uterine size determined by bimanual examination should guide treatment. Medical regimens for abortion and postabortion care change based on the gestational age or uterine size. Techniques for vacuum aspiration and dilatation and evacuation, including instrument choice and need for cervical preparation, depend on accurate knowledge of uterine size.

Determining uterine size

The position of the uterus in the pelvis, orientation of the fundus to the cervix and firmness of the uterus are best determined with bimanual examination. Knowledge of uterine position assists providers in avoiding complications, particularly perforation, during procedures (Chen et al., 1995; Mittal & Misra, 1985; Nathanson, 1972).

Resources

www.ipas.org/ClinicalResources

Abortion Care Videos—Ipas:
Dating a Pregnancy

Steps for performing manual
vacuum aspiration using
the Ipas MVA Plus® and
EasyGrip® cannulae—Ipas



References

Chen, L. H., Lai, S. F., Lee, W. H., & Leong, N. K. (1995). Uterine perforation during elective first trimester abortions: A 13-year review. *Singapore Medical Journal*, 36(1): 63-67.

Mittal, S., & Misra, S. L. (1985). Uterine perforation following medical termination of pregnancy by vacuum aspiration. *International Journal of Gynecology and Obstetrics*, 23(1): 45-50.

Nathanson, B. (1972). Management of uterine perforations suffered at elective abortion. *American Journal of Obstetrics & Gynecology*, 114(8): 1054-9.

World Health Organization. (2042). *Abortion care guideline, 2nd ed.* Geneva: World Health Organization.

3.4

3. Abortion before 13 weeks gestation

Vacuum Aspiration

3.4.4. Examining products of conception

Recommendation:

- Clinicians performing vacuum aspiration must inspect products of conception immediately after vacuum aspiration.
- Sending products of conception for routine histopathology evaluation is not recommended.

In practice:

- To improve visualization, products of conception can be rinsed, floated in water, and viewed through a clear dish using a light source from underneath.
- If no products of conception are visible, or less tissue is seen than expected, further evaluation is required.

Strength of recommendation:

Strong

Quality of evidence:

Very Low

Last reviewed:

October 8, 2025

Visual inspection of products of conception

Visual inspection of products of conception is a routine step in vacuum aspiration as recommended by the World Health Organization (WHO, 2024), the Royal College of Obstetricians and Gynaecologists (RCOG, 2022), and the National Abortion Federation (NAF, 2020). Presence of products of conception on visual inspection confirms that the pregnancy was intrauterine and is consistent with successful abortion (Westfall et al., 1998). If products of conception are not seen, the individual should not leave the facility until plans are made to follow local guidelines to exclude the diagnosis of ectopic pregnancy. Immediate examination of the products of conception expedites the diagnosis of ectopic pregnancy and decreases related morbidity and mortality (Goldstein, Danon, & Watson, 1994). In cases where abnormal pathology is suspected, such as molar pregnancy, histopathology may be used in addition to visual inspection.

Sending products of conception for routine histopathology exam does not affect clinical outcomes and increases the cost of abortion (Heath et al., 2000; Paul et al., 2002).

Instructions for visually inspecting products of conception are in Ipas's *Woman-Centered Comprehensive Abortion Care Reference Guide*, 2nd edition, page 177 (Ipas, 2013).

Resources

www.ipas.org/ClinicalResources

Abortion Care Videos—
*Ipas: performing a Manual
Vacuum Aspiration*
("Inspect the Tissue" begins
at 10:27 in this video)



Steps for performing manual vacuum
aspiration using the Ipas MVA Plus® and
EasyGrip® cannulae—Ipas

References

- Goldstein, S. R., Danon, M., & Watson, C. (1994). An updated protocol for abortion surveillance with ultrasound and immediate pathology. *Obstetrics & Gynecology*, 83(1), 55-58.
- Heath, V., Chadwick, V., Cooke, I., Manek, S., & MacKenzie, I. Z. (2000). Should tissue from pregnancy termination and uterine evacuation routinely be examined histologically? *BJOG: An International Journal of Obstetrics & Gynaecology*, 107(6), 727-730.
- Ipas. (2013). Woman-centered, comprehensive abortion care: *Reference manual* (second ed.) K. L. Turner & A. Huber (Eds.). Chapel Hill, NC: Ipas.
- National Abortion Federation. (2024). *Clinical Policy Guidelines*. Washington, DC: National Abortion Federation.
- Paul, M., Lackie, E., Mitchell, C., Rogers, A., & Fox, M. (2002). Is pathology examination useful after early surgical abortion? *Obstetrics & Gynecology*, 99(4), 567-571.
- Royal College of Obstetricians and Gynaecologists. (2022). *Best practice in abortion care*. London: Royal College of Obstetricians and Gynaecologists.
- Westfall, J. M., Sophocles, A., Burggraf, H., & Ellis, S. (1998). Manual vacuum aspiration for first-trimester abortion. *Archives of Family Medicine*, 7(6), 559-62.
- World Health Organization. (2024). *Abortion care guideline, 2nd ed.* Geneva: World Health Organization.

3.4

3. Abortion before 13 weeks gestation

Vacuum Aspiration

3.4.5. Processing Ipas MVA Plus® and Ipas Single-Valve aspirators

Recommendation:

- All Ipas multiple-use aspirators and adapters must be pre-soaked, rinsed or sprayed with water or enzymatic spray at the point-of-use, then cleaned and high-level disinfected or sterilized between patients.

In practice:

- Instruments processed using wet methods should be reprocessed daily.

Last reviewed:

October 8, 2025

Importance of correctly processing instruments

During use, the cylinder of the manual vacuum aspirator (MVA) fills with blood. There is a potential risk that contaminants from a previous patient could be introduced to a new patient if the MVA is not appropriately processed (sterilized or high-level disinfected) between each use.

Steps

Step 1: Point-of-use preparation

After use, do not let the device dry. Presoak, rinse or spray the device with water or enzymatic spray. Do not use chlorine or saline as these may damage some medical instruments. Additionally, chlorine can be less effective when used before cleaning instruments in Step 2, and can lead to the development of antimicrobial resistance.

Step 2: Cleaning

Disassemble aspirator and adaptor (if used) and clean with warm water and detergent using a soft brush.

Step 3: Sterilization or high-level disinfection

All aspirators and adaptors must be sterilized or high-level disinfected after use.

Sterilization options	High-level disinfection options
Steam autoclave* instruments at 121°C (250°F) with a pressure of 106kPa (15lbs/in2) for 30 minutes Glutaraldehyde** soak for the time recommended by the manufacturer—most recommend 10 hours*** Sporox II solution soak for 6 hours***	Boil* the instruments for 20 minutes Glutaraldehyde** soak for the time recommended by the manufacturer—recommendations range from 20-90 minutes*** Sporox II solution soak for 30 minutes*** 0.5% chlorine solution soak for 20 minutes***

* IPAS SINGLE-VALVE ASPIRATOR CANNOT BE BOILED OR AUTOCLAVED.

** Because there are several glutaraldehyde products available with different recommendations for processing time, always follow the recommendations

that come with your brand of glutaraldehyde.

*** If chemical agents were used in processing, aspirator parts and adaptors (if used) should be thoroughly rinsed in clean, potable water (drinking water).

Step 4: Store appropriately or use immediately

Aspirators and adapters may be dried, the O-ring lubricated and the device reassembled and stored in a clean dry area until use. The aspirator does not need to remain high-level disinfected or sterilized at the time of use and can be placed in a clean area or stored according to local standards.

Instruments processed by wet methods should be reprocessed daily.

These validated methods of instrument processing do not negatively affect the MVA for at least 25 reuse cycles (Powell & Kapp, 2019). In practice, MVA devices are often used until they are no longer functional. Where data are recorded, devices are used an average of 34 times, ranging from single use in some facilities, to as many as 500 reuses reported in others (Eckersberger et al., 2023). Detailed information on MVA processing and other processing options are in Ipas's Woman-centered comprehensive abortion care: Reference manual, 2nd edition, page 150 (Ipas, 2013).

Resources

www.ipas.org/ClinicalResources

Processing the Ipas MVA Plus® Aspirator and Ipas EasyGrip® Cannulae (wall chart)



Ipas MVA reprocessing videos—Ipas (available in English, French, Spanish and Arabic)

Abortion Care Videos—Ipas: MVA Instrument Reprocessing

References

Curless, M. S., Ruparelia, C. S., Thompson, E., & Trexler, P. A. (Eds.) (2018). *Infection Prevention and Control: Reference Manual for Health Care Facilities with Limited Resources*. Jhpiego: Baltimore, MD.

Eckersberger, E., Dijkerman, S., Perkins, M., Overholt, T., Asport, S., Aziz, H., Barata, I., Gulati, S., Chekol, B. M., Mulase, L., Mulunda, J.-C., Oginni, A., Smith, M., Powell, B., & Kapp, N. (2023). Examining reuse and replacement procedures for Ipas manual vacuum aspiration and cannulae in nine countries. *International Journal of Gynecology & Obstetrics*, 163(2), 651–659.

Ipas. (2013). Woman-centered comprehensive abortion care: *Reference manual, 2nd edition*. Turner, K. L. & Huber, A., eds. Chapel Hill, North Carolina: Ipas.

Powell, B., & Kapp, N. (2019). Validation of instrument reprocessing methods for the Ipas manual vacuum aspiration devices. *International Journal of Gynecology & Obstetrics*, 147(1), 89-95.

World Health Organization and Pan American Health Organization. (2016). *Decontamination and Reprocessing of Medical Devices for Health-care Facilities*. Geneva: World Health Organization and Pan American Health Organization.

3.5

3. Abortion before 13 weeks gestation

Medical abortion

3.5.1. Self-management

Recommendation:

- Individuals can safely and effectively self-manage medical abortion with either mifepristone and misoprostol, or misoprostol-only when they have accurate information, quality-assured medicines, and access to health services, if needed.

Quality of evidence:

High

Last reviewed:

October 8, 2025

What is medical abortion self-management?

Self-management of medical abortion is the process by which an individual procures abortion medications (mifepristone and misoprostol, or misoprostol-only) and performs the component parts of their own abortion with or without support of a healthcare provider (World Health Organization [WHO], 2022). While some individuals will prefer to manage all of the component parts of medical abortion outside of the health care system, others may choose to interact with trained health workers via traditional or innovative service delivery mechanisms as needed; importantly it is the individual who decides which aspects of care they will self-manage, and when and where to seek support (WHO, 2024; WHO, 2022). Barriers to clinical access, such as cost or inaccessibility of services, are the most commonly reported reason for self-managed abortion (Amo-Adjei et al., 2025; Aiken, Starling, & Gomperts, 2021). While self-managed abortion has the potential to dramatically increase access to safe abortion, particularly in settings where access is limited (Jayaweera et al., 2021), individuals choose abortion self-management for many reasons. These reasons include more autonomy and control over the experience, possibility of greater comfort or privacy, and the ability to avoid stigma, discrimination, or other barriers associated with seeking care in a health facility (Aiken et al., 2018; Harries et al., 2021; Moseson et al., 2020). The American College of Obstetricians and Gynecologists (ACOG) states that criminalization-not the abortion itself-is the most important source of potential harm associated with abortion self-management (ACOG, 2024).

Many models of medical abortion self-management exist, depending on the extent that the formal health system, health workers, or other supportive services are involved in the process (Dragoman et al., 2022; Sorhaido & Sedgh, 2020). A 2025 systematic review combined data from 21 studies (n=10,693) examining multiple different models of medical abortion self-management with mifepristone and misoprostol to find an overall efficacy rate of 94% through 63 days gestation and 95% through 70 days (Ralph et al., 2025). Uterine evacuation was needed by 4% of patients, rates of ectopic pregnancy and blood transfusion were < 1%, and no deaths were reported.

Self-management of medical abortion

Medical abortion before 13 weeks is a process that takes place over a period of hours to days, consisting of three components: (1) determining eligibility for medical abortion; (2) administration of abortion medicines and management of the abortion process; and (3) assessment of the success of the abortion. Abundant clinical evidence documents the ability of pregnant people to safely and effectively perform each of these components. See 3.2: *Recommendations for abortion before 13 weeks: Gestational dating* and 3.3: *Recommendations for abortion before 13 weeks: Screening for ectopic pregnancy* for a summary of evidence supporting individuals' ability to self-assess their eligibility for medical abortion; see 3.5.6: *Recommendations for abortion before 13 weeks: Medical abortion: Home use of medications up to 12 weeks* for a summary of evidence supporting individuals' ability to self-administer abortion medications and manage the abortion process; and see 3.5.7: *Recommendations for abortion before 13 weeks: Medical abortion: Confirmation of success* for a summary of evidence supporting individuals' ability to self-assess the success of their abortion.

Models of abortion self-management

Telemedicine abortion

In telemedicine abortion, a health worker geographically separate from the abortion seeker facilitates a medical abortion. Telemedicine health workers assess abortion eligibility based on history, provide medications for abortion seekers to use at home, and offer follow up—this can occur both within or outside of the formal health system, and may be synchronous or asynchronous (Endler et al., 2019 ; Raymond et al., 2020). A 2025 Cochrane review assessed the safety and effectiveness of telemedicine for medical abortion, including six randomized controlled studies and 16 non-randomized studies, accounting for 131,278 individuals undergoing medical abortion up to 12 weeks gestation (Cleeve et al., 2025). This review found that medical abortion provided by telemedicine was as safe and effective as in-person abortion provision. Many prospective comparative cohort studies confirm this finding (Aiken et al., 2021; Anger & Raymond, 2024; Ralph et al., 2024; Upadhyay et al., 2024). The largest of these, a UK-based prospective cohort study that compared outcomes between individuals receiving a traditional, in-person medical abortion (n=22,158) and those receiving a telemedicine abortion with no pre-abortion testing, examination or ultrasonography up to 10 weeks gestation (n=18,435), found that more than 98% of individuals in both groups had a complete abortion and fewer participants in the telemedicine group (0.02%) suffered a serious adverse event than in the traditional care group (0.04%) (Aiken et al., 2021). WHO recommends telemedicine as an alternative to in-person medical abortion care (WHO, 2024).

Accompaniment models

In accompaniment models, trained non-clinical community agents provide abortion seekers with evidence-based medical abortion information, guidance for obtaining medication abortion drugs and step-by-step instructions for their use, guidance assessing abortion success and warning signs of complications, and support during the abortion process when needed. Accompaniment groups typically work outside of the formal health care system and may work in settings where abortion is highly restricted (Zurbriggen, Keefe-Oates, & Gerds, 2018). A prospective cohort study of abortion accompaniment included 1,352 participants up to 24 weeks gestation in Nigeria, Argentina and Southeast Asia (Moseson et al., 2023; Moseson et al., 2021). For participants with gestations up to nine weeks, self-reported abortion success rates were comparable to in-clinic care: 98% for both the combined mifepristone and misoprostol regimen and the misoprostol-only regimen (Jayaweera et al., 2023a; Jayaweera et al., 2023b; Moseson et al., 2021). Success rates for participants with gestations between 9 and 12 weeks (n=222) were 87% for the combined regimen and 98% for the misoprostol-only regimen (Jayaweera et al., 2023b; Moseson et al., 2021; Moseson et al., 2023). A smaller retrospective cohort study from Bolivia included 302 participants seeking abortion before 12 weeks gestation (Acre et al., 2023). Participants used both the combined and misoprostol-only regimens; the success rate was 99% with only 6 individuals seeking additional care, most commonly to confirm abortion success.

Community-based distribution

Two studies have documented the safety and effectiveness of misoprostol-only, self-managed abortion accessed through community-based distribution (Foster, Arnott, & Hobstetter, 2017; Foster et al., 2022). In these studies, lay or volunteer community health workers provided misoprostol and instructions for its use to individuals seeking abortion before 9 or 10 weeks gestation, based on their reported last menstrual period. In both studies, abortion success rates exceeded those seen in clinical misoprostol-only medical abortion studies (94-96%) with no serious adverse events recorded.

Pharmacy acquisition

Two comparative cohort studies have demonstrated the effectiveness of medical abortion with mifepristone and misoprostol acquired directly from pharmacies or drug sellers, compared to a health clinic. In Cambodia, a study including 1,847 women with an average gestational age of < 7 weeks found that 9% of women in the pharmacy group required additional treatment to complete their abortion, compared to 13% in the health clinic group (Kapp et al., 2023). A similar study in Ghana which included 1,958 women found that 3% of pharmacy patients and 5% of health clinic patients required additional treatment to complete their abortions (Kapp et al., 2024). One prospective cohort study conducted in Nigeria assessed success rates in pregnant individuals (n=394) who self-managed their abortion with misoprostol purchased from drug sellers (Stillman et al., 2020). Despite receiving inadequate information about the drugs, what to expect, or where and when to seek additional care, 94% of the sample reported a complete abortion without surgical intervention; one participant required a blood transfusion. A population based cross sectional study from India found that the self-reported complication rate was lower for women who had self-managed their medical abortion with pharmacy acquired medications (13%, n=2229) than those who had a provider-supported medical abortion (15%, n=2860); the type of complication was not specified (Banerjee, Gulati, & Pearson, 2025). A comparative cohort study in Bangladesh established comparable client-reported quality of abortion care received from pharmacies and in health clinics (Jacobsen et al., 2024). Pharmacy clients were more likely to report that the abortion was affordable, while health clinic clients received better quality of information and were more prepared in case of an adverse event.

Resources

www.ipas.org/ClinicalResources

Abortion with pills—Ipas
(Several evidence-based
resources for people about
how to safely self-manage
an abortion using pills at at
this link.)



Abortion Care Videos—Ipas: *Abortion Care
Videos for Women* (3 videos)

References

- ACOG Committee Statement No. 13: Self-Managed Abortion. (2024). *Obstetrics & Gynecology*, 144(6), e152.
- Acre, V. N., Küng, S. A., Arce, C., Yapu, A., Iriondo, D., & Morales, M. (2023). Reach, experience, and acceptability of an abortion self-care intervention in Bolivia: a mixed-methods evaluation. *Sexual and Reproductive Health Matters*, 31(1), 2139888.
- Aiken, A.R.A., Broussard, K., Johnson, J.M., & Padron, E. (2018). Motivations and experiences of people seeking medical abortion online in the United States. *Perspectives on Sexual and Reproductive Health*, 50(4), 157-163.
- Aiken, A.R.A., Starling, J.E., & Gomperts, R. (2021). Factors associated with use of an online telemedicine service to access self-managed medical abortion in the US. *JAMA Network Open*, 4(5), e2111852.
- Aiken, A., Lohr, P.A., Lord, J., Ghosh, N., & Starling, J. (2021). Effectiveness, safety and acceptability of no-test medical abortion (termination of pregnancy) provided via telemedicine: A national cohort study. *BJOG: An International Journal of Obstetrics and Gynaecology*, 128(9), 1464-1474.
- Aiken, A.R.A., Romanova, E.P., Morber, J.R., & Gomperts, R. (2022). Safety and effectiveness of self-managed medication abortion provided using online telemedicine in the United States: A population based study. *Lancet Regional Health Americas*, 10, 100200. Doi:10.1016/j.lana.2022.100200.
- Amo-Adjei, J., Boateng, K. A., Nicholson, M., Wilkins, R., Wachsmann, H., & Adu-Manu, K. (2025). Feasibility of medication abortion self-care service delivery in Ghana. *Reproductive Health*, 22, 64.
- Anger, H. A., & Raymond, E. G. (2024). Clinical and service delivery outcomes following medication abortion provided with or without pretreatment ultrasound or pelvic examination: An updated comparative analysis. *Contraception*, 140.
- Banerjee, S. K., Gulati, S., & Pearson, E. (2025). The transformative terrain: An in-depth analysis of trends in self-managed abortion in India using NFHS-5 national data. *Global Public Health*, 20(1), 2467796.
- Cleeve, A., Lavelanet, A., Gemzell-Danielsson, K., & Endler, M. (2025). The use of telemedicine services for medical abortion. *The Cochrane Database of Systematic Reviews*, 2025(6), CD013764.
- Dragoman, M., Fofie, C., Bergen, S., & Chavkin, W. (2022). Integrating self-managed medication abortion with medical care. *Contraception*, 108, 1-3.
- Endler, M., Lavelanet, A., Cleeve, A., Ganatra, B., Gomperts, R., & Gemzell-Danielsson, K. (2019). Telemedicine for medical abortion: A systematic review. *BJOG: An International Journal of Obstetrics & Gynaecology*, 126, 1094-1102.
- Foster, A.M., Arnott, G., & Hobstetter, M. (2017). Community-based distribution of misoprostol for early abortion: Evaluation of a program along the Thailand-Burma border. *Contraception*, 96, 242-247.
- Foster, A.M., Messier, K., Aslam, M., & Shabir, N. (2022). Community-based distribution of misoprostol for early abortion: Outcomes from a program in Sindh, Pakistan. *Contraception*, 109, 49-51.
- Harries, J., Daskilewicz, K., Bessenaar, T., & Gerdt, C. (2021). Understanding abortion seeking care outside of formal health care settings in Cape Town, South Africa: A qualitative study. *Reproductive Health*, 18, 190.
- Harries, J., Daskilewicz, K., Bessenaar, T., & Gerdt, C. (2021). Understanding abortion seeking care outside of formal health care settings in Cape Town, South Africa: A qualitative study. *Reproductive Health*, 18, 190.
- Jacobson, L. E., Baum, S. E., Pearson, E., Chowdhury, R., Chakraborty, N. M., Goodman, J. M., Gerdt, C., & Darney, B. G. (2024). Client-reported quality of facility-sourced self-managed abortion compared with pharmacy-sourced self-managed abortion in Bangladesh. *BMJ Sexual & Reproductive Health*, 50(1), 33-42.
- Jayaweera, R. T., Bradshaw, P. T., Gerdt, C., Egwuatu, I., Grosso, B., Kristianingrum, I., Nmezi, S., Zurbriggen, R., Ahern, J., & Moseson, H. (2023a). Accounting for Misclassification and Selection Bias in Estimating Effectiveness of Self-managed Medication Abortion. *Epidemiology*, 34(1), 140.
- Jayaweera, R., Egwuatu, I., Nmezi, S., Kristianingrum, I. A., Zurbriggen, R., Grosso, B., Bercu, C., Gerdt, C., & Moseson, H. (2023b). Medication Abortion Safety and Effectiveness With Misoprostol Alone. *JAMA Network Open*, 6(10), e2340042.
- Jayaweera, R., Powell, B., Gerdt, C., Kakesa, J., Ouedraogo, R., Ramazani, U., Wado, Y.D., Wheeler, E., & Feters, T. (2021). The potential of self-managed abortion to expand abortion access in humanitarian contexts. *Frontiers in Global Women's Health*, 2:681039. Doi: 10.3389/fgwh.2021.681039.

References continued

- Kapp, N., Bawah, A. A., Agula, C., Menzel, J. L., Antobam, S. K., Asuming, P. O., Eckersberger, E., & Pearson, E. E. (2024). Medical abortion in Ghana: A non-randomized, non-inferiority study of access through pharmacies compared with clinics. *Contraception*, 140.
- Kapp, N., Mao, B., Menzel, J., Eckersberger, E., Saphonn, V., Rathavy, T., & Pearson, E. (2023). A prospective, comparative study of clinical outcomes following clinic-based versus self-use of medical abortion. *BMJ Sexual & Reproductive Health*, 49(4), 300–307.
- Moseson, H., Herold, S., Filippa, S., Barr-Walker, J., Baum, S.E., & Gerdt, C. (2020a). Self-managed abortion: A systematic scoping review. *Best Practice & Research Clinical Obstetrics and Gynaecology*, 63, 87–110.
- Moseson, H., Jayaweera, R., Egwuatu, I., Grosso, B., Kristianingrum, I.A., Nmezi, S., Zurbriggen, R., Motana, R., Bercu, C., Carbone, S., & Gerdt, C. (2021). Effectiveness of self-managed medication abortion with accompaniment support in Argentina and Nigeria (SAFE): A prospective, observational cohort study and non-inferiority analysis with historical controls. *Lancet Global Health*, 10(1), e105–e113.
- Moseson, H., Jayaweera, R., Egwuatu, I., Grosso, B., Kristianingrum, I. A., Nmezi, S., Zurbriggen, R., Bercu, C., Motana, R., & Gerdt, C. (2023). Effectiveness of Self-Managed Medication Abortion Between 9 and 16 Weeks of Gestation. *Obstetrics & Gynecology*, 142(2), 330.
- Ralph, L. J., Baba, C. F., Biggs, M. A., McNicholas, C., Hagstrom Miller, A., & Grossman, D. (2024). Comparison of No-Test Telehealth and In-Person Medication Abortion. *JAMA*, 332(11), 898–905.
- Ralph, L. J., Ehrenreich, K., Kaller, S., Gurazada, T., Biggs, M. A., Blanchard, K., Hauser, D., Kapp, N., Kromenaker, T., Moayed, G., Gil, J. P., Perritt, J. B., Raymond, E., Taylor, D., White, K., Valladares, E. S., Williams, S., & Grossman, D. (2025). Accuracy of survey-based assessment of eligibility for medication abortion compared with clinician assessment. *American Journal of Obstetrics & Gynecology*, 233(1), 44.e1–44.e15.
- Raymond, E., Grossman, D., Mark, A., Upadhyay, U.D., Dean, G., Creinin, M.D., Coplon, L., Perritt, J., Atria, J.M., Taylor, D., & Gold, M. (2020). No-test medication abortion: A sample protocol for increasing access during a pandemic and beyond. *Contraception*, 101(6), 361–366.
- Stillman, M., Owolabi, A., Fatusi, A.O., Akinyemi, A.I., Berry, A.L., Erinfolami, T.P., Olagunju, O.S., Vaisanen, H., & Bankole, A. (2020). Women's self-reported experiences using misoprostol obtained from drug sellers: A prospective cohort study in Lagos state, Nigeria. *BMJ Open*, 10:e034670. Doi:10.1136/bmjopen-2019-034670.
- Sorhaindo, A., & Sedgh, G. (2021). Scoping review of research on self-managed medication abortion in low-income and middle-income countries. *BMJ Global Health*, 6(5), e004763.
- Upadhyay, U. D., Koenig, L. R., Meckstroth, K., Ko, J., Valladares, E. S., & Biggs, M. A. (2024). Effectiveness and safety of telehealth medication abortion in the USA. *Nature Medicine*, 30(4), 1191–1198.
- World Health Organization. (2015). *Health worker roles in providing safe abortion care and post abortion contraception*. Geneva: World Health Organization.
- World Health Organization. (2024). *Abortion care guideline, 2nd ed*. Geneva: World Health Organization.
- World Health Organization. (2022). *WHO recommendations on self-care interventions: Self-management of medical abortion, 2022 update*. Geneva: World Health Organization.
- Zurbriggen, R., Keefe-Oates, B., & Gerdt, C. (2018). Accompaniment of second-trimester abortions: The model of the feminist Socorrista network of Argentina. *Contraception*, 97, 108–115.

3.5

3. Abortion before 13 weeks gestation

Medical abortion

3.5.2. Risk of fetal malformations

Recommendation:

- Exposure to mifepristone alone has not been shown to cause fetal malformations. Exposure to misoprostol is associated with a small increased risk of malformations if the person has an ongoing pregnancy and decides not to terminate. Individuals with an ongoing pregnancy after using misoprostol should be counseled about the risk if they choose to continue the pregnancy.

Strength of recommendation:

Strong

Quality of evidence:

- Mifepristone: Very low
- Misoprostol: Very low

Last reviewed:

October 8, 2025

Background

The expected rate of fetal malformations in the general population is approximately 3% (Dolk, Loane, & Garne, 2010). Exposure to certain medications, infections, radiation or drugs of abuse during embryonic or fetal development may result in an increased risk of malformations if the pregnancy continues.

Mifepristone

Data on continuing pregnancy after mifepristone exposure without misoprostol are limited. Two 2024 systematic reviews, each including 13 observational studies found no evidence that mifepristone is a teratogen (Jingran, Yan, & Xiaoying, 2024; Turner et al., 2024). The largest prospective study of 46 women continuing a pregnancy after mifepristone resulted in eight miscarriages and, in the pregnancies that continued, two major malformations (5.3%). Neither malformation was thought to be related to mifepristone exposure but may have been a result of other medical conditions (Bernard et al., 2013). A 2025 analysis of postmarketing safety reports found that mifepristone was not associated with structural fetal heart defects (Liu et al., 2025).

Misoprostol

Case reports, cohort studies (da Silva Dal Pizzol et al., 2005; Vauzelle et al., 2013) and case-control studies (da Silva Dal Pizzol, Knop, & Mengue, 2006) show that the incidence of malformations peaks if misoprostol is used between 5-8 weeks after the last menstrual period (LMP) and is not associated with anomalies following exposure after 13 weeks following an individual's LMP (Philip, Shannon, & Winikoff, 2002). The most typical malformations associated with misoprostol use are Möbius sequence, a rare disorder of cranial nerve palsies associated with limb anomalies and craniofacial defects, and terminal transverse limb defects (da Silva Dal Pizzol, et al., 2006; Jingran, Yan, & Xiaoying, 2024). Although not clearly established, the proposed mechanism is vascular disruption from uterine contractions leading to disordered fetal development (Gonzalez et al., 2005; Shepard, 1995).

A 2024 systematic review of 9 observational studies including 5,073 cases with anomalies and 11,778 controls estimated an odds ratio of 2.69 for congenital anomalies after misoprostol exposure (Jingran, Yan, & Xiaoying, 2024). Consistent with earlier studies (Auffret et al., 2016; da Silva Del Pizzol et al., 2006), the estimated odds ratio for Möbius sequence was 26, for terminal transverse limb defects was 11, and for hydrocephalus was 3.

Although the rate of misoprostol exposure is higher in children born with characteristic defects such as Möbius sequence, the anomalies are so rare that the overall risk is low that a woman who takes misoprostol before 13 weeks gestation and carries a pregnancy to term will have a child born with a malformation related to misoprostol exposure. The risk of fetal malformation related to misoprostol exposure is less than 10 per 1,000 exposures (Philip, et al., 2002).

References

- Auffret, M., Bernard-Phalippon, N., Dekemp, J., Carlier, P., Gervoise Boyer, M., Vial, T., & Gautier, S. (2016). Misoprostol exposure during the first trimester of pregnancy: Is the malformation risk varying depending on the indication? *European Journal of Obstetrics & Gynecology and Reproductive Biology*, 207, 188-192.
- Bernard, N., Elefant, E., Carlier, P., Tebacher, M., Barjhoux, C., Bos-Thompson, M., & Vial, T. (2013). Continuation of pregnancy after first-trimester exposure to mifepristone: An observational prospective study. *BJOG: An International Journal of Obstetrics & Gynaecology*, 120(5), 568-574.
- da Silva Dal Pizzol, T., Knop, F. P., & Mengue, S. S. (2006). Prenatal exposure to misoprostol and congenital anomalies: Systematic review and meta-analysis. *Reproductive Toxicology*, 22(4), 666-671.
- da Silva Dal Pizzol, T., Tierling, V. L., Schüler-Faccin, L., Sanseverino, M. T. V., & Mengue, S. S. (2005). Reproductive results associated with misoprostol and other substances utilized for interruption of pregnancy. *European Journal of Clinical Pharmacology*, 61(1), 71-72.
- Dolk, H., Loane, M., & Garne, E. (2010). The prevalence of congenital anomalies in Europe. *Rare Diseases Epidemiology*, 349-364.
- Gonzalez, C. H., Vargas, F. R., Perez, A. B. A., Kim, C., Brunoni, D., Marques-Dias, M. J., & de Almeida, J. C. C. (2005). Limb deficiency with or without Möbius sequence in seven Brazilian children associated with misoprostol use in the first trimester of pregnancy. *American Journal of Medical Genetics*, 47(1), 59-64.
- Jingran, G., Yan, D., & Xiaoying, Y. (2024). Risk of teratogenicity in continued pregnancy after gestational exposure to mifepristone and/or misoprostol: a systematic review and meta-analysis. *Archives of Gynecology and Obstetrics*, 310(3), 1331-1342.
- Liu, R., Wang, J., Wang, Q., Zhang, Y., & Yuan, F. (2025). Mifepristone-related foetal cardiac adverse events: findings from the postmarketing safety reports. *Journal of Obstetrics and Gynaecology*, 45(1), 2528093.
- Philip, N. M., Shannon, C., & Winikoff, B. (2002). *Misoprostol and teratogenicity: Reviewing the evidence*. New York: Population Council.
- Shepard, T. H. (1995). Möbius syndrome after misoprostol: A possible teratogenic mechanism. *The Lancet*, 346(8977), 780.
- Turner, J. V., Garratt, D., Barwick, A., McLindon, L. A., Spark, M. J., & Smith, A. (2024). Congenital and Fetal Effects After Mifepristone Exposure and Continuation of Pregnancy: A Systematic Review. *Clinical Pharmacology & Therapeutics*, 116(5), 1207-1216.
- Vauzelle, C., Beghin, D., Cournot, M.-P., & Elefant, E. (2013). Birth defects after exposure to misoprostol in the first trimester of pregnancy: Prospective follow-up study. *Reproductive Toxicology*, 36, 98-103.

3.5

3. Abortion before 13 weeks gestation

Medical abortion

3.5.3. Mifepristone and misoprostol: Recommended regimen

Recommendation:

- Mifepristone 200mg orally followed 1-2 days later by misoprostol 800mcg buccally, sublingually or vaginally. The dose of misoprostol can be repeated to achieve abortion success.
- After 9 weeks gestation, routinely using at least two doses of misoprostol, administered 3-4 hours apart, improves abortion success rates.
- A combined regimen of mifepristone and misoprostol is effective and safe with abortion success rates over 95%, continuing pregnancy rates around 2% and complication rates of 1-3%.

In practice:

- A combined mifepristone and misoprostol regimen is more effective than misoprostol used alone and is recommended for medical abortion before 13 weeks; where mifepristone is unavailable, the misoprostol-only regimen can be used.
- Additional doses of misoprostol can be used if bleeding, cramping, or pregnancy expulsion have not occurred, and at least 3 hours have passed since the previous misoprostol dose.

Strength of recommendation:

Strong

Quality of evidence:

- Up to nine weeks gestation: High
- 9-13 weeks gestation: Low

Last reviewed:

July 16, 2026

Background

Medical abortion success is defined as a complete abortion that needs no further intervention. A combined regimen of mifepristone and misoprostol is recommended for medical abortion as it is more effective than letrozole and misoprostol or misoprostol alone (Abubeker et al., 2020; Blum et al., 2012; Kapp et al., 2019; Zhang et al., 2022; Ngoc et al., 2011; Raymond, Harrison, & Weaver, 2019; Teong et al., 2026; World Health Organization [WHO], 2024). Where mifepristone is unavailable, the misoprostol-only regimen may be used.

Up to nine weeks (63 days since LMP)

Multiple randomized controlled clinical trials have shown that the combination of mifepristone and misoprostol is an effective medical abortion regimen with success rates ranging from 95-98% up to nine weeks gestation (Abubeker et al., 2020; Brandell et al., 2024; Brandell et al., 2023; Chen & Creinin, 2015; Kapp, Baldwin, & Rodriguez, 2018; Zhang et al., 2022; Raymond et al., 2012). A 2020 systematic review of medical abortion with 200mg mifepristone and 800mcg misoprostol up to 9 weeks gestation in low- and middle-in-

come countries included 52 studies and found an average abortion success rate of 95% (Ferguson & Scott, 2020). Vaginal, buccal, and sublingual misoprostol are more effective than oral misoprostol (Zhang et al., 2022). Buccal dosing (Middleton et al., 2005) and sublingual dosing (Tang et al., 2003; von Hertzen et al., 2010) have higher rates of gastrointestinal side effects than vaginal dosing (Zhang et al., 2022). Sublingual dosing is associated with more side effects than buccal dosing (Chai, Wong, & Ho, 2013). Decreasing the sublingual misoprostol dose to 400mcg decreased side effects but increased the rates of incomplete abortion and ongoing pregnancy (Bracken et al., 2014; Raghavan et al., 2013; von Hertzen et al., 2010); therefore, the recommended dose of sublingual misoprostol remains 800mcg. Buccal or sublingual dosing may be preferred over vaginal dosing to accommodate individual preferences or legal restrictions.

Simultaneous dosing of mifepristone and misoprostol for those with gestations up to 63 days has demonstrated a success rate of approximately 95%, compared to 97-98% when misoprostol is used 24-48 hours after mifepristone (Creinin et al., 2007; Goel et al., 2011; Lohr et al., 2018; Schmidt-Hansen et al., 2022; Verma et al., 2017). Although this method is slightly less effective, it may be preferable in certain settings, such as where home use of medical abortion drugs is restricted (Lohr et al., 2018).

Four large cohort studies, including a total of 300,112 women who had mifepristone and misoprostol medical abortions up to nine weeks gestation (Cleland et al., 2013; Gatter, Cleland, & Nucatola, 2015; Goldstone, Walker, & Hawtin, 2017; Liu & Ray, 2023), found rates of uterine aspiration ranging from 2.3-4.8%. A Danish cohort study which included 86,437 mifepristone and misoprostol medical abortions before nine weeks concluded that increasing gestational age was most strongly associated with requiring surgical intervention (Meaidi et al. 2019). Rates of complications observed during medical abortion with mifepristone and misoprostol up to nine weeks gestation are less than 1% (Cleland et al., 2013; Gatter, Cleland, & Nucatola, 2015; Goldstone, Walker, & Hawtin, 2017; Liu & Ray, 2023).

	Goldstone, 2017	Cleland, 2013	Gatter, 2015
Number of women included	13,078	233,805	13,373
Gestational age	≤ 63 days	≤ 63 days	≤ 63 days
Location/organization	MSI Australia	Planned Parenthood USA	Planned Parenthood USA
Time period	2013-2015	2009-2010	2006-2011
Incomplete abortion requiring aspiration	4.84%	Not reported	2.3%
Unrecognized ectopic pregnancy	Not reported	0.007%	Not reported
Ongoing pregnancy	0.76%	0.5%	0.5%
Transfusion	0.13%	0.05%	0.03%
Infection	0.11%	0.02%	0.01%
Death	<0.01% (1 death from pneumonia, likely unrelated)	0.0004% (1 death from unrecognized ectopic pregnancy)	No deaths

9-11 weeks

A 2022 retrospective chart review assessed abortion success for 8,825 patients who took mifepristone followed by 800mcg of vaginal or buccal misoprostol up to 70 days gestation (Young et al., 2022). Before 64 days gestation, 97% of patients using vaginal misoprostol and 98% of patients using buccal misoprostol had a successful abortion; between 64 and 70 days of gestation, 93% of vaginal and buccal patients had a successful abortion. A 2015 review reports data from five comparative studies including 801 women with gestations between 64-70 days and 1,163 with gestations from 57-63 days (Abbas, Chong, & Raymond, 2015). In four studies, women received 200mg mifepristone followed by a single dose of 800mcg buccal misoprostol (Boersma, Meyboom-de Jong, & Kleiverda, 2011; Pena et al., 2014; Sanhueza Smith et al., 2015; Winikoff et al., 2012) and in one study, women received mifepristone and a single dose of 400mcg sublingual misoprostol (Bracken et al., 2014). There was no difference in success rates between the two gestational groups (93.9% at 57-63 days compared to 92.3% at 64-70 days), and there were no differences in serious adverse events, such as hospital admissions or transfers, between the groups (0.7% and 0.5% respectively).

A prospective, open-label, non-inferiority trial compared the efficacy of a medical abortion regimen of 200mg mifepristone, followed by a single dose of 800mcg misoprostol, in 362 women at 64-70 days gestation to efficacy of the same regimen in 286 women from 71-77 days gestation (Dzuba et al., 2020b). The success rate was 92% in the 64-70 day group, with an ongoing pregnancy rate of 4%, compared to 87% and 9% in the 71-77 day group, respectively. A subsequent retrospective cohort study compared success rates when two doses of 800mcg misoprostol were taken at home, four hours apart, for pregnancies between 64-70 days and 71-77 days (Dzuba et al., 2020a). Although a high loss to follow up (25%) limits conclusions that can be drawn, investigators found abortion success rates improved to greater than 99% from 64-70 days, and 98% from 71-77 days. A 2019 systematic review of medical abortion between 63 and 84 days gestation similarly concluded that abortion success rates are higher when routine, repeated doses of misoprostol are used, and when the vaginal route is used for misoprostol administration, compared to oral (Kapp et al., 2019). However, the review does not recommend a specific mifepristone and misoprostol regimen (Kapp et al., 2019).

11-13 weeks

One trial randomized 340 women with pregnancies up to 13 weeks to two groups: 1) 200mg mifepristone followed by either 800mcg vaginal, or 2) 600mcg sublingual misoprostol administration, followed by up to two additional doses of 400mcg sublingual or vaginal misoprostol every 3 hours (Hamoda et al., 2005). The overall success rate for this regimen was 95.8%. In both groups, most people required 2 doses of misoprostol to have a successful abortion; 3.4% of those in the vaginal group required surgical evacuation of the uterus, compared to 2.9% in the sublingual group. Those using misoprostol sublingually were more likely to experience side effects. A prospective cohort study (Lokeland et al., 2010), including 254 women with pregnancies between 63 and 90 days gestation, reported an abortion success rate of 91.7% and an ongoing pregnancy rate of less than 1% using a similar regimen of mifepristone followed by repeated doses of misoprostol. Between 10 and 13 weeks, reported rates of uterine aspiration for any reason range from 4-8% (Hamoda et al., 2005; Lokeland et al., 2010) and complication rates are around 3% (Hamoda et al., 2005).

Who can provide medical abortion before 13 weeks gestation?

The World Health Organization (WHO) makes service delivery recommendations for the provision of medical abortion before 13 weeks gestation, which includes assessment of medical abortion eligibility (determining pregnancy duration and assessing for contraindications to abortion medications), administration of abortion medications, management of the abortion process, and assessment of abortion success (WHO, 2024). WHO advises that all cadres of health care workers (specialty and general medical practitioners, associate and advanced associate clinicians, midwives, nurses, auxiliary nurses and auxiliary nurse midwives, traditional and complementary medicine professionals, pharmacists and pharmacy workers, and community health workers) can safely and effectively provide medical abortion with mifepristone and misoprostol or misoprostol-only based on a variety of evidence and the expected skills and knowledge for that type of health worker

(WHO, 2024). WHO also recommends that the pregnant person can safely and effectively self-manage the medical abortion process, in whole or in part, when they have access to accurate information, quality assured medications including for pain management, the support of trained health care workers, and access to a health facility if needed (WHO, 2024). For more information about self-managed medical abortion, see 3.5.2: *Recommendations for abortion before 13 weeks: Medical abortion self-management*. For further information about health worker roles in abortion care, see *Appendix C: World Health Organization recommendations for health worker roles in abortion care*.

References

- Abbas, D., Chong, E., & Raymond, E. G. (2015). Outpatient medical abortion is safe and effective through 70 days gestation. *Contraception*, 92(3), 197-199.
- Abubeker, F. A., Lavelanet, A., Rodriguez, M.I. & Kim, C. (2020). Medical termination for pregnancy in early first trimester (≤ 63 days) using combination of mifepristone and misoprostol alone: a systematic review. *BMC Women's Health*, 20, 142.
- Blum, J., Raghavan, S., Dabash, R., Ngoc, N. T., Chelli, H., Hajri, S., & Winikoff, B. (2012). Comparison of misoprostol-only and combined mifepristone-misoprostol regimens for home-based early medical abortion in Tunisia and Vietnam. *International Journal of Gynecology & Obstetrics*, 118, 166-171.
- Boersma, A. A., Meyboom-de Jong, B., & Kleiverda, G. (2011). Mifepristone followed by home administration of buccal misoprostol for medical abortion up to 70 days of amenorrhea in a general practice in Curacao. *European Journal of Contraception & Reproductive Health Care*, 16(2), 61-66.
- Bracken, H., Dabash, R., Tsertsivadze, G., Posohova, S., Shah, M., Hajri, S., ... Winikoff, B. (2014). A two-pill sublingual misoprostol outpatient regimen following mifepristone for medical abortion through 70 days' LMP: A prospective comparative open-label trial. *Contraception*, 89(3), 181-186.

Resources

www.ipas.org/ClinicalResources

Protocols for medical abortion (dosage card)

Mifepristone/Misoprostol Gestational Dating Wheels

Abortion Care Videos—Ipas: *Medical Abortion in Early Pregnancy*



Brandell, K., Jar-Allah, T., Reynolds-Wright, J., Kallner, H. K., Hognert, H., Gyllenberg, F., Kaislasuo, J., Tamang, A., Tuladhar, H., Boerma, C., Schimanski, K., Gibson, G., Løkeland, M., Teleman, P., Bixo, M., Kjaer, M. M., Kallfa, E., Bring, J., Heikinheimo, O., ... Gemzell-Danielsson, K. (2024). Randomized Trial of Very Early Medication Abortion. *New England Journal of Medicine*, 391(18), 1685-1695.

Brandell, K., Reynolds-Wright, J. J., Boerma, C., Gibson, G., Hognert, H., Tuladhar, H., Heikinheimo, O., Cameron, S., Gemzell-Danielsson, K., & Group, O. B. of the V. S. (2023). Medical Abortion before Confirmed Intrauterine Pregnancy: A Systematic Review. *Seminars in Reproductive Medicine*, 40, 258-263.

Chai, J., Wong, C. Y. G., & Ho, P. C. (2013). A randomized clinical trial comparing the short-term side effects of sublingual and buccal routes of misoprostol administration for medical abortions up to 63 days' gestation. *Contraception*, 87(4), 480-485.

Chen, M. J., & Creinin, M. D. (2015). Mifepristone with buccal misoprostol for medical abortion: A systematic review. *Obstetrics & Gynecology*, 126(1), 12-21.

Cleland, K., Creinin, M. D., Nucatola, D., Nshom, M., & Trussell, J. (2013). Significant adverse events and outcomes after medical abortion. *Obstetrics & Gynecology*, 121(1), 166-171.

Creinin, M. D., Schreiber, C. A., Bednarek, P., Lintu, H., Wagner, M. S., Meyn, L. A., & Medical abortion at the same time (MAST) study group. (2007). Mifepristone and misoprostol administered simultaneously versus 24 hours apart for abortion: A randomized controlled trial. *Obstetrics & Gynecology*, 109, 885-894.

References continued

- Dzuba, I.G., Castillo, P.W., Bousiequez, M., Hernandez, E.M.L., Vivar, J.J.C., & Smith, P. S. (2020a). A repeat dose of misoprostol 800mcg following mifepristone for outpatient medical abortion at 64-70 and 71-77 days of gestation: A retrospective chart review. *Contraception* 102, 104-108.
- Dzuba, I.G., Chong, E., Hannum, C., Lichtenberg, S., Hernandez, E.M.L., Ngoc, N. ... & Winikoff, B. (2020b). A non-inferiority study of outpatient mifepristone-misoprostol medical abortion at 64-70 days and 71-77 days of gestation. *Contraception*, 101, 302-308.
- Ferguson, I., & Scott, H. (2020). Systematic review of the effectiveness, safety, and acceptability of mifepristone and misoprostol for medical abortion in low-and middle-income countries. *Journal of Obstetrics and Gynaecology Canada*, 42(12), 1532-1542.
- Gatter, M., Cleland, K., & Nucatola, D. L. (2015). Efficacy and safety of medical abortion using mifepristone and buccal misoprostol through 63 days. *Contraception*, 91(4), 269-73.
- Goel, A., Mittal, S., Taneja, B. K., Singal, N., & Attri, S. (2011) Simultaneous administration of mifepristone and misoprostol for early termination of pregnancy: A randomized controlled trial. *Archives of Gynecology and Obstetrics*, 283, 1409-13.
- Goldstone, P., Walker, C., & Hawtin, K. (2017). Efficacy and safety of mifepristone-buccal misoprostol for early medical abortion in an Australian setting. *Australian and New Zealand Journal of Obstetrics and Gynaecology*, 57, 366-371.
- Hamoda, H., Ashok, P. W., Flett, G. M., & Templeton, A. (2005). A randomised controlled trial of mifepristone in combination with misoprostol administered sublingually or vaginally for medical abortion up to 13 weeks of gestation. *BJOG: An International Journal of Obstetrics & Gynaecology*, 112, 1102-1108.
- Kapp, N., Baldwin, M. K., & Rodriguez, M. I. (2018). Efficacy of medical abortion prior to 6 gestational weeks: A systematic review. *Contraception*, DOI: 10.1016/j.contraception.2017.09.006.
- Kapp, N., Eckersberger, E., Lavelanet, A., & Rodriguez, M. I. (2019). Medical abortion in the late first trimester: a systematic review. *Contraception*, 99(2), 77-86.
- Liu, N., & Ray, J. G. (2023). Short-Term Adverse Outcomes After Mifepristone–Misoprostol Versus Procedural Induced Abortion. *Annals of Internal Medicine*, 176(2), 145–153.
- Lohr, P. A., Starling, J. E., Scott, J. G., & Aiken, A. R. A. (2018). Simultaneous compared with interval medical abortion regimens where home use is restricted. *Obstetrics & Gynecology*, 131(4), 635-641.
- Lokeland, M., Iverson, O. E., Dahle, G. S., Nappen, M. H., Ertzeid, L., & Bjorge, L. (2010). Medical abortion at 63 to 90 days of gestation. *Obstetrics & Gynecology*, 115(2), 962-968.
- Meaidi, A., Friedrich, S., Gerds, T. A., & Lidegaard, O. (2019). Risk factors for surgical intervention of early medical abortion. *American Journal of Obstetrics and Gynecology*, 220, 478.e1-478.e15.
- Middleton, T., Schaff, E., Fielding, S. L., Scahill, M., Shannon, C., Westheimer, E., & Winikoff, B. (2005). Randomized trial of mifepristone and buccal or vaginal misoprostol for abortion through 56 days of last menstrual period. *Contraception*, 72(5), 328-332.
- Ngoc, N. T., Blum, J., Raghavan, S., Nga, N. T., Dabash, R., Diop, A., & Winikoff, B. (2011). Comparing two early medical abortion regimens: Mifepristone + misoprostol vs. misoprostol alone. *Contraception*, 83, 410-417.
- Pena, M., Dzuba, I. G., Smith, P. S., Mendoza, L. J., Bousiequez, M., Martinez, M. L., ... Winikoff, B. (2014). Efficacy and acceptability of a mifepristone-misoprostol combined regimen for early induced abortion among women in Mexico City. *International Journal of Gynecology & Obstetrics*, 127(1), 82-85.
- Raghavan, S., Tesereteli, T., Kamilov, A., Kurbanbekova, D., Yusupov, D., Kasimova, F., ... Winikoff, B. (2013). Acceptability and feasibility of the use of 400mcg of sublingual misoprostol after mifepristone for medical abortion up to 63 days since the last menstrual period: Evidence from Uzbekistan. *The European Journal of Contraception and Reproductive Health Care*, 18(2), 104-111.
- Raymond, E., Harrison, M., & Weaver, M. (2019). Efficacy of misoprostol alone for first-trimester medical abortion: A systematic review. *Obstetrics & Gynecology*, 133, 137-147.
- Raymond, E. G., Shannon, C., Weaver, M. A., & Winikoff, B. (2012). First-trimester medical abortion with mifepristone 200 mg and misoprostol: A systematic review. *Contraception*, 87(1), 26-37.

References continued

Sanhueza Smith, P., Pena, M., Dzuba, I. G., Garcia Martinez, M. L., Aranque Peraza, A. G., Bousiequez, M., ... Winikoff, B. (2015). Safety, efficacy and acceptability of outpatient mifepristone-misoprostol medical abortion through 70 days since last menstrual period in public sector facilities in Mexico City. *Reproductive Health Matters*, 22(44 Suppl 1), 75-82.

Schmidt-Hansen, M., Lord, J., Hasler, E., & Cameron, S. (2020). Simultaneous compared to interval administration of mifepristone and misoprostol for medical abortion up to 10 weeks' gestation: A systematic review with meta-analyses. *BMJ Sexual and Reproductive Health*, 46(4), 270-278.

Teong, A.C.A., Wong, T.T.C., Soe, N.N., Lau, H.C.Q., Ang, C.Y.X., Loy, S.L., ... Seet, M.J. (2026). The use of letrozole or mifepristone for pre-treatment of medical temrination of pregnancy: A randomized, non-inferiority trial. *International Journal of Gynecology & Obstetrics*, 00, 1-9.

Verma, M.L., Singh, U., Singh, N., Sankhwar, P.L., & Qureshi, S. (2017). Efficacy of concurrent administration of mifepristone and misoprostol for termination of pregnancy. *Human Fertility*, 20(1), 43-47.

von Hertzen, H., Huong, N. T., Piaggio, G., Bayalag, M., Cabezas, E., Fang, A. H., & Peregoudov, A. (2010). Misoprostol dose and route after mifepristone for early medical abortion: A randomised controlled noninferiority trial. *BJOG: An International Journal of Obstetrics & Gynaecology*, 117(10), 1186-1196.

Winikoff, B., Dzuba, I. G., Chong, E., Goldberg, A. B., Lichtenberg, E. S., Ball, C., ... Swica, Y. (2012). Extending outpatient medical abortion services through 70 days of gestational age. *Obstetrics & Gynecology*, 120(5), 1070-1076.

World Health Organization. (2024). *Abortion care guideline, 2nd ed.* Geneva: World Health Organization.

Young, D., Fitzgerald, K., Laursen, L., & Whitaker, A. K. (2022). Comparison of vaginal and buccal misoprostol after mifepristone for medication abortion through 70 days of gestation: A retrospective chart review. *Contraception*, 115, 62-66.

Zhang, J., Zhou, K., Shan, D., & Luo, X. (2022). Medical methods for first trimester abortion. *Cochrane Database of Systematic Reviews*, 5(5), CD002855.

3.5

3. Abortion before 13 weeks gestation

Medical abortion

3.5.4. Misoprostol only: Recommended regimen

Recommendation:

- Misoprostol 800mcg buccally, sublingually or vaginally every three hours until expulsion.
- A misoprostol-only regimen has success rates of 84-93%, with continuing pregnancy rates of 3-10% and complication rates of 1-4%.

In practice:

- A combined mifepristone and misoprostol regimen is more effective than misoprostol used alone and is recommended for medical abortion before 13 weeks; where mifepristone is unavailable the misoprostol-only regimen can be used.
- Additional doses of misoprostol can be used if bleeding, cramping, or pregnancy expulsion have not occurred and at least 3 hours have passed since the previous misoprostol dose.
- Individuals undergoing misoprostol-only medical abortion outside of a health facility should be provided with 3-4 doses of misoprostol depending on the scenario. An extra dose of misoprostol, and information describing when to use additional doses, should be provided to be used if needed.

Strength of recommendation:

Strong

Quality of evidence:

- Up to nine weeks gestation: Moderate
- 9-13 weeks gestation: Low

Last reviewed:

October 9, 2025

Background

Medical abortion success is defined as a complete abortion that needs no further intervention. A combined regimen of mifepristone and misoprostol is recommended for medical abortion, as it is more effective than misoprostol alone (Abubeker et al., 2020; Blum et al., 2012; Kapp et al., 2019; Kulier et al., 2011; Ngoc et al., 2011; Raymond, Harrison, & Weaver, 2019; World Health Organization [WHO], 2022). Where mifepristone is unavailable, the misoprostol-only regimen may be used.

Misoprostol-only abortion regimens

A 2023 systematic review assessed effectiveness of misoprostol alone by reviewing 49 studies where at least one group of participants received misoprostol alone to induce abortion up to 91 days gestation (Raymond, Weaver, & Shochet, 2023). The misoprostol regimens differed across the included studies. The review, which included 16,3549 women with abortion outcome data, found an overall abortion success rate of 85% and an ongoing pregnancy rate of 6%. When the analysis was restricted to participants who used at least three doses of misoprostol administered by a non-oral route, the failure rate was 11% and ongoing pregnancy rate was 5%.

A very small number of participants (0.2%) required hospitalization, most commonly for transfusion. The largest randomized trial using the recommended misoprostol-only regimen of 3 doses of 800mcg of misoprostol by either the vaginal or sublingual route, included 2,046 participants with gestations of seven weeks or less (von Hertzen et al., 2007). Success of misoprostol-only abortion was 84%. A more recent study randomized 390 people with pregnancies up to 10 weeks of gestation to receive 3 doses of misoprostol 800mcg by either the buccal or sublingual route, with the option for an additional dose of misoprostol if the abortion was not complete at the time of follow up (Sheldon et al., 2019). At initial follow up, the ongoing pregnancy rate for both groups combined was 3%, and abortion success rate was 86%. After offering an additional dose of misoprostol to any participants who did not have a successful abortion, success rates increased to 93%. Smaller studies using similar regimens have reported success rates of 92% for gestations up to eight weeks (Fekih, 2010), 89-91% up to nine weeks (Salakos et al., 2005; Velazco et al., 2000), and from 84-87% from 9-13 weeks (Carbonell et al., 1999; Carbonell Esteve et al., 1998, Carbonell et al., 2001). In studies that used the recommended misoprostol-only regimen or similar regimens, the rate of subsequent uterine aspiration for any reason ranges from 7-17%, with ongoing pregnancy rates of 3-10% (Carbonell et al., 1999; Carbonell et al., 2001; Sheldon et al., 2019; Velazco et al., 2000; von Hertzen et al., 2007).

Studies examining strategies to support safe and effective abortion outside the clinical setting, such as those exploring abortion accompaniment or community-based distribution of misoprostol for medical abortion self-management, have reported abortion success rates for misoprostol-only abortion that exceed those for facility based care (Moseson et al., 2020b). In the SAFE study, which documents effectiveness of abortion self-management with accompaniment support, 98% of the misoprostol-only users reported a successful abortion without surgical intervention (Jayaweera et al., 2023a; Jayaweera et al., 2023b; Moseson et al., 2022). Two studies have documented the safety and effectiveness of misoprostol-only, self-managed abortion, accessed through community-based distribution up to either 9 or 10 weeks gestation; abortion success rates were 94-96% with no serious adverse events recorded (Foster, Arnott, & Hobstetter, 2017; Foster et al., 2022). One prospective cohort study conducted in Nigeria assessed success rates in pregnant individuals who purchased misoprostol from drug sellers to self-manage their medical abortion (Stillman et al., 2020). Despite receiving inadequate information about the drugs, what to expect, or where and when to seek additional care, 94% of the sample reported a complete abortion without surgical intervention. Of the sample, one participant required a blood transfusion.

The only multicenter randomized controlled trial to compare different misoprostol-only dosing intervals showed that complete abortion rates are equivalent when misoprostol is given vaginally every 3-12 hours or sublingually every three hours for three doses. Sublingual dosing had a higher incidence of side effects than vaginal dosing (von Hertzen et al., 2007). Systematic reviews from 2022 and 2023 summarizing data on effectiveness of misoprostol alone for medical abortion found that vaginal, buccal and sublingual administration result in similar rates of surgical intervention, while oral administration resulted in significantly more (Raymond, Weaver, & Shochet, 2023; Zhang et al., 2022). A trial that randomized women with pregnancies up to 10 weeks to either buccal or sublingual misoprostol (800mcg every three hours for three doses) found that sublingual administration led to significantly fewer continuing pregnancies at follow-up, 1.1% compared with 5.5% (Sheldon et al., 2019). Participants in the sublingual group experienced more fever and chills than those in the buccal administration group.

In general, higher rates of success with misoprostol-only regimens are associated with a gestational age of less than 7 weeks (von Hertzen et al., 2007; Zikopoulos et al., 2002), higher number of repeat doses of misoprostol (Carbonell et al., 1999; Jain et al., 2002; Kapp et al., 2018), higher initial doses of misoprostol (Raymond et al., 2019), non-oral routes of misoprostol administration (Kapp et al., 2018; Raymond, Weaver, & Shochet, 2023; Zhang et al., 2022), and a longer time period before provider follow-up to confirm abortion success (Bugalho et al., 2000; Sheldon et al., 2019). However, individual satisfaction decreases the longer the abortion process lasts (Ngai et al., 2000).

The addition of letrozole

One high quality, randomized controlled trial has assessed if the addition of letrozole—a third generation aromatase inhibitor that decreases estrogen levels and leads to pregnancy loss—to a misoprostol-only regimen improves success of medical abortion up to 9 weeks gestation (Lee et al., 2011a). One hundred and sixty-eight participants were randomized to a three day course of letrozole (10mg orally each day followed, by a single dose of vaginal misoprostol on day three), or to placebo, followed by misoprostol. Complete abortion was more likely in the letrozole group (87%), than the placebo group (73%, $p=0.021$); there were no statistically significant differences in continuing pregnancies between the two groups (8% compared to 11%, $p=0.6$). An earlier pilot study conducted in 20 participants with gestations up to 9 weeks examined a two dose letrozole regimen (10mg orally for two days, followed by a single dose of 800mcg of misoprostol administered vaginally on day three), finding a lower success rate of 80% (Lee et al., 2011b). A subsequent pilot study, including 20 participants with gestations up to 9 weeks, found a higher abortion completion rate (95%), comparable to that seen with the mifepristone and misoprostol regimen, when a seven-day course of letrozole 10mg was administered before a single dose of misoprostol 800mcg vaginally on day 7 (Yeung et al., 2021).

One randomized controlled trial has examined the addition of letrozole to misoprostol compared to placebo and misoprostol in 46 participants with an average gestational age of 11 to 13 weeks (Javanmanesh, Kashanian, & Mirpangi, 2018). The letrozole group, which took 10mg of letrozole daily for three days, followed by repeated doses of sublingual misoprostol, had a 78% success rate, compared to 13% in the placebo group ($p=0.0001$), with no differences in side effects and no complications reported. These findings must be interpreted with caution given the very low quality of the study, the small sample size, the discrepancy in mean gestational age between the two groups (11.2 ± 4 weeks in the letrozole group compared to 13.2 ± 3 weeks in the placebo group), and the markedly low success rate reported for the placebo group, which is not in alignment with other studies' reported success rates with misoprostol-only abortion regimens. Two additional randomized trials, conducted in participants with gestations after 13 weeks, have compared letrozole and misoprostol to placebo and misoprostol (Lee et al., 2011b; Naghshineh, Allame, & Farhat, 2015). Naghshineh, Allame, & Farhat (2015) included 121 participants with an average gestational age of 13 weeks and found a significantly higher success rate in the group that took letrozole (10mg daily for three days prior to sublingual misoprostol)—77%—compared to placebo (43%, $p<0.0001$). Lee et al. (2011b) used a smaller dose of letrozole (7.5mg) and found no difference in complete abortion rates in a sample of 130 participants with an average gestational age of 15 weeks. In both of these studies, side effects were comparable between the two groups and no complications were reported. Two systematic reviews examining letrozole and misoprostol, compared to placebo and misoprostol—both of which included studies of second trimester abortion and one of which included a study using letrozole as a treatment for missed abortion—came to conflicting conclusions. Zhou et al. (2021), based on 4 heterogeneous randomized controlled trials including a total of 497 patients, found that complete abortion was more likely with the addition of letrozole (relative risk [RR]: 1.38, 95% Confidence Interval [CI]: 1.07, 1.78). Nash et al. (2018), based on 3 randomized controlled trials including 503 patients, found no statistically significant difference in abortion success between letrozole and misoprostol (74%), or placebo and misoprostol (56%, RR: 1.24, 95% CI: 0.92, 1.66).

Despite the limited evidence available to support its use, World Health Organization (WHO) has suggested that letrozole (10mg orally each day for three days), followed by misoprostol can be used for medical abortion before 12 weeks of gestation in settings where mifepristone is not available (WHO, 2024).

Young people

Safety and effectiveness of misoprostol-only abortion has been demonstrated in adolescents with pregnancies up to nine weeks gestation (Velazco et al., 2000) and between 9-12 weeks gestation (Carbonell et al., 2001). Success rates of misoprostol-only abortion in young women are similar to those seen in studies of older women.

Who can provide medical abortion before 13 weeks gestation?

The World Health Organization (WHO) makes service delivery recommendations for the provision of medical abortion before 13 weeks gestation, which includes assessment of medical abortion eligibility (determining pregnancy duration and assessing for contraindications to abortion medications), administration of abortion medications, management of the abortion process, and assessment of abortion success (WHO, 2024). WHO advises that all cadres of health care workers (specialty and general medical practitioners, associate and advanced associate clinicians, midwives, nurses, auxiliary nurses and auxiliary nurse midwives, traditional and complementary medicine professionals, pharmacists and pharmacy workers, and community health workers) can safely and effectively provide medical abortion with mifepristone and misoprostol or misoprostol-only based on a variety of evidence, and the expected skills and knowledge for that type of health worker (WHO, 2024). WHO also recommends that the pregnant person can safely and effectively self-manage the medical abortion process, in whole or in part, when they have access to accurate information, quality assured medications including for pain management, the support of trained health care workers, and access to a health facility, if needed (WHO, 2024). For more information about self-managed medical abortion, see 3.5.2: *Recommendations for abortion before 13 weeks: Medical abortion self-management*. For further information about health worker roles in abortion care, see *Appendix C: World Health Organization recommendations for health worker roles in abortion care*.

Resources

www.ipas.org/ClinicalResources

Protocols for medical abortion (dosage card)

Misoprostol-only Gestational Dating Wheels

Abortion Care Videos—Ipas: *Medical Abortion in Early Pregnancy*



References

Abubeker, F. A., Lavelanet, A., Rodriguez, M.I. & Kim, C. (2020). Medical termination for pregnancy in early first trimester (≤ 63 days) using combination of mifepristone and misoprostol alone: a systematic review. *BMC Women's Health*, 20, 142.

Blum, J., Raghavan, S., Dabash, R., Ngoc, N. T., Chelli, H., Hajri, S., & Winikoff, B. (2012). Comparison of misoprostol-only and combined mifepristone-misoprostol regimens for home-based early medical abortion in Tunisia and Vietnam. *International Journal of Gynecology & Obstetrics*, 118, 166-171.

Bugalho, A., Mocumbi, S., Faundes, A., & David, E. (2000). Termination of pregnancies of < 6 weeks gestation with a single dose of 800 microg of vaginal misoprostol. *Contraception*, 61(1), 47-50.

Carbonell Esteve, J. L., Varela, L., Velazco, A., Cabezas, E., Tanda, R., & Sanchez, C. (1998). Vaginal misoprostol for late first trimester abortion. *Contraception*, 57(5), 329-333.

Carbonell, J. L., Varela, L., Velazco, A., Tanda, R., & Sanchez, C. (1999). Vaginal misoprostol for abortion at 10-13 weeks' gestation. *The European Journal of Contraception and Reproductive Health Care*, 4(1), 35-40.

Carbonell, J. L., Velazco, A., Varela, L., Tanda, R., Sanchez, C., Barambio, S., & Mari, J. (2001). Misoprostol for abortion at 9-12 weeks' gestation in adolescents. *The European Journal of Contraception and Reproductive Health Care*, 6(1), 39-45.

References continued

- Fekih, M., Fathallah, K., Regaya, L. B., Bouguizane, S., Chaieb, A., Bibi, M., & Khairi, H. (2010). Sublingual misoprostol for first trimester termination of pregnancy. *International Journal of Gynecology & Obstetrics*, 109, 67-70.
- Foster, A.M., Arnott, G., & Hobstetter, M. (2017). Community-based distribution of misoprostol for early abortion: Evaluation of a program along the Thailand-Burma border. *Contraception*, 96, 242-247.
- Foster, A.M., Messier, K., Aslam, M., & Shabir, N. (2022). Community-based distribution of misoprostol for early abortion: Outcomes from a program in Sindh, Pakistan. *Contraception*, 109, 49-51.
- Ganguly, R. P., Saha, S. P., Mukhopadhyay, S., Bhattacharjee, N., Bhattacharyya, S. K., & Patra, K. K. (2010). A comparative study on sublingual versus oral and vaginal administration of misoprostol for later first and early second trimester abortion. *Journal of the Indian Medical Association*, 108(5), 283-286.
- Grapsas, X., Liberis, V., Vassaras, G., Tsikouras, P., Vlachos, G., & Galazios, G. (2008). Misoprostol and first trimester pregnancy termination. *Clinical and Experimental Obstetrics and Gynecology*, 35(1), 32-34.
- Jain, J. K., Dutton, C., Harwood, B., Meckstroth, K. R., & Mishell, D. (2002). A prospective randomized, double-blinded, placebo-controlled trial comparing mifepristone and vaginal misoprostol to vaginal misoprostol alone for elective termination of pregnancy. *Human Reproduction*, 17(6), 1477-1482.
- Javanmanesh, F., Kashanian, M., Mirpangi, S. (2018). Comparison of using misoprostol with or without letrozole in abortion induction: A placebo-controlled clinical trial. *Journal of Obstetrics, Gynecology and Cancer Research*, 3(2), 49-52.
- Jayaweera, R. T., Bradshaw, P. T., Gerdt, C., Egwuatu, I., Grosso, B., Kristianingrum, I., Nmezi, S., Zurbriggen, R., Ahern, J., & Moseson, H. (2023a). Accounting for misclassification and selection bias in estimating effectiveness of self-managed medication abortion. *Epidemiology*, 34(1), 140.
- Jayaweera, R., Egwuatu, I., Nmezi, S., Kristianingrum, I. A., Zurbriggen, R., Grosso, B., Bercu, C., Gerdt, C., & Moseson, H. (2023b). Medication abortion safety and effectiveness with misoprostol alone. *JAMA Network Open*, 6(10), e2340042.
- Kapp, N., Eckersberger, E., Lavelanet, A., & Rodriguez, M. I. (2019). Medical abortion in the late first trimester: a systematic review. *Contraception*, 99(2), 77-86.
- Kulier, R., Kapp, N., Gulmezoglu, A. M., Hofmeyr, G. J., Cheng, L., & Campana, A. (2011). Medical methods for first trimester abortion. *Cochrane Database of Systematic Reviews*, 11, Art No.: CD002855. DOI: 10.1002/14651858.CD002855.pub4.
- Lee, V.C.Y., Ng, E.H.Y., Yeung, W.S.B., & Ho, P.C. (2011a). Misoprostol with or without letrozole pretreatment for termination of pregnancy: A randomized controlled trial. *Obstetrics & Gynecology*, 117(2Pt1), 317-323.
- Lee, V.C.Y., Tang, O.S., Ng, E.H.Y., Yeung, W.S.B., & Ho, P.C. (2011b). A pilot study on the use of letrozole with either misoprostol or mifepristone for termination of pregnancy up to 63 days. *Contraception*, 83(1), 62-67.
- Lee, V.C.Y., Tang, O.S., Ng, E.H.Y., Yeung, W.S.B., & Ho, P.C. (2011c). A prospective double-blinded, randomized, placebo-controlled trial on the use of letrozole pretreatment with misoprostol for second-trimester medical abortion. *Contraception*, 84, 628-633.
- Moseson, H., Herold, S., Filippa, S., Barr-Walker, J., Baum, S.E., & Gerdt, C. (2020a). Self-managed abortion: A systematic scoping review. *Best Practice & Research Clinical Obstetrics and Gynaecology*, 63, 87-110.
- Moseson, H., Jayaweera, R., Egwuatu, I., Grosso, B., Kristianingrum, I.A., Nmezi, S., Zurbriggen, R., Motana, R., Bercu, C., Carbone, S., & Gerdt, C. (2022). Effectiveness of self-managed medication abortion with accompaniment support in Argentina and Nigeria (SAFE): A prospective, observational cohort study and non-inferiority analysis with historical controls. *Lancet Global Health*, 10(1), e105-e113.
- Naghshineh, E., Allame, Z., & Farhat, F. (2015). The effectiveness of using misoprostol with and without letrozole for successful medical abortion: A randomized placebo-controlled clinical trial. *Journal of Research in Medical Sciences*, 20(6), 585-589.
- Ngai, S. W., Tang, O. S., Chan, Y. M., & Ho, P. C. (2000). Vaginal misoprostol alone for medical abortion up to 9 weeks of gestation: Efficacy and acceptability. *Human Reproduction*, 15(5), 1159-1162.
- Ngoc, N. T., Blum, J., Raghavan, S., Nga, N. T., Dabash, R., Diop, A., & Winikoff, B. (2011). Comparing two early medical abortion regimens: Mifepristone + misoprostol vs. misoprostol alone. *Contraception*, 83, 410-417.

References continued

- Raymond, E., Harrison, M., & Weaver, M. (2019). Efficacy of misoprostol alone for first-trimester medical abortion: A systematic review. *Obstetrics & Gynecology*, 133, 137-147.
- Raymond, E. G., Weaver, M. A., & Shochet, T. (2023). Effectiveness and safety of misoprostol-only for first-trimester medication abortion: An updated systematic review and meta-analysis. *Contraception*, 127.
- Salakos, N., Kountouris, A., Botsis, D., Rizos, D., Gregoriou, O., Detsis, G., & Creatsas, G. (2005). First-trimester pregnancy termination with 800mcg of vaginal misoprostol every 12 h. *The European Journal of Contraception and Reproductive Health Care*, 10(4), 249-254.
- Sheldon, W. R., Durocher, J., Dzuba, I. G., Sayette, H., Martin, R., Velasco, M. C., & Winikoff, B. (2019). Early abortion with buccal versus sublingual misoprostol alone: A multicenter, randomized trial. *Contraception*, 99(5), 272-277.
- Stillman, M., Owolabi, A., Fatusi, A.O., Akinyemi, A.I., Berry, A.L., Erinfolami, T.P., Olagunju, O.S., Vaisanen, H., & Bankole, A. (2020). Women's self-reported experiences using misoprostol obtained from drug sellers: A prospective cohort study in Lagos state, Nigeria. *BMJ Open*, 10:e034670. Doi:10.1136/bmjopen-2019-034670.
- Tang O. S., Miao, B. Y., Lee, S. W. H., & Ho, P. C. (2002). Pilot study on the use of repeated doses of sublingual misoprostol in termination of pregnancy up to 12 weeks gestation: Efficacy and acceptability. *Human Reproduction*, 17(3), 654-658.
- Velazco A., Varela, L., Tanda, R., Sanchez, C., Barambio, S., Chami, S., ... Carbonell, J. L. (2000). Misoprostol for abortion up to 9 weeks' gestation in adolescents. *European Journal of Contraception and Reproductive Health Care*, 5(4), 227-233.
- Van Bogaert, L. J., & Misra, A. (2010). Anthropometric characteristics and success rates of oral or vaginal misoprostol for pregnancy termination in the first and second trimesters. *International Journal of Gynecology & Obstetrics*, 109(3), 213-215.
- Von Hertzen, H., Piaggio, G., Huong, N. T., Arustamyan, K., Cabezas, E., Gomez, M., & Peregoudov, A. (2007). Efficacy of two intervals and two routes of administration of misoprostol for termination of early pregnancy: A randomised controlled equivalence trial. *The Lancet*, 369(9577), 1938-1946.
- Von Hertzen, H., Piaggio, G., Wojdyla, D., Nguyen, T. M., Marions, L., Okoev, G., & Peregoudov, A. (2009). Comparison of vaginal and sublingual misoprostol for second trimester abortion: Randomized controlled equivalence trial. *Human Reproduction*, 24(1), 106-112.
- World Health Organization. (2024). *Abortion care guideline, 2nd ed.* Geneva: World Health Organization.
- Yeung, T.W.Y., Lee, V.C.Y., Ng, E.H.Y., & Ho, P.C. (2012). A pilot study on the use of a 7-day course of letrozole followed by misoprostol for the termination of early pregnancy up to 63 days. *Contraception*, 86(6), 763-769.
- Zhang, J., Zhou, K., Shan, D., & Luo, X. (2022). Medical methods for first trimester abortion. *Cochrane Database of Systematic Reviews*, 5(5), CD002855.
- Zikopoulos, K. A., Papanikolaou, E. G., Kalantaridou, S. N., Tsanadis, G. D., Plachouras, N. I., Dalkalitsis, N. A., & Paraskevaidis, E. A. (2002). Early pregnancy termination with vaginal misoprostol before and after 42 days gestation. *Human Reproduction*, 17(12), 3079-3083.

3.5

3. Abortion before 13 weeks gestation

Medical abortion

3.5.5. Home use of medications up to 12 weeks gestation

Recommendation:

- Mifepristone can be taken in a facility or at home.
- Home use of misoprostol following mifepristone or in a misoprostol-only regimen may be offered up to 12 weeks gestation.
- After 12 weeks gestation, misoprostol should be used in a facility.

Strength of recommendation:

Strong

Quality of evidence:

- Up to 70 days gestation: High
- Over 70 days gestation: Very low

Last reviewed:

October 9, 2025

A 2025 Cochrane review assessed the safety and effectiveness of telemedicine for medical abortion in which both mifepristone and misoprostol were used at home up to 12 weeks gestation, including six randomized controlled studies and 16 non-randomized studies and accounting for 131,278 individuals (Cleeve et al., 2025). This review found that medical abortion provided by telemedicine was as safe and effective as in-person abortion provision, although data beyond 9 weeks gestation are limited. Many studies have documented the safety and effectiveness of mifepristone and misoprostol used at home for abortion self-management, see 3.5.1: *Abortion before 13 weeks: Medical abortion self-management* for a summary of this evidence.

Mifepristone and misoprostol regimen

Home use of mifepristone

A 2024 systematic review assessed the safety and effectiveness of mifepristone taken at home as part of a combined medical abortion regimen up to 10 weeks of gestation (Gemzell-Danielsson et al., 2024). The review included 6 studies and data from 54,233 people seeking abortion, finding no difference in safety or effectiveness when mifepristone was taken at home compared to in a facility.

Home use of misoprostol up to 70 days

Two systematic reviews have confirmed the safety and effectiveness of misoprostol taken at home as part of a mifepristone-misoprostol regimen up to nine (Gambir et al., 2020) and 10 weeks gestation (Schmidt-Hansen et al., 2020). In Gambir et al. (2020), an examination of 19 prospective studies—three randomized controlled trials and 16 nonrandomized comparative trials including 11,576 people up to 63 days gestation—found that complete abortion rates and adverse event rates were the same for home- and facility-based misoprostol use. Women found home use as acceptable as clinic use. Schmidt-Hansen et al. (2020) compared the safety and effectiveness of home-based misoprostol for abortions up to 9 weeks gestation to those beyond 9 weeks, reported in 6 prospective and retrospective cohort studies including 3,381 people. The review found

no difference in complete abortion rates or adverse events, confirming the safety and efficacy of home use of misoprostol up to 10 weeks. Since these reviews, a number of prospective and retrospective cohort studies have reported on the safety and effectiveness of telemedicine for the provision of medical abortion. In the largest prospective study, from the United Kingdom, 52,142 women who used misoprostol at home for abortions up to 70 days gestation, and reported a complete abortion rate greater than 98% and serious complication rate of less than 1% (Aiken et al., 2021). Several smaller prospective and retrospective cohort studies evaluating the safety and effectiveness of telemedicine abortion provision with home use of misoprostol have similar findings (Chong et al., 2021; Pena et al., 2022; Reynolds-Wright et al., 2021; Upadhyay, Koenig, & Meckstroth, 2021; Upadhyay et al., 2022). The Royal College of Obstetricians and Gynaecologists (RCOG, 2019) and the American College of Obstetricians and Gynecologists (ACOG, 2020) recommend offering home use of misoprostol up to 70 days gestation.

Home use of misoprostol from 10–13 weeks

Data regarding home use of misoprostol between 10 and 13 weeks gestation is more limited. A non-inferiority trial compared the effectiveness of a medical abortion regimen of mifepristone followed by a single dose of misoprostol taken at home among women with pregnancies of 64–70 days to those with pregnancies of 71–77 days (Dzuba et al., 2020b). Investigators found a success rate of 92% in the earlier gestational age group compared to 87% in the later group, and significantly more ongoing pregnancies in the later group (9% compared to 4%), suggesting that additional doses of misoprostol are needed at gestations of more than 70 days. A subsequent retrospective cohort study compared success rates when two doses of misoprostol 800mcg were taken at home, four hours apart, for pregnancies between 64–70 days and 71–77 days (Dzuba et al., 2020a).

Although a high loss to follow up (25%) limits conclusions that can be drawn, investigators found abortion success rates of greater than 99% and 98%, respectively. One small retrospective cohort study compared safety and effectiveness of home use of misoprostol for medical abortion at gestational age 57–63 days to home use from 64–76 days, where study participants self-administered a single dose of misoprostol 800mcg vaginally, followed by up to four additional doses of 400mcg if bleeding did not occur (Larsson, & Ronnberg, 2019). Success rates were 96% and 94%, with no difference in incomplete abortion, excessive bleeding, or surgical intervention. An additional retrospective cohort study where women self-administered two doses of misoprostol 800mcg at home for medical abortions up to 77 days found a similar success rate (96%) (Kerestes et al., 2021). A prospective cohort study from Scotland that reported on the safety and efficacy of telemedicine for mifepristone and misoprostol medical abortion during the COVID-19 pandemic included women with gestations up to 12 weeks (Reynolds-Wright et al., 2021). Of the 663 people included in the study, only 21 (3%) had gestations between 10 and 12 weeks. Almost all women (98%) had a successful abortion; there were nine abortion failures (1.4%), only one of which occurred after 10 weeks. A prospective cohort study examining the safety and effectiveness of abortion accompaniment as a model of abortion self-management in Argentina, Nigeria, and Southeast Asia—the SAFE study—included 119 participants with gestations between 9 and 12 weeks who used misoprostol at home as part of a combined medication regimen; 87% successfully completed their abortion without further intervention (Moseson et al., 2023). The World Health Organization (WHO) recommends that pregnant people can self-manage the three component parts of the medical abortion process—self-assessment for eligibility, self-administration of abortion medicines and management of the abortion process, and self-assessment of the success of the abortion—up to 12 weeks gestation, when they have access to a source of accurate information and to a health-care provider, if needed (WHO, 2024).

Misoprostol-only regimen

Although no studies have directly compared safety and effectiveness of home use of misoprostol in a misoprostol-only regimen to health facility use, a number of studies provide evidence to support the safety and effectiveness of misoprostol taken at home for medical abortion. Several randomized studies with misoprostol-only arms (Blum et al., 2012; Ngoc et al., 2011; Sheldon et al., 2019) and several prospective cohort studies of misoprostol-only medical abortion up to 9 (Carbonell, Valera, Velazco, Fernandez, & Sanchez, 1997; Velazco

et al., 2000), or between 9-12 gestational weeks (Carbonell et al., 2001), have allowed participants to self-administer misoprostol at home without an effect on safety or medical abortion success. Studies examining abortion accompaniment or community-based distribution of misoprostol for medical abortion self-management, have reported abortion success rates for misoprostol-only abortion that exceed those for facility based care (Moseson et al., 2020b). In the SAFE study, more than 98% of at home misoprostol-only users with gestations up to 12 weeks reported a successful abortion without surgical intervention (Moseson et al., 2022; Moseson et al., 2023). Two studies have documented the safety and effectiveness of misoprostol-only, self-managed abortion accessed through community-based distribution up to either 9 or 10 weeks gestation; abortion success rates were 94-96% with no serious adverse events recorded (Foster, Arnott, & Hobstetter, 2017; Foster et al., 2022). One prospective cohort study conducted in Nigeria assessed success rates in pregnant individuals who purchased misoprostol from drug sellers to self-manage their medical abortion (Stillman et al., 2020). Despite receiving inadequate information about the drugs, what to expect, or where and when to seek additional care, 94% of the sample reported a complete abortion without surgical intervention. Of the sample, one participant required a blood transfusion.

References

- Aiken, A., Lohr, P.A., Lord, J., Ghosh, N., & Starling, J. (2021). Effectiveness, safety and acceptability of no-test medical abortion provided via telemedicine: a national cohort study. *BJOG: An International Journal of Obstetrics & Gynaecology*, 128(9), 1464-1474.
- American College of Obstetricians and Gynecologists & Society of Family Planning. (2020). Medication abortion up to 70 days of gestation: ACOG practice bulletin, number 225. *Obstetrics & Gynecology*, 136(4), e31-e47.
- Blum, J., Raghavan, S., Dabash, R., Ngoc, N. T. N., Chelli, H., Hajri, S., ... Winikoff, B. (2012). Comparison of misoprostol-only and combined mifepristone-misoprostol regimens for home-based early medical abortion in Tunisia and Vietnam. *International Journal of Gynecology & Obstetrics*, 118, 166-171.
- Carbonell, J. L. L., Velazco, A., Varela, L., Tanda, R., Sanchez, C., Barambio, S., ... Mari, J. (2001). Misoprostol for abortion at 9-12 weeks' gestation in adolescents. *The European Journal of Contraception and Reproductive Health Care*, 6, 39-45.
- Carbonell, J. L. L., Varela, L., Velazco, A., Fernandez, C., & Sanchez, C. (1997). The use of misoprostol for abortion at ≤ 9 weeks' gestation. *The European Journal of Contraception and Reproductive Health Care*, 2(3), 181-185.
- Chong, E., Shochet, T., Raymond, E., Platais, I., Anger, H.A., Raidoo, S., Soon, R., Grant, M., Haskell, S., Tocce, K., Baldwin, M.K., Boraas, C.M., Bednarek, P.H., Banks, J., Coplon, L., Thompson, F., Priegue, E., & Winikoff, B. (2021). Expansion of direct-to-patient telemedicine abortion service in the United States and experience during the COVID-19 pandemic. *Contraception*, 104, 43-48.
- Cleeve, A., Lavelanet, A., Gemzell-Danielsson, K., & Endler, M. (2025). The use of telemedicine services for medical abortion. *The Cochrane Database of Systematic Reviews*, 2025(6), CD013764.
- Dzuba, I.G., Castillo, P.W., Bousiequez, M., Hernandez, E.M.L., Vivar, J.J.C., & Smith, P. S. (2020a). A repeat dose of misoprostol 800mcg following mifepristone for outpatient medical abortion at 64-70 and 71-77 days of gestation: A retrospective chart review. *Contraception* 102, 104-108.
- Dzuba, I.G., Chong, E., Hannum, C., Lichtenberg, S., Hernandez, E.M.L., Ngoc, N. ... & Winikoff, B. (2020b). A non-inferiority study of outpatient mifepristone-misoprostol medical abortion at 64-70 days and 71-77 days of gestation. *Contraception*, 101, 302-308.
- Foster, A.M., Arnott, G., & Hobstetter, M. (2017). Community-based distribution of misoprostol for early abortion: Evaluation of a program along the Thailand-Burma border. *Contraception*, 96, 242-247.
- Foster, A.M., Messier, K., Aslam, M., & Shabir, N. (2022). Community-based distribution of misoprostol for early abortion: Outcomes from a program in Sindh, Pakistan. *Contraception*, 109, 49-51.
- Gambir, K., Garnsey, C., Necastro, K.A., & Ngo, T.D. (2020). Effectiveness, safety and acceptability of medical abortion at home versus in the clinic: A systematic review and meta-analysis in response to COVID-19. *BMJ Global Health*, 5(12), e003934.
- Gemzell-Danielsson, K., Lindh, I., Brynhildsen, J., Christensson, A., Moberg, K., Wernersson, E., & Johansson, S. (2024). Home use of mifepristone for medical abortion: a systematic review. *BMJ Sexual*

References continued

& *Reproductive Health*, 51(3), e202302. <https://doi.org/10.1136/bmj.srh-2024-202302>

Kerestes, C., Murayama, S., Tyson, J., Natavio, M., Seamon, S., Raidoo, S., Lacar, L., Bowen, E., Soon, R., Platais, I., Kaneshiro, B., & Stower, P. (2021). Provision of medication abortion in Hawai'i during COVID-19: Practical experience with multiple care delivery models. *Contraception*, 104(1), 49-53.

Larsson, A., & Ronnberg, A. M. (2019). Expanding a woman's options to include home use of misoprostol for medical abortion up until 76 days: An observational study of efficacy and safety. *Acta Obstetrica et Gynecologica Scandinavica*, 98(6), 747-752.

Moseson, H., Herold, S., Filippa, S., Barr-Walker, J., Baum, S.E., & Gerdt, C. (2020a). Self-managed abortion: A systematic scoping review. *Best Practice & Research Clinical Obstetrics and Gynaecology*, 63, 87-110.

Moseson, H., Jayaweera, R., Egwuatu, I., Grosso, B., Kristianingrum, I.A., Nmezi, S., Zurbriggen, R., Motanan, R., Bercu, C., Carbone, S., & Gerdt, C. (2022). Effectiveness of self-managed medication abortion with accompaniment support in Argentina and Nigeria (SAFE): A prospective, observational cohort study and non-inferiority analysis with historical controls. *Lancet Global Health*, 10(1), e105-e113.

Moseson, H., Jayaweera, R., Egwuatu, I., Grosso, B., Kristianingrum, I. A., Nmezi, S., Zurbriggen, R., Bercu, C., Motana, R., & Gerdt, C. (2023). Effectiveness of Self-Managed Medication Abortion Between 9 and 16 Weeks of Gestation. *Obstetrics & Gynecology*, 142(2), 330.

Ngo, T. D., Park, M. H., Shakur, H., & Free, C. (2011). Comparative effectiveness, safety and acceptability of medical abortion at home and in a clinic: A systematic review. *Bulletin of the World Health Organization*, 89(5), 360-370.

Ngoc, N. T., Blum, J., Raghavan, S., Nga, N. T., Dabash, R., Diop, A., & Winikoff, B. (2011). Comparing two early medical abortion regimens: Mifepristone + misoprostol vs. misoprostol alone. *Contraception*, 83, 410-417.

Pena, M., Flores, K.F., Ponce, M.M., Serafin, D.F., Zavala, A.M.C., Cruz, C.R., Salgado, I.G.O., Rosado, Y.O., Socarras, T., Lopez, A.P., & Bousiequez, M. (2022). Telemedicine for medical abortion service provision in Mexico: A safety, feasibility, and acceptability study. *Contraception*, 114, 67-73.

Reynolds-Wright, J.J., Johnstone, A., McCabe, K., Evans, E., & Cameron, S. (2021). Telemedicine medical abortion at home under 12 weeks; gestation: A prospective observational cohort study during the COVID-19 pandemic. *BMJ Sexual & Reproductive Health*, 47(4), 246-251.

Royal College of Obstetricians and Gynaecologists. (2019). *Abortion care*. NICE Guideline, NG140. <https://www.nice.org.uk/guidance/NG140>. Accessed February 12, 2021.

Schmidt-Hansen, M., Pandey, A., Lohr, P.A., Nevill, M., Taylor, P., Hasler, E., & Cameron, S. (2020). Expulsion at home for early medical abortion: A systematic review with meta-analyses. *Acta Obstetrica et Gynecologica Scandinavica*, 00, 1-9

Schummers, L., Darling, E.K., Dunn, S., McGrail, K., Gayowsky, A., Law, M.R., Laba, T.L., Kaczorowski, J., & Norman, W.V. (2022). Abortion safety and use with normally prescribed mifepristone in Canada. *New England Journal of Medicine*, 386(1), 57-67.

Sheldon, W.R., Durocher, J., Dzuba, I.G., Sayette, H., Martin, R., Velasco, M.C., & Winikoff, B. (2019). Early abortion with buccal versus sublingual misoprostol alone: A multicenter, randomized trial. *Contraception*, 99, 272-277.

Stillman, M., Owolabi, A., Fatusi, A.O., Akinyemi, A.I., Berry, A.L., Erinfolami, T.P., Olagunju, O.S., Vaisanen, H., & Bankole, A. (2020). Women's self-reported experiences using misoprostol obtained from drug sellers: A prospective cohort study in Lagos state, Nigeria. *BMJ Open*, 10:e034670. Doi:10.1136/bmjopen-2019-034670.

Upadhyay, U.D., Koenig, L.R., & Meckstroth, K.R. (2021). Safety and efficacy of telehealth medication abortions in the US during the COVID-19 pandemic. *JAMA Network Open*, 4(8), e2122320.

Upadhyay, U.D., Raymond, E.G., Koenig, L.R., Coplon, L., Gold, M., Kaneshiro, B., Boraas, C.M., & Winikoff, B. (2022). Outcomes and safety of history-based screening for medication abortion: A retrospective multicenter cohort study. *JAMA Internal Medicine*, 182(5), 482-491.

Velazco, A., Varela, L., Tanda, R., Sanchez, S., Barambino, S., Chami, S., ... Carbonell, J. L. L. (2000). Misoprostol for abortion up to 9 weeks' gestation in adolescents. *The European Journal of Contraception and Reproductive Health Care*, 5, 227-233.

World Health Organization. (2024). *Abortion care guideline, 2nd ed*. Geneva: World Health Organization.

3.5

3. Abortion before 13 weeks gestation

Medical abortion

3.5.6. Confirmation of success

Recommendation:

- Most people undergoing medical abortion with a recommended medication regimen will have a successful abortion; routine follow-up is not required.
- Providers may perform a clinical assessment to assist in the confirmation of successful abortion.
- Ultrasound or other testing is needed only in cases where the diagnosis is unclear.

In practice:

- Individuals undergoing medical abortion should be given adequate information about when to seek additional care for a possible complication. This includes:
 - Heavy bleeding or soaking through more than 2 sanitary pads an hour for 2 hours in a row;
 - Fever or flu-like illness developing more than 24 hours after using misoprostol;
 - Severe or worsening pain, including pain which could indicate an undiagnosed ectopic pregnancy;
 - Unusual or foul-smelling vaginal discharge.
- Individuals undergoing medical abortion should be given adequate information about signs and symptoms that might indicate an ongoing pregnancy for which clients should seek medical attention, including:
 - Experiencing no bleeding or only spotting in the 24 hours after using misoprostol;
 - Continuing to feel pregnant 1 week after using abortion medications.
- Urine pregnancy tests may still have a positive result up to 4 weeks after a successful medical abortion.

Strength of recommendation:

Strong

Quality of evidence:

Moderate

Last reviewed:

October 9, 2025

Medical abortion with mifepristone and misoprostol

The success rate of mifepristone followed by misoprostol for medical abortion up to 10 weeks gestation is over 95%, with ongoing pregnancy rates of less than 2% (Chen & Creinin, 2015; Kulier et al., 2011; Raymond et al., 2012). The World Health Organization (WHO) states that routine follow-up after medical abortion with mifepristone and misoprostol is not required (2024), advising instead that individuals should be adequately informed about symptoms of ongoing pregnancy and other medical reasons to return for follow-up such as prolonged heavy bleeding, no bleeding at all with medical management of abortion, pain not relieved by medication, or fever. Multiple strategies have been examined to confirm a successful medical abortion and identify rare ongoing pregnancies when using the mifepristone and misoprostol regimen.

Self-assessment based on symptoms

Evidence indicates that individuals can accurately determine when their mifepristone and misoprostol medical abortion is successful—that is, whether pregnancy expulsion has occurred. In studies comparing self-assessments of expulsion based on symptoms to those made by clinicians (Cameron et al., 2015; Clark et al., 2010; Perriera et al., 2010; Rossi, Creinin, & Meyn, 2004) and by ultrasound (Rossi et al., 2004), self-assessment has repeatedly proven to be nearly as accurate as both.

Clinical assessment

Providers may help confirm successful mifepristone and misoprostol abortion at a follow-up visit by reviewing the client's history and performing a bimanual exam, if indicated. In studies comparing clinical assessment to ultrasound (Rossi et al., 2004; Pymar, Creinin, & Schwartz, 2001), clinicians determined pregnancy expulsion with high levels of accuracy.

Ultrasound

Ultrasound can be used to confirm successful abortion but is not necessary and can add to the cost and complexity of medical abortion, particularly where providers are inexperienced in reading post-medical abortion ultrasound (Kaneshiro et al., 2011). Ultrasound is helpful in cases where there is doubt about the presence of an ongoing pregnancy.

Serum pregnancy testing

Serum pregnancy testing has been used as an alternative to ultrasound to diagnose an ongoing pregnancy following mifepristone and misoprostol and compares favorably to ultrasound in reducing interventions at the time of follow-up (Clark et al., 2007; Dayananda et al., 2013; Fiala et al., 2003). Serum pregnancy testing is most useful when a pre-treatment hCG has been obtained for comparison; hCG declines by more than 90% seven days after mifepristone is administered in the case of a successful medical abortion (Pocius et al., 2016). A serum hCG level below 900 IU 14–21 days after early (<63 days gestation) medical abortion excludes ongoing pregnancy (Le Lous et al., 2018). In very early medical abortion (< 42 days gestation), an hCG decline of 80% seven days after mifepristone confirms successful medical abortion (Bharadwa et al., 2024; Jar-Allah et al., 2025).

Urine pregnancy testing

A negative urine pregnancy test is reassuring that an abortion has been successful. Rarely, however, a pregnancy test is negative but a person is still pregnant (false negative). Both high-sensitivity and low-sensitivity urine pregnancy tests can have positive results even when the medical abortion has been successful (false positive) due to hcg levels that remain elevated for at least 18 days after a medical abortion (Cameron et al., 2012; Clark et al., 2010; Godfrey et al., 2007; Perriera et al., 2010; Raymond et al., 2021). In a case series including 258 people with successful medical abortions who performed a high-sensitivity pregnancy test four weeks after taking mifepristone, 19% had a false positive result (Raymond et al., 2021). A number of studies have examined use of low-sensitivity (Cameron et al., 2012, Cameron et al., 2015; Constant et al., 2017; Iyengar et al., 2015; Michie & Cameron, 2014) and semi-quantitative or multi-level (Anger et al., 2019; Chong et al., 2020; Oppegaard et al., 2015; Raymond et al., 2017; Raymond et al., 2018b) urine pregnancy tests, often in combination with a symptom checklist, to confirm a successful abortion or identify an ongoing pregnancy without returning for follow-up. One small trial randomized 88 participants with pregnancies of less than 63 days to independently use a low-sensitivity or a multi-level pregnancy test to determine medical abortion success, finding that individuals could correctly use and accurately interpret the results of these tests (Fok et al., 2021). A 2018 systematic review assessed the accuracy of using low-sensitivity pregnancy testing to identify ongoing pregnancy after medical abortion (Raymond, Shocket, & Bracken, 2018a), finding that a positive or invalid low-sensitivity pregnancy test had only moderate sensitivity for detecting ongoing pregnancy. A subsequent diagnostic accuracy study found that a low-sensitivity pregnancy test performed two weeks after mifepristone administration correctly identified all continuing pregnancies in a cohort of 558 people between 64 and 70 days gestation; the false positive rate was 15% (Whitehouse, Shochet, & Lohr, 2022). A 2017 meta-analysis, which included seven studies that examined use of multi-level pregnancy tests to confirm

abortion success when using the combined regimen up to 9 weeks gestation, found that the tests identified all continuing pregnancies (21 out of 1,599 participants, 1.3%) and that most people can successfully perform the tests themselves at home (Raymond et al., 2017). Multi-level pregnancy tests measure the approximate concentration of urinary hcg; a decline in hcg concentration between a test performed immediately before and one to two weeks after medical abortion indicates abortion success. Because hcg levels naturally fall in the late first trimester, multilevel pregnancy tests can only be used in the early first trimester (Chong, et al., 2020). Two systematic reviews in 2019 compared outcomes for women who self-assessed medical abortion success at home using a low-sensitivity or semi-quantitative urine pregnancy test in combination with a pictorial instruction sheet, symptom checklist or no checklist, to women who received routine clinic follow-up (Baiju et al., 2019; Schmidt-Hansen et al., 2019). Both reviews included four studies and more than 5,000 women and agreed that there were no differences in successful abortion, ongoing pregnancy, need for surgical intervention, or incidence of infection or hemorrhage between self-assessment and clinic follow-up groups.

Medical abortion with mifepristone and misoprostol

The WHO states that routine follow-up after medical abortion with misoprostol alone is not required (2024), advising instead that individuals should be adequately informed about symptoms of ongoing pregnancy and other medical reasons to return for follow-up such as prolonged heavy bleeding, no bleeding at all with medical management of abortion, pain not relieved by medication, or fever. Due to the lower success rate (80-85%) and higher rate of ongoing pregnancy following misoprostol-only medical abortion before 13 weeks gestation (von Hertzen et al., 2007), more people using misoprostol alone for their medical abortion will require additional care than those using the combined mifepristone and misoprostol regimen.

Follow-up assessment

There are no studies examining different strategies to determine abortion success when using the misoprostol-only regimen. Possible follow-up strategies, extrapolated from studies about the combined regimen (detailed above) and programmatic data, include a history and physical examination, bimanual examination, ultrasound and/or serum or urine pregnancy testing to rule out an ongoing pregnancy.

References

- Anger, H., Dabash, R., Pena, M., Coutino, D., Bousiequez, M., Sanhueza, P., & Winikoff, B. (2019). Use of an at-home multilevel pregnancy test and an automated call-in system to follow-up the outcome of medical abortion. *International Journal of Gynaecology and Obstetrics*, 144(1), 97-102.
- Baiju, N., Acharya, G., D'Antonio, F., & Berg, R. C. (2019). Effectiveness, safety and acceptability of self-assessment of the outcome of first-trimester medical abortion: A systematic review and meta-analysis. *BJOG: An International Journal of Obstetrics and Gynaecology*, 126(13), 1536-1544.
- Bharadwa, S., Fulcher, I., Fortin, J., Pocius, K. D., & Goldberg, A. B. (2024). hCG trends after mifepristone and misoprostol for undesired pregnancy of unknown location. *Contraception*, 131.
- Cameron, S. T., Glasier, A., Dewart, H., Johnstone, A., & Burnside, A. (2012). Telephone follow-up and self-performed urine pregnancy testing after early medical abortion: A service evaluation. *Contraception*, 86(1), 67-73.
- Cameron, S. T., Glasier, A., Johnstone, A., Dewart, H., & Campbell, A. (2015). Can women determine the success of early medical termination of pregnancy themselves? *Contraception*, 91, 6-11.
- Chong, E., Sheldon, W.R., Lopez-Green, D., Gonzalez, H.C., Castillo, B.H., Ogando, M.G., Tuladhar, N., & Blum, J. (2020). Feasibility of multilevel pregnancy tests for telemedicine abortion service follow-up: A pilot study. *International Perspectives on Sexual and Reproductive Health*, 46(Supple1), 67-75.
- Clark, W., Bracken, H., Tanenhaus, J., Schweikert, S., Lichtenberg, E. S., & Winikoff, B. (2010). Alternatives to a routine follow-up visit for early medical abortion. *Obstetrics & Gynecology*, 115(2 Pt 1), 264-272.
- Clark, W., Panton, T., Hann, L., & Gold, M. (2007). Medication abortion employing routine sequential measurements of serum hCG and sonography only when indicated. *Contraception*, 75(2), 131-135.

References continued

- Chen, M. J., & Creinin, M. D. (2015). Mifepristone with buccal misoprostol for medical abortion: A systematic review. *Obstetrics & Gynecology*, 126(1), 12-21.
- Constant, D., Harries, J., Daskilewicz, K., Myer, L., & Gemzell-Danielsson, K. (2017). Is self-assessment of medical abortion using a low-sensitivity pregnancy test combined with a checklist and phone text messages feasible in South African primary healthcare settings? A randomized trial. *PLoS One*, 12(6), e0179600. Doi: 10.1371/journal.pone.0179600.
- Dayananda, I., Maurer, R., Fortin, J., & Goldberg, A. B. (2013). Medical abortion follow-up with serum human chorionic gonadotropin compared with ultrasonography: A randomized controlled trial. *Obstetrics & Gynecology*, 121(3), 607-613.
- Fiala, C., Safar, P., Bygdeman, M., & Gemzell-Danielsson, K. (2003). Verifying the effectiveness of medical abortion; ultrasound versus hCG testing. *European Journal of Obstetrics and Gynecology and Reproductive Biology*, 109(2), 190-195.
- Fok, W.K., Lerma, K., Shaw, K.A., & Blumenthal, P.D. (2021). Comparison of two home pregnancy tests for self-confirmation of medication abortion status: A randomized trial. *Contraception*, 104(3), 296-300.
- Godfrey, E. M., Anderson, A., Fielding, S. L., Meyn, L., & Creinin, M. D. (2007). Clinical utility of urine pregnancy assays to determine medical abortion outcome is limited. *Contraception*, 75(5), 378-382.
- Iyengar, K., Paul, M., Iyengar, S. D., Klingberg-Allvin, M., Essen, B., Bring, J., ... Gemzell-Danielsson, K. (2015). Self-assessment of the outcome of early medical abortion vs. clinic follow-up in India: A randomised, controlled, non-inferiority trial. *Lancet Global Health*, 3(9), e537-545.
- Jar-Allah, T., Brandell, K., Gyllenberg, F., Kaislasuo, J., Kopp-Kallner, H., Cederblad, K., Heikinheimo, O., Gemzell-Danielsson, K., & Hognert, H. (2025). Change in hCG levels after very early medication abortion for pregnancy of unknown location or probable intrauterine pregnancy. *Contraception*, 147.
- Kaneshiro, B., Edelman, A., Sneeringer, R. K., & Gómez Ponce de León, R. (2011). Expanding medical abortion: Can medical abortion be effectively provided without the routine use of ultrasound? *Contraception*, 83(3), 194-201.
- Kulier, R., Kapp, N., Gulmezoglu, A. M., Hofmeyr, G. J., Cheng, L., & Campana, A. (2011). Medical methods for first trimester abortion. *The Cochrane Database of Systematic Reviews* (11), CD002855.
- Le Lous, M., Gallinand, A. C., Laviolle, B., Peltier, L., Nyangoh Timoh, K., & Lavoue, V. (2018). Serum hCG threshold to assess medical abortion success. *The European Journal of Contraception & Reproductive Health Care*, 23(6), 458-463.
- Michie, L., & Cameron, S. T. (2014). Simplified follow-up after early medical abortion: 12 months experience of a telephone call and self-performed low sensitivity urine pregnancy test. *Contraception*, 89(5), 440-445.
- Oppegaard, K. S., Qvigstad, R., Fiala, C., Heikinheimo, O., Benson, L., & Gemzell-Danielsson, K. (2015). Clinical follow-up compared with self-assessment of outcome after medical abortion: A multicentre, non-inferiority, randomised, controlled trial. *The Lancet*, 385(9969), 698-704.
- Perriera, L. K., Reeves, M. F., Chen, B. A., Hohmann, H. L., Hayes, J., & Creinin, M. D. (2010). Feasibility of telephone follow-up after medical abortion. *Contraception*, 81(2), 143-149.
- Pocius, K. D., Bartz, D., Maurer, R., Stenquist, A., Fortin, J., & Goldberg, A. B. (2016). Serum human chorionic gonadotropin (hCG) trend within the first few days after medical abortion: A prospective study. *Contraception*, 94(4), 394-395.
- Pymar H., Creinin, M. D., Schwartz, J. L. (2001). Mifepristone followed on the same day by vaginal misoprostol for early abortion. *Contraception*, 64, 87-92.
- Raymond, E.G., Anger, H.A., Chong, E., Haskell, S., Grant, M., Boraas, C., Tocce, K., Banks, J., Kaneshiro, B., Baldwin, M.K., Coplon, L., Bednarek, P., Shochet, T., & Platais, I. (2021). "False positive" urine pregnancy test results after successful medication abortion. *Contraception*, 103(6), 400-403.
- Raymond, E. G., Shannon, C., Weaver, M. A., & Winikoff, B. (2012). First-trimester medical abortion with mifepristone 200 mg and misoprostol: A systematic review. *Contraception*, 87(1), 26-37.
- Raymond, E. G., Shochet, T., Blum, J., Sheldon, W. R., Platais, I., Bracken, H., ... Winikoff, B. (2017). Serial multilevel urine pregnancy testing to assess medical abortion outcome: A meta-analysis. *Contraception*, 95(5), 442-448.
- Raymond, E. G., Shochet, T., & Bracken, H. (2018a). Low-sensitivity urine pregnancy testing to assess medical abortion outcome: A systematic review. *Contraception*, 58, 30-35.

References continued

Raymond, E. G., Tan, Y. L., Grant, M., Benavides, E., Reis, M., Sacks, D., ... Weaver, M. A. (2018b). Self-assessment of medical abortion outcome using symptoms and home pregnancy testing. *Contraception*, 97, 324-328.

Rossi, B., Creinin, M. D., & Meyn, L. A. (2004). Ability of the clinician and patient to predict the outcome of mifepristone and misoprostol medical abortion. *Contraception*, 70(4), 313-317.

Schmidt-Hansen, M., Cameron, S., Lohr, P. A., & Hasler, E. (2019). Follow-up strategies to confirm the success of medical abortion of pregnancies up to 10 weeks' gestation: A systematic review with meta-analyses. *American Journal of Obstetrics and Gynecology*, 222(6):551-563.

von Hertzen, H., Piaggio, G., Huong, N. T., Arustamyan, K., Cabezas, E., Gomez, M., & Peregoudov, A. (2007). Efficacy of two intervals and two routes of administration of misoprostol for termination of early pregnancy: A randomised controlled equivalence trial. *The Lancet*, 369(9577), 1938-1946.

Whitehouse, K.C., Shochet, T., & Lohr, P.A. (2022). Efficacy of a low-sensitivity urine pregnancy test for identifying ongoing pregnancy after medication abortion at 64 to 70 days of gestation. *Contraception*, 110, 21-26.

World Health Organization. (2024). *Abortion care guideline*, 2nd ed. Geneva: World Health Organization.

3.5

3. Abortion before 13 weeks gestation

Medical abortion

3.5.7. Ultrasound findings at follow-up

Recommendation:

- If clinicians choose to use ultrasound for medical abortion follow-up, the only ultrasound finding that requires intervention is an ongoing viable pregnancy.

Strength of recommendation:

Strong

Quality of evidence:

Low

Last reviewed:

October 9, 2025

Background

Ultrasound is not necessary to provide abortion care (World Health Organization [WHO], 2024) but may be common in some settings. Ultrasound for follow-up after medical abortion has diagnostic limitations. Except for the case of an ongoing viable pregnancy, intervention after a medical abortion should be based on clinical symptoms and not ultrasound findings.

Ultrasound findings at follow-up

Endometrial thickening: After a successful medical abortion, endometrial thickness varies and can be associated with a complex or heterogeneous appearance.



Endometrial thickening

Courtesy of Mary Fjerstad



Persistent gestational sac

Courtesy of Mary Fjerstad

A 2021 systematic scoping review, which included 79 randomized controlled trials and 169 observational studies, examined criteria for diagnosing retained products of conception following induced or spontaneous abortion before 14 weeks gestation, finding that although most studies utilized ultrasound, there was little diagnostic accuracy of this method (Hamel et al., 2021). Multiple retrospective and prospective cohort studies have shown that endometrial thickness ranges widely in women after medical abortion, with significant overlap between women with successful and failed medical abortion (Cowett et al., 2004; Markovitch et al., 2006; Parashar et al., 2007; Rørbye, Nørgaard, & Nilas, 2004; Tzeng et al., 2013). In a pooled analysis of 2,208 women one week after medical abortion, after women with a persistent gestational sac were excluded, the average endometrial thickness was 10.9mm in women who did not require more intervention and 14.5mm in 30 women who did require intervention (Reeves et al., 2009). Although the average endometrial thickness in women who require intervention tends to be higher, because of the range and overlap between successful and unsuccessful abortion, no study has found that there is a thickness above which a diagnosis of unsuccessful medical abortion can be made. The decision to intervene should be made on clinical signs and symptoms, such as ongoing or heavy bleeding, rather than on ultrasound findings.

Persistent gestational sac: A persistent gestational sac, in which the sac is present but there is no viable embryonic tissue, occurs in less than 1% of medical abortions with the recommended mifepristone and misoprostol regimen (Creinin et al., 2004; Creinin et al., 2007; Winikoff et al., 2008). A persistent gestational sac is not a viable pregnancy and may be managed with aspiration, additional misoprostol or expectant management according to individual preference. In a study of women with a persistent gestational sac within 11 days of medical abortion, a second dose of misoprostol was found to lead to expulsion in 69% of women (Reeves, Kudva, & Creinin, 2008).

Ongoing viable pregnancy: An ongoing pregnancy, in which a growing sac and/or embryo with cardiac activity are present, occurs in less than 1% of medical abortions with the recommended mifepristone and misoprostol regimen (Chen & Creinin, 2015; Von Hertzen et al., 2009; Winikoff et al., 2008). Some women will be able to identify this outcome without ultrasound due to lack of bleeding or continued pregnancy symptoms. A woman with an ongoing pregnancy should be offered uterine evacuation as soon as possible with either vacuum aspiration or additional misoprostol, depending on gestational age and local context. The success rate of misoprostol after failed medical abortion is 36% (Reeves et al., 2008). If a woman chooses misoprostol, she must be followed to see if it is successful.

References

- Cowett, A. A., Cohen, L. S., Lichtenberg, E. S., & Stika, C. S. (2004). Ultrasound evaluation of the endometrium after medical termination of pregnancy. *Obstetrics & Gynecology*, 103(5, Part 1), 871-875.
- Chen, M. J., & Creinin, M. D. (2015). Mifepristone with buccal misoprostol for medical abortion: A systematic review. *Obstetrics & Gynecology*, 126(1), 12-21.
- Creinin, M. D., Fox, M. C., Teal, S., Chen, A., Schaff, E. A., & Meyn, L. A. (2004). A randomized comparison of misoprostol 6 to 8 hours versus 24 hours after mifepristone for abortion. *Obstetrics & Gynecology*, 103(5, Part 1), 851-859.
- Creinin, M. D., Schreiber, C. A., Bednarek, P., Lintu, H., Wagner, M. S., & Meyn, L. A. (2007). Mifepristone and misoprostol administered simultaneously versus 24 hours apart for abortion: A randomized controlled trial. *Obstetrics & Gynecology*, 109(4), 885-894.
- Hamel, C.C., van Wessel, S., Carnegy, A., Coppus, S.F.P.J., Snijders, M.P.L., Clark, J., & Emanuel, M.H. (2021). Diagnostic criteria for retained products of conception—A scoping review. *Acta Obstetrica et Gynecologica Scandinavica* 100(12), 2135-2143.
- Markovitch, O., Tepper, R., Klein, Z., Fishman, A., & Aviram, R. (2006). Sonographic appearance of the uterine cavity following administration of mifepristone and misoprostol for termination of pregnancy. *Journal of Clinical Ultrasound*, 34(6), 278-282.
- Parashar, P., Iversen, O. E., Midbøe, G., Myking, O., & Bjørge, L. (2007). Medical abortion in the first trimester: The use of serum hCG and endometrial thickness as markers of completeness. *European Journal of Contraception and Reproductive Health Care*, 12(4), 366-371.

References continued

- Reeves, M., Fox, M., Lohr, P., & Creinin, M. (2009). Endometrial thickness following medical abortion is not predictive of subsequent surgical intervention. *Ultrasound in Obstetrics & Gynecology*, 34(1), 104-109.
- Reeves, M. F., Kudva, A., & Creinin, M. D. (2008). Medical abortion outcomes after a second dose of misoprostol for persistent gestational sac. *Contraception*, 78(4), 332-335.
- Rørbye, C., Nørgaard, M., & Nilas, L. (2004). Prediction of late failure after medical abortion from serial β -hCG measurements and ultrasonography. *Human Reproduction*, 19(1), 85-89.
- Tzeng, C.R., Hwang, J.L., Au, H.K., & Chien, L.W. (2013). Sonographic patterns of the endometrium in assessment of medical abortion outcomes. *Contraception*, 88(1), 153-9.
- Von Hertzen, H., Piaggio, G., Wojdyla, D., Marions, L., My Huong, N., Tang, O., & Mittal, S. (2009). Two mifepristone doses and two intervals of misoprostol administration for termination of early pregnancy: A randomised factorial controlled equivalence trial. *BJOG: An International Journal of Obstetrics & Gynaecology*, 116(3), 381-389.
- Winikoff, B., Dzuba, I. G., Creinin, M. D., Crowden, W. A., Goldberg, A. B., Gonzales, J., ... & Shannon, C. S. (2008). Two distinct oral routes of misoprostol in mifepristone medical abortion: A randomized controlled trial. *Obstetrics & Gynecology*, 112(6), 1303-1310.
- World Health Organization. (2022). *Abortion care guideline*. Geneva: World Health Organization.

4.1

4. Recommendations for abortion at or after 13 weeks gestation

Who has abortions at 13 weeks or later?

Key information:

- People who present for abortion at 13 weeks of pregnancy or later are more likely than those who present at earlier gestations to be young or a victim of violence, have detected their pregnancy later, feel ambivalent about the abortion decision, and/or have financial and logistical barriers to care. Additionally, medical or fetal indications for an abortion may not be apparent until after 13 weeks. Reasons for presenting at or after 13 weeks gestation appear similar across countries and cultures and disproportionately affect underserved people.

Quality of evidence:

Low

Last reviewed:

October 17, 2025

Epidemiology of abortion at 13 weeks and later

While abortions at or after 13 weeks gestation comprise a minority (around 10-15%) of the total abortions worldwide, they are responsible for the majority of serious abortion-related complications (Harris & Grossman, 2011; Jatlaoui et al., 2019; Loeber & Wijsen, 2008). In more restrictive settings, or where safe abortion access is limited, presentation at or after 13 weeks gestation for postabortion care is more common. In Cambodia 17%, in Ethiopia 38%, and in Kenya 41% of individuals needing postabortion care present at or after 13 weeks gestation. (African Population and Health Research Center et al., 2013; Fetters et al., 2008; Gebreselassie et al., 2010).

Why do people need abortions at 13 weeks and later?

Young age: Young people are disproportionately likely to seek abortion at or after 13 weeks (Espinoza, Samandari, & Andersen, 2022; Kebede et al., 2025). In the United States, 23.7% of those younger than age 15 and 12.4% of adolescents ages 15-19 seeking abortion care do so after 13 weeks gestation (Jatlaoui et al., 2019). In Mexico City, adolescents comprised 9% of all women seeking abortion from 2007-2015; yet, they accounted for 13% of women seeking abortion beyond 12 weeks gestation (Saavedra-Avendano et al., 2018). Smaller studies in Ethiopia, India, Kenya, Nepal, Singapore and the United States have found young age to be a risk factor for later presentation (Bonnen, Tuijje, & Rasch, 2014; Foster & Kimport, 2013; Lim, Wong, Yong, & Singh, 2012; Sowmini, 2013; Ushie et al., 2018). A US survey of people seeking abortion found that many adolescents did not know where to access abortion care, leading to delays (Chiu, Braccia, & Jones, 2024).

Late detection of pregnancy: A common risk factor in all studies for presenting for abortion at or after 13 weeks is late recognition of pregnancy. Poor understanding and awareness of fertility and pregnancy signs and symptoms affects individual recognition of pregnancy (Somefun, Harries, & Constant, 2021), particularly among young people (Chiu, Braccia, & Jones, 2024; Espinoza, Samandari, & Andersen, 2020). Absence of pregnancy signs and symptoms, menstrual irregularity, contraceptive use, or amenorrhea after recent preg-

nancy can mask physical signs of pregnancy and delay pregnancy diagnosis (Constant et al., 2019; Drey et al., 2006; Foster, Gould, & Biggs, 2021; Foster & Kimport, 2013; Gallo & Nghia, 2007; Harries et al., 2007; Ingham et al., 2008; Jones & Jerman, 2017; Kebede et al., 2025; Mehiretie et al., 2025; Purcell et al., 2014). In one case-control study in the United States, women who sought abortion after 20 weeks were much more likely to have been eight weeks pregnant or more at the time they discovered they were pregnant (68%), compared to women who had abortions before 13 weeks gestation (12%) (Foster & Kimport, 2013).

Ambivalence and/or difficulty with abortion decision: Women's decision making may be delayed due to social pressures, fears, religious attitudes and changes in relationship status. Changes in circumstance (such as abandonment by partner) cause some to seek an abortion after initially planning to continue the pregnancy (Foster & Kimport, 2013; Gallo & Nghia, 2007; Harries et al., 2007). Discouraging family and friends may also delay care-seeking (Waddington, Hahn, & Reid, 2015).

Financial and logistical barriers: Poverty (Goyal et al., 2020; Sium et al., 2022; Usta et al., 2008), immigrant status (Gonzalez-Rabago et al., 2017; Loeber & Wijssen, 2008), rural residence (Bonnen et al., 2014; Kebede et al., 2025; Mehiretie et al., 2025; Ushie et al., 2018), unemployment (Gonzalez, Quast, & Venanzi, 2019; Van de Velde et al., 2019), and lack of health insurance (Raidoo et al., 2020) are risk factors for presentation for abortion care at or after 13 weeks gestation. Delays may be related to raising enough money to cover the cost of the procedure, particularly as procedures later in gestation are more expensive (Foster & Kimport, 2013; Kiley, Yee, Niemi, Feinglass, & Simon, 2010). Abortions at or after 13 weeks gestation are provided at a limited number of facilities and travel logistics present difficulties for many (Goyal et al., 2020; Ludwigson et al., 2024; Sium et al., 2021; White et al., 2021). In one case-control study women presenting for abortion at over 20 weeks gestation were much more likely than those with earlier gestations to have travelled over three hours to access care (Foster & Kimport, 2013). Clients at 13 weeks gestation or later may be referred by other providers or have trouble finding a provider before finally accessing care (Drey et al., 2006; Harries et al., 2007). Women may also need to travel out of their own country to access legal abortion after 13 weeks (Cameron et al., 2016; Loeber & Wijssen, 2008).

Fetal indications: Prenatal diagnosis of fetal anomalies typically occurs after the first 12 weeks of pregnancy, and women may make the decision to terminate pregnancy based on the diagnosis (Edling, Lindstrom, & Bergman, 2021; Lyus et al., 2013).

Maternal indications: Medical conditions that worsen during the course of pregnancy or a new condition arising in pregnancy may endanger the life or health of the pregnant person (Kiver, Altmann, Kamhieh-Milz, & Weichert, 2019). Severe preeclampsia or preterm premature rupture of membranes may require termination of pregnancy to save pregnant person's life (American College of Obstetricians and Gynecologists, 2015).

Victims of violence: Victims of violence have a higher risk of late presentation (Colarossi & Dean, 2014; Perry et al., 2015). Adolescents and young people, particularly those aged 10-14 years, are more likely to have a pregnancy due to rape, incest or transactional sex, and to subsequently present later in pregnancy for abortion (Espinoza, Samandari, & Andersen, 2020).

Failed abortion: Although failures are rare, those who experience an ongoing pregnancy after an abortion before 13 weeks may not discover they are still pregnant until after 13 weeks gestation (Gallo & Nghia, 2007).

Cultural beliefs: In rare cases there are local beliefs that having an abortion at 13 weeks or later is safer than the first 12 weeks of pregnancy, thus causing a delay in care-seeking (Marlow et al., 2014). Data from a nationally representative household survey in India found that women who did not have a son were more likely to delay an abortion until after 13 weeks (Shekar, Sahoo, & Das, 2024).

References

- African Population and Health Research Center, Ministry of Health Kenya, Ipas Kenya, & Guttmacher Institute. (2013). Incidence and complications of unsafe abortion in Kenya: Key findings of a national study. Retrieved from <https://www.guttmacher.org/pubs/abortion-in-Kenya.pdf>
- American College of Obstetricians and Gynecologists. (2013, reaffirmed 2023). Practice Bulletin No. 135: Second-trimester abortion. *Obstetrics & Gynecology*, 121(6), 1394-1406.
- Bonnen, K. I., Tuijje, D. N., & Rasch, V. (2014). Determinants of first and second trimester induced abortion—results from a cross-sectional study taken place 7 years after abortion law revisions in Ethiopia. *BioMed Central Pregnancy & Childbirth*, 14(416), 014-0416.
- Cameron, S. T., Ridell, J., Brown, A., Thomson, A., Melville, C., Flett, G., ... Laird, G. (2016). Characteristics of women who present for abortion towards the end of the mid-trimester in Scotland: National audit 2013-2014. *European Journal of Contraception and Reproductive Health Care*, 21(2), 183-188.
- Chiu, D. W., Braccia, A., & Jones, R. K. (2024). Characteristics and Circumstances of Adolescents Obtaining Abortions in the United States. *International Journal of Environmental Research and Public Health*, 21(4), 477.
- Colarossi, L., & Dean, G. (2014). Partner violence and abortion characteristics. *Women Health*, 54(3), 177-193.
- Constant, D., Kluge, J., Harries, J., & Grossman, D. (2019). An analysis of delays among women accessing second-trimester abortion in the public sector in South Africa. *Contraception*, 100(3), 209-213.
- Drey, E. A., Foster, D. G., Jackson, R. A., Lee, S. J., Cardenas, L. H., & Darney, P. D. (2006). Risk factors associated with presenting for abortion in the second trimester. *Obstetrics and Gynecology*, 107(1), 128-135.
- Edling, A., Lindstrom, L., & Bergman, E. (2021). Second trimester induced abortions due to fetal anomalies—A population-based study of diagnoses, examinations and clinical management. *Acta Obstetrica et Gynaecologica Scandinavica*, 100, 2202-2208.
- Espinoza, C., Samandari, G., & Andersen, K. (2020). Abortion knowledge, attitudes and experiences among adolescent girls: A review of the literature. *Sexual and Reproductive Health Matters*, 28(1), 175-195.
- Fetters, T., Vonthanak, S., Picardo, C., & Rathavy, T. (2008). Abortion-related complications in Cambodia. *BJOG: An International Journal of Obstetrics & Gynaecology*, 115(8), 957-968.
- Foster, D.G., Gould, H., & Biggs, M.A. (2021). Timing of pregnancy discovery among women seeking abortion. *Contraception*, 104(6), 642-647.
- Foster, D. G., & Kimport, K. (2013). Who seeks abortions at or after 20 weeks? *Perspectives on Sexual and Reproductive Health*, 45(4), 210-218.
- Gallo, M. F., & Nghia, N. C. (2007). Real life is different: A qualitative study of why women delay abortion until the second trimester in Vietnam. *Social Science & Medicine*, 64(9), 1812-1822.
- Gebreselassie, H., Fetters, T., Singh, S., Abdella, A., Gebrehiwot, Y., Tesfaye, S., & Kumbi, S. (2010). Caring for women with abortion complications in Ethiopia: National estimates and future implications. *International Perspectives on Sexual and Reproductive Health*, 36(1), 6-15.
- Gonzalez-Rabago, Y., Rodriguez-Alvarez, E., Borrell, L. N., & Martin, U. (2017). The role of birthplace and educational attainment on induced abortion inequalities. *BMC Public Health*, 17, 69.
- Gonzalez, F., Quast, T., & Venanzi, A. (2019). Factors associated with the timing of abortions. *Health economics*, 1-11.
- Goyal, V., Wallace, R., Dermish, A.I., Kumar, B., Schutt-Aine, A., Beasley, A., & Aiken, A.R.A. (2020). Factors associated with abortion at 12 or more weeks gestation after implementation of a restrictive Texas law. *Contraception*, 102(5), 314-317.
- Harries, J., Orner, P., Gabriel, M., & Mitchell, E. (2007). Delays in seeking an abortion until the second trimester: A qualitative study in South Africa. *Reproductive Health*, 4(7), 13-26.
- Harris, L. H., & Grossman, D. (2011). Confronting the challenge of unsafe second-trimester abortion. *International Journal of Gynecology & Obstetrics*, 115(1), 77-79.
- Ingham, R., Lee, E., Clements, S. J., & Stone, N. (2008). Reasons for second trimester abortions in England and Wales. *Reproductive Health Matters*, 16(31 Suppl), 18-29.

References continued

- Jatloui, T. C., Eckhaus, L., Mandel, M.G., Nguyen, A., Pduyebo, T., Petersen, E., Whiteman, M.K. (2019). Abortion surveillance-United States, 2016. *MMWR Surveillance Summaries*, 68(11): 1-41.
- Jones, R. K., & Jerman, J. (2017). Characteristics and circumstances of women who obtain very early or second trimester abortions. *PLoS ONE*, DOI: 10.1371/journal.pone.0169969.
- Kebede, T. N., Abebe, K. A., Kitaw, T. M., Chekole, M. S., Haile, A. B., Yesuf, T. E., Tadesse, M., Kassa, M. T., Zerihun, M. S., Taye, B. T., & Ayele, T. A. (2025). Late request for safe abortion and its determinants among reproductive age women in Ethiopia: systematic review and meta-analysis. *International Journal for Equity in Health*, 24, 230.
- Kiley, J. W., Yee, L. M., Niemi, C. M., Feinglass, J. M., & Simon, M. A. (2010). Delays in request for pregnancy termination: Comparison of patients in the first and second trimesters. *Contraception*, 81(5), 446-451.
- Kiver, V.I., Altmann, J., Kamhieh-Milz, J. & Weichert, A. (2019) A 17-year analysis of pregnancy termination ≥ 14 weeks of gestation in a German level 1 perinatal center. *Journal of Perinatal Medicine*, 47(8):847-856.
- Lim, L., Wong, H., Yong, E., & Singh, K. (2012). Profiles of women presenting for abortions in Singapore: Focus on teenage abortions and late abortions. *European Journal of Obstetrics & Gynecology and Reproductive Biology*, 160(2), 219-222.
- Loeber, O., & Wijnen, C. (2008). Factors influencing the percentage of second trimester abortions in the Netherlands. *Reproductive Health Matters*, 16(31 Suppl), 30-36.
- Ludwigson, A., Euser, A. G., Walsh, C., Zahedi-Spung, L., S. Hirshberg, J., French-Stewart, L., Scott, J., Reeves, S., & Putra, M. (2025). Characteristics of Patients Undergoing Fetal Potassium Chloride Injection at a Single Center Over Time. *Journal of Women's Health*, 34(6), 768-773.
- Lyus, R., Robson, S., Parsons, J., Fisher, J., & Cameron, M. (2013). Second trimester abortion for fetal abnormality. *BMJ: British Medical Journal*, 3(347).
- Marlow, H. M., Wamugi, S., Yegon, E., Feters, T., Wanaswa, L., & Msipa-Ndebele, S. (2014). Women's perceptions about abortion in their communities: Perspectives from western Kenya. *Reproductive Health Matters*, 22(43), 149-158.
- Mehiretie, E. B., Getahun, W. T., Fetene, M. G., & Ferede, A. A. (2025). Induced second trimester abortion and its determinants in East Gojjam public hospitals. *Scientific Reports*, 15, 25463.
- Perry, R., Zimmerman, L., Al-Saden, I., Fatima, A., Cowett, A., & Patel, A. (2015). Prevalence of rape-related pregnancy as an indication for abortion at two urban family planning clinics. *Contraception*, 91(5), 393-397.
- Purcell, C., Cameron, S., Caird, L., Flett, G., Laird, G., Melville, C., & McDaid, L. M. (2014). Access to and experience of later abortion: Accounts from women in Scotland. *Perspectives on Sexual and Reproductive Health*, 46(2), 101-108.
- Raidoo, S., Tschann, M., Kaneshiro, B. & Sentell, T. (2020). Impact of insurance coverage for abortion in Hawai'i on gestational age at presentation and type of abortion, 2010-2013. *Hawaii Journal of Health & Social Welfare*, 79(4):117-122.
- Saavedra-Avendano, B., Schiavon, R., Sanhueza, P., Rios-Polanco, R., Garcia-Martinez, L., & Darney, B. G. (2018). Who presents past the gestational age limit for first trimester abortion in the public sector in Mexico City? *PLoS One*, 13(2), e0192547.
- Shekhar, C., Sahoo, H., & Das, L. (2025). Assessment of delayed termination of pregnancy in India: Evidence from National Family Health Survey, 2019-21. *Sexual & Reproductive Healthcare*, 43, 101047.
- Sium, A.F., Lucero-Prisno, D.E., Wondafrash, M., Tolu, L.B., & Shiferaw, M.A. (2022). Late request for safe abortion care at a tertiary hospital in Ethiopia; the role of emotional factors: A cross-sectional study. *International Journal of Gynaecology and Obstetrics*, 158(2), 462-468.
- Somefun, O.D., Harries, J., & Constant, D. (2021). Reproductive awareness and recognition of unintended pregnancy: Young women, key informants and health care providers perspectives in South Africa. *Reproductive Health*, 19(1), 211.
- Sowmini, C. V. (2013). Delay in termination of pregnancy among unmarried adolescents and young women attending a tertiary hospital abortion clinic in Trivandrum, Kerala, India. *Reproductive Health Matters*, 21(41), 243-250. DOI: 10.1016/s0968-8080(13)41700-7
- Ushie, B. A., Izugbara, C. O., Mutua, M. M., & Kabiru, C. W. (2018). Timing of abortion among adolescent and young women presenting for post-abortion care in Kenya: A cross-sectional analysis of nationally-representative data. *BMC Womens Health*, 18(1), 41.

References continued

Usta, M. B., Mitchell, E. M., Gebreselassie, H., Brookman-Amissah, E., & Kwizera, A. (2008). Who is excluded when abortion access is restricted to twelve weeks? Evidence from Maputo, Mozambique. *Reproductive Health Matters*, 16(31 Suppl), 14-17.

Van de Velde, S., Van Eekert, N., Van Assche, K., Sommerland, N., & Wouters, E. (2019) Characteristics of women who present for abortion beyond the legal limit in Flanders, Belgium. *Perspectives in Sexual Reproductive Health*, 51(3):175-183.

Waddington, A., Hahn, P. M., & Reid, R. (2015). Determinants of late presentation for induced abortion care. *Journal of Obstetrics and Gynaecology Canada*, 37(1), 40-45.

White, K., Sierra, G., Evans, T., & Roberts, S.C.M. (2022). Abortion at 12 or more weeks' gestation and travel for later abortion care among Mississippi residents. *Contraception*, 108, 19-24.

4.2

4. Abortion at or after 13 weeks gestation

Comparing methods

Key information:

Dilatation and evacuation (D&E) and medical abortion with mifepristone and misoprostol or misoprostol only are safe and effective methods of abortion.

- Medical abortion has a higher rate of retained products of conception, failed abortion and minor adverse events.
- D&E requires a trained, experienced provider and specialized equipment.

In practice:

- Individuals should be offered a choice of methods when both D&E and medical abortion are available.

Quality of evidence:

Moderate

Last reviewed:

October 17, 2025

Comparison of methods

Safety

In the largest randomized trial comparing methods of abortion at or after 13 weeks gestation, 58 women with gestations between 13-20 weeks received D&E and 52 received medical abortion with mifepristone and misoprostol (Kelly et al., 2010). Overall rates of complications were the same in the two groups (12%), although the types of complications differed. Five participants in the medical arm required uterine evacuation for retained products of conception and one suffered bleeding requiring transfusion; only one person in the surgical arm required repeat uterine evacuation, one suffered a cervical laceration, and five had hemorrhage that did not require transfusion. A statistically significant proportion of those randomized to medical abortion had more bleeding and pain and found the abortion process less acceptable than those who had D&E. A pilot randomized trial of 18 women with gestations between 14-19 weeks comparing D&E and medical abortion with mifepristone and misoprostol found a higher rate of adverse events, specifically retained placenta and fever, in women undergoing medical abortion, although none were serious (Grimes, Smith, & Witham, 2004). A prospective, nonrandomized trial, in which abortion seekers between 13-20 weeks chose their method of uterine evacuation, included 219 medical abortion and 60 D&E participants and found no difference in complication rates between the two groups (Tufa et al., 2021). However, nine patients (4%) in the medical arm required additional intervention to complete the abortion (Tufa et al., 2021).

The largest available retrospective cohort study comes from Nepal and included 2,294 women at or after 13 weeks gestation; 595 underwent D&E and 1,701 had a medical abortion (Kapp et al., 2020). Complications were rare overall (<1% for D&E, 1.4% for medical abortion), mostly consisting of hemorrhage, amongst both groups. A US based retrospective cohort compared 1,049 D&E procedures to 212 medical abortions between 16 and 24 weeks, finding a higher complication rate in the medical abortion group (8% compared to 17%)

(Naseem et al., 2025). Cervical laceration was the most common complication during D&E, and hemorrhage was the most common in medical abortion. In smaller retrospective cohort studies, people with gestations 13-24 weeks who had medical abortions had an increased rate of failed abortion and retained products of conception with a need for further intervention compared to people who had D&E; the rate of major adverse events including infection, transfusion, hysterectomy and death did not differ between the two methods (Autry et al., 2002; Bryant et al., 2011; Sonalkar et al., 2017). A small retrospective cohort study comparing people undergoing medical abortion (n=77) or D&E (n=41) for IUFD between 13-24 weeks found similar rates of complications in both groups (19% and 17% respectively), although 2 patients in the medical abortion group (3%) experienced a major complication (McLaren et al., 2022).

In published studies of medical abortion compared to D&E, rates of intervention for medical abortion may be artificially high because failure has been defined as no expulsion within 24 hours (Bryant et al., 2011) and retained placenta has been diagnosed after two hours (Grimes et al., 2004). In practice, more time may be allowed for successful medical abortion to occur.

Subsequent perinatal outcomes

A Finnish register-based study of first-time mothers compared incidence of adverse birth outcomes among those with no history of previous abortion (364,392 women), those with past history of a medical or surgical abortion at 12 weeks gestation or less (46,589 women), and those with history of a medical or surgical abortion at greater than 12 weeks (7,709 women) (KC, Gissler, & Klemetti, 2020). Investigators found that the risk of any subsequent adverse birth outcome was small, but that risk is higher with increasing gestational age at the time of induced abortion. Women undergoing a later medical abortion had a 1.4 fold increased risk of both preterm birth and low birthweight compared to those having an earlier medical abortion. Women who had a late surgical abortion had a 2.6 fold and 1.5 fold increased risk of extremely preterm birth and very low birthweight compared with women who had an earlier surgical abortion.

Comparison of methods

The characteristics of medical abortion and D&E vary widely; in settings where both abortion methods are available and a person is a candidate for either, they should be offered a choice of abortion method. The choice of abortion procedure is an intensely personal one (Kerns et al., 2018)—some prefer the speed and predictability of D&E, while others prefer a more “labor-like” process with an intact fetus (Kelly et al., 2010; Kerns et al., 2012). Acceptability and satisfaction with the abortion process is highest when each individual can choose to receive their preferred method (Kapp & Lohr, 2020). Both randomized trials referenced above (Kelly et al., 2010; Grimes et al., 2004) had difficulty with recruitment due to participants’ strong preferences for one method—generally D&E—over the other. In the most recent of these studies, 100% of those randomized to D&E reported they would choose it again compared with only 53% of those randomized to medical abortion (Kelly et al., 2010). To choose the abortion procedure that best facilitates their coping, people need adequate information regarding the two abortion methods and the ability to make their decision autonomously (Kerns et al., 2018).

References

- Autry, A. M., Hayes, E. C., Jacobson, G. F., & Kirby, R. S. (2002). A comparison of medical induction and dilation and evacuation for second-trimester abortion. *American Journal of Obstetrics & Gynecology*, 187(2), 393-397.
- Bryant, A. G., Grimes, D. A., Garrett, J. M., & Stuart, G. S. (2011). Second-trimester abortion for fetal anomalies or fetal death: Labor induction compared with dilation and evacuation. *Obstetrics & Gynecology*, 117(4), 788-792.
- Grimes, D. A., Smith, M. S., & Witham, A. D. (2004). Mifepristone and misoprostol versus dilation and evacuation for midtrimester abortion: A pilot randomised controlled trial. *BJOG: An International Journal of Obstetrics & Gynaecology*, 111(2), 148-153.
- Kapp, N., Griffin, R., Bhattarai, N., & Dangol, D.S. (2020). Does prior ultrasonography affect the safety of induced abortion at or after 13 weeks’ gestation? A retrospective study. *Acta Obstetrica et Gynecologica Scandinavica*, doi: 10.1111/aogs.14040. Epub ahead of print. PMID: 33185906.

References continued

Kapp, N. & Lohr, P.A. (2020). Modern methods to induce abortion: Safety, efficacy and choice. *Best Practice and Research: Clinical Obstetrics and Gynaecology*, 63, 37-44.

KC, S., Gissler, M., & Klemetti, R. (2020). The duration of gestation at previous induced abortion and its impacts on subsequent births: A nationwide registry based study. *Acta Obstetrica et Gynecologica Scandinavica*, 99(5), 651-659.

Kelly, T., Suddes, J., Howel, D., Hewison, J., & Robson, S. (2010). Comparing medical versus surgical termination of pregnancy at 13-20 weeks of gestation: A randomised controlled trial. *BJOG: An International Journal of Obstetrics & Gynaecology*, 117(12), 1512-1520.

Kerns, J. L., Light, A., Dalton, V., McNamara, B., Steinauer, J., & Kuppermann, M. (2018). Decision satisfaction among women choosing a method of pregnancy termination in the setting of fetal anomalies and other pregnancy complications: A qualitative study. *Patient Education and Counseling*, 101(10), 1859-1864.

Kerns, J., Vanjani, R., Freedman, L., Meckstroth, K., Drey, E. A., & Steinauer, J. (2012). Women's decision making regarding choice of second trimester termination method for pregnancy complications. *International Journal of Gynecology & Obstetrics*, 116(3), 244-248.

McLaren, H., Cancino, D., McCulloch, M. Wolff, S., & French, V. (2022). Rates of complication for dilation and evacuation versus induction of labor in treatment of second trimester intrauterine fetal demise. *European Journal of Obstetrics, Gynecology and Reproductive Biology*, 277, 16-20.

Naseem, A., Valenzuela, A., Venuti, K., Kominiarek, M. A., Lancki, N., & Kiley, J. W. (2025). Medication abortion and procedural abortion in the second trimester: Comparison of complications at 16–23 6/7 Weeks' gestation. *European Journal of Obstetrics and Gynecology and Reproductive Biology*, 314.

Sonalkar, S., Ogden, S. N., Tran, L. K., & Chen, A. Y. (2017). Comparison of complications associated with induction by misoprostol versus dilation and evacuation for second-trimester abortion. *International Journal of Gynecology & Obstetrics*, 138, 272-275.

Tufa, T.H., Prager, S., Wondafrash, M., Mohammed, S., Byl, N., & Bell, J., (2021). Comparison of surgical versus medical termination of pregnancy between 13-20 weeks of gestation in Ethiopia: A quasi-experimental study. *PLoS One*, 16(4), e0249529.

4.3

4. Abortion at or after 13 weeks gestation

Gestational dating

Key information:

- Gestational age should be calculated using a person's last menstrual period (LMP) combined with physical examination.
- Routine use of ultrasound for gestational age determination is not necessary.

Strength of recommendation

Strong

Quality of evidence:

Moderate

Last reviewed:

October 17, 2025

Importance of accurate gestational dating

Errors in gestational dating can increase the risks associated with abortion. If gestational age is underestimated prior to dilatation and evacuation (D&E), providers may not have the experience and equipment to complete the procedure safely. Accurate assessment of gestational age enables providers to determine whether the facility is equipped to provide the requested service and refer to another facility if necessary.

Dating

Gestational age assessment using bimanual examination and LMP is well established during prenatal care, as is the use of ultrasound. No prospective trials have compared the accuracy of different methods of gestational dating prior to abortion at or after 13 weeks, however, in a retrospective cohort of 2,223 women undergoing abortion at or after 13 weeks gestation in Nepal, gestational age assessed by measuring fetal foot length after pregnancy expulsion was highly correlated with ultrasonography (81%), physical exam (77%) and LMP (72%) assessments (Kapp et al., 2020). In the United States, virtually all providers use ultrasound for gestational age assessment after 12 weeks gestation, but data are lacking from other country contexts.

Prior to medical abortion, gestational age can be estimated using the first day of a woman's LMP and a physical examination that includes bimanual and abdominal examination (Nautiyal et al., 2015; Ngoc et al., 2011; Royal College of Obstetricians and Gynaecologists [RCOG], 2022a; World Health Organization [WHO], 2024). Measuring fundal height, as in routine obstetric care, can provide additional information as the pregnancy advances (Pugh et al., 2018). Ultrasound can be used to confirm gestational age if the LMP and clinical examination are discordant or if there is uncertainty about gestational age but is not required prior to medical abortion.

In published studies of D&E, including reports of implementation of D&E programs (Castleman et al., 2006; Jacot et al., 1993), ultrasound has been routinely used to establish or confirm gestational age prior to D&E. However, one published report (Altman et al., 1985), unpublished programmatic data (A. Edelman, personal communication, January 12, 2018) and expert opinion support use of LMP and physical examination for gestational age assessment, with use of ultrasound as needed (RCOG, 2022a; WHO, 2024). If ultrasound is used, biparietal diameter is a simple and accurate method to confirm gestational age (Goldstein & Reeves, 2009). A femur length measurement can be used to confirm the biparietal diameter or used if there are technical difficulties in obtaining a biparietal measurement.

People who present with fetal demise, incomplete abortion or for postabortion care may have discordant LMP dates and uterine size; they should be treated according to uterine size (RCOG, 2022b; WHO, 2024).

After the abortion, clinicians can confirm gestational age by comparing actual fetal measurements (fetal foot length) to the expected gestational age (Drey et al., 2005; Mokkarala et al., 2020). This comparison provides feedback regarding the accuracy of pre-procedure dating estimates. Pregnancy dating tools, such as fetal measurements, are included in Ipas's *Dilatation & Evacuation (D&E) Reference Guide: Induced Abortion and Postabortion Care at or After 13 Weeks Gestation*, page 38 (2017), and *Medical Abortion Reference Guide: Induced Abortion and Postabortion Care at or After 13 Weeks Gestation*, page 30 (2017).

References

- Altman, A. M., Stubblefield, P. G., Schlam, J. F., Loberfeld, R., & Osathanondh, R. (1985). Midtrimester abortion with laminaria and vacuum evacuation on a teaching service. *The Journal of Reproductive Medicine*, 30(8), 601-606.
- Castleman, L. D., Oanh, K. T. H., Hyman, A. G., Thuy, L. T. T., & Blumenthal, P. D. (2006). Introduction of the dilation and evacuation procedure for second-trimester abortion in Vietnam using manual vacuum aspiration and buccal misoprostol. *Contraception*, 74, 272-276.
- Drey, E. A., Kang, M. S., McFarland, W., & Darney, P. D. (2005). Improving the accuracy of fetal foot length to confirm gestational duration. *Obstetrics & Gynecology*, 105(4), 773-778.
- Edelman, A., & Kapp, N. (2017). *Dilatation & Evacuation (D&E) Reference Guide: Induced abortion and postabortion care at or after 13 weeks gestation*. Chapel Hill, NC: Ipas.
- Edelman, A., & Mark, A. (2017). *Medical Abortion Reference Guide: Induced abortion and postabortion care at or after 13 weeks gestation*. Chapel Hill, NC: Ipas.
- Goldstein, S. R., & Reeves, M. F. (2009). Clinical assessment and ultrasound in early pregnancy. In M. Paul, E. S. Lichtenberg, L. Borgatta, D. A. Grimes, P. G. Stubblefield & M. D. Creinin (Eds.), *Management of unintended and abnormal pregnancy: Comprehensive abortion care*. Oxford: Wiley-Blackwell.
- Jacot, F. R. M., Poulin, C., Bilodeau, A. P., Morin, M., Moreau, S., Gendron, F., & Mercier, D. (1993). A five-year experience with second-trimester induced abortions: No increase in complication rate as compared to the first trimester. *American Journal of Obstetrics & Gynecology*, 168, 633-637.
- Kapp, N., Griffin, R., Bhattarai, N., & Dangol, D.S. (2020). Does prior ultrasonography affect the safety of induced abortion at or after 13 weeks' gestation? A retrospective study. *Acta Obstetrica et Gynecologica Scandinavica*, doi: 10.1111/aogs.14040. Epub ahead of print. PMID: 33185906.
- Kulier, R., & Kapp, N. (2011). Comprehensive analysis of the use of pre-procedure ultrasound for first- and second-trimester abortion. *Contraception*, 83(1), 30-33.
- Mokkarala, S., Creinin, M. D., Wilson, M. D., Yee, N. S., & Hou, M. Y. (2020). Comparing preoperative dating and postoperative dating for second-trimester surgical abortions. *Contraception*, 101(1), 5-9.
- Nautiyal, D., Mukherjee, K., Perhar, I., & Banerjee, N. (2015). Comparative study of misoprostol in first and second trimester abortions by oral, sublingual, and vaginal routes. *The Journal of Obstetrics and Gynecology of India*, 64(4), 246-250.
- Pugh, S. J., Ortega-Villa, A. M., Grobman, W., Newman, R. B., Owen, J., Wing, D. A., ...Grantz, K. L. (2018). Estimating gestational age at birth from fundal height and additional anthropometrics: a prospective cohort study. *BJOG: An International Journal of Obstetrics and Gynaecology*, 125(11), 1397-1404.
- Ngoc, N. T. N., Shochet, T., Raghavan, S., Blum, J., Nga, N. T. B., Minh, N. T. H., & Winikoff, B. (2011). Mifepristone and misoprostol compared with misoprostol alone for second-trimester abortion: A randomized controlled trial. *Obstetrics & Gynecology*, 118(3), 601-608.
- Royal College of Obstetricians and Gynaecologists. (2022a). *Best practice in abortion care*. London: Royal College of Obstetricians and Gynaecologists.
- Royal College of Obstetricians and Gynaecologists. (2022b). *Best practice in postabortion care*. London: Royal College of Obstetricians and Gynaecologists.
- White, K. O., Jones, H. E., Shorter, J., Norman, W. V., Guilbert, E., Lichtenberg, E. S., & Paul, M. (2018). Second-trimester surgical abortion practices in the United States. *Contraception*, 98, 95-99.
- World Health Organization. (2024). *Abortion Care Guideline, 2nd ed*. Geneva: World Health Organization.

4.4

4. Abortion at or after 13 weeks gestation

Induced fetal demise

Recommendation:

- Induced fetal demise prior to medical abortion or dilatation and evacuation (D&E) at or after 13 weeks gestation does not increase the safety of abortion. However, there may be legal, facility or social reasons for inducing preprocedure fetal demise.

Strength of recommendation:

Strong

Quality of evidence:

Low

Last reviewed:

October 17, 2025

Background

Some providers may induce fetal demise before medical abortion or D&E at or after 13 weeks gestation for a variety of reasons. Clients, providers or staff may prefer that fetal demise occurs before an abortion procedure (Jackson et al., 2001) or it may be dictated by the facility's practices. Additionally, induced fetal demise is one way to prevent transient fetal survival following a medical abortion. A large Canadian retrospective cohort study that included 13,777 abortions between 15 and 29 gestational weeks found that transient fetal survival occurred in 11% of cases and that risk increased with more advanced gestational age (Auger et al., 2024).

Safety and benefit of inducing fetal demise

A retrospective cohort study comparing people who received an intrauterine digoxin injection prior to D&E with historical controls who did not receive digoxin showed an increase in complications, including more hospital admissions, extramural deliveries and infections in the group who received digoxin (Dean et al., 2012). One case series including nearly 5,000 D&E abortions after digoxin injection found rates of extramural deliveries (0.3%) and infection (0.04%) that authors concluded were acceptably low (Steward et al., 2012). A retrospective cohort study comparing women who underwent fetal intracardiac potassium chloride injection before D&E to women who did not undergo the additional procedure found that while procedure duration was decreased by 3.5 minutes when fetal demise was induced, there was an increase in women's pain and in the incidence of uterine atony (Lohr et al., 2018).

A retrospective cohort from Ethiopia compared intra-amniotic digoxin, intracardiac lidocaine, and no induced demise in 208 patients undergoing medical abortion between 20 and 28 weeks, finding no differences in induction-to-abortion interval or successful abortion between the three groups (Sium, Shimles, & Gudu, 2023). Two retrospective comparative cohort studies measured the effect of intracardiac potassium chloride on induction-to-abortion interval when administered before medical abortion. In one study with a gestational age range of 17-28 weeks, the induction-to-abortion interval was significantly shorter in women who received the injection (15 hours) compared to those who did not (19.9 hours) (Akkurt et al., 2018). A similar study among women with a mean gestational age of 21 weeks found no difference in time-to-abortion between those with pre-procedure potassium chloride for feticide (35 hours) versus those without (32 hours) (Sik et al., 2019). Use of potassium chloride before medical abortion is associated with increased tissue degeneration at fetal autopsy (Chiu et al., 2025).

Technique

Fetal demise can be achieved prior to abortion at or after 13 weeks by injecting potassium chloride or xylocaine directly into the fetal heart, or digoxin into the fetus or amniotic fluid (Nandi, Schultz, & Roncari, 2022).

Potassium chloride/xylocaine: Potassium chloride or xylocaine injection requires skill in ultrasound guidance techniques and has more potential risk due to the possibility of maternal intravascular injection which can cause cardiac arrest (Borgatta & Kapp, 2011; Coke et al., 2004; Maurice et al., 2019). One study randomized 158 people with pregnancies between 22 and 36 weeks gestation to either fetal intracardiac intraventricular potassium chloride injection or intraseptal injection, and found that both methods were 100% successful with no complications. Intraseptal injection achieved asystole more quickly with lower doses of potassium chloride than intraventricular (Süzen Çaypınar et al., 2023). In one retrospective cohort study including 80 people with pregnancies between 21 and 27 weeks gestation, the administration of intracardiac xylocaine resulted in fetal demise in 95% of pregnancies with no serious adverse events, although two participants developed side effects attributed to the injection (Tolu et al., 2020).

Digoxin: Digoxin is injected either transabdominally or transvaginally (Tocce et al., 2013) 1-2 days before the planned abortion procedure.

In a pharmacokinetic study of eight women between 19-23 weeks who had intra-amniotic injection of digoxin 1mg prior to D&E, maternal serum digoxin levels were in the low therapeutic range and were not associated with cardiac changes (Drey et al., 2000). A pilot randomized trial of intra-amniotic or intra-fetal digoxin at doses of 1mg or 1.5mg showed an overall rate of fetal demise of 87% with no difference in effectiveness based on the dose or route of administration (Nucatola, Roth, & Gatter, 2010). In a prospective cohort study of 59 women undergoing termination of pregnancy between 21-30 weeks, digoxin 2mg administered intra-amniotically resulted in fetal demise for more than 90% of cases, with no adverse maternal effects (Sharvit, et al., 2018). In one retrospective cohort study including 49 people undergoing medical abortion between 20-27 weeks, digoxin 1mg administered intra-amniotically resulted in fetal demise in 90% of cases. Two participants expelled the pregnancy outside of the hospital (Tufa, et al., 2020). One prospective cohort study compared effectiveness of intra-amniotic lidocaine (n=50) to digoxin (n=101) prior to medical abortion between 20 and 28 weeks gestation, finding no differences in induction-to-abortion interval or effectiveness between the two groups, although interval from drug administration to fetal asystole was longer in the digoxin group (Sium et al., 2025). In this same cohort of patients, intra-amniotic digoxin was more acceptable to patients than lidocaine (Sium, Prager, & Reeves, 2024).

References

- Akkurt, M. O., Akkurt, I., Yavuz, A., Yalcin, S. E., Coskun, B., & Sezik, M. (2018). The Utility of Feticide Procedure to Shorten the Induction-to-Abortion Interval in Medical Abortion. *Gynecology and Obstetric Investigation*, 1-7. DOI: 10.1159/000491085.
- Auger, N., Brousseau, É., Ayoub, A., & Fraser, W. D. (2024). Second-trimester abortion and risk of live birth. *American Journal of Obstetrics & Gynecology*, 230(6), 679.e1-679.e9.
- Borgatta, L., & Kapp, N. (2011). Clinical guidelines. Labor induction abortion in the second trimester. *Contraception*, 84(1), 4-18.
- Chui, K., Terry, J., Hutcheon, J. A., Mayer, C., & Liauw, J. (2025). Potassium chloride intracardiac fetal injection and tissue degeneration at fetal autopsy following induction abortion. *Contraception*, 150.
- Coke, G. A., Baschat, A. A., Mighty, H. E., & Malinow, A. M. (2004). Maternal cardiac arrest associated with attempted fetal injection of potassium chloride. *International Journal of Obstetric Anesthesia*, 13(4), 287-290.
- Dean, G., Colarossi, L., Lunde, B., Jacobs, A. R., Porsch, L. M., & Paul, M. E. (2012). Safety of digoxin for fetal demise before second-trimester abortion by dilation and evacuation. *Contraception*, 85(2), 144-149.

References continued

- Denny, C. C., Baron, M. B., Lederle, L., Drey, E. A., & Kerns, J. L. (2015). Induction of fetal demise before pregnancy termination: *Practices of family planning providers. Contraception*, 92(3), 241-245.
- Drey, E. A., Thomas, L. J., Benowitz, N. L., Goldschlager, N., & Darney, P. D. (2000). Safety of intra-amniotic digoxin administration before late second-trimester abortion by dilation and evacuation. *American Journal of Obstetrics & Gynecology*, 182(5), 1063-1066.
- Lohr, P. A., Parsons, J. H., Taylor, J., & Morroni, C. (2018). Outcomes of dilation and evacuation with and without feticide by intra-cardiac potassium chloride injection: a service evaluation. *Contraception*, 98, 100-5.
- Maurice, P., Letourneau, A., Benachi, A., & Jouannic, J.M. (2019). Feticide in second- and third-trimester termination of pregnancy for fetal anomalies: Results of a national survey. *Prenatal Diagnosis*, 39(13), 1269-1272.
- Nandi, P., Schultz, A., & Roncari, D. (2022). The Use of Feticidal Agents Before Dilation and Evacuation or Induction of Labor for Later Abortion. *Clinical Obstetrics and Gynecology*, 65(4), 708.
- Nucatola, D., Roth, N., & Gatter, M. (2010). A randomized pilot study on the effectiveness and side-effect profiles of two doses of digoxin as feticide when administered intraamniotically or intrafetally prior to second-trimester surgical abortion. *Contraception*, 81(1), 67-74.
- Sharvit, M., Klein, Z., Silber, M., Pomeranz, M., Agizim, R., Schonman, R., & Fishman, A. (2019). Intra-amniotic digoxin for feticide between 21 and 30 weeks of gestation: A prospective study. *BJOG: An International Journal of Obstetrics & Gynaecology*, 126(7), 885-889.
- Sik, A., Bilecan, S., Kumbasar, S., Akpak, Y.K., & Aba, Y.A. (2019). Does feticide shorten termination duration in second trimester pregnancy termination? *African Health Science*, 19(1), 1544-1553.
- Sium, A. F., Lemma, K., Beyene, Z., Tolu, L. B., Hailu, D., Reeves, M. F., & Prager, S. (2025). Inducing fetal demise in a low-middle income country: A prospective cohort of intracardiac lidocaine versus intra-amniotic digoxin for inducing fetal demise before second-trimester medication abortion. *International Journal of Gynecology & Obstetrics*, 170(3), 1262-1266.
- Sium, A. F., Prager, S., & Reeves, M. (2025). Patient acceptability of intra-amniotic digoxin versus intracardiac lidocaine for inducing foetal demise prior to second trimester medical abortion: a prospective cohort. *The European Journal of Contraception & Reproductive Health Care*, 30(2), 119-122.
- Sium, A. F., Shimeles, T., & Gudu, W. (2023). The effect of induced fetal demise on induction to expulsion interval during later medication abortion: A retrospective cohort. *Contraception*, 125.
- Steward, R., Melamed, A., Kim, R., Nucatola, D., & Gatter, M. (2012). Infection and extramural delivery with use of digoxin as a feticidal agent. *Contraception*, 85(2), 150-154.
- Süzen Çaypınar, S., Oğlak, S. C., Polat, İ., Kurt Bilirer, K., Sezer, S., Gedik Özköse, Z., & Karakaş, S. (2023). A new and more effective feticide technique in late termination of pregnancy: potassium chloride injection into the interventricular septum of the fetal heart. *Archives of Gynecology and Obstetrics*, 307(3), 779-787.
- Tocce, K., Sheeder, J.L., Edwards, L.J., & Teal, S. (2013). Feasibility, effectiveness and safety of transvaginal digoxin administration prior to dilation and evacuation. *Contraception*, 88(6), 706-711.
- Tolu, L.B., Tufa, T.H., Abas, F., Kahn, C., MacAfee, L., Prager, S. & Bell, J.D. (2021). Intra-cardiac lidocaine administration to induce fetal demise before late second-trimester abortion: Retrospective review. *International Journal of Gynaecology and Obstetrics*, 153(1), 125-129.
- Tufa, T.H., Lavelanet, A.F., Belay, L., Seboka, B., & Bell, J. (2020). Feasibility of intra-amniotic digoxin administration by obstetrics and gynecology trainees to induce fetal demise prior to medical abortion beyond 20 weeks. *BMJ Sexual and Reproductive Health*, 46(4), 308-312.

4.5

4. Abortion at or after 13 weeks gestation

Follow-up

Recommendation:

- Routine follow-up care is not necessary unless desired by the individual or necessary for their chosen contraceptive method.
- At the time of the abortion, clients should receive adequate information regarding postabortion care and warning signs.

Strength of recommendation:

Weak

Quality of evidence:

Low

Last reviewed:

October 17, 2025

Follow-up

There is no scientific data to demonstrate that routine follow-up is beneficial after uncomplicated abortion at or after 13 weeks. In addition, there is no evidence to suggest that a pelvic examination is beneficial in an asymptomatic person that does return for a routine follow-up visit. Those undergoing abortion at or after 13 weeks should be adequately informed about medical reasons to return for follow-up, and should receive appropriate supplies and information to meet contraceptive needs. Follow-up can be offered to patients, and a follow-up visit may include an assessment for grief, emotional support, and review of strategies to address physical symptoms, including breast engorgement (Spach & Henkel, 2024).

Quality of evidence

Very low. The recommendation is based on expert opinion (Royal College of Obstetricians and Gynaecologists, 2022; World Health Organization [WHO], 2024).

References

Royal College of Obstetricians and Gynaecologists. (2022). *Best practice in abortion care*. London: Royal College of Obstetricians and Gynaecologists.

Spach, N. C., & Henkel, A. (2024). Aftercare following second trimester abortion procedures. *Current Opinion in Obstetrics and Gynecology*, 36(6), 388.

World Health Organization. (2024). *Abortion Care Guideline*. Geneva: World Health Organization.

4.6

4. Abortion at or after 13 weeks gestation

Dilatation and evacuation

4.6.1. Cervical preparation

Recommendation:

- Routine preoperative cervical preparation is recommended before dilatation and evacuation (D&E).
- Osmotic dilators, misoprostol and mifepristone are options for cervical preparation. The choice depends on availability, expense, gestational age and timing of the procedure.

Strength of recommendation:

Strong

Quality of evidence:

High

Last reviewed:

October 17, 2025

Background

Cervical preparation prior to D&E reduces the risk of procedure-related complications (Fox & Krajewski, 2014; Peterson et al., 1983). There is limited data to suggest the best method of cervical preparation before D&E because the trials that exist have heterogeneous comparisons, proxy outcomes for adverse events, small sample sizes, and include few individuals with pregnancies over 20 weeks (Ralph & Shulman, 2019; Tufa et al., 2025). Available trials typically show differences in cervical dilation or procedure times, however they do not include enough participants to show differences in rare but more serious outcomes such as cervical or uterine injuries or inability to complete the procedure (O'Shea et al., 2021). One retrospective noninferiority cohort study reported complication rates for patients with gestational ages between 14 and 16 weeks who received an overnight method of cervical preparation (n=455 patients who received overnight osmotic dilators with or without misoprostol) or same day cervical preparation (n=864 patients who received same-day osmotic dilators with or without misoprostol or same day misoprostol alone), finding no difference in complication rates between the groups (Ngo et al., 2023). Choice of method of cervical preparation is often limited by supply availability, especially in low-resource settings.

Method	Dosing	Note
Osmotic dilators (laminaria or synthetic osmotic dilators)	6-24 hours prior to procedure	Synthetic osmotic dilators may be used the day of the D&E
Misoprostol	400mcg buccally or vaginally 3 hours prior to procedure	May be used as a single agent up to 18 weeks, very limited data to support use as a single agent over 18-20 weeks May be combined with osmotic dilators or mifepristone May be repeated as needed
Mifepristone	200mg orally 24-48 hours prior to procedure	Limited data support use as a single agent up to 18 weeks Often used prior to misoprostol

Osmotic dilators

Osmotic dilators are safe, effective and do not increase infectious morbidity (Bryman, Granberg, & Norström, 1988; Fox & Krajewski, 2014; Jonasson et al., 1989; Peterson et al., 1983). A 2025 Cochrane systematic review and meta-analysis of cervical preparation before D&E between 14-24 weeks gestation showed that cervical priming regimens that included osmotic dilators provided better cervical dilation and reduced procedure difficulty when compared to regimens that did not include dilators (Tufa et al., 2025); but dilator regimens were also associated with decreased patient satisfaction (O'Shea et al., 2021). In one randomized controlled trial, synthetic dilators placed on the day of D&E resulted in less initial cervical dilation and required more mechanical dilation than overnight laminaria, although there were no differences in procedure duration or complications between the two groups (Newmann et al., 2014; Tufa et al., 2025). Decisions about the number and timing of dilators to place should be individualized and take into consideration the type of dilator and its size, the gestational age of the pregnancy, parity and cervical compliance, and the provider's experience (Fox & Krajewski, 2014; Diedrich, Drey, & Newmann, 2020).

People experience pain both during dilator placement and overnight as dilators expand in the cervix; pain typically peaks two hours after dilator placement (Creinin et al., 2020; Liu & Flink-Bochacki, 2020; Nagendra et al., 2020) and does not differ by type of dilator used (Liu & Flink-Bochacki, 2020). In randomized controlled trials, provider-administration of paracervical block (Shaw et al., 2021; Soon et al., 2017) or self-administration of 2% lidocaine gel (Schivone et al., 2019) prior to osmotic dilator insertion eases the discomfort of dilator placement and use of non-steroidal anti-inflammatory medications (NSAIDs) decreases the experience of cramping pain for the hours following insertion until procedure, compared to oral opioids (Nagendra et al., 2020).

Misoprostol

Misoprostol is inexpensive, safe (Nucatola et al., 2008), and more readily available than osmotic dilators in many low-resource settings. Misoprostol may be used alone for cervical preparation prior to D&E up to 20 weeks gestation (Fox & Krajewski, 2014; O'Connell et al., 2008; Shakir-Reese et al., 2019); there is limited data to support use of misoprostol as a single agent after 18 weeks (Maurer, Jacobson, & Turok, 2013; Shakir-Reese et al., 2019). In studies comparing osmotic dilators to misoprostol, dilators provided more cervical dilation

(Goldberg et al., 2005; Sagiv et al., 2015; Shakir-Reese et al., 2019; Tufa et al., 2025). However, those who received misoprostol for cervical preparation were able to have their procedures safely completed on the same day (Bartz et al., 2013; Goldberg et al., 2005; Sagiv et al., 2015), and patients often preferred misoprostol to dilators (Goldberg et al., 2005). Misoprostol may be given to individuals with a prior cesarean delivery, as uterine rupture is rare (Fox & Krajewski, 2014). A study of same-day use of osmotic dilators plus adjunctive 400mcg misoprostol versus only misoprostol 4-6 hours prior to D&E up to 20 weeks gestation resulted in comparable D&E procedure times between the two groups, although the osmotic dilator plus misoprostol group had significantly greater dilation at D&E initiation (Shakir-Reese et al., 2019). Because placing osmotic dilators takes more time than was saved by having greater baseline dilation, the overall procedure time (placing osmotic dilators plus D&E procedure) was longer by 3.2 minutes in the osmotic dilator plus misoprostol group.

Misoprostol plus osmotic dilators

A 2025 Cochrane review and meta-analysis of cervical preparation between 12 and 24 weeks included four randomized controlled trials of misoprostol versus placebo added to overnight laminaria, finding that adjuvant misoprostol did not change the ability to complete the procedure, but decreased procedure time and reduced the need for initial dilation (Tufa et al., 2025). Side effects are greater among those using misoprostol (Cahill et al., 2019; Drey et al., 2013; Edelman et al., 2006; Goldberg et al., 2015). The Royal College of Obstetricians and Gynaecologists and the Society of Family Planning recommend against adjuvant misoprostol for patients who received uncomplicated dilator insertions the day prior to D&E (Diedrich, Drey, & Newmann, 2020; O'Shea et al., 2021), while the World Health Organization (WHO) recommends adding an adjuvant medication (misoprostol, mifepristone, or both) to osmotic dilators for D&E at or after 19 weeks (WHO, 2024).

Two small prospective randomized trials have examined adding misoprostol to dilators for same-day D&E (Borras et al., 2016; Kim et al., 2022). Investigators ended both studies early—one due to difficulty recruiting participants (Kim et al., 2022) and the other due to an unexpectedly high rate of complications, specifically serious cervical lacerations, in participants over 19 weeks gestation who received dilators alone for cervical preparation (Borras et al., 2016).

Mifepristone

One randomized trial of 50 women between 14-16 weeks gestation compared mifepristone as a single agent to dilators, both administered the day prior to the abortion procedure (Borgatta et al., 2012). Study participants who had cervical preparation with osmotic dilators had a slightly shorter procedure time and greater dilation compared to those given mifepristone, but women had less pain with mifepristone and strongly preferred it. A second randomized trial of 49 women between 15-18 weeks gestation with similar design (single-agent mifepristone compared with osmotic dilators placed the day prior to procedure) found no difference in procedure time between the two treatment groups (Paris et al., 2019). When asked, most participants who received mifepristone preferred it, while most who received osmotic dilators reported that they would have preferred a different treatment option for cervical priming.

In studies examining the use of mifepristone in combination with misoprostol, same-day administration of mifepristone plus misoprostol is no better than misoprostol alone (Casey et al., 2016), and while administration of mifepristone 2 days prior to misoprostol resulted in improved cervical dilation in one study, the rate of preprocedure fetal expulsion was also increased (Carbonell et al., 2007). When compared to overnight dilators plus misoprostol, mifepristone administered the day prior to the abortion plus same-day misoprostol is less effective (Shaw et al., 2017).

Mifepristone plus osmotic dilators

Two randomized trials have assessed the addition of mifepristone to overnight osmotic dilators plus misoprostol for cervical preparation; neither study showed additional benefit with mifepristone (Shaw et al., 2017; Shaw et al., 2015). A third randomized trial compared overnight dilators alone, overnight dilators plus misoprostol,

and overnight dilators plus mifepristone (Goldberg et al., 2015), and found that procedure times were no different between the three groups, although providers reported that procedures between 19-24 weeks gestation were easier in the dilators plus mifepristone group.

Who can perform cervical preparation before D&E?

WHO makes service delivery recommendations for the provision of D&E, which includes assessment of gestational age, cervical preparation, the procedure itself, pain management including the provision of a paracervical block, and the assessment of procedure completeness through visual examination of the products of conception (WHO, 2024). WHO advises that provision of medication for cervical preparation is within the scope of practice of specialty and general medical practitioners; and recommends the provision of cervical preparation medications by associate and advanced associate clinicians, midwives, nurses, auxiliary nurses and auxiliary nurse midwives, and traditional and complementary medicine professionals, based on expected competencies for these roles and low-certainty evidence of safety and effectiveness. Although there is insufficient direct evidence, WHO suggests that community health workers, pharmacists and pharmacy workers can safely and effectively provide medications for cervical preparation based on expected competencies for these roles, adding that these health workers need to ensure continuity of care for the individual obtaining the medications before an abortion procedure (WHO, 2024). WHO advises that cervical preparation with osmotic dilators is within the scope of practice of specialty and general medical practitioners, and recommends the placement of osmotic dilators by associate and advanced associate clinicians, based on indirect evidence and the expected competencies for these health worker roles. Although there is insufficient direct evidence, WHO recommends that midwives, nurses, auxiliary nurses and auxiliary nurse midwives can perform transcervical procedures—including osmotic dilator placement—based on the expected competencies for these roles. For further information about health worker roles in abortion care, see *Appendix C: World Health Organization recommendations for health worker roles in abortion care*.

References

- Bartz, D., Maurer, R., Allen, R. H., Fortin, J., Kuang, B., & Goldberg, A. B. (2013). Buccal misoprostol compared with synthetic osmotic cervical dilator before surgical abortion: A randomized controlled trial. *Obstetrics & Gynecology*, 122(1), 57-63.
- Boraas, C. M., Achilles, S. L., Cremer, M. L., Chappell, C. A., Lim, S. E., & Chen, B. A. (2016). Synthetic osmotic dilators with adjunctive misoprostol for same-day dilation and evacuation: A randomized controlled trial. *Contraception*, 94(5), 467-472.
- Borgatta, L., Roncari, D., Sonalkar, S., Mark, A., Hou, M. Y., Finneseth, M., & Vragovic, O. (2012). Mifepristone vs. osmotic dilator insertion for cervical preparation prior to surgical abortion at 14–16 weeks: A randomized trial. *Contraception*, 86(5), 567-571.
- Bryman, I., Granberg, S., & Norström, A. (1988). Reduced incidence of postoperative endometritis by the use of laminaria tents in connection with first trimester abortion. *Acta Obstetrica et Gynecologica Scandinavica*, 67(4), 323-325.
- Cahill, E.P., Henkel, A., Shaw, J.G., & Shaw, K.A. (2020). Misoprostol as an adjunct to overnight osmotic dilators prior to second trimester dilation and evacuation: A systematic review and meta-analysis. *Contraception*, 101(2): 74-78.
- Carbonell, J. L., Gallego, F. G., Llorente, M. P., Bermudez, S. B., Sala, E. S., González, L. V., & Texido, C. S. (2007). Vaginal vs. sublingual misoprostol with mifepristone for cervical priming in second-trimester abortion by dilation and evacuation: A randomized clinical trial. *Contraception*, 75(3), 230.
- Casey, F. E., Ye, P. P., Perritt, J. D., Moreno-Ruiz, N. L., & Reeves, M. F. (2016). A randomized controlled trial evaluating same-day mifepristone and misoprostol compared to misoprostol alone for cervical preparation prior to second-trimester surgical abortion. *Contraception*, 94(2), 127-133.
- Creinin, M.D., Schimmoeller, N.R., Matulich, M.C., Hou, M.Y., Melo, J., & Chen, M.J. (2020). Gabapentin for pain management after osmotic dilator insertion and prior to dilation and evacuation: A randomized trial. *Contraception*, 101, 167-173.

References continued

- Diedrich, J.T., Drey, E.A., & Newmann, S.J. (2020). Society of Family Planning clinical recommendations: Cervical preparation for dilation and evacuation at 20-24 weeks' gestation. *Contraception*, 101, 286-292.
- Drey, E. A., Benson, L. S., Sokoloff, A., Steinauer, J. E., Roy, G., & Jackson, R. A. (2013). Buccal misoprostol plus laminaria for cervical preparation before dilation and evacuation at 21-23 weeks' gestation: A randomized controlled trial. *Contraception*, 89(4), 307-13.
- Edelman, A. B., Buckmaster, J. G., Goetsch, M. F., Nichols, M. D., & Jensen, J. T. (2006). Cervical preparation using laminaria with adjunctive buccal misoprostol before second-trimester dilation and evacuation procedures: A randomized clinical trial. *American Journal of Obstetrics & Gynecology*, 194(2), 425-430.
- Fox, M. C., & Krajewski, C. M. (2014). Society of Family Planning Clinical Guideline 20134: Cervical preparation for second-trimester surgical abortion prior to 20 weeks' gestation. *Contraception*, 89(2), 75-82.
- Goldberg, A. B., Drey, E. A., Whitaker, A. K., Kang, M. S., Meckstroth, K. R., & Darney, P. D. (2005). Misoprostol compared with laminaria before early second-trimester surgical abortion: A randomized trial. *Obstetrics & Gynecology*, 106(2), 234-241.
- Goldberg, A. B., Fortin, J. A., Drey, E. A., Dean, G., Lichtenberg, E. S., Bednarek, P. H., ... Fitzmaurice, G. M. (2015). Cervical preparation before dilation evacuation using adjunctive misoprostol or mifepristone compared with overnight osmotic dilators alone: A randomized controlled trial. *Obstetrics & Gynecology*, 126(3), 599-609.
- Jonasson, A., Larsson, B., Bygdeman, S., & Forsum, U. (1989). The influence of cervical dilatation by laminaria tent and with Hegar dilators on the intrauterine microflora and the rate of postabortal pelvic inflammatory disease. *Acta Obstetrica et Gynecologica Scandinavica*, 68(5), 405-410.
- Kim, C., Dragoman, M., Porsch, L., Markowitz, J., Lunde, B., Stoffels, G., & Dayananda, I. (2022). Same-day compared with overnight cervical preparation before dilation and evacuation between 16 and 19 6/7 weeks of gestation. *Obstetrics & Gynecology*, 139, 1141-1144.
- Liu, S.M., & Flink-Bochacki, R. (2021). A single-blinded randomized controlled trial evaluating pain and opioid use after dilator placement for second-trimester abortion. *Contraception*, 103(3), 171-177.
- Maurer, K. A., Jacobson, J. C., & Turok, D. K. (2013). Same-day cervical preparation with misoprostol prior to second trimester D&E: A case series. *Contraception*, 88(1), 116-121.
- Nagendra, D., Sonalkar, S., McAllister, A., Roe, A.H., Shorter, J.M., Sammel, M.D., & Schreiber, C.A. (2020). Opioid prescription for pain after osmotic dilator placement in abortion care: A randomized controlled trial. *Contraception*, 101(3), 167-173.
- Newmann, S.J., Sokoloff, A., Tharull, M., Illangasekare, T., Steinauer, J.E., & Drey, E.A. (2014). Same-day synthetic osmotic dilators compared with overnight laminaria before abortion at 14-18 weeks of gestation: A randomized controlled trial. *Obstetrics & Gynecology*, 123(2, pt 1), 271-278.
- Ngo, L. L., Mokashi, M., Janiak, E., Bartz, D., Fortin, J., Maurer, R., & Goldberg, A. B. (2023). Acute complications with same-day versus overnight cervical preparation before dilation and evacuation at 14 to 16 weeks. *Contraception*, 117, 61-66.
- Nucatola, D., Roth, N., Saulsberry, V., & Gatter, M. (2008). Serious adverse events associated with the use of misoprostol alone for cervical preparation prior to early second trimester surgical abortion (12-16 weeks). *Contraception*, 78(3), 245-248.
- O'Connell, K., Jones, H. E., Lichtenberg, E. S., & Paul, M. (2008). Second-trimester surgical abortion practices: A survey of National Abortion Federation members. *Contraception*, 78(6), 492-499.
- O'Shea, L.E., Lohr, P.A., Lord, J., Hasler, E., & Cameron, S. (2021). Cervical priming before surgical abortion between 14 and 24 weeks: A systematic review and meta-analyses for the National Institute for Health and Care Excellence-new clinical guidelines for England. *American Journal of Obstetrics and Gynecology MFM*, 3(1), 100283.
- Paris, A.E., Vragovic, O., Sonalkar, S., Finneseth, M., & Borgatta, L. (2020). Mifepristone and misoprostol compared to osmotic dilators for cervical preparation prior to surgical abortion at 15-18 weeks' gestation: A randomised controlled non-inferiority trial. *BMJ Sexual & Reproductive Health*, 46, 67-72.
- Peterson, W. F., Berry, F. N., Grace, M. R., & Gulbranson, C. L. (1983). Second-trimester abortion by dilatation and evacuation: An analysis of 11,747 cases. *Obstetrics & Gynecology*, 62(2), 185-190.

References continued

Ralph, J.A., & Shulman, L.P. (2019). Adjunctive agents for cervical preparation in second trimester surgical abortion. *Advances in Therapy*, 36(6), 1246-1251.

Sagiv, R., Mizrachi, Y., Glickman, H., Kerner, R., Keider, R., Bar, J., & Golan, A. (2015). Laminaria vs. vaginal misoprostol for cervical preparation before second-trimester surgical abortion: A randomized clinical trial. *Contraception*, 91(5), 406-411.

Schivone, G.B., Lerma, K., Montgomery, C., Wright, P., Conti, J.A., Blumenthal, P.D., & Shaw, K.A. (2019). Self-administered lidocaine gel for local anesthesia prior to osmotic dilator placement: A randomized trial. *Contraception*, 99, 148-151.

Shakir-Reese, J.M., Ye, P.P., Perritt, J.B., Lotke, P.S., & Reeves, M.F. (2019). A factorial-design randomized controlled trial comparing misoprostol dilation & evacuation at 14 weeks 0 days-19 weeks 6 days gestation. *Contraception*, 100(6), 445-450.

Shaw, K.A., Lerma, K., Hughes, T., Hastings, C., Fok, W.K., & Blumenthal, P.D. (2021). A comparison of paracervical block volumes before osmotic dilator placement. *Obstetrics & Gynecology*, 138, 443-448.

Shaw, K.A., Lerma, K., Shaw, J.G., Scrivner, K.J., Hugin, M., Hopkins, F.W., & Blumenthal, P.D. (2017). Pre-operative effects of mifepristone (POEM) for dilation and evacuation after 19 weeks gestation: A randomised controlled trial. *BJOG: An International Journal of Obstetrics & Gynaecology*, 124(13), 1973-1981.

Shaw, K. A., Shaw, J. G., Hugin, M., Velasquez, G., Hopkins, F. W., & Blumenthal, P. D. (2015). Adjunct mifepristone for cervical preparation prior to dilation and evacuation: A randomized trial. *Contraception*, 91(4), 313-319.

Soon, R., Tschann, M., Salcedo, J., Stevens, K., Ahn H.J., & Kaneshiro, B. (2017). Paracervical block for laminaria insertion before second-trimester abortion: A randomized controlled trial. *Obstetrics & Gynecology*, 130(2), 387-392.

Tufa, T. H., Stewart, F., Meckstroth, K., Diedrich, J. T., & Newmann, S. J. (2025). Cervical preparation for dilation and evacuation at 12 to 24 weeks gestation. *The Cochrane Database of Systematic Reviews*, 3(3), CD007310.

World Health Organization. (2024). *Abortion care guideline, 2nd ed.* Geneva: World Health Organization.

4.7

4. Abortion at or after 13 weeks gestation

Medical abortion

4.7.1. Mifepristone and misoprostol:

Recommended regimen

Recommended regimen for 13-24 weeks gestation

- Mifepristone 200mg orally followed 1-2 days later by misoprostol 400mcg buccally, sublingually or vaginally every three hours until fetal and placental expulsion.
- The combined regimen is safe and effective, with fetal expulsion rates of over 90% at 24 hours and major complication rates around 1%.
- The median time to abortion is 6-10 hours after beginning misoprostol, although some individuals will require more time to successfully abort.

In practice:

- A combined mifepristone and misoprostol regimen is more effective than misoprostol used alone, and is recommended for medical abortion at or after 13 weeks; where mifepristone is unavailable the misoprostol-only regimen can be used.
- If the individual is stable and it is convenient to do so, providers should allow at least four hours after fetal expulsion to expel the placenta before intervening.

Strength of recommendation:

Strong

Quality of evidence:

- Up to 20 weeks gestation: Moderate
- 21-24 weeks gestation: Low

Last reviewed:

October 17, 2025

Background

Mifepristone combined with misoprostol is the preferred regimen for medical abortion at or after 13 weeks gestation, as it is highly efficacious, resulting in a short induction-to-abortion interval with an excellent safety profile (; Wildschut et al., 2011; World Health Organization [WHO], 2024; Zwerling et al., 2024). Mifepristone combined with misoprostol has a consistently shorter induction-to-abortion interval and higher expulsion rate at 15 (Ngoc et al., 2011), 24 (Constant et al., 2016; Shay et al., 2021) and 48 hours when compared to misoprostol alone (Dabash et al., 2015).

Combined regimen with mifepristone and misoprostol

Expulsion rates

Studies using the recommended regimen of mifepristone and misoprostol show fetal expulsion rates of 94% at 24 hours and 97% at 48 hours (Abbas et al., 2016), and fetal and placental expulsion rates of 88% at 24 hours and 92% at 48 hours (Dabash et al., 2015). When individuals continue misoprostol until expulsion with no cut off time, 99% of people eventually have a successful abortion (Ashok et al., 2004; Louie et al., 2017).

Induction-to-abortion interval

In studies using the recommended mifepristone and misoprostol regimen, the median times to fetal expulsion were from 6-10 hours, with a wide range of times until complete expulsion (Abbas et al., 2016; Dabash et al., 2015; Louie et al., 2017; Ngoc et al., 2011; Prodan et al., 2019; Shaw et al., 2013). The induction-to-abortion interval is longer in nulliparous people and those with pregnancies at a later gestational age (Abbas et al., 2016; Ashok et al., 2004; Dabash et al., 2015; Louie et al., 2017; Platais et al., 2019; Yitina et al., 2025). The addition of mifepristone to a misoprostol medical abortion regimen consistently reduces the induction-to-abortion interval (Constant et al., 2016; Dabash et al., 2015; Kapp et al., 2007; Ngoc et al., 2011; Prodan et al., 2019).

Complication rates

The rate of major complications from mifepristone and misoprostol medical abortion at or after 13 weeks gestation is low, although minor complications—such as needing a procedure for bleeding or retained products of conception—are more frequent than for dilatation and evacuation (Autry et al., 2002). In the largest study, a retrospective cohort including 1393 people with gestations between 13 and 28 weeks, 19% had placenta retention after 1 hour, 4% had blood loss of more than 1000 mL, and 1.7% required a transfusion (Dickinson & Doherty, 2023). A smaller retrospective cohort study included 1,002 women between 13-21 weeks gestation (Ashok et al., 2004). Eighty-one women (8.1%) needed a uterine evacuation procedure, the majority of which were needed for retained placenta; only two women needed an evacuation to terminate the pregnancy. In this study, serious complications such as hemorrhage, blood transfusion, or unanticipated surgery occurred in eight women (less than 1%). In a more recent but smaller prospective cohort study of mifepristone and misoprostol abortion between 13-18 gestational weeks conducted in Nepal, 35 out of 230 women required placental removal (15%) and three women experienced hemorrhage, for a serious adverse event rate of 1.3% (Blum et al., 2019). In a 2017 cohort study in which 120 women between 13-22 weeks gestation received mifepristone followed by unlimited dosing of misoprostol until fetal and placental expulsion, 99% of women evacuated the uterus without any additional intervention (Louie et al., 2017). No serious adverse events were reported in this study and only one woman failed to abort with the combined regimen.

In a meta-analysis of data from medical abortion studies at or after 13 weeks gestation using either the combined regimen or a misoprostol-only regimen, the overall rate of uterine rupture was 0.08%, with a rate of 0.28% in women with a previous cesarean section (Goyal, 2009).

Mifepristone timing

A 2013 systematic review evaluating the effect of dosing interval between mifepristone and misoprostol on induction-to-abortion interval included 20 randomized controlled trials and nine observational studies (Shaw et al., 2013). Based on the results of three randomized controlled trials, the review found that when mifepristone was given 12-24 hours before misoprostol, the induction-to-abortion interval was slightly longer (median 7.3 hours, range 7 to 8.5) than when mifepristone was administered 36 to 48 hours before misoprostol initiation (6.8 hours, range 6.3 to 7.2), but the abortion rate at 12 and 24 hours was the same (Shaw et al., 2013). A 2024 randomized controlled trial compared a mifepristone to misoprostol interval of 12 hours to 24 hours, finding that the induction-to-abortion interval was significantly longer in the 12 hour group (12.5 and 9.5 hours respectively) (Meyer et al., 2024). The number of patients who completed their abortion at 12 and 24 hours did not differ between the groups. A 2020 systematic review which included three randomized controlled trials, two of which were included in the Shaw, 2013 review, found no significant differences in the induction-to-abortion interval or successful abortion rate when misoprostol was started one day, or two days, after mifepristone (Wu et al., 2021). A multi-country randomized non-inferiority trial that included 531 participants found that a 24 hour interval between mifepristone and misoprostol was not non-inferior to a 48 hour interval. Participants in the 48 hour interval group were more likely to abort within 12 hours of initiating misoprostol (Endler et al., 2025). A smaller retrospective cohort study also found that the induction-to-abortion interval was shorter when mifepristone was given 48 hours compared to 24 hours before misoprostol in pregnancies at 20 to 28 weeks (Sium et al., 2024). In studies examining simultaneous administration of mifepristone and misoprostol, median expulsion times in the simultaneous group ranged from 10 to 13 hours, compared to 5 to 8

hours in women who waited 24 to 36 hours between mifepristone and misoprostol; however, rates of expulsion at 48 hours were equivalent in the two groups (Abbas et al., 2016; Chai et al., 2009).

Misoprostol loading dose

Although an early, large case series used an initial loading dose of vaginal misoprostol (Ashok, Templeton, Wagaarachchi & Flett, 2004), a more recent small, randomized controlled trial assigned 77 women to receive a loading dose of misoprostol vaginally (600mcg, followed by 400mcg every six hours) and 80 women to receive a no-loading dose regimen (400mcg every six hours) (Pongsatha & Tongsong, 2014). Median induction-to-abortion intervals and rates of complete abortion at 24 and 48 hours did not differ between groups, but the loading dose group suffered significantly more misoprostol-related side effects. Recent clinical trials that did not use loading doses of misoprostol showed average induction-to-abortion intervals of 8-10 hours and similar or better success rates as studies with loading doses (Abbas et al., 2016; Dabash et al., 2015; Louie et al., 2017; Ngoc et al., 2011). Therefore, a high initial dose of misoprostol appears to confer no benefit on expulsion times.

Misoprostol dosing

Route: In clinical trials of medical abortion at or after 13 weeks, misoprostol 400mcg vaginally or sublingually has higher success and shorter induction-to-abortion intervals than oral dosing (Dickinson, Jennings & Doherty, 2014; Tang, Chang, Kan & Ho, 2005). Buccal misoprostol has not been directly compared to other routes in a combined regimen for medical abortion at or after 13 weeks, but has similar efficacy as other routes of administration in abortion before 13 weeks (Kulier et al., 2011; Raymond, Shannon, Weaver, & Winikoff, 2013). Studies that use buccal misoprostol as part of a combined mifepristone-misoprostol regimen show an average induction-to-abortion interval of 8-10 hours (Abbas et al., 2016; Dabash, 2015; Louie et al., 2017; Ngoc et al., 2011; Blum et al., 2019).

Dose: Misoprostol 400mcg has higher expulsion rates, shorter induction-to-abortion intervals and similar side effects compared to 200mcg, regardless of route of administration (Brouns et al., 2010; Shaw et al., 2013).

Timing: In one randomized trial examining two regimens of misoprostol-only medical abortion at or after 13 weeks gestation, the induction-to-abortion interval was shorter and the expulsion rate at 24 hours was higher when misoprostol was given every three hours compared to every six hours; rates of adverse events were similar (Wong et al., 2000).

Number of doses: A prospective cohort study of 120 people between 13 and 22 weeks gestation who received mifepristone followed 24 hours later by misoprostol 400mcg buccally every 3 hours until fetal and placental expulsion reported a complete abortion rate of 99% without additional intervention (Louie et al., 2017). The median number of misoprostol doses necessary was four (range 2 to 6) and no adverse events were reported. In a similar prospective study of 306 people between 13-22 weeks, 90% required five or fewer doses of misoprostol (Platais et al., 2019).

Placental expulsion

In a prospective study of women between 13-18 weeks gestation utilizing mifepristone and misoprostol, most women expelled the fetus and placenta at about the same time, with a median time between fetal and placental expulsion of 15 minutes (range 0-4.5 hours) and 15.5% requiring a manual removal of the placenta (Blum et al., 2019). One retrospective cohort study measured intervention rates for placental removal in 233 women receiving a feticidal agent and repeated doses of misoprostol to induce abortion for pregnancies between 18-23 weeks gestation (Green et al., 2007). Following fetal expulsion, the placenta was allowed to expel spontaneously; operative intervention was performed only for excessive bleeding following fetal expulsion or to expedite hospital discharge after a minimum of four hours had elapsed since fetal expulsion. The overall intervention rate for retained placenta was 6%, and most removals were to expedite discharge. The study found no increase in morbidity for those managed expectantly during this time frame.

Who can provide medical abortion at or after 13 weeks gestation?

The World Health Organization (WHO) makes service delivery recommendations for the provision of medical abortion at or after 13 weeks gestation, which includes assessment of medical abortion eligibility (determining pregnancy duration and assessing for contraindications to abortion medications), administration of abortion medications, management of the abortion process, and assessment of abortion success (WHO, 2024). WHO recommends the provision of medical abortion at or after 13 weeks by specialty and general medical practitioners, and suggests that in contexts where established and easy access to appropriate surgical backup and other infrastructure necessary to address possible complications exists, associate and advanced associate clinicians, midwives, nurses, auxiliary nurses and auxiliary nurse midwives, and traditional and complementary medicine professionals can also safely and effectively provide this service based on the expected competencies for these health workers (WHO, 2024). A 2024 randomized controlled trial found no difference in safety or efficacy of medical abortion between 13 and 20 weeks when physician provision was compared to provision by midlevel providers (Kapp et al., 2024). For further information about health worker roles in abortion care, see *Appendix C: World Health Organization recommendations for health worker roles in abortion care*.

References

- Abbas, D.F., Blum, J., Ngoc, N.T., Nga, N.T., Chi, H.T., Martin, R., & Winikoff, B. (2016) Simultaneous administration compared with a 24-hour mifepristone-misoprostol interval in second-trimester abortion. *Obstetrics & Gynecology*, 128,(5), 1077-1083.
- Ashok, P. W., Templeton, A., Wagaarachchi, P. T., & Flett, G. M. (2004). Midtrimester medical termination of pregnancy: A review of 1002 consecutive cases. *Contraception*, 69(1), 51-58.
- Autry, A. M., Hayes, E. C., Jacobson, G. F., & Kirby, R. S. (2002). A comparison of medical induction and dilation and evacuation for second-trimester abortion. *American Journal of Obstetrics & Gynecology*, 187(2), 393-397.
- Blum, J., Karki, C., Tamang, A., et al. (2019). Feasibility of a hospital outpatient day procedure for medication abortion at 13-18 weeks gestation: Findings from Nepal. *Contraception*, 100(6), 451-456.
- Brouns, J. F., van Wely, M., Burger, M. P., & van Wijngaarden, W. J. (2010). Comparison of two dose regimens of misoprostol for second-trimester pregnancy termination. *Contraception*, 82(3), 266-275.
- Chai, J., Tang, O. S., Hong, Q. Q., Chen, Q. F., Cheng, L. N., Ng, E., & Ho, P. C. (2009). A randomized trial to compare two dosing intervals of misoprostol following mifepristone administration in second trimester medical abortion. *Human Reproduction*, 24(2), 320-324.
- Constant, D., Harries, J., Malaba, T., Myer, L., Patel, M., Petro, G., & Grossman, D. (2016). Clinical outcomes and women's experiences before and after the introduction of mifepristone into second-trimester medical abortion services in South Africa. *PLoS ONE*, 11(9), e0161843. DOI: 10.1371/journal.pone.0161843.
- Dabash, R., Chelli, H., Hajri, S., Shochet, T., Raghavan, S., & Winikoff, B. (2015). A double-blind randomized controlled trial of mifepristone or placebo before buccal misoprostol for abortion at 14-21 weeks of pregnancy. *International Journal of Gynecology & Obstetrics*, 130(1), 40-44.
- Dickinson, J. E., & Doherty, D. A. (2023). Maternal complications associated with second trimester medical abortion using mifepristone priming and subsequent misoprostol. *Contraception*, 125.
- Dickinson, J. E., Jennings, B. G., & Doherty, D. A. (2014). Mifepristone and oral, vaginal, or sublingual misoprostol for second-trimester abortion. *Obstetrics & Gynecology*, 123(6), 1162-1168.
- Endler, M., Jaisamrarn, U., Mittal, S., Phanupong, P., Du, V. V., Ngo, T. A., Vemer, H., Gülmezoglu, A. M., & Gemzell-Danielsson, K. (2025). Effectiveness and acceptability of a 24-h interval versus a 48-h interval between mifepristone intake and misoprostol administration for in-hospital abortion at 9–20 gestational weeks: An international, open-label, randomised, controlled, non-inferiority trial. *The Lancet Global Health*, 13(1), e112–e120.
- Goyal, V. (2009). Uterine rupture in second-trimester misoprostol-induced abortion after cesarean delivery: A systematic review. *Obstetrics & Gynecology*, 113(5), 1117-1123.
- Green, J., Borgatta, L., Sia, M., Kapp, N., Saia, K., Carr-Ellis, S., & Vragovic, O. (2007). Intervention rates for placental removal following induction abortion with misoprostol. *Contraception*, 76, 310-313.

References continued

- Kapp, N., Dijkerman, S., Getachew, A., Eckersberger, E., Pearson, E., Abubeker, F. A., & Birara, M. (2024). Can mid-level providers manage medical abortion after 12 weeks' gestation as safely and effectively as physicians? A non-inferiority, randomized controlled trial in Addis Ababa, Ethiopia. *International Journal of Gynecology & Obstetrics*, 165(3), 1268–1276.
- Kulier, R., Kapp, N., Gulmezoglu, A. M., Hofmeyr, G. J., Cheng, L., & Campana, A. (2011). Medical methods for first trimester abortion. *The Cochrane Database of Systematic Reviews*, 11, CD002855.
- Louie, K. S., Chong, E., Tsereteli, T., Avagyan, G., Abrahamyan, R., & Winikoff, B. (2017). Second trimester medical abortion with mifepristone followed by unlimited dosing of buccal misoprostol in Armenia. *European Journal of Contraception & Reproductive Health Care*, 22(1), 76-80.
- Meyer, R., Toussia-Cohen, S., Shats, M., Segal, O., Mohr-Sasson, A., Peretz-Bookstein, S., Amitai-Komem, D., Sindel, O., Levin, G., Mashiach, R., & Blumenthal, P. D. (2024). 24-Hour Compared With 12-Hour Mifepristone–Misoprostol Interval for Second-Trimester Abortion: A Randomized Controlled Trial. *Obstetrics & Gynecology*, 144(1), 60.
- Ngoc, N. T. N., Shochet, T., Raghavan, S., Blum, J., Nga, N. T. B., Minh, N. T. H., ... Winikoff, B. (2011). Mifepristone and misoprostol compared with misoprostol alone for second-trimester abortion: A randomized controlled trial. *Obstetrics & Gynecology*, 118 (3), 601-8. DOI:10.1097/AOG.0b013e318227214e.
- Platais, I., Tsereteli, T., Maystruk, G., Kurbanbekova, D., & Winikoff, B. (2019). A prospective study of mifepristone and unlimited dosing of sublingual misoprostol for termination of second-trimester pregnancy in Uzbekistan and Ukraine. *BMJ Sexual & Reproductive Health*, 45, 177-182.
- Pongsatha, S., & Tongsong, T. (2014). Randomized controlled trial comparing efficacy between a vaginal misoprostol loading and non-loading dose regimen for second-trimester pregnancy termination. *The Journal of Obstetrics and Gynaecology Research*, 40(1), 155-160.
- Prodan, N., Breisch, J., Hoopmann, M., Abele, H., Wagner, P., & Kagan, K.O. (2019). Dosing interval between mifepristone and misoprostol in second and third trimester termination. *Archives of Gynecology and Obstetrics*, 99(3), 675-679.
- Raymond, E. G., Shannon, C., Weaver, M. A., & Winikoff, B. (2013). First-trimester medical abortion with mifepristone 200 mg and misoprostol: A systematic review. *Contraception*, 87(1), 26-37.
- Shaw, K., Topp, N. J., Shaw, J. G., & Blumenthal, P. D. (2013). Mifepristone-misoprostol dosing interval and effect on induction abortion times: A systematic review. *Obstetrics & Gynecology*, 121(6), 1335-1347.
- Sium, A. F., Teklu, H., Reeves, M., Tolu, L. B., & Prager, S. (2024). One-day versus two-day mifepristone–misoprostol interval prior to initiation of misoprostol during late second trimester medication abortion: A cohort study. *Contraception*, 132.
- Tang, O. S., Chan, C. C., Kan, A. S., & Ho, P. C. (2005). A prospective randomized comparison of sublingual and oral misoprostol when combined with mifepristone for medical abortion at 12-20 weeks gestation. *Human Reproduction*, 20(11), 3062-3066.
- Wildschut, H., Both, M. I., Medema, S., Thomee, E., Wildhagen, M. F., & Kapp, N. (2011). Medical methods for mid-trimester termination of pregnancy. *The Cochrane Database of Systematic Reviews*, 1, CD005216.
- Wong, K. S., Ngai, C. S., Yeo, E. L., Tang, L. C., & Ho, P. C. (2000). A comparison of two regimens of intravaginal misoprostol for termination of second trimester pregnancy: A randomized comparative trial. *Human Reproduction*, 15(3), 709-712.
- World Health Organization. (2024). *Abortion care guideline, 2nd ed.* Geneva: World Health Organization Press.
- Wu, L., Xiong, W., Zeng, M., Yan, A., Song, L., Chen, M., Wei, T., Zu, Q. & Zhang, J. (2021). Different dosing intervals of mifepristone-misoprostol for second-trimester termination of pregnancy: A meta-analysis and systematic review. *International Journal of Gynaecology and Obstetrics*, 154(2), 195-203.
- Yitina, E. F., Mihrete, G. S., Bicha, M. M., Andualem, B. S., Addis, N. A., Abebe, S. M., Tolu, L. B., & Lakew, A. M. (2025). Determinants of induction-to-expulsion time and adverse maternal outcomes of second trimester medical abortion in Amhara Region, Ethiopia: Prospective follow-up study. *African Journal of Reproductive Health*, 29(9s).
- Zwerling, B., Edelman, A., Jackson, A., Burke, A., & with the assistance of Prabhu, M. (2024). Society of Family Planning Clinical Recommendation: Medication abortion between 14 0/7 and 27 6/7 weeks of gestation: Jointly developed with the Society for Maternal-Fetal Medicine. *Contraception*, 129.

4.7

4. Abortion at or after 13 weeks gestation

Medical abortion

4.7.2. Misoprostol only: Recommended regimen

Recommended regimen for 13-24 weeks gestation

- Misoprostol 400mcg buccally, sublingually or vaginally every three hours until fetal and placental expulsion. Vaginal dosing is more effective than other routes.
- Misoprostol-only medical abortion is safe and effective, with fetal expulsion rates of 72-91% at 24 hours and major complication rates of less than 1%.
- The average time to abortion is 10-15 hours after beginning misoprostol, although some individuals will require multiple days to successfully abort.

In practice:

- A combined mifepristone and misoprostol regimen is more effective than misoprostol used alone and is recommended for medical abortion at or after 13 weeks; where mifepristone is unavailable the misoprostol-only regimen can be used.
- If the individual is stable and it is convenient to do so, providers should allow at least four hours after fetal expulsion to expel the placenta before intervening.

Strength of recommendation:

Strong

Quality of evidence:

- Up to 20 weeks gestation: Moderate
- 20-24 weeks gestation: Low

Last reviewed:

October 17, 2025

Background

A combination regimen with mifepristone and misoprostol has shorter induction-to-abortion intervals and higher success rates than misoprostol only for medical abortion at or after 13 weeks gestation (Wildschut et al., 2011). If mifepristone is not available, a misoprostol-only regimen with dosing every three hours is an acceptable alternative (Wildschut et al., 2011; World Health Organization [WHO], 2024; Zwerling et al., 2024).

Misoprostol-only regimen

Expulsion rates

The largest international randomized controlled trial of medical abortion at or after 13 weeks gestation, with the recommended vaginal or sublingual misoprostol-only regimen, included 681 women between 13-20 weeks gestation (von Hertzen et al., 2009). The fetal expulsion rate was 84.8% at 24 hours and 94.3% at 48 hours. Smaller randomized trials using vaginal or sublingual misoprostol every three hours showed fetal expulsion rates of 72-91% at 24 hours and 91-95% at 48 hours (Bhattacharjee et al., 2008; Tang et al., 2004), and fetal and placental expulsion rates of 62-64% at 24 hours and 79-82% at 48 hours (Bhattacharjee et al., 2008).

Induction-to-abortion interval

In the von Hertzen trial, the median time to fetal expulsion was 12 hours (range 4.1-61.8 hours), with parous women having faster induction-to-abortion times than nulliparous (von Hertzen et al., 2009). In smaller randomized trials, time to expulsion ranges from 10-15 hours (Bhattacharjee et al., 2008; Tang et al., 2004). Lengthening the dosing interval of misoprostol from every three to every six hours increases the induction-to-abortion time (Wong et al., 2000).

Complication rates

The rate of major complications from misoprostol-only abortion at or after 13 weeks is low. In the trial cited above, 12 adverse events (0.02%) were reported; 10 women required blood transfusions (von Hertzen et al., 2009).

Routes of misoprostol administration

In randomized controlled clinical trials, misoprostol 400mcg vaginally every three hours is associated with a median induction-to-abortion interval of 10-15 hours and a 48-hour successful abortion rate of 90-95% (Bhattacharjee et al., 2008; Koh et al., 2017; Tang et al., 2004; von Hertzen et al., 2009). A 400mcg dose vaginally is more effective than a 200mcg dose (Koh et al., 2017).

In a meta-analysis of 1,178 women from three randomized controlled trials, misoprostol 400mcg sublingually is similar (Bhattacharjee et al., 2008) or slightly inferior to vaginal dosing when given every three hours (Tang et al., 2004; von Hertzen et al., 2009; Wildschut et al., 2011). In the trials that showed reduced efficacy, the difference was driven by an inferior response to sublingual misoprostol in nulliparous women only. Of note, all of these studies found that women prefer the sublingual route to vaginal administration by health care workers.

One trial randomized 130 women to misoprostol 400mcg every three hours either vaginally or buccally. Those in the vaginal group had a shorter mean induction-to-fetal expulsion interval (25 compared to 40 hours, $p=0.001$) and higher rates of fetal expulsion at both 24 hours (63% compared to 42%, $p=0.014$) and 48 hours (91% compared to 68%, $p=0.001$) (Al & Yapca, 2015). A smaller trial of 64 women showed buccal misoprostol was as effective as vaginal; however, all of the women received an initial loading dose of misoprostol 400mcg vaginally and were randomized to 200mcg buccally or vaginally every six hours thereafter (Ellis et al., 2010). Finally, a trial including a cohort of 60 women who received misoprostol 400mcg buccally every three hours until fetal and placental expulsion found a complete abortion rate of 71% at 48 hours (Dabash et al., 2015). Based on these studies, vaginal and sublingual administration appear to be superior to buccal misoprostol dosing in this gestational age range.

In multiple randomized clinical trials, oral dosing has been shown to be less effective with longer time-to-abortion intervals than vaginal or sublingual dosing (Akoury et al., 2004; Bebbington et al., 2002; Behrashi & Mahdian, 2008; Nautiyal et al., 2015).

Placental expulsion

One retrospective cohort study measured intervention rates for placental removal in 233 women receiving a feticidal agent and repeated doses of misoprostol to induce abortion for pregnancies between 18-23 weeks gestation (Green et al., 2007). Following fetal expulsion, the placenta was allowed to expel spontaneously; operative intervention was performed only for excessive bleeding following fetal expulsion or to expedite hospital discharge after a minimum of four hours had elapsed since fetal expulsion. The overall intervention rate for retained placenta was 6%, and most removals were to expedite discharge. The study found no increase in morbidity for those managed expectantly during this time frame.

Quality of evidence

The recommendation is based on multiple randomized clinical trials and a Cochrane meta-analysis comparing different misoprostol doses, dosing intervals and routes of administration at or after 13 weeks gestation (Wildschut et al., 2011). This body of evidence is limited by the fact that most randomized controlled trials of medical abortion do not include people with pregnancies over 20 weeks gestation.

Who can provide medical abortion at or after 13 weeks gestation?

The World Health Organization (WHO) makes service delivery recommendations for the provision of medical abortion at or after 13 weeks gestation, which includes assessment of medical abortion eligibility (determining pregnancy duration and assessing for contraindications to abortion medications), administration of abortion medications, management of the abortion process, and assessment of abortion success (WHO, 2024). WHO recommends the provision of medical abortion at or after 13 weeks by specialty and general medical practitioners, and suggests that in contexts where established and easy access to appropriate surgical backup and other infrastructure necessary to address possible complications exists, associate and advanced associate clinicians, midwives, nurses, auxiliary nurses and auxiliary nurse midwives, and traditional and complementary medicine professionals can also safely and effectively provide this service based on the expected competencies for these health workers (WHO, 2024). For further information about health worker roles in abortion care, see *Appendix C: World Health Organization recommendations for health worker roles in abortion care*.

Resources

www.ipas.org/ClinicalResources

Protocols for medical abortion (dosage card)



References

- Akoury, H. A., Hannah, M. E., Chitayat, D., Thomas, M., Winsor, E., Ferris, L. E., & Windrim, R. (2004). Randomized controlled trial of misoprostol for second-trimester pregnancy termination associated with fetal malformation. *American Journal of Obstetrics & Gynecology*, 190(3), 755-762.
- Al, R. A., & Yapca, O. E. (2015). Vaginal misoprostol compared with buccal misoprostol for termination of second-trimester pregnancy: A randomized controlled trial. *Obstetrics & Gynecology*, 126(3), 593-8.
- Bebbington, M. W., Kent, N., Lim, K., Gagnon, A., Delisle, M. F., Tessier, F., & Wilson, R. D. (2002). A randomized controlled trial comparing two protocols for the use of misoprostol in midtrimester pregnancy termination. *American Journal of Obstetrics & Gynecology*, 187(4), 853-857.
- Behrashi, M., & Mahdian, M. (2008). Vaginal versus oral misoprostol for second-trimester pregnancy termination: A randomized trial. *Pakistan Journal of Biological Sciences*, 11(21), 2505-2508.
- Bhattacharjee, N., Saha, S. P., Ghoshroy, S. C., Bhowmik, S., & Barui, G. (2008). A randomised comparative study on sublingual versus vaginal administration of misoprostol for termination of pregnancy between 13 to 20 weeks. *Australian and New Zealand Journal of Obstetrics and Gynaecology*, 48(2), 165-171.
- Dabash, R., Chelli, H., Hajri, S., Shochet, T., Raghavan, S., & Winikoff, B. (2015). A double-blind randomized controlled trial of mifepristone or placebo before buccal misoprostol for abortion at 14-21 weeks of pregnancy. *International Journal of Gynecology & Obstetrics*, 130, 40-44.
- Ellis, S. C., Kapp, N., Vragovic, O., & Borgatta, L. (2010). Randomized trial of buccal versus vaginal misoprostol for induction of second trimester abortion. *Contraception*, 81(5), 441-445.
- Green, J., Borgatta, L., Sia, M., Kapp, N., Saia, K., Carr-Ellis, S., & Vragovic, O. (2007). Intervention rates for placental removal following induction abortion with misoprostol. *Contraception*, 76, 310-313.
- Koh, D. S. C., Ang, E. P. J., Coyuco, J. C., Teo, H. Z., Huang, X., Wei, X., ... Tan, K. H. (2017). Comparing two regimens of intravaginal misoprostol with intravaginal gemprost for second-trimester pregnancy termination: A randomised controlled trial. *Journal of Family Planning and Reproductive Health Care*, DOI: 10.1136/jfprhc-2016-101652.
- Nautiyal, D., Mukherjee, K., Perhar, I., & Banerjee, N. (2015). Comparative study of misoprostol in first and second trimester abortions by oral, sublingual and vaginal routes. *Journal of Obstetrics and Gynecology of India*, 65(4), 246-50.

References continued

Tang, O. S., Lau, W. N., Chan, C. C., & Ho, P. C. (2004). A prospective randomised comparison of sublingual and vaginal misoprostol in second trimester termination of pregnancy. *BJOG: An International Journal of Obstetrics & Gynecology*, 111(9), 1001-1005.

von Hertzen, H., Piaggio, G., Wojdyla, D., Nguyen, T. M., Marions, L., Okoev, G., & Peregoudov, A. (2009). Comparison of vaginal and sublingual misoprostol for second trimester abortion: Randomized controlled equivalence trial. *Human Reproduction*, 24(1), 106-112.

Wildschut, H., Both, M. I., Medema, S., Thomee, E., Wildhagen, M. F., & Kapp, N. (2011). Medical methods for mid-trimester termination of pregnancy. *The Cochrane Database of Systematic Reviews* (1), CD005216.

Wong, K. S., Ngai, C. S., Yeo, E. L., Tang, L. C., & Ho, P. C. (2000). A comparison of two regimens of intravaginal misoprostol for termination of second trimester pregnancy: A randomized comparative trial. *Human Reproduction*, 15(3), 709-712.

World Health Organization. (2024). *Abortion care guideline, 2nd ed.* Geneva: World Health Organization.

Zwerling, B., Edelman, A., Jackson, A., Burke, A., & with the assistance of Prabhu, M. (2024). Society of Family Planning Clinical Recommendation: Medication abortion between 14 0/7 and 27 6/7 weeks of gestation: Jointly developed with the Society for Maternal-Fetal Medicine. *Contraception*, 129.

4.7

4. Abortion at or after 13 weeks gestation

Medical abortion

4.7.3. Presence of uterine scar: Recommended regimen

Recommended regimen for 13-24 weeks gestation

- **Less than 22-24 weeks gestation with one uterine scar:** No changes to recommended regimens necessary.
- **More than 22-24 weeks gestation with one uterine scar or 13-24 weeks gestation with more than one uterine scar:** Consider decreasing the misoprostol dose with or without lengthening the misoprostol dosing interval. There is insufficient evidence to know if this impacts the risk of uterine rupture.

Strength of recommendation:

Weak

Quality of evidence:

Very low

Last reviewed:

October 17, 2025

Risk of uterine rupture with medical abortion

Uterine rupture has been reported during medical abortion at or after 13 weeks gestation in people with and without a uterine scar. A meta-analysis of 22 studies including 7,118 participants undergoing medical abortion with mifepristone and misoprostol found a uterine rupture risk of 1.1% in women with a prior scar, compared to 0.01% in those without a scar (Henkel et al., 2023). In a meta-analysis of 16 studies of 3,556 women undergoing medical abortion at or after 13 weeks gestation with combined or misoprostol-only regimens, three women suffered uterine rupture resulting in a rate of 0.28% with a previous cesarean section and 0.04% without (Goyal, 2009). Risk of rupture appears to increase when more than one scar is present (Latta et al., 2023; Zwerling et al., 2024).

Additional misoprostol-only studies published since the meta-analysis referenced above have found that uterine rupture is rare, even with multiple scars. A single-center prospective comparative cohort included 158 people without a prior scar, and 80 people with a scar undergoing misoprostol-only medical abortion between 14 and 28 weeks, finding no differences in abortion success or induction-to-abortion interval. One person in the scar group experienced a uterine rupture (1.3%) (Pongsatha, Suntornlimsiri, & Tongsong, 2024). A single-center retrospective review of 279 women undergoing abortion between 14-26 weeks included 60 women with one and 26 women with more than one uterine scar (Küçüköz Güleç et al., 2013). Women received misoprostol 200mcg vaginally every four hours; three had a uterine rupture. In another retrospective review of 263 women between 12-24 weeks undergoing misoprostol-only abortion, 48 had one and 29 had more than one scar; one rupture was observed in a woman with three prior cesarean sections who received a misoprostol regimen of 200mcg sublingually every three hours (Cetin et al., 2016). A third retrospective review included 231 women with one and 37 women with two prior cesarean deliveries, and used a regimen of 800mcg of misoprostol as a loading dose followed by 200mcg every two hours for three doses; no one experienced

rupture (Torriente, Steinberg, & Joubert, 2017). A retrospective cohort that compared women with no scar (n=80) to those with 1 scar (n=79) and with 2 scars (n=58) found no difference in complications between the groups when either misoprostol 400mcg, or misoprostol 400mcg followed by repeated doses of 200mcg was used (Erturk et al., 2022). One patient with 2 scars experienced uterine rupture; they received the lower dose misoprostol regimen. One single-center prospective study of 250 women undergoing uterine evacuation for fetal demise using a low-dose misoprostol regimen included 95 participants with a uterine scar (Shakir, 2022). Those with gestations between 13-17 weeks received 100mcg of misoprostol vaginally every six hours for 24 hours, and between 18-24 weeks received 50mcg of misoprostol. No ruptures occurred, however only 67% had completely aborted after 24 hours.

Regimen for women with a uterine scar

Due to the rarity of uterine rupture in individuals with a previous scar, no clear guidance can be obtained from the published literature (Daponte, Nzewenga, Dimopoulos, & Guidozi, 2006; Daskalakis et al., 2004; Dickinson, 2005; Morris et al., 2017; Zwerling et al., 2024).

Expert opinion supports:

- No change in medical abortion regimen for people with one uterine scar whose gestation is less than 22-24 weeks.
- After 22-24 weeks gestation with a single uterine scar or 13-24 weeks gestation with more than one uterine scar:
 - Consider decreasing the dose of misoprostol with or without lengthening the dosing interval (Ho et al., 2007; Küçüköz Güleç et al., 2013).

There is insufficient evidence to know if changing the dosing regimen will decrease the risk of uterine rupture.

References

- Cetin, C., Buyukkurt, S., Seydaoglu, G., Kahveci, B., Soysal, C., & Ozgunen, F. T. (2016). Comparison of two misoprostol regimens for mid-trimester pregnancy terminations after FIGO's misoprostol dosage recommendation in 2012. *The Journal of Maternal-Fetal & Neonatal Medicine*, 29(8), 1314-1317.
- Daponte, A., Nzewenga, G., Dimopoulos, K. D., & Guidozi, F. (2006). The use of vaginal misoprostol for second-trimester pregnancy termination in women with previous single cesarean section. *Contraception*, 74(4), 324-327.
- Daskalakis, G. J., Mesogitis, S. A., Papantoniou, N. E., Moulopoulos, G. G., Papapanagiotou, A. A., & Antsaklis, A. J. (2004). Misoprostol for second trimester pregnancy termination in women with prior cesarean section. *BJOG: An International Journal of Obstetrics & Gynaecology*, 112(1), 97-99.
- Dickinson, J. E. (2005). Misoprostol for second-trimester pregnancy termination in women with a prior cesarean delivery. *Obstetrics & Gynecology*, 105(2), 352-356.
- Erturk, A., Karapinar, B. T., Tasgoz, F. N., Dundar, B., & Kender Erturk, N. (2022). The safety of misoprostol alone used for second-trimester termination of pregnancy in women with previous caesarean deliveries. *The European Journal of Contraception & Reproductive Health Care*, 27(6), 473-477.
- Goyal, V. (2009). Uterine rupture in second-trimester misoprostol-induced abortion after cesarean delivery: A systematic review. *Obstetrics & Gynecology*, 113(5), 1117-1123.
- Henkel, A., Miller, H. E., Zhang, J., Lyell, D. J., & Shaw, K. A. (2023). Prior Cesarean Birth and Risk of Uterine Rupture in Second-Trimester Medication Abortions Using Mifepristone and Misoprostol: A Systematic Review and Meta-analysis. *Obstetrics & Gynecology*, 142(6), 1357.
- Ho, P. C., Blumenthal, P. D., Gemzell-Danielsson, K., Gómez Ponce de León, R., Mittal, S., & Tang, O. S. (2007). Misoprostol for the termination of pregnancy with a live fetus at 13 to 26 weeks. *International Journal of Gynecology & Obstetrics*, 99(2), 178-181.
- Küçüköz Güleç, Ü., Urunsak, I. F., Eser, E., Guzel, A. B., Ozgunen, F. T., Evruke, I. C., & Buyukkurt, S. (2013). Misoprostol for midtrimester termination of pregnancy in women with 1 or more prior cesarean deliveries. *International Journal of Gynecology & Obstetrics*, 120, 85-87.

References continued

Latta, K., Barker, E., Kendall, P., Testani, E., Laursen, L., McClosky, L., & York, S. (2023). Complications of second trimester induction for abortion or fetal demise for patients with and without prior cesarean delivery. *Contraception*, 117, 55–60.

Morris, J. L., Winikoff, B., Dabash, R., Weeks, A., Faundes, A., Gemzell-Danielsson, K., ... Visser, G. H. A. (2017). FIGO's updated recommendations for misoprostol used alone in gynecology and obstetrics. *International Journal of Gynecology & Obstetrics*, 138(3), 363-366.

Pongsatha, S., Suntornlimsiri, N., & Tongsong, T. (2024). Comparing the outcomes of termination of second trimester pregnancy with a live fetus using intravaginal misoprostol between women with and without previous cesarean section. *BMC Pregnancy and Childbirth*, 24, 274.

Shakir, H.M. (2022). Safety of vaginal misoprostol for the termination of second trimester miscarriage in women with previous uterine scar in Iraq. *Archives of Razi Institute*, 77(1), 199-204.

Torriente, M. C., Steinberg, W. J., & Joubert, G. (2017). Misoprostol use for second-trimester termination of pregnancy among women with one or more previous cesarean deliveries. *International Journal of Gynecology & Obstetrics*, 138, 23-27.

Zwerling, B., Edelman, A., Jackson, A., Burke, A., & with the assistance of Prabhu, M. (2024). Society of Family Planning Clinical Recommendation: Medication abortion between 14 0/7 and 27 6/7 weeks of gestation: Jointly developed with the Society for Maternal-Fetal Medicine. *Contraception*, 129.

5.1

5. Postabortion care

Treatment of incomplete and missed abortion for less than 13 weeks uterine size

Recommendation:

- Medical methods or vacuum aspiration may be offered for treatment of incomplete or missed abortion.
- Recommended medication regimen:
 - **Incomplete abortion:** Misoprostol 600mcg orally in a single dose or 400mcg in a single dose buccally, sublingually or, in the absence of vaginal bleeding, vaginally.
 - **Missed abortion:** Misoprostol 800mcg buccally, sublingually or, in the absence of vaginal bleeding, vaginally every three hours until pregnancy expulsion (generally 1-3 doses). Where available, add pretreatment with mifepristone 200mg orally 1-2 days before misoprostol.

In practice:

- Uterine size, not gestational age, should be used to determine treatment for postabortion care.

Strength of recommendation:

Strong

Quality of evidence:

Moderate

Last reviewed:

November 6, 2025

Incomplete abortion

A 2021 systematic review and network meta-analysis examining methods for managing miscarriage before 13 weeks gestation included 26 randomized trials reporting on 5,735 women who were treated for incomplete abortion (Ghosh et al., 2021). Suction aspiration (RR 1.19, 95% confidence interval [CI] 1.09, 1.31) and misoprostol therapy (RR 1.14, 95%CI 1.03, 1.25) were slightly more effective than expectant management or placebo in achieving abortion completion, however success rates were similar for all management strategies. Reported completion rates range from 52-85% for expectant management, 80-99% for treatment with misoprostol, and 91-100% for surgical treatment (Kim et al., 2017). Oral, sublingual and vaginal misoprostol show similar efficacy and side effect profiles; lengthening the time to follow-up assessment increases the success of misoprostol treatment (Kim et al., 2017).

Missed abortion

A 2021 systematic review and network meta-analysis examining methods for managing miscarriage before 13 weeks gestation included 16 randomized trials reporting on 4,397 women who were treated for missed abortion (Ghosh et al., 2021). Suction aspiration (RR 2.43, 95%CI 1.69, 3.49), mifepristone plus misoprostol (RR 1.82, 95%CI 1.28, 2.58) and misoprostol alone (RR 1.67, 95%CI 1.18, 2.37) were all more effective in achieving a complete abortion than expectant management or placebo treatment. Four randomized controlled trials found

that people with a missed abortion who receive pretreatment with mifepristone before receiving misoprostol are more likely to successfully complete their abortion than those who receive misoprostol only. In Schreiber et al. (2018), women received either mifepristone, followed 24 hours later by a single dose of 800mcg misoprostol vaginally, or misoprostol with no pretreatment. Abortion success, determined the day after misoprostol was used, was 84% in the mifepristone group compared to 67% in the misoprostol-only group. In another study (Sinha et al., 2018), women received either mifepristone or placebo, followed 48 hours later by identical multidose regimens of misoprostol. Abortion success rates were 87% and 58% respectively; more women in the mifepristone group than in the placebo group expelled the pregnancy after a single misoprostol dose (66% compared to 11%, respectively) and had a significantly shorter induction to abortion interval (4.7 hours compared to 8 hours, respectively). A third study of mifepristone or placebo, followed 48 hours later by misoprostol 800mcg, demonstrated successful expulsion in 83% and 76% of the 696 women in the trial, respectively, at seven days post-mifepristone (Chu et al., 2020). A fourth study including 216 participants found a success rate of 94% when mifepristone was used, compared to 83% when misoprostol-only was used, when follow-up occurred more than 2 weeks after medication administration (Bettencourt-Silva et al., 2023). Management of early pregnancy loss with mifepristone and misoprostol is associated with a lower rate of subsequent uterine evacuation procedures (Benson, Gunaje, Holt, Gore, & Dalton, 2024). In a prospective cohort study, risk of failure following mifepristone and misoprostol for missed abortion was increased among people with a uterine size of greater than nine weeks gestation (Ehrnsten et al., 2019). Despite the relatively high cost of mifepristone, two studies from the United States and one from the United Kingdom have shown that use of a combined mifepristone and misoprostol regimen for treatment of missed abortion is cost-effective, particularly in settings where surgical evacuation of the uterus is performed in an operating theater (Berkley, Greene, & Wittenberger, 2020; Nagendra et al., 2020; Okeke Ogwulu et al., 2021). The World Health Organization (WHO), the Society of Family Planning, and the National Institute for Health Care and Excellence (NICE) recommend the addition of mifepristone to misoprostol when treating early pregnancy loss (WHO, 2024; Tarleton, Benson, Moayed, & Trevino, 2025; NICE, 2023).

A 2017 systematic review and network meta-analysis of misoprostol management of missed abortion, which included 18 studies reporting on 1,802 women, concluded that misoprostol 800mcg vaginally or 600mcg sublingually are the most effective treatments (Wu et al., 2017). A single dose of misoprostol 800mcg vaginally results in successful uterine evacuation in 76 to 93% of women (Fernlund et al., 2017; Mizrachi et al., 2017; Ngoc et al., 2004). In two studies, when women were managed expectantly over seven days after a single dose of misoprostol, their abortion success rates increased over time (Ngoc et al., 2004) up to 88% at seven days compared with 72% at four days (Mizrachi et al., 2019). Although a number of studies have reported an increase in abortion success when an additional dose of misoprostol is administered 24 (Barcelo et al., 2012; Graziosi et al., 2004; Muffley, Stitely, & Gherman, 2002), 48 (Lyra et al., 2017) or 72 hours after the initial dose (Gilles et al., 2004; Zhang et al., 2005), it has been unclear whether this is due to the additional medication or the increased time to evaluation. A 2017 trial which randomized women to receive a single dose of misoprostol 800mcg vaginally, or to receive an additional dose of misoprostol after four days, found that both groups had nearly identical success rates after seven days: 77 and 76% respectively (Mizrachi et al., 2017).

Misoprostol 600mcg sublingually repeated every three hours following the initial dose for a maximum of two more doses achieves abortion success rates of 88-92% (Tang et al., 2003; Tang et al., 2006). No studies have evaluated single doses of sublingual misoprostol for treatment of missed abortion.

Who can provide postabortion care for individuals with a uterine size less than 13 weeks gestation?

The World Health Organization (WHO) makes service delivery recommendations for the provision of post-abortion care for individuals with a uterine size of less than 13 weeks gestation (WHO, 2024). Health workers with the skills to perform transcervical procedures, and a bimanual examination to diagnose pregnancy and determine gestational age based on uterine size, can be trained to perform vacuum aspiration for postabortion care. WHO advises that uterine aspiration is within the scope of practice for specialty and general medical

practitioners, and recommends the provision of vacuum aspiration by associate and advanced associate clinicians, midwives, and nurses based on moderate certainty evidence of safety and effectiveness. Traditional and complementary medicine professionals are recommended to provide uterine aspiration based on low certainty evidence of safety and effectiveness, and WHO suggests that auxiliary nurses and auxiliary nurse midwives may be able to perform aspiration in settings where they provide basic emergency obstetric care (WHO, 2024). WHO advises that all cadres of health care workers (specialty and general medical practitioners, associate and advanced associate clinicians, midwives, nurses, auxiliary nurses and auxiliary nurse midwives, traditional and complementary medicine professionals, pharmacists and pharmacy workers, and community health workers) can safely and effectively provide medical management of uncomplicated incomplete abortion and missed abortion, based on a variety of evidence and the expected skills and knowledge for that type of health worker (WHO, 2024). For further information about health worker roles in abortion care, see Appendix C: World Health Organization recommendations for health worker roles in abortion care.

Resources

www.ipas.org/ClinicalResources

Protocols for medical abortion (dosage card)

Abortion Care Videos—Ipas: *Caring for a Woman with a Miscarriage*



References

- Barcelo, F., De Paco, C., Lopez-Espin, J. J., Silva, Y., Abad, L., & Parrilla, J. J. (2012). The management of missed miscarriage in an outpatient setting: 800 versus 600 µg of vaginal misoprostol. *Australian and New Zealand Journal of Obstetrics and Gynaecology*, 52(1), 39-43.
- Benson, L. S., Gunaje, N., Holt, S. K., Gore, J. L., & Dalton, V. K. (2024). Outcomes after early pregnancy loss management with mifepristone plus misoprostol vs misoprostol alone. *JAMA Network Open*, 7(10), e2435906.
- Berkley, H.H., Greene, H.L., & Wittenberger, M.D. (2020). Mifepristone combination therapy compared with misoprostol monotherapy for the management of miscarriage: A cost-effectiveness analysis. *Obstetrics & Gynecology*, 136(4), 774-781.
- Bettencourt-Silva, B., Rego, M. T., Miranda, C., Cunha, A. I., Brás, F., Lopes-Guerra, C., Miguelote, R., Sousa-Santos, R., & Furtado, J. M. (2023). The role of mifepristone on first trimester miscarriage treatment—A double-blind randomized controlled trial—MiFirsT. *European Journal of Obstetrics and Gynecology and Reproductive Biology*, 289, 145–151.
- Chu, J.J., Devall, A.J., Beeson, L.E., Hardy, P., Cheed, V., Sun, Y., ... & Commarasamy, A. (2020). Mifepristone and misoprostol versus misoprostol alone for the management of missed miscarriage (MifeMiso): a randomised, double-blind, placebo-controlled trial. *Lancet*, 396, 770-78.
- Ehrnsten, L., Altman, D., Ljungblad, A., & Kopp Kallner, H. (2019). Efficacy of mifepristone and misoprostol for medical treatment of missed miscarriage in clinical practice: A cohort study. *Acta Obstetrica et Gynecologica Scandinavica*, 00, 1-6.
- Fernlund, A., Jokubkiene, L., Sladkevicius, P., & Valentin, L. (2018). Misoprostol treatment vs expectant management in early non-viable pregnancy in women with vaginal bleeding: A pragmatic randomized controlled trial. *Ultrasound in Obstetrics and Gynecology*, 51(1), 24-3232.
- Ghosh, J., Papadopoulou, A., Devall, A.J., Jeffery, H.C., Beeson, L.E., Do, V., Price, M.J., Tobias, A., Tuncalp, O., Lavelanet, A., Gulmezoglu, A.M., Coomarasamy, A., & Gallos, I.D., (2021). Methods for managing miscarriage: A network meta-analysis. *Cochrane Database of Systematic Reviews*, 6(6), CD012602.
- Gilles, J. M., Creinin, M. D., Barnhart, K., Westhoff, C., Frederick, M. M., & Zhang, J. (2004). A randomized trial of saline solution-moistened misoprostol versus dry misoprostol for first-trimester pregnancy failure. *American Journal of Obstetrics & Gynecology*, 190(2), 389-394.
- Graziosi, G. C., Mol, B. W., Ankum, W. M., & Bruinse, H. W. (2004). Management of early pregnancy loss. *International Journal of Gynecology & Obstetrics*, 86(3), 337-346.

References continued

- Kim, C., Barnard, S., Neilson, J. P., Hickey, M., Vazquez, J. C., & Dou L. (2017). Medical treatment for incomplete miscarriage. *Cochrane Database of Systematic Reviews*, 1:CD007223. DOI: 10.1002/14651858.CD007223.pub4.
- Lyra, J., Cavaco-Gomes, J., Moucho, M., & Montenegro, N. (2017). Medical termination of delayed miscarriage: Four year experience with an outpatient protocol. *Revista Brasileira de Ginecologia e Obstetrica*, 39(10), 529-533.
- Medical management of miscarriage: Ectopic pregnancy and miscarriage: Evidence review D.* (2023). National Institute for Health and Care Excellence (NICE).
- Mizrachi, Y., Dekalo, A., Gluck, O., Miremberg, H., Dafna, L., Feldstein, O., ... Sagiv, R. (2017). Single versus repeat doses of misoprostol for treatment of early pregnancy loss-a randomized clinical trial. *Human Reproduction*, 32(6), 1202-1207.
- Mizrachi, Y., Tamayev, L., Shemer, O., Kleiner, I., Bar, J., & Sagiv, R. (2019). Early versus delayed follow-up after misoprostol treatment for early pregnancy loss. *Reproductive Biomedicine Online*, 39(1), 155-160.
- Muffley, P. E., Stitely, M. L., & Gherman, R. B. (2002). Early intrauterine pregnancy failure: A randomized trial of medical versus surgical treatment. *American Journal of Obstetrics & Gynecology*, 187(2), 321-325.
- Nagendra, D., Koelper, N., Loza-Avalos, S.E., Sonalkar, S., Chen, M., Atrio, J., ... & Harvie, H.S. (2020). Cost-effectiveness of mifepristone pretreatment for the medical management of nonviable early pregnancy: Secondary analysis of a randomized trial. *JAMA Network Open*, 3(3), e201594.
- Ngoc, N. T., Blum, J., Westheimer, E., Quan, T. T., & Winikoff, B. (2004). Medical treatment of missed abortion using misoprostol. *International Journal of Gynecology & Obstetrics*, 87(2), 138-142.
- Okeke Ogwulu, C.B.O., Williams, E.V., Chu, J.J., Devall, A.J., Beeson, L.E., Hardy, P., Cheed, V., Yongzhong, S., Jones, L.L., Papadopoulos, J.H.L., Bender-Atik, R., Brewin, J., Hinshar, K., Choudhary, M., Ahmed, A., Naftalin, J., Nunes, N., Oliver, A., Izzat, F., ... Roberts, T.E. (2021). Cost-effectiveness of mifepristone and misoprostol versus misoprostol alone for the management of missed miscarriage: An economic evaluation based on the MifeMiso trial. *BJOG: An International Journal of Obstetrics and Gynaecology*, 128(9), 1534-1545.
- Schreiber, C. A., Creinin, M. D., Atrio, J., Sonalkar, S., Ratcliffe, S. J., & Barnhart, K. T. (2018). Mifepristone pretreatment for the medical management of early pregnancy loss. *New England Journal of Medicine*, 378(23), 2161-2170.
- Sinha, P., Suneja, A., Guleria, K., Aggarwal, R., & Vaid, N. B. (2018). Comparison of mifepristone followed by misoprostol with misoprostol alone for treatment of early pregnancy failure: A randomized double-blind placebo-controlled trial. *Journal of Obstetrics and Gynaecology of India*, 68(1), 39-44.
- Tang, O. S., Lau, W. N., Ng, E. H., Lee, S. W., & Ho, P. C. (2003). A prospective randomized study to compare the use of repeated doses of vaginal with sublingual misoprostol in the management of first trimester silent miscarriages. *Human Reproduction*, 18(1), 176-181.
- Tang, O. S., Ong, C. Y., Tse, K. Y., Ng, E. H., Lee, S. W., & Ho, P. C. (2006). A randomized trial to compare the use of sublingual misoprostol with or without an additional 1 week course for the management of first trimester silent miscarriage. *Human Reproduction*, 21(1), 189-192.
- Tarleton, J. L., Benson, L. S., Moayed, G., & Trevino, J. (2025). Society of Family Planning Clinical Recommendation: Medication management for early pregnancy loss. *Contraception*, 144.
- Van den Berg, J., Gordon, B. B. M., Snijders, M. P. M. L., Vandenbussche, F. P. H. A., & Coppus, S. F. P. J. (2015). The added value of mifepristone to non-surgical treatment regimens for uterine evacuation in case of early pregnancy failure: A systematic review of the literature. *European Journal of Obstetrics & Gynecology and Reproductive Biology*, 195, 18-26.
- Wu, H. L., Marwah, S., Wang, P., Wang, Q. M., & Chen, X. W. (2017). *Misoprostol for medical treatment of missed abortion: A systematic review and network meta-analysis*. *Science Reports*, 7(1), 1664.
- Zhang, J., Gilles, J. M., Barnhart, K., Creinin, M. D., Westhoff, C., & Frederick, M. M. (2005). A comparison of medical management with misoprostol and surgical management for early pregnancy failure. *The New England Journal of Medicine*, 353(8), 761-769.
- World Health Organization. (2024). *Abortion care guideline, 2nd ed.* Geneva: World Health Organization Press.

5.2

5. Postabortion care

Treatment of incomplete abortion and intrauterine fetal demise for 13 weeks or larger uterine size

Recommendation:

- Medical methods or dilatation and evacuation (D&E) may be offered for treatment of incomplete abortion or intrauterine fetal demise.
- Recommended medication regimen:
 - **Incomplete abortion:** Misoprostol 400mcg buccally, sublingually or, in the absence of vaginal bleeding, vaginally every three hours until expulsion.
 - **Intrauterine fetal demise (up to 24 weeks):** Misoprostol 400mcg buccally, sublingually or, in the absence of vaginal bleeding, vaginally every 4-6 hours until expulsion. Where available, add pretreatment with mifepristone 200mg orally 1-2 days before misoprostol.

In practice:

- Uterine size, not gestational age, should be used to determine treatment for postabortion care.

Strength of recommendation:

Strong

Quality of evidence:

Low

Last reviewed:

November 6, 2025

Background

The majority of postabortion care research and programs focus on women with uterine size less than 13 weeks (Ipas, 2013). However, where unsafe abortion is prevalent, as many as 40% of people needing postabortion care present at or after 13 weeks gestation (Ministry of Health of Kenya, Ipas, & Guttmacher Institute, 2013). Individuals may present with incomplete abortion, retained placenta, fetal demise or ruptured membranes, all of which require uterine evacuation.

Medical regimens

Evidence is limited to suggest the optimal medical regimen for postabortion care at or after 13 weeks uterine size, but systematic reviews of the literature suggests that at least 200mcg vaginally, sublingually or buccally given every six hours is effective (Bracken et al., 2014; Mark, Borgatta, & Edelman, 2015). Two trials that randomized women to treatment with 200mcg or 400mcg of vaginal misoprostol found that the higher dose of misoprostol resulted in higher expulsion rates at 24 and 48 hours (Dickinson & Evans, 2002; Eslamian et al., 2007). Multiple studies and two systematic reviews show that pretreatment with mifepristone 1-2 days before misoprostol increases rates of abortion success within 24 hours and reduces the time to fetal expulsion (Allan-

son et al., 2021; Bracken et al., 2020; Chaudhuri & Datta, 2015; Oliveira et al., 2024; Panda & Singh, 2013; Pirrami & Reinert, 2025). A systematic review of medical treatment for intrauterine fetal demise found when the dose of 400mcg was administered every four hours, it was more effective with lower rates of adverse events when compared with other doses; however, no direct comparisons exist to inform whether four hours is indeed the ideal interval (Cleeve, Fonhus & Lavelanet, 2019).

D&E

No studies have compared medical management versus vacuum aspiration or D&E for postabortion care at or after 13 weeks. D&E can be offered for postabortion care where skilled providers and supportive facilities exist (World Health Organization [WHO], 2024).

Who can provide postabortion care for individuals with a uterine size of 13 weeks gestation or larger?

WHO makes service delivery recommendations for the provision of postabortion care for individuals with a uterine size of 13 weeks gestation or larger (WHO, 2024). WHO advises that D&E is within the scope of practice of specialty medical practitioners, and recommends provision of D&E by generalist medical practitioners based on expected competencies for that role. WHO suggests that in settings where established mechanisms exist to include associate and advanced associate clinicians, midwives, and traditional and complementary medicine professions in other tasks related to maternal and reproductive health care, they can safely and effectively provide D&E, based on expected skills and knowledge for these health worker roles. WHO recommends the provision of medical management of IUFD by specialty and general medical practitioners, and suggests that in contexts where established and easy access to appropriate surgical backup and other infrastructure necessary to address possible complications exists, associate and advanced associate clinicians, midwives, nurses, auxiliary nurses and auxiliary nurse midwives, and traditional and complementary medicine professionals can also safely and effectively provide this service, based on the expected competencies for these health workers (WHO, 2024). A randomized controlled trial conducted in Uganda established that midwives can provide medical management for incomplete abortion at > 13 weeks uterine size as safely and effectively as physicians (Atuhairwe et al., 2022). For further information about health worker roles in abortion care, see *Appendix C: World Health Organization recommendations for health worker roles in abortion care*.

Resources

www.ipas.org/ClinicalResources

Protocols for medical
abortion (dosage card)



References

- Allanson, E.R., Copson, S., Spilsbury, K., Criddle, S., Jennings, B., Doherty, D.A., Wong, A.M., & Dickinson, J.E. (2021). Pretreatment with mifepristone compared with misoprostol alone for delivery after fetal death between 14 and 28 weeks gestation: A randomized controlled trial. *Obstetrics & Gynecology*, 137(5), 801-809.
- Atuhairwe, S., Byamugisha, J., Kakaire, O., Hanson, C., Cleeve, A., Klingberg-Allvin, M., Tumwesigye, N. M., & Gemzell-Danielsson, K. (2022). Comparison of the effectiveness and safety of treatment of incomplete second trimester abortion with misoprostol provided by midwives and physicians: A randomised, controlled, equivalence trial in Uganda. *The Lancet. Global Health*, 10(10), e1505–e1513.
- Bracken, H., Ngoc, N. T., Banks, E., Blumenthal, P. D., Derman, R. J., Patel, A., ...Winikoff, B. (2014). Buccal misoprostol for treatment of fetal death at 14-28 weeks of pregnancy: A double-blind randomized controlled trial. *Contraception*, 89(3), 187-192. DOI:10.1016/j.contraception.2013.11.014.
- Bracken, H., Ngoc, N.T.N., Ha, D.Q., Paredes, N.R., Quyet, V.B., Linh, N.T.H., Ortiz, M.A., Bousiequez, M., & Winikoff, B. (2020). Mifepristone pretreatment followed by misoprostol 200mcg buccal for the medical management of intrauterine fetal death at 14-28 weeks: A randomized, placebo-controlled, double blind trial. *Contraception*, 102(1), 7-12.
- Chaudhuri, P., & Datta, S. (2015). Mifepristone and misoprostol compared with misoprostol alone for induction of labor in intrauterine fetal death: A randomized trial. *Journal of Obstetrics and Gynaecology Research*, 41(12), 1884-1890.
- Cleeve, A., Fonhus, M.S., & Lavelanet, A. (2019). A systematic review of the effectiveness, safety, and acceptability of medical management of intrauterine fetal death at 14-28 weeks of gestation. *International Journal of Gynaecology and Obstetrics*, 147(3), 301-312.
- Dickinson, J. E., & Evans, S. F. (2002). The optimization of intravaginal misoprostol dosing schedules in second-trimester pregnancy termination. *American Journal of Obstetrics & Gynecology*, 186(3), 470-474.
- Eslamian, L., Gosili, R., Jamal, A., & Alyassin, A. (2007). A prospective randomized controlled trial of two regimens of vaginal misoprostol in second trimester termination of pregnancy. *Acta Medica Iranica*, 45(6), 497-500.
- Ipas. (2013). *Woman-centered postabortion care: Reference manual* (2nd ed.). K.L. Turner & A.B. Huber (Eds.). Chapel Hill, NC: Ipas.
- Mark, A., Borgatta, L., & Edelman, A. (2015). Second trimester postabortion care for ruptured membranes, fetal demise, and incomplete abortion. *International Journal of Obstetrics & Gynaecology*, 129(2), 98-103.
- Ministry of Health of Kenya, Ipas, and Guttmacher Institute. (2013). *Incidence and complications of unsafe abortion In Kenya: Key findings of a national study*. African Population and Health Research Center: Nairobi.
- Oliveira, P. S., de Almeida, A. M., Cabral, M. A. A. S. K., Guilherme, G. L., Ribeiro, A. J. R., Giusti, J. A. Z., de Lima, R. M. E., da Silva Garcia, J. C., & de Oliveira, R. (2025). Mifepristone and misoprostol versus misoprostol alone for induction of labor in women with intrauterine fetal death: A meta-analysis and systematic review. *International Journal of Gynecology & Obstetrics*, 168(3), 904–912.
- Panda, S., Jha, V., & Singh, S. (2013). Role of combination of mifepristone and misoprostol verses misoprostol alone in induction of labour in late intrauterin [sic] fetal death: A prospective study. *Journal of Family and Reproductive Health*, 7(4), 177-179.
- Pirrami, R. G., & Reinert, J. P. (2025). Efficacy and Safety of Mifepristone and Misoprostol Compared to Misoprostol Alone for the Resolution of Miscarriage and Intrauterine Fetal Death: A Systematic Review and Meta-Analysis. *Annals of Pharmacotherapy*, 59(7), 636–647.
- World Health Organization. (2024). *Abortion care guideline, 2nd ed*. Geneva: World Health Organization.

5.3

5. Postabortion care

Postabortion contraception: When and what type

Recommendation:

- Following vacuum aspiration or dilatation and evacuation (D&E), hormonal and non-hormonal contraception, including intrauterine device (IUD) placement and female sterilization, may be initiated immediately.
- Hormonal methods, including pills, patches, rings, injectables and implants may be started on the day of the first pill of medical abortion. IUD placement and female sterilization should be performed when it is reasonably certain the person is no longer pregnant.
- Male sterilization (vasectomy) is safe and effective and can be performed at any time.
- Long-acting contraceptive methods have higher continuation rates and lower pregnancy rates compared to short-acting methods.

In practice:

- People, including adolescents, should be able to choose whether to use a contraceptive method, and to select their preferred method, based on accurate contraceptive information and their personal needs and preferences.
- Satisfaction with contraceptive services/uptake amongst medical abortion clients is greater when contraception is initiated at the same time as mifepristone.
- Individuals starting DMPA injection on the same day as mifepristone for medical abortion before 13 weeks should be informed of the slightly increased risk of ongoing pregnancy.

Strength of recommendation:

Strong

Quality of evidence:

- IUDs and combined oral contraceptives: High
- Implants: Moderate
- Other methods: Low to Moderate

Last reviewed:

November 11, 2025

Fertility return

Following induced abortion at less than 13 weeks gestation, ovulation typically resumes within three to four weeks; however, some people can ovulate in as little as eight days (Boyd & Holmstrom, 1972; Lahteenmaki & Luukkainen, 1978; Schreiber et al., 2010; Stoddard & Eisenberg, 2011). At least 85% of people will ovulate before their first menses (Boyd & Holmstrom, 1972; Lahteenmaki & Luukkainen, 1978; Cameron & Baird, 1988). There is no difference in time to ovulation following medical abortion compared to vacuum aspiration (Cameron & Baird, 1988).

Data for return to fertility after abortion performed at or after 13 weeks gestation are limited. One study with only nine participants found that 66% ovulated within 21 days (Marrs et al., 1979). Given the rapid return to fertility, all people who wish to begin contraception should receive their preferred method at the time of their abortion. If the preferred method is not available, a referral should be provided and, if desired, an interim method (World Health Organization [WHO], 2014b).

Safety and acceptability of postabortion contraception

For adults, WHO's 2015 *Medical Eligibility Criteria for Contraceptive Use* (WHO, 2015) and the 2024 US Medical Eligibility Criteria for Contraception Use (Nguyen et al., 2024) classify all contraceptive methods as category one, or safe for immediate use, following first-trimester uncomplicated abortion; recommendations do not differ based on the type of abortion. Female sterilization is classified as acceptable after an uncomplicated abortion.

Similarly, both the US and WHO *Medical Eligibility Criteria for Contraceptive Use* (Nguyen et al., 2024; WHO, 2015) classify all contraceptive methods as category one, or safe for immediate use, following uncomplicated second-trimester abortion—except IUDs. Due to an increased risk of expulsion when used after abortion at or after 13 weeks gestation, IUDs are classified as category two, meaning the advantages of using the method generally outweigh the risks. Female sterilization is classified as acceptable after an uncomplicated abortion at or after 13 weeks gestation.

Two of these recommendations differ for adolescents: Depot medroxyprogesterone acetate (DMPA) injection is classified by the US and WHO as a category two for those under 18 years of age, due to concerns about effects on bone mineral density. Sterilization may be performed on young people, but special precautions may need to be taken due to the increased risk of regret (Nguyen et al., 2024; WHO, 2015).

In comparison to short-acting methods, long-acting methods of contraception such as implants and IUDs have higher continuation rates and lower pregnancy and abortion rates (Blumenthal et al., 1994; Cameron et al., 2012; Kilander et al., 2016; Korjamo, Mentula, & Heikinheimo, 2017; Langston, Joslin-Rohr, & Westhoff, 2014; Peipert et al., 2012; Pohjoranta et al., 2015; Roberts, Silva, & Xu, 2010; Rose, Garrett, & Stanley, 2015). Uptake of long-acting methods is higher after surgical abortion as compared with medical abortion (Laursen et al., 2017; Rocca et al., 2018). A systematic review and meta-analysis of randomized controlled trials has demonstrated significantly higher rates of patient satisfaction with immediate start (day of mifepristone) of implants and injectables compared with a delayed start (Schmidt-Hansen et al., 2020).

Contraceptive start

Following vacuum aspiration, D&E or medical abortion where pregnancy expulsion occurs in a facility, all hormonal and nonhormonal contraceptive methods, including IUD insertion and female sterilization, may be initiated immediately (Kim et al., 2021; Nguyen et al., 2024; WHO, 2015; WHO, 2024). Fertility awareness-based methods may be initiated once the person has had at least one postabortion menses. Male sterilization (vasectomy) may be performed at any time.

For medical abortion where pregnancy expulsion is expected to occur at home, most forms of contraception (including pills, injectables and implants) may be started with the first pill of the medical abortion if there are no medical contraindications (Kim et al., 2021; Nguyen et al., 2024; WHO, 2015; WHO, 2024). IUDs may be inserted and sterilization performed as soon as it is reasonably certain that the person is no longer pregnant (WHO, 2014a; WHO, 2024).

A person's immediate need for reliable contraception after abortion, coupled with the reduced uptake of contraception when provision is delayed, strongly supports the recommendation to start contraceptive methods immediately (WHO, 2024).

Evidence related to specific contraceptive methods

IUDs: See section 5.4 Postabortion IUD use: Safety and timing.

Progestin-only subdermal implants: Two randomized non-inferiority trials conducted in women undergoing medical abortion before 13 weeks gestation (Hognert et al., 2016; Raymond et al., 2016b) have demonstrated that abortion success rates are the same in women receiving a contraceptive implant on the day they receive mifepristone compared to delayed placement. In both studies, insertion rates were higher for women receiving their implant on the day they received mifepristone. One study (Hognert et al., 2016) reported a significantly higher pregnancy rate in the delayed insertion group at follow-up six months after the abortion (3.8% compared to 0.8%). An additional study randomized women undergoing D&E to either delayed or immediate implant insertion (Cowett et al., 2018). Fewer than half of women in the delayed group had their implant inserted, compared to 100% in the immediate group. A 2022 systematic review, which included these three studies, concluded that provision of progestin-releasing implants, concurrently with abortifacients, has little or no negative impact on medical abortion success, and decreases subsequent unintended pregnancy (Sothornwit et al., 2022).

WHO recommends that generalist and specialist medical practitioners, associate and advance associate clinicians, midwives, and nurses can safely and effectively insert and remove subdermal implants. WHO suggests that in contexts with established health system mechanisms to include traditional and complementary medicine professionals in other tasks related to maternal and reproductive health, and where training in implant removal is given along with training in insertion, these health workers can insert and remove implants. Auxiliary nurses and auxiliary nurse midwives can insert and remove implants in the context of targeted monitoring and evaluation, and community health workers can insert and remove implants in the context of rigorous research. For further information about health worker roles in abortion care, see *Appendix C: World Health Organization recommendations for health worker roles in abortion care*.

Progestin-only injection: A study of 132 women using DMPA immediately after aspiration abortion reported no serious adverse events but low method continuation rates (22%) at one year and high repeat pregnancy rates (Goldberg et al., 2002). However limited evidence indicates that administration of DMPA at the same time as mifepristone may decrease the effectiveness of medical abortion. One randomized, controlled non-inferiority trial (Raymond et al., 2016a) comparing 220 women undergoing medical abortion up to 75 days gestation who received intramuscular DMPA on the day of mifepristone to 226 women who did not found similar rates of surgical intervention for any reason after medical abortion (6.4% and 5.3%, respectively) and pregnancy rates at six months after the intervention (2.3% and 3.2%, respectively). However, ongoing pregnancy as a reason for medical abortion failure in the DMPA injection group was significantly higher (3.6% vs 0.9%). Retrospective cohort study findings conflict in regards to medical abortion success rates and ongoing pregnancy rates in women who start progestin-only injections on the same day as mifepristone administration (Carroll et al., 2024; Creinin & Boraas, 2025; Douthwaite et al., 2016; Park et al., 2016). The US Medical Eligibility Criteria for Contraception Use categorizes DMPA administered at the same time as mifepristone as category two for this reason, and a 2021 systematic review suggests that those choosing DMPA initiation on the same day as mifepristone should be informed of the slightly increased risk of ongoing pregnancy (Kim et al., 2021; Nguyen et al., 2024). Women report high satisfaction with same-day administration of progestin-only contraceptives (Raymond et al., 2016a).

WHO recommends that generalist and specialist medical practitioners, associate and advanced associate clinicians, midwives, nurses, auxiliary nurses and auxiliary nurse midwives, traditional and complementary medicine professionals, pharmacists, pharmacy workers, community health workers, and the individual using the progestin-only injection can safely and effectively administer this type of contraception. For further information about health worker roles in abortion care, see *Appendix C: World Health Organization recommendations for health worker roles in abortion care*.

Combined oral contraceptives (COCs): A review of seven studies including 1,739 women demonstrated no serious adverse events using COCs immediately after aspiration or medical abortion before 13 weeks gestation (Gaffield, Kapp, & Ravi, 2009). Additionally, women who used COCs immediately demonstrate similar bleeding patterns to women using no contraception, and less bleeding than copper IUD users (Kim et al., 2021). Two randomized controlled trials of COCs compared to placebo started immediately after medical abortion up to 49 or 63 days gestation showed that pills do not have a significant effect on the efficacy of medical abortion or the quantity or duration of blood loss (Tang et al., 1999; Tang et al., 2002).

Combined vaginal ring: A cohort study of 81 women who placed a vaginal ring one week after aspiration or medical abortion before 13 weeks gestation showed no serious adverse events or infections (Fine et al., 2007).

Combined contraceptive patch: A trial of 298 women randomized to either immediate postabortion start or delayed start the Sunday after an abortion showed no difference in continuation rates at two and six months. In the 53% of women who could be contacted at six months, half had stopped using the contraceptive patch (Steinauer et al., 2014).

Informed decision making

WHO recommends that sexual and reproductive health services, including contraceptive services, be delivered in a way that ensures fully informed decision-making, respects dignity, autonomy, privacy and confidentiality, and is sensitive to individuals' needs and perspectives (WHO, 2014b). People should be able to choose or refuse contraception based on their personal needs and preferences. Evidence-based, comprehensive contraceptive information, non-directive contraceptive counseling and support should be accessible for all people, including adolescents, so that patients are able to make an informed decision. Ideally a range of contraceptive methods should be available, appropriate referrals for methods not available on site should be offered, and these services should be integrated with abortion and postabortion care (Baynes et al., 2019; WHO, 2014b). Two systematic reviews of randomized comparative trials (Cavallaro et al., 2020; Nelson et al., 2022) found that contraceptive counseling and provision at the time of abortion increases contraceptive use, although some individuals may prefer not to discuss contraception in depth at the time of their abortion visit, particularly if they already know what postabortion contraceptive method they want (Cansino et al., 2018). When contraception is delivered at the time of abortion and a wide range of contraceptive commodities is available, contraceptive uptake in postabortion patients can be as high as 73%, including among young women (Benson et al., 2017; Benson et al., 2016). A recent systematic review examining contraceptive preferences included four studies among people seeking abortion services (Dam et al., 2022). Ease of use and effectiveness were important features of preferred contraceptive methods, as were cost, familiarity with the method, presence of hormones, and side effects, among others.

References

- Baynes, C., Kahwa, J., Lusiola, G., Mwanga, F., Bantambya, J., Ngosso, L., & Hiza, M. (2019). What contraception do women use after experiencing complications from abortion? An analysis of cohort records of 18,688 postabortion care clients in Tanzania. *BMC Women's Health*, 19(1), 22.
- Benson, J., Andersen, K., Healy, J., & Brahmi, D. (2017). What factors contribute to postabortion contraceptive uptake by young women? A program evaluation in 10 Countries in Asia and sub-Saharan Africa. *Global Health: Science and Practice*, 5(4), 644-657.
- Benson, J., Andersen, K., Brahmi, D., Healy, J., Mark, A., Ajode, A., & Griffin, R. (2018). What contraception do women use after abortion? An analysis of 319,385 cases from eight countries. *Global Public Health*, 13(1), 35-50.
- Blumenthal, P. D., Wilson, L. E., Remsburg, R. E., Cullins, V. E., & Huggins, G. R. (1994). Contraceptive outcomes among post-partum and post-abortal adolescents. *Contraception*, 50(5), 451-460.
- Boyd Jr, E. F., & Holmstrom, E. G. (1972). Ovulation following therapeutic abortion. *American Journal of Obstetrics & Gynecology*, 113(4), 469.

References continued

- Cameron, I. T., & Baird, D. T. (1988). The return to ovulation following early abortion: A comparison between vacuum aspiration and prostaglandin. *Acta Endocrinologica (Copenhagen)* 118, 161-167.
- Cameron, S., Glasier, A., Chen, Z., Johnstone, A., Dunlop, C., & Heller, R. (2012). Effect of contraception provided at termination of pregnancy and incidence of subsequent termination of pregnancy. *BJOG: An International Journal of Obstetrics & Gynaecology*, 119(9), 1074-1080.
- Cansino, C., Lichtenberg, E. S., Perriera, L. K., Hou, M. Y., Melo, J., & Creinin, M. D. (2018). Do women want to talk about birth control at the time of a first-trimester abortion? *Contraception*, 98(6), 535-540.
- Carroll, A. L., Strauss, A. M., Philipps, N. M., Kaczmarczik, K. D., Shakur, Z., Ramirez, G., Klc, T. R., Tessier, K. M., & Boraas, C. M. (2024). Efficacy of medication abortion with concurrent initiation of progestin contraceptives: A retrospective cohort study. *Contraception*, 140.
- Cavallaro, F.L., Benova, L., Owolabi, O.O., & Ali, M. (2020). A systematic review of the effectiveness of counselling strategies for modern contraceptive methods: What works and what doesn't? *BMJ Sexual and Reproductive Health*, 46(4), 254-269.
- Cowett, A. A., Ali, R., Cooper, M. A., Evans, M., Conzuelo, G., & Cremer, M. (2018). Timing of etonogestrel implant insertion after dilation and evacuation: A randomized controlled trial. *Obstetrics & Gynecology*, 131(5), 856-862.
- Creinin, M. D., & Boraas, C. M. (2025). Depomedroxyprogesterone acetate impact on mifepristone action during medication abortion. *The European Journal of Contraception & Reproductive Health Care*, 30(4), 200-204.
- Dam, A., Yeh, P.T., Burke, A.E., & Kennedy, C.E. (2022). Contraceptive values and preferences of pregnant women, postpartum women, women seeking emergency contraceptives, and women seeking abortion services: A systematic review. *Contraception*, 111, 39-47.
- Douthwaite, M., Candelas, J. A., Reichwein, B., Eckhardt, C., Ngo, T. D., & Dominguez, A. (2016). Efficacy of early induced medical abortion with mifepristone when beginning progestin-only contraception on the same day. *International Journal of Gynaecology & Obstetrics*, 133 (3), 329-333.
- Fine, P. M., Tryggstad, J., Meyers, N. J., & Sangi-Haghpeykar, H. (2007). Safety and acceptability with the use of a contraceptive vaginal ring after surgical or medical abortion. *Contraception*, 75(5), 367-371.
- Gaffield, M. E., Kapp, N., & Ravi, A. (2009). Use of combined oral contraceptives post abortion. *Contraception*, 80(4), 355-362.
- Goldberg, A. B., Cardenas, L. H., Hubbard, A. E., & Darney, P. D. (2002). Post-abortion depot medroxyprogesterone acetate continuation rates: A randomized trial of cyclic estradiol. *Contraception*, 66(4), 215-220.
- Hognert, H., Kopp Kallner, H., Cameron, S., Nyreli, C., Jawad, I., Heller, R., ... Gemzell-Danielsson, K. (2016). Immediate versus delayed insertion of an etonogestrel releasing implant at medical abortion-a randomized controlled equivalence trial. *Human Reproduction*, 31(11), 2484-2490.
- Kilander, H., Alehagen, S., Svedlund, L., Westlund, K., Thor, J., & Brynhildsen, J. (2016). Likelihood of repeat abortion in a Swedish cohort according to the choice of post-abortion contraception: A longitudinal study. *Acta Obstetrica et Gynecologica Scandinavica*, 95(5), 565-571.
- Kim, C., Nguyen, A.T., Berry-Bibee, E., Ermias, Y., Gaffield, M.E., & Kapp, N. (2021). Systemic hormonal contraception initiation after abortion: A systematic review and meta-analysis. *Contraception*, 103(5), 291-304.
- Korjamo, R., Mentula, M., & Heikinheimo, O. (2017). Immediate versus delayed initiation of the levonorgestrel-releasing intrauterine system following medical termination of pregnancy - 1 year continuation rates: A randomised controlled trial. *BJOG: An International Journal of Obstetrics & Gynaecology*, 124(13), 1957-1964.
- Lahteenmaki, P., & Luukkainen, T. (1978). Return of ovarian function after abortion. *Clinical Endocrinology*, 8(2), 123-132.
- Langston, A.M., Joslin-Rohr, S.L., & Westhoff, C.L. (2014). Immediate postabortion access to IUDs, implants and DMPA reduces repeat pregnancy within 1 year in a New York City practice. *Contraception*, 89(2), 103-8.
- Laursen, L., Stumbras, K., Lewnard, I., & Haider, S. (2017). Contraceptive provision after medication and surgical abortion. *Women's Health Issues*, 27(5), 546-550.
- Marrs, R. P., Kletzky, O. A., Howard, W. F., & Mishell, D. R. (1979). Disappearance of human chorionic gonadotropin and resumption of ovulation following abortion. *American Journal of Obstetrics & Gynecology*, 135, 731-736.

References continued

- Nelson, H.D., Cantor, A., Jungbauer, R.M., Eden, K.B., Darney, B., Ahrens, K., Burgess, A., Atchison, C., Goueth, R., & Fu, R. (2022). Effectiveness and harms of contraceptive counseling and provision interventions for women: A systematic review and meta-analysis. *Annals of Internal Medicine*, 175(7), 980-993.
- Nguyen, A. T., Curtis, K. M., Tepper, N. K., Kortsmid, K., Brittain, A. W., Snyder, E. M., Cohen, M. A., Zapata, L. B., Whiteman, M. K., Baker, C., Dethier, D., Garbarino, S., Gold, H., Halper, E., Kapp, N., Krishna, G., Meurice, M., Ramer, S., Rodenhizer, J., ... Wright, S. (2024). U.S. Medical Eligibility Criteria for Contraceptive Use, 2024. *MMWR Recommendations and Reports*, 73(4), 1-126.
- Park, J., Robinson, N., Wessels, U., Turner, J., & Geller, S. (2016). Progestin-based contraceptive on the same day as medical abortion. *International Journal of Gynaecology & Obstetrics*, 133(2), 217-220.
- Peipert, J. F., Madden, T., Allsworth, J. E., & Secura, G. M. (2012). Preventing unintended pregnancies by providing no-cost contraception. *Obstetrics & Gynecology*, 120(6), 1291-1297.
- Pohjoranta, E., Mentula, M., Gissler, M., Suhonen, S., & Heikinheimo, O. (2015). Provision of intrauterine contraception in association with first trimester induced abortion reduces the need of repeat abortion: First-year results of a randomized controlled trial. *Human Reproduction*, 30(11), 2539-46.
- Raymond, E. G., Weaver, M. A., Louie, K. S., Tan, Y. L., Bousiequez, M., Arangure-Peraza, A. G., ... Winikoff, B. (2016a). Effects of depot medroxyprogesterone acetate injection timing on medical abortion efficacy and repeat pregnancy: A randomized controlled trial. *Obstetrics & Gynecology*, 128(4), 739-745.
- Raymond, E. G., Weaver, M. A., Tan, Y. L., Louie, K. S., Bousiequez, M., Lugo-Hernandez, E. M., ... Winikoff, B. (2016b). Effect of immediate compared with delayed insertion of etonogestrel implants on medical abortion efficacy and repeat pregnancy: A randomized controlled trial. *Obstetrics & Gynecology*, 127(2), 306-312.
- Roberts, H., Silva, M., & Xu, S. (2010). Post abortion contraception and its effect on repeat abortions in Auckland, New Zealand. *Contraception*, 82(3), 260-265.
- Rocca, C. H., Goodman, S., Grossman, D., Cadwallader, K., Thompson, K. M. J., Talmont, E., ... Harper, C. C. (2018). Contraception after medication abortion in the United States: Results from a cluster randomized trial. *American Journal of Obstetrics & Gynecology*, 218(1), 107.e101-107.e108
- Rose, S. B., Garrett, S. M., & Stanley, J. (2015). Immediate postabortion initiation of levonorgestrel implants reduces the incidence of births and abortions at 2 years and beyond. *Contraception*, 92(1), 17-25.
- Sothornwit, J., Eamudomkarn, N., Lumbiganon, P., Jampathong, N., Festin, M.R., & Salang, L. (2022). Immediate versus delayed postabortal insertion of contraceptive implants. *Cochrane Database of Systematic Reviews*, 5(5), CD013565.
- Schmidt-Hansen, M., Hawkins, J.E., Lord, J., Williams, K., Lohr, P.A., Hasler, E., & Cameron, S. (2020). Long-acting reversible contraception immediately after medical abortion: systematic review with meta-analyses. *Human Reproduction Update*, 26(2), 141-160.
- Schreiber, C. A., Sober, S., Ratcliffe, S., & Creinin, M. D. (2011). Ovulation resumption after medical abortion with mifepristone and misoprostol. *Contraception*, 84(3), 230-233.
- Steinauer, J. E., Sokoloff, A., Roberts, E., Drey, E. A., Dehlendorf, C. E., & Prager, S. W. (2014). Immediate versus delayed initiation of the contraceptive patch after abortion: A randomized trial. *Contraception*, 89(1), 42-7.
- Stoddard, A., & Eisenberg, D. L. (2011). Controversies in family planning: Timing of ovulation after abortion and the conundrum of postabortion intrauterine device insertion. *Contraception*, 84, 119-121.
- Tang, O. S., Gao, P. P., Cheng, L., Lee, S. W., & Ho, P. C. (1999). A randomized double-blind placebo-controlled study to assess the effect of oral contraceptive pills on the outcome of medical abortion with mifepristone and misoprostol. *Human Reproduction*, 14(3), 722-725.
- Tang, O. S., Xu, J., Cheng, L., Lee, S. W., & Ho, P. C. (2002). The effect of contraceptive pills on the measured blood loss in medical termination of pregnancy by mifepristone and misoprostol: A randomized placebo controlled trial. *Human Reproduction*, 17(1), 99-102.
- World Health Organization. (2014b). Ensuring human rights in the provision of contraceptive information and services: Guidance and recommendations. Geneva: World Health Organization Press.
- World Health Organization. (2015). *Medical eligibility criteria for contraceptive use (5th ed.)*. Geneva: World Health Organization Press.
- World Health Organization. (2024). *Abortion care guideline, 2nd ed.* Geneva: World Health Organization.

5.4

5. Postabortion care

Postabortion IUD use: Safety and timing

Recommendedation:

- When an individual chooses an intrauterine contraceptive device (IUD), it should be placed immediately following a successful, uncomplicated vacuum aspiration or dilatation and evacuation (D&E) abortion.
- When an individual chooses an IUD following medical abortion, it should be placed when it is reasonably certain they are no longer pregnant.

Strength of recommendation:

Strong

Quality of evidence:

High

Last reviewed:

November 11, 2025

IUD placement after abortion before 13 weeks gestation

The World Health Organization's (WHO) 2015 *Medical Eligibility Criteria for Contraceptive Use* and the 2024 *US Medical Eligibility Criteria for Contraceptive Use* classify IUDs as category one, or safe for immediate use, following first-trimester abortion; recommendations do not differ based on type of abortion (Nguyen et al., 2024; WHO, 2015).

In comparison to short-acting methods, long-acting reversible methods of contraception such as implants and IUDs have higher continuation rates and lower pregnancy and abortion rates (Blumenthal et al., 1994; Cameron et al., 2012; Korjamo, Mentula & Heikinheimo, 2017b; Langston, Joslin-Rohr, & Westhoff, 2014; Peipert, Madden, Allsworth, & Secura, 2012; Pohjoranta et al., 2015; Roberts, Silva, & Xu, 2010). A 2014 Cochrane review of 12 trials including 7,119 women concluded that IUD insertion following vacuum aspiration and D&E is safe and practical (Okusanya, Oduwole, & Effa, 2014). The review found no differences in serious adverse events, such as infection or perforation, between immediate and delayed insertion. A 2011 trial randomized 575 women to immediate or delayed IUD insertion after uterine aspiration before 12 weeks (Bednarek et al., 2011). Although rates of IUD expulsion were slightly higher following immediate postabortion insertion (5% compared to 2.7%), women assigned to the delayed insertion group were significantly less likely to receive an IUD (75% compared to 100% in the immediate group) and more likely to have a subsequent pregnancy (five compared to none). A historical cohort study compared immediate postprocedure IUD insertion performed by midlevel providers to physicians, and found no difference in adverse outcomes between the two groups (Patil et al., 2016).

Following a medical abortion before 13 weeks gestation, IUDs may be placed as soon as it is reasonably certain that the individual is no longer pregnant (WHO, 2024). IUDs placed within 48 hours of abortion success are associated with less pain than delayed insertions (Hogmark et al., 2023). IUDs placed within 5-10 days of a successful medical abortion have low rates of expulsion, high continuation rates (Betstadt et al., 2011; Sääv, Stephansson, & Gemzell-Danielsson, 2012) and lower pregnancy rates than delayed insertion (Pohjoranta et al., 2017; Saav et al., 2012; Shimoni et al., 2011). A systematic review of three randomized trials found no differ-

ences between early and delayed insertion after abortion at gestations less than nine weeks, and higher rates of expulsion, continuation and uptake after immediate compared to delayed insertion at 9–12 weeks of gestation (Schmidt-Hansen et al., 2020). Uptake of IUDs is higher after surgical abortion as compared to medical abortion, despite similar contraceptive choices and desires (Fang, Sheeder, & Teal, 2018; Rocca et al., 2018).

IUD placement after abortion at or after 13 weeks gestation

The WHO (2015) and the US *Medical Eligibility Criteria for Contraceptive Use* (2024) classify IUD use following uncomplicated second-trimester abortion as category two, meaning the advantages of using the method outweigh risks, due to an increased risk of IUD expulsion. The Cochrane review of immediate postabortion insertion of IUDs following an abortion procedure referenced above concluded that although expulsion rates may be higher with immediate placement, continuation is higher with no increase in complications (Okusanya et al., 2014). In two randomized controlled trials of immediate versus delayed IUD placement after D&E, rates of IUD use were significantly higher with immediate insertion, without an increase in infection or complication rates (Cremer et al., 2011; Hohmann et al., 2012). Expulsion rates for women who had immediate insertion in both studies were low (3.1% and 6.8%) and were not different from delayed insertion. Notably, in both studies, about half of those randomized to delayed insertion did not return to have the IUD inserted. Requiring a follow-up visit for IUD insertion is a significant barrier to obtaining the IUD (Stanek et al., 2009).

A 2022 study that randomized 114 people seeking medical abortion between 17 and 20 weeks gestation to receive either an immediate postabortion copper IUD, or placement three weeks later, found that many more people in the immediate group were using an IUD after 6 weeks (56%, compared to 19%), despite a significantly higher expulsion rate in the immediate group (32%, compared to 7%) (Constant et al., 2022). A smaller study randomized 57 people to immediate or delayed hormonal IUD placement following medical abortion between 12 and 20 weeks gestation, and found that insertion is feasible and safe; however the study was underpowered to assess rate of expulsions (Korjamo, Mentula, & Heikinheimo, 2017a; Korjamo et al., 2017b). An IUD may be placed following fetal and placental expulsion.

Young people

The IUD for people under the age of 20 is classified by the WHO and US *Medical Eligibility Criteria for Contraceptive Use* as category two, in which the benefits generally outweigh the risks (Nguyen et al., 2024; WHO, 2015). A large, US-based, prospective cohort study which examined pregnancy, birth and abortion rates in women provided all birth control methods at no cost included 1,056 women under the age of 20 and found that 62% of young women chose a long acting reversible contraceptive method—either the IUD (22%) or implant (40%)—compared to 71% of older women (Mestad et al., 2011). Continuation rates at 12 and 24 months were the same among older and younger women (Birgisson et al., 2015). Pregnancy, birth and induced abortion rates among the young women in the study were reduced by 75% compared to national averages (Secura et al., 2014).

A large 2017 systematic review and meta-analysis exploring risk factors for repeat pregnancies among teens, which included 26 studies reporting on more than 160,000 adolescent women, found that use of long acting reversible contraceptives exerted a significant protective effect, along with improved educational attainment and school continuation (Maravilla et al., 2017).

A 2017 systematic review examining risk of adverse outcomes in young women using the IUD found no differences in rates of perforation, contraceptive failure, pelvic inflammatory disease, or heavy bleeding in women younger than 25 compared to older women; rates of IUD expulsion were slightly higher in young women (Jatlaoui, Riley, & Curtis, 2017). IUDs do not increase young women's risk of infertility (Grimes, 2000), and women's fertility returns to baseline rates rapidly following IUD removal (Hov, Skjeldestad, & Hilstad, 2007).

Who can insert and remove IUDs?

WHO makes service delivery recommendations for the provision of IUDs (WHO, 2024), recommending that IUD insertion and removal is within the scope of practice of specialty and generalist medical practitioners, associate and advance associate clinicians, nurses, midwives, and auxiliary nurse midwives, based on expected skills and knowledge for these health worker roles. WHO suggests that in settings where established mechanisms exist to include traditional and complementary medicine professions in other tasks related to maternal and reproductive health care, they can safely and effectively insert and remove IUDs, and that auxiliary nurses can insert and remove IUDs in the context of research. For further information about health worker roles in abortion care, see *Appendix C: World Health Organization recommendations for health worker roles in abortion care*.

References

- Bednarek, P. H., Creinin, M. D., Reeves, M. F., Cwiak, C., Espey, E., & Jensen, J. T. (2011). Immediate versus delayed IUD insertion after uterine aspiration. *New England Journal of Medicine*, 364(23), 2208-2217.
- Betstadt, S. J., Turok, D. K., Kapp, N., Feng, K. T., & Borgatta, L. (2011). Intrauterine device insertion after medical abortion. *Contraception*, 83(6), 517-521.
- Birgisson, N. E., Zhao, Q., Secura, G. M., Madden, T., & Peipert, J. (2015). Preventing unintended pregnancy: The Contraceptive CHOICE Project in review. *Journal of Women's Health Larchmont*, 24(5), 349-353.
- Blumenthal, P. D., Wilson, L. E., Remsburg, R. E., Cullins, V. E., & Huggins, G. R. (1994). Contraceptive outcomes among post-partum and post-abortion adolescents. *Contraception*, 50(5), 451-460.
- Cameron, S., Glasier, A., Chen, Z., Johnstone, A., Dunlop, C., & Heller, R. (2012). Effect of contraception provided at termination of pregnancy and incidence of subsequent termination of pregnancy. *BJOG: An International Journal of Obstetrics & Gynaecology*, 119(9), 1074-1080.
- Cremer, M., Bullard, K. A., Mosley, R. M., Weiselberg, C., Molaei, M., Lerner, V., & Alonzo, T. A. (2011). Immediate vs. delayed post-abortion copper T 380A IUD insertion in cases over 12 weeks of gestation. *Contraception*, 83(6), 522-527.
- Fang, N., Sheeder, J., & Teal, S. (2018). Factors associated with initiating long-acting reversible contraception immediately after first-trimester abortion. *Contraception*, 98, 292-295.
- Grimes, D. (2000). Intrauterine device and upper genital tract infection. *The Lancet*, 356, 1013-1019.
- Hogmark, S., Liljeblad, K. L., Envall, N., Gemzell-Danielsson, K., & Kallner, H. K. (2023). Placement of an intrauterine device within 48 hours after early medical abortion—A randomized controlled trial. *American Journal of Obstetrics & Gynecology*, 228(1), 53.e1-53.e9.
- Hohmann, H. L., Reeves, M. F., Chen, B. A., Perriera, L. K., Hayes, J. L., & Creinin, M. D. (2012). Immediate versus delayed insertion of the levonorgestrel-releasing intrauterine device following dilation and evacuation: A randomized controlled trial. *Contraception*, 85(3), 240-245.
- Hov, G. G., Skjeldestad, F. E., & Hilstad, T. (2007). Use of IUD and subsequent fertility-follow-up after participation in a randomized clinical trial. *Contraception*, 75, 88-92.
- Jatlaoui, T. C., Riley, H. E. M., & Curtis, K. (2017). The safety of intrauterine devices among young women: A systematic review. *Contraception*, 95, 17-39.
- Korjamo, R., Mentula, M., & Heikinheimo, O. (2017a). Expulsions and adverse events following immediate and later insertion of a levonorgestrel-releasing intrauterine system after medical termination of later first- and second-trimester pregnancy: A randomised controlled trial. *BJOG: An International Journal of Obstetrics & Gynaecology*, <https://doi.org/10.1111/147-0528.14813>.
- Korjamo, R., Mentula, M., & Heikinheimo, O. (2017b). Immediate versus delayed initiation of the levonorgestrel-releasing intrauterine system following medical termination of pregnancy - 1 year continuation rates: A randomised controlled trial. *BJOG: An International Journal of Obstetrics & Gynaecology*, <https://doi.org/10.1111/1471-0528.14802>.
- Langston, A. M., Joslin-Roher, S. L., & Westhoff, C. L. (2014). Immediate postabortion access to IUDs, implants and DMPA reduces repeat pregnancy within one year in a New York City practice. *Contraception*, 89(2), 103-108.
- Maravilla, J. C., Betts, K. S., Cuoto e Cruz, C., & Alati, R. (2017). Factors influencing repeated teenage pregnancy: A review and meta-analysis. *Australian Journal of Obstetrics & Gynecology*, 527-545.

References continued

- Mestad, R., Secura, G., Allsworth, J. E., Madden, T., Zhou, Q., & Peipert, J. (2011). Acceptance of long-acting reversible contraceptive methods by adolescent participants in the Contraceptive CHOICE Project. *Contraception*, 84(5), 493-498.
- Nguyen, A. T., Curtis, K. M., Tepper, N. K., Kortsmitt, K., Brittain, A. W., Snyder, E. M., Cohen, M. A., Zapata, L. B., Whiteman, M. K., Baker, C., Dethier, D., Garbarino, S., Gold, H., Halper, E., Kapp, N., Krishna, G., Meurice, M., Ramer, S., Rodenhizer, J., ... Wright, S. (2024). U.S. Medical Eligibility Criteria for Contraceptive Use, 2024. *MMWR Recommendations and Reports*, 73(4), 1-126.
- Okusanya, B. O., Oduwole, O., & Effa, E. E. (2014). Immediate postabortal insertion of intrauterine devices. *Cochrane Database of Systematic Reviews*, 7, DOI: 10.1002/14651858.CD001777.pub4.
- Patil, E., Darney, B., Orme-Evans, K., Beckley, E. H., Bergander, L., Nichols, M., & Bednarek, P. H. (2016). Aspiration abortion with immediate intrauterine device insertion: Comparing outcomes of advanced practice clinicians and physicians. *Journal of Midwifery and Women's Health*, 61(3), 325-330. DOI:10.1111/jmwh.12412
- Peipert, J. F., Madden, T., Allsworth, J. E., & Secura, G. M. (2012). Preventing unintended pregnancies by providing no-cost contraception. *Obstetrics & Gynecology*, 120(6), 1291-1297.
- Pohjoranta, E., Mentula, M., Gissler, M., Suhonen, S., & Heikinheimo, O. (2015). Provision of intrauterine contraception in association with first trimester induced abortion reduces the need of repeat abortion: First-year results of a randomized controlled trial. *Human Reproduction*, 30(11), 2539-46.
- Pohjoranta, E., Suhonen, S., Mentula, M., & Heikinheimo O. (2017). Intrauterine contraception after medical abortion: Factors affecting success of early insertion. *Contraception*, 95(3), 257-262.
- Roberts, H., Silva, M., & Xu, S. (2010). Post abortion contraception and its effect on repeat abortions in Auckland, New Zealand. *Contraception*, 82(3), 260-265.
- Rocca, C. H., Goodman, S., Grossman, D., Cadwallader, K., Thompson, K. M. J., Talmont, E., ... Harper, C. C. (2018). Contraception after medication abortion in the United States: results from a cluster randomized trial. *American Journal of Obstetrics & Gynecology*, 218(1), 107.e101-107.e108
- Sääv, I., Stephansson, O., & Gemzell-Danielsson, K. (2012). Early versus delayed Insertion of intrauterine contraception after medical abortion—A randomized controlled trial. *PLoS One*, 7(11), e48948.
- Schmidt- Hansen, M., Hawkins, J.E., Lord, J., Williams, K., Lohr, P.A., Hasler, E., & Cameron, S. (2020). Long-acting reversible contraception immediately after medical abortion: systematic review with meta-analyses. *Human Reproduction Update*, 26(2), 141-160.
- Secura, G. M., Madden, T., McNicholas, C., Mullersman, J., Buckel, C. M., Zhao, Q., & Peipert, J. (2014). Provision of no-cost, long-acting contraception and teenage pregnancy. *New England Journal of Medicine*, 371(14), 1316-1323.
- Shimoni, N., Davis, A., Ramos, M. E., Rosario, L., & Westhoff, C. (2011). Timing of copper intrauterine device insertion after medical abortion: A randomized controlled trial. *Obstetrics & Gynecology*, 118(3), 623-628.
- Stanek, A. M., Bednarek, P. H., Nichols, M. D., Jensen, J. T., & Edelman, A. B. (2009). Barriers associated with the failure to return for intrauterine device insertion following first-trimester abortion. *Contraception*, 79(3), 216-220.
- World Health Organization. (2024). *Abortion care guideline, 2nd ed.* Geneva: World Health Organization.
- World Health Organization. (2015). *Medical eligibility criteria for contraceptive use (5th ed.)*. Geneva: World Health Organization Press.

5.5

5. Postabortion care

Postabortion hemorrhage: Prevention and management

Recommendedation:

- Clinicians should consider measures to prevent or prepare for increased bleeding in individuals who are at high risk for hemorrhage and are undergoing abortion.
- Hemorrhage caused by atony may be treated with uterine massage, uterotonic medications, re-aspiration, tamponade or surgery.
- Closely monitor hemorrhaging person for signs of shock.

Strength of recommendation:

Strong

Quality of evidence:

Low

Last reviewed:

November 11, 2025

Epidemiology

The Society for Family Planning defines postabortion hemorrhage as excessive bleeding that requires a clinical response such as transfusion or hospital admission, and/or bleeding in excess of 500mL (Glibert et al., 2023; Kerns, Brown, Nippita & Steinauer, 2024). Hemorrhage after induced abortion is rare, occurring in 0-3 per 1,000 cases following medical abortion up to 9 weeks gestation or vacuum aspiration before 13 weeks gestation, and 0.3-10 per 1,000 cases following uterine evacuation at or after 13 weeks gestation (Kerns, Brown, Nippita & Steinauer, 2024; Kerns et al., 2019; Upadhyay et al., 2014). Causes of bleeding include placenta previa or accreta, uterine atony, retained products of conception, cervical or vaginal laceration, uterine injury, and coagulopathy (Kerns, Brown, Nippita & Steinauer, 2024; Perriera, Arslan, & Masch, 2017).

Prevention

All individuals presenting for abortion care should be asked about aspects of their medical history associated with increased risk for bleeding. That includes a review of obstetric complications—especially hemorrhage, having had two or more cesarean deliveries, a bleeding disorder, gestational age of more than 20 weeks, fetal death, obesity, increased maternal age, and placenta previa or accreta (Kerns, Brown, Nippita & Steinauer, 2024; Kerns et al., 2019; Whitehouse et al., 2017). Providers may consider measures to prevent or prepare for increased bleeding—such as assessing a preabortion hemoglobin or hematocrit, ensuring uterotonic medications are readily available, preparing for possible transfusion, or referral to a higher-level facility—although there is little evidence to guide practice (Kerns, Brown, Nippita & Steinauer, 2024). In one randomized trial, addition of four units of vasopressin to a preprocedure paracervical block significantly decreased blood loss during dilatation and evacuation procedures and reduced the incidence of postabortion hemorrhage when compared to placebo (Schulz, Grimes, & Christensen, 1985). This effect was larger at later gestational ages. Administration of prophylactic oxytocin or syntocinon (five or 10 units) has not been shown to decrease post-procedure bleeding following first-trimester vacuum aspiration in a clinically meaningful way (Nygaard et al., 2010; Ali & Smith, 1996). When administered prior to dilatation and evacuation (D&E) procedures performed between 18-24 weeks, 30 units of oxytocin decreased blood loss and the incidence of hemorrhage compared

to placebo (Whitehouse et al., 2019). Methylergonovine, a medicine commonly administered prophylactically to prevent excessive bleeding after D&E, was found to increase, rather than decrease, bleeding when administered prophylactically immediately after D&E at 20-24 weeks (Kerns, et al., 2021).

Diagnosis

When postabortion hemorrhage is suspected, clinicians should take a rapid, systematic approach to assessment and treatment. Initial assessment includes inspection of the cervix for laceration, bimanual examination to assess for uterine atony and tenderness, and uterine aspiration or ultrasound examination to evaluate for retained products of conception or blood (Kerns, Brown, Nippita & Steinauer, 2024).

Management

Cervical lacerations may be treated with direct pressure with gauze or ring forceps, application of topical clotting agents (silver nitrate or ferric subsulfate solution), or by placing absorbable sutures (Kerns, Brown, Nippita & Steinauer, 2024).

Uterine atony requires a rapid, sequential response starting with uterine massage, followed by uterotonics, re-aspiration, uterine tamponade and finally surgical measures. Clinicians should move quickly to the next step if bleeding is not controlled. When uterotonic medications are used, additional or repeat doses may be used if bleeding does not improve after the first dose (Kerns, Brown, Nippita & Steinauer, 2024).

Uterotonic medications and dosages*

Medication	Dosage
Methylergonovine	0.2mg intramuscularly or intracervically; can be repeated every 2-4 hours. Avoid in people with hypertension
Misoprostol	800-1000mcg buccally or sublingually
Intrauterine tamponade	Sterile gauze or 30-75mL Foley catheter balloon, condom catheter or obstetric balloon placed in uterus

* Extrapolated from postpartum data (American College of Obstetricians and Gynecologists, 2017 reaffirmed 2024; Escobar et al., 2022; Kerns, Brown, Nippita & Steinauer, 2024; Mavrides et al., 2016; ; Prata & Weidert, 2016; World Health Organization (WHO), 2020).

If tamponade is used to stop bleeding, the Foley balloon, obstetric balloon, gauze or inflated condom catheter should be left in place for several hours while the patient is observed. If they remain stable after the balloon or gauze is removed, the patient may be discharged.

When bleeding continues after assurance of complete uterine evacuation and no visible lacerations, providers must consider other complications, such as perforation, coagulopathy or placenta accreta (National Abortion Federation, 2024). If coagulopathy, such as disseminated intravascular coagulation, is present, blood products may be required. Surgical measures including hysterectomy, uterine compression sutures, uterine artery ligation or uterine artery embolization can be performed for severe bleeding that cannot be controlled by other measures. Providers at health centers without available operating theaters or expertise should have clear protocols for resuscitation and transfer to a higher level of care. Individuals at risk of shock require intravenous line placement, supplemental oxygen, fluid resuscitation and replacement of blood products as indicated.

Who can provide initial management of non-life-threatening postabortion hemorrhage?

WHO makes service delivery recommendations for the initial management of postabortion hemorrhage, which includes recognizing the complication, stabilizing the person, and providing intravenous fluids prior to referral to an appropriate health worker or facility (WHO, 2024). WHO recommends that specialty and generalist medical practitioners, associate and advanced associate clinicians, midwives, nurses, auxiliary nurses and auxiliary nurse midwives, and traditional and complementary medicine professionals can provide this care based on their established scope of practice or expected knowledge and skills for the health worker role (WHO, 2024). For further information about health worker roles in abortion care, see *Appendix C: World Health Organization recommendations for health worker roles in abortion care*.

References

- Ali, P.B. & Smith, G. (1996). The effect of syntocinon on blood loss during first trimester suction curettage. *Anesthesia*, 51, 483-485.
- American College of Obstetricians and Gynecologists. (2017 reaffirmed 2024). ACOG Practice Bulletin Number 183: Postpartum hemorrhage. *Obstetrics & Gynecology*, 130(4), e168-e186.
- Escobar, M. F., Nassar, A. H., Theron, G., Barnea, E. R., Nicholson, W., Ramasauskaite, D., Lloyd, I., Chandrachan, E., Miller, S., Burke, T., Ossanan, G., Andres Carvajal, J., Ramos, I., Hincapie, M. A., Loaiza, S., Nasner, D., & FIGO Safe Motherhood and Newborn Health Committee. (2022). FIGO recommendations on the management of postpartum hemorrhage 2022. *International Journal of Gynecology & Obstetrics*, 157(S1), 3-50.
- Gilbert, C. M., Matulich, M. C., Ponzini, M. D., Wilson, M. D., & Creinin, M. D. (2023). Clinical interventions are more accurate than quantitative measurements for defining hemorrhage with dilation and evacuation. *Contraception*, 120, 109914.
- Kerns, J.L., Pearlson, G., Mengesha, B., Harter, K., Jackson, R.A. & Drey, E.A. (2021). A randomized controlled trial of methylergonovine prophylaxis after dilation and evacuation abortion. *Contraception*, 103(2), 116-120.
- Kerns, J. L., Brown, K., Nippita, S., & Steinauer, J. (2024). Society of Family Planning Clinical Recommendation: Management of hemorrhage at the time of abortion. *Contraception*, 129.
- Kerns, J., Ti, A., Askel, S., Lederle, L., Sokoloff, A., & Steinauer, J. (2019). Disseminated intravascular coagulation and hemorrhage after dilation and evacuation abortion for fetal death. *Obstetrics & Gynecology*, 134(4), 708-713.
- Lauerson, N. H., & Conrad, P. (1974). Effect of oxytocic agents on blood loss during first trimester suction curettage. *Obstetrics & Gynecology*, 44(3), 428-433.
- Mavrides, E., Allard, S., Chandrachan, E., Collins, P., Green, L., Hunt, B. J., ... on behalf of the Royal College of Obstetricians and Gynaecologists. (2016). Prevention and management of postpartum hemorrhage. *BJOG: An International Journal of Obstetrics & Gynaecology* 124, e106-e149.
- Morris, J. L., Winikoff, B., Dabash, R., Weeks, A., Faundes, A., Gemzell-Danielsson, ... Visser, G. H. A. (2017). FIGO's updated recommendations for misoprostol used alone in gynecology and obstetrics. *International Journal of Gynecology & Obstetrics*, 138(3), 363-366.
- National Abortion Federation. (2024). *Clinical Policy Guidelines*. Washington DC: National Abortion Federation.
- Nygaard, I. H. H., Valbo, A., Heide, H. C., & Kresovic, M. (2010). Is oxytocin given during surgical termination of first trimester pregnancy useful? A randomized controlled trial. *Acta Obstetrica et Gynecologica Scandinavica*, 90, 174-178.
- Perriera, L. K., Arslan, A. A., & Masch, R. (2017). Placenta previa and the risk of adverse outcomes during second trimester abortion: A retrospective cohort study. *Australian and New Zealand Journal of Obstetrics and Gynaecology*, 57(1), 99-104.
- Prata, N., & Weidert, K. (2016). Efficacy of misoprostol for the treatment of postpartum hemorrhage: Current knowledge and implications for health care planning. *International Journal of Women's Health*, 8, 341-349.
- Schulz, K. F., Grimes, D. A., & Christensen, D. D. (1985). Vasopressin reduces blood loss from second-trimester dilatation and evacuation abortion. *The Lancet*, 2, 353-356.

References continued

Upadhyay, U., Desai, S., Zlidar, V., Weitz, T. A., Grossman, D., Anderson, P., & Taylor, D. (2014). Incidence of emergency department visits and complications after abortion. *Obstetrics & Gynecology*, 125, 175-183.

Whitehouse, K., Tschann, M., Davis, J., Soon, R., Salcedo, J., Friedlander, E., & Kaneshiro, B. (2017). Association between prophylactic oxytocin use during dilation and evacuation and estimated blood loss. *Contraception*, 96, 19-24.

Whitehouse, K., Tschann, M., Soon, R., Davis, J., Micks, E., Salcedo, J., ... & Kaneshiro, B. (2019). Effects of prophylactic oxytocin on bleeding outcomes in women undergoing dilation and evacuation. *Obstetrics & Gynecology*, 133(3), 484-491.

World Health Organization. (2020). *WHO recommendation on routes of oxytocin administration for the prevention of postpartum haemorrhage after vaginal birth*. Geneva: World Health Organization.

World Health Organization. (2024). *Abortion care guideline, 2nd ed*. Geneva: World Health Organization.

5.6

5. Postabortion care

Managing uterine perforation

Recommendedation:

- Anyone with suspected uterine perforation, even if asymptomatic, should be informed of the complication and their clinical status should be observed.
- If stable, individuals should be told warning signs for when to seek emergency care, if needed, and have a plan for follow-up before discharge from a health center.
- If unstable or worsening clinical status is noted, transfer to tertiary-level facility for further management.
- Anyone with a known uterine perforation with evidence of bowel injury should be transferred to a tertiary-level facility for further management.

Strength of recommendation:

Strong

Quality of evidence:

Low

Last reviewed:

November 11, 2025

Epidemiology

Uterine perforation at the time of vacuum aspiration is a rare but potentially serious complication, estimated to occur in between 0.1-3 per 1,000 induced abortion procedures (Kerns, Brown, Nippita & Steinauer, 2024; Pridmore & Chambers, 1999). This frequency increases with advancing gestational age and when performed by less experienced providers (American College of Obstetricians and Gynecologists, 2013 reaffirmed 2023).

Factors that may increase the risk for uterine perforation at time of surgical abortion (Shakir & Diab, 2013; Obed & Wilson, 1999; Grimes, et al., 2006):

- Uterine position—retroverted, acutely anteverted or retroflexed
- Infection
- Multiparity
- Multiple gestation
- Advanced gestational age
- Inadequate cervical preparation
- Difficult cervical dilation
- Uterine anomalies or cavity distorted by fibroids
- Previous cervical/uterine surgery, including cesarean section
- Provider inexperience
- Presentation for postabortion care (after unsafe abortion procedure)

Uterine perforation can occur at almost any step of the abortion process as instruments pass into the uterus. Additionally, perforation may occur from a foreign object or implement used to perform an unsafe abortion.

The location of the perforation can be anywhere in the uterus, although the midline anterior or posterior surface of the fundus is the most common (Sharma, Malhotra & Pundir, 2003). Uterine perforation often goes undetected and resolves without the need for intervention for people who have procedures before 13 weeks (Kaali, Szigetvari & Bartfai, 1989; Sharma, Malhotra & Pundir, 2003). For example, perforation with a small,

blunt instrument in the fundus is likely to cause no problems, heal quickly, and need no additional management. Lateral uterine perforations are rare, but are particularly concerning, given the proximity of the branches of the uterine artery and risk for serious bleeding (Berek & Stubblefield, 1979).

Diagnosis

A provider should suspect uterine perforation when a sudden loss of resistance occurs during cervical dilation or vacuum aspiration, allowing an instrument to pass well beyond the expected length of the uterus. If available, ultrasound may be a helpful diagnostic aid (Coughlin et al., 2013; Crosfil & Hughes, 2006; Gakhal & Levy, 2009; Shalev, Ben-Ami & Zuckerman, 1986; Skolnick, Katz & Lancet, 1982).

Uterine perforation can be visualized during laparoscopy and laparotomy. A provider does not need to definitively diagnose a perforation if the patient is stable and the concern for intra-abdominal injury is low. If a provider sees yellow fatty tissue in the uterine aspirate, their suspicion for uterine perforation and bowel injury should be high and the individual should be referred for immediate surgical management whether stable or not. Prompt recognition and management of injury to abdominopelvic viscera (bowel, bladder, blood vessels, etc.) resulting from uterine perforation is necessary to avoid serious complications (Obed & Wilson, 1999; Amarin & Badria, 2005).

Management

In many cases, providers can manage uncomplicated uterine perforation before 13 weeks gestation conservatively by observing for any changes in clinical status (Moburg, 1976; Freiman & Wulff, 1977; Grimes, Schultz & Cates, 1984; Mittal & Misra, 1985; Chen, Lai, Lee & Leong, 1995; Lindell & Flam, 1995; Peterson et al., 1983; Pridmore & Chambers, 1999). Providers should have a higher level of suspicion for intra-abdominal injury when a perforation occurs during an abortion at or after 13 weeks or during dilation and evacuation; these patients should be promptly referred for further evaluation as additional treatment may be warranted (Darney, Atkinson & Hirabayashi, 1990).

If there is concern for damage to abdominopelvic viscera, including bowel, but the individual is stable, and the experience and equipment are available, then laparoscopy is the investigative method of choice. With obvious bowel damage or herniation through the uterine defect, excessive bleeding, or hemodynamic instability, immediate laparotomy may be preferable (Lauersen & Birnbaum, 1973; Grimes, Schultz & Cates, 1984; Chen et al., 1995; Lindell & Flam, 1995; Kumar & Rao, 1998; Obed & Wilson, 1999). If the abortion was not completed, the uterus should be evacuated under direct visualization at the time of laparoscopy or laparotomy (Lauersen & Birnbaum, 1973; Goldschmitt et al., 1995; Chen et al., 1995). No evidence is available to support the safety or effectiveness of medical management to complete uterine evacuation immediately following suspected or confirmed uterine perforation.

Providers at health centers without available operating theaters or expertise should have clear protocols for resuscitation and transfer to a higher level of care. Patients at risk of shock require intravenous line placement, supplemental oxygen, fluid resuscitation and replacement of blood products as indicated.

References

- Amarin, Z.O. & Badria, L.F. (2005) A survey of uterine perforation following dilatation and curettage or evacuation of retained products of conception. *Archives of Gynecology and Obstetrics*, 271(3), 203-6.
- American College of Obstetricians and Gynecologists. (2013 reaffirmed 2023). Second-trimester abortion: ACOG Practice Bulletin No. 135. *Obstetrics & Gynecology*, 121(6), 1394-406.
- Berek J.S. & Stubblefield, P.G. (1979). Anatomic and clinical correlates of uterine perforation. *American Journal of Obstetrics and Gynecology*, 135(2), 181-4.
- Chen, L.H., Lai, S.F., Lee, W.H., & Leong, N.K. (1995). Uterine perforation during elective first trimester abortions: A 1 year review. *Singapore Medical Journal*, 36(1), 63-7.
- Coughlin, L.M., Sparks, D.A., Chase, D.M., & Smith, J. (2013). Incarcerated small bowel associated with elective abortion uterine perforation. *Journal of Emergency Medicine*, 44(3), e303-306.
- Crosfill, F.M., & Hughes, S. (2006). Ultrasound scan appearance of perforated uterus after surgical evacuation of retained products of conception. *Journal of Obstetrics and Gynaecology*, 26(3), 278-9.
- Darney, P.D., Atkinson, E., & Hirabayashi, K. (1990). Uterine perforation during second-trimester abortion by cervical dilation and instrumental extraction: A review of 15 cases. *Obstetrics & Gynecology*, 75(3 Pt 1), 441-4.
- Freiman, S.M., & Wulff, G.J. (1977). Management of uterine perforation following elective abortion. *Obstetrics & Gynecology*, 50(6), 647-50.
- Gakhal, M.S., & Levy, H.M. (2009). Sonographic diagnosis of extruded fetal parts from uterine perforation in the retroperitoneal pelvis after termination of intrauterine pregnancy that were occult on magnetic resonance imaging. *Journal of Ultrasound in Medicine*, 28(12): 1723-7.
- Grimes, D.A., Schulz, K.F., & Cates WJ. (1984) Prevention of uterine perforation during curettage abortion. *The Journal of the American Medical Association*, 27;251(16), 2108-11.
- Grimes, D.A., Benson, J., Singh, S., Romero, M., Ganatra, B., Okonofua, F.E., & Shah I.H. (2006). Unsafe abortion: the preventable pandemic. *The Lancet*, 368(9550), 1908-19.
- Goldschmit, R., Elchalal, U., Dgani, R., Zalel, Y., & Matzkel, A. (1995). Management of uterine perforation complicating first-trimester termination of pregnancy. *Israel Journal of Medical Sciences*, (4), 232-4.
- Kaali, S.G., Szigetvari, I.A., & Bartfai, G.S. (1989). The frequency and management of uterine perforations during first trimester abortions. *American Journal of Obstetrics & Gynecology*, 161(2), 406-8.
- Kerns, J. L., Brown, K., Nippita, S., & Steinauer, J. (2024). Society of Family Planning Clinical Recommendation: Management of hemorrhage at the time of abortion. *Contraception*, 129.
- Kumar, P., Rao, P. (1988). Laparoscopy as a diagnostic and therapeutic technique in uterine perforations during first trimester abortions. *Asia-Oceania Journal of Obstetrics and Gynaecology*, 14(1), 55-9.
- Lauersen, N.H., Birnbaum, S. (1973). Laparoscopy as a diagnostic and therapeutic technique in uterine perforations during first trimester abortions. *American Journal of Obstetrics & Gynecology*, 117(4), 522-6.
- Lindell, G., Flam, F. (1995). Management of uterine perforations in connection with legal abortions. *Acta Obstetrica et Gynecologica Scandinavica*, 74(5), 373-5.
- Mittal, S., Misra, S.L. (1985). Uterine perforation following medical termination of pregnancy by vacuum aspiration. *International Journal of Gynaecology and Obstetrics*, 23(1), 45-50.
- Moberg, P.J. (1976). Uterine perforation in connection with vacuum aspiration for legal abortion. *International Journal of Gynaecology and Obstetrics*, 14(1), 77-80.
- Obed, S.A., & Wilson, J.B. (1999). Uterine perforation from induced abortion at Korle Bu Teaching Hospital, Accra, Ghana: A five year review. *West African Journal of Medicine*, 18(4), 286-9.
- Peterson, W.F., Berry, N., Grace, M.R., Gulbranson, C. L. (1983). Second-trimester abortion by dilatation and evacuation: an analysis of 11,747 cases. *Obstetrics & Gynecology*, 62(2), 185-190.
- Pridmore, B.R., & Chambers, D.G. (1999). Uterine perforation during surgical abortion: a review of diagnosis, management and prevention. *Australian and New Zealand Journal of Obstetrics and Gynaecology*, 39(3), 349-53.

References continued

Shakir, F, & Diab, Y. (2013). The perforated uterus. *The Obstetrician & Gynaecologist*, 15(4), 256-61.

Shalev, E., Ben-Ami, M., & Zuckerman, H. (1986). Real-time ultrasound diagnosis of bleeding uterine perforation during therapeutic abortion. *Journal of Clinical Ultrasound*, 14(1), 66-7.

Sharma, J.B., Malhotra, M., & Pundir, P. (2003). Laparoscopic oxidized cellulose (Surgicel) application for small uterine perforations. *International Journal of Gynaecology and Obstetrics*, 83(3), 271-5.

Skolnick, M.L., Katz, Z., & Lancet, M. (1982). Detection of intramural uterine perforation with real-time ultrasound during curettage. *Journal of Clinical Ultrasound*, 10(7), 337-8.

A.

Appendix A

Pain medication table

The medications listed in the table below are commonly used for pain management during vacuum aspiration and dilatation and evacuation. Many other options exist. This table does not cover general anesthetic agents.

Both anxiolytics and narcotics may cause respiratory depression, especially when they are used together. Accordingly, lower doses should be used when they are used together than when they are used separately. When medications are given intravenously immediately before a procedure they should be given slowly and intermittently by a specially trained provider. Problematic side effects can be avoided by repeated small intravenous doses that are titrated to an individual's level of pain and sedation. The peak analgesic effect should occur during the procedure to avoid excessive postprocedure sedation.

Even clinicians using lighter sedation analgesia must be able to manage respiratory arrest, in the unlikely event that an unintentional overdose should occur. Providers should be trained in airway management and cardiopulmonary resuscitation. Resuscitative equipment and appropriate antagonist drugs (naloxone and flumazenil) should be available.

Disclaimer: *This resource is designed to be a supplemental resource for clinicians and is NOT intended to serve as a replacement for drug label information or clinical judgment that accounts for patients' and facilities' unique circumstances.*

Last reviewed: January 10, 2026

Drug type	Generic drug name	Dose and timing	Half-life	Side effects	Comments
Local anesthetic See section 2.5 Paracervical block	Lidocaine	20ml of 1% solution or 10mL of 2% solution in a paracervical block not to exceed 4.5mg/kg	60-90 minutes	Ring in ears; dizziness; numbness in lips, mouth and tongue; metallic taste Extremely rare: Seizures	- Pull back plunger before injecting to avoid intravascular injection. - Allergic reaction is very rare. Reactions that do occur may be due to preservatives in multi-dose vials. Preservative-free lidocaine allergy is extremely rare.
Nonsteroidal anti-inflammatory drug (NSAID)	Ibuprofen	Oral: 400-800mg 1 hour before the procedure	2 hours	Possible gastrointestinal upset	Do not use in people with active peptic ulcer disease or renal failure
	Naproxen	Oral: 500mg 1 hour before the procedure	2 hours	Possible gastrointestinal upset	Do not use in people with active peptic ulcer disease or renal failure
	Ketorolac	Oral: 20mg 1 hour before procedure IV: 30mg over at least 15 seconds 30-60 minutes before procedure IM: 60mg 30-60 minutes before procedure For women less than 50kg, all doses should be halved	4-6 hours		- Single dose IM ketorolac prior to surgery may reduce opioid use and postoperative pain (de Oliveira, 2012; Roche, 2011) - Do not use in women with active peptic ulcer disease, renal failure, breastfeeding or sensitivity to other NSAIDs - Breakthrough pain should be managed with narcotics rather than increasing ketorolac beyond the recommended doses
Analgesic	Acetaminophen	Oral: 500-1,000mg 30-60 minutes before procedure	2-4 hours	Ring in ears; dizziness; numbness in lips, mouth and tongue; metallic taste Extremely rare: Seizures	- Not a first-line pain medication for vacuum aspiration or medical abortion. May be used as an antipyretic - Liver toxicity from overdose (maximum dose = 4,000mg/day) is a risk
Narcotic/analgesic combination	Acetaminophen 300mg + codeine 30mg	Oral: 1-2 tablets 1 hour before procedure	2-4 hours	Drowsiness; light-headedness; nausea and vomiting	Be aware of combining with other acetaminophen-containing products. Liver toxicity from over dose of acetaminophen (maximum dose=4,000 mg/day) is a risk.
Narcotic/analgesic combination	Acetaminophen 500mg + hydrocodone 5mg	Oral: 1-2 tablets 1 hour before procedure	4-6 hours	Drowsiness; light-headedness; nausea and vomiting	Be aware of combining with other acetaminophen-containing products. Liver toxicity from overdose of acetaminophen (maximum dose=4,000 mg/day) is a risk.

Drug type	Generic drug name	Dose and timing	Half-life	Side effects	Comments
Narcotic	Meperidine	Oral: 100-150mg 30-60 minutes before procedure IV: 25-50mg 5-15 minutes prior to procedure IM/SC: 50-100mg 30-90 minutes prior to procedure	2-4 hours	Drowsiness; light-headedness; nausea and vomiting; decreased breathing rate; loss of consciousness; hypotension; seizures	- IM or SC administration preferred over IV - If respiration is compromised, assist with breathing (airway management, oxygen and ambu bag) and reverse with naloxone (see Reversal agent for narcotic, below) - More rapid onset and shorter duration of action than morphine - Meperidine 300mg PO=Meperidine 75mg IV=morphine 10mg IV
	Fentanyl	IV: 50-100mcg immediately before procedure (may repeat every 5-10 minutes, not to exceed 250mcg)	4 hours	Drowsiness; light-headedness; weakness; bradycardia; decreased breathing rate; loss of consciousness; hypotension; seizures	- If respiration is compromised, assist with breathing (airway management, oxygen and ambu bag) and reverse with naloxone (see end of chart) - More rapid onset and shorter duration of action than meperidine - Fentanyl 100mcg IV = morphine 10mg IV - Onset of action is 2-7 minutes when given IV
	Lorazepam	Oral: 1-2mg 30-60 minutes before procedure IV: 2mg given over 1 minute 15-20 minutes before the procedure IM: 0.05mg/kg up to a maximum of 4mg within 2 hours before the procedure	14 hours	Blurred vision; dizziness; disorientation; decreased breathing rate; loss of consciousness	- If respiration is compromised, assist with breathing (airway management, oxygen and ambu bag) and reverse with flumazenil (see Reversal agent for narcotic, below) - Amnestic effect
Reversal agent for narcotic	Naloxone	IV/IM/SC: 0.4mg every 2 minutes until reversal is seen	1-1.5 hours		- Naloxone's duration of action is 1 hour and may wear off before the narcotic. Therefore, patients treated with naloxone must be monitored closely for several hours. - Maintain airway and respirations while giving naloxone
Reversal agent for benzodiazepine	Flumazenil	IV: 0.2mg every minute until respirations return. Do not exceed 1mg	1 hour		- Flumazenil's duration of action is 1 hour and may wear off before the benzodiazepine. Therefore, patients treated with flumazenil must be monitored closely for several hours. In the event of overdose with narcotic and benzodiazepine, reverse the narcotic first with naloxone and use flumazenil subsequently if needed. - Maintain airway and respirations while giving flumazenil

Drug type	Generic drug name	Dose and timing	Half-life	Side effects	Comments
Treatment for hypersensitivity reaction/anaphylaxis	Epinephrine	IM/SC: 0.2-0.5mg every 5 to 15 minutes IV: 0.1mg diluted with 10mL of saline administered over 5 to 10 minutes	1 hour	Tachycardia; palpitations; nausea; diaphoresis; dizziness; anxiety	- There are no contraindications to epinephrine in the setting of anaphylaxis - IM administration preferred - Consider giving methylprednisolone 125mg IV - Support respiration. If wheezing is present, inhaler may be helpful - Immediate intubation if evidence of impending airway obstruction

References

De Oliveira, G. S., Agarwal, D., & Benzon, H. T. (2012). Perioperative single dose ketorolac to prevent postoperative pain: a meta-analysis of randomized trials. *Anesthesia & Analgesia*, 114(2), 424-433.

Roche, N. E., Li, D., James, D., Fechner, A., & Tilak, V. (2011). The effect of perioperative ketorolac on pain control in pregnancy termination. *Contraception*, 85(3), 299-303.

B.

Appendix B

Continuum of depth of sedation: Definition of general anesthesia and levels of sedation/analgesia

American Society of Anesthesiologists, Committee of Origin: Quality management and departmental administration (approved by the ASA House of Delegates on October 13, 1999 and last amended on October 23, 2024). Accessed at: <https://www.asahq.org/standards-and-practice-parameters/statement-on-continuum-of-depth-of-sedation-definition-of-general-anesthesia-and-levels-of-sedation-analgesia> on 01/25/2026. (reprinted with permission).

	Minimal Sedation Anxiolysis	Moderate sedation/ analgesia ("conscious sedation")	Deep sedation/ Analgesia	General Anesthesia
Responsiveness	Normal response to verbal stimulation	Purposeful** response to verbal or tactile stimulation	Purposeful** response following repeated or painful stimulation	
Airway	Unaffected	No intervention required	Intervention may be required	
Spontaneous Ventilation	Unaffected	Adequate	May be inadequate	Tachycardia; palpitations; nausea; diaphoresis; dizziness; anxiety
Cardiovascular Function	Unaffected	Usually maintained	Usually maintained	

Minimal sedation (anxiolysis) is a drug-induced state during which patients respond normally to verbal commands. Although cognitive function and physical coordination may be impaired, airway reflexes and ventilatory and cardiovascular functions are unaffected. This is typically accomplished by a single oral dose of a sedative or an analgesic administered before the procedure.

Moderate sedation/analgesia ("conscious sedation") is a drug-induced depression of consciousness during which patients respond purposefully** to verbal commands, either alone or accompanied by light tactile stimulation. No interventions are required to maintain a patent airway, and spontaneous ventilation is adequate. Cardiovascular function is usually maintained. This is typically accomplished by titration of IV sedatives and/or analgesics during the procedure.

Deep sedation/analgesia is a drug-induced depression of consciousness during which patients cannot be easily aroused but respond purposefully** following repeated or painful stimulation. The ability to independently maintain ventilatory function may be impaired. Patients may require assistance in maintaining a patent airway, and spontaneous ventilation may be inadequate. Cardiovascular function is usually maintained. This is typically accomplished by titration of IV sedatives and/or analgesics and/or anesthetics during the procedure.

General anesthesia is a drug-induced loss of consciousness during which patients are not arousable, even by painful stimulation. The ability to independently maintain ventilatory function is often impaired. Patients often require assistance in maintaining a patent airway, and positive pressure ventilation may be required because of depressed spontaneous ventilation or drug-induced depression of neuromuscular function. Cardiovascular function may be impaired.

Because sedation is a continuum, it is not always possible to predict how an individual patient will respond. Hence, practitioners intending to produce a given level of sedation should be able to rescue*** patients whose level of sedation becomes deeper than initially intended. Individuals administering Moderate Sedation/Analgesia (“Conscious Sedation”) should be able to rescue*** patients who enter a state of Deep Sedation/Analgesia, while those administering of Deep Sedation/Analgesia should be able to rescue*** patients who enter a state of General Anesthesia.

* Monitored Anesthesia Care (“MAC”) does not describe the continuum of depth of sedation, rather it describes “a specific anesthesia service performed by a qualified anesthesia provider, for a diagnostic or therapeutic procedure.” Indications for monitored anesthesia care include “the need for deeper levels of analgesia and sedation than can be provided by moderate sedation (including potential conversion to a general or regional anesthetic.”

** Reflex withdrawal from a painful stimulus is NOT considered a purposeful response.

*** Rescue of a patient from a deeper level of sedation than intended is an intervention by a practitioner proficient in airway management and advanced life support. The qualified practitioner corrects adverse physiologic consequences of the deeper-than-intended level of sedation (such as hypoventilation, hypoxia and hypotension) and returns the patient to the originally intended level of sedation. It is not appropriate to continue the procedure at an unintended level of sedation.

Reference

American Society of Anesthesiologists. (2018). *Position on Monitored Anesthesia Care*. Last amended on October 23, 2024.

C.

Appendix C

World Health Organization recommendations for health worker roles in abortion care

In their *Abortion Care Guideline* (2024), the World Health Organization (WHO) provides evidence-based guidance on how to involve a wider range of health workers and pregnant people themselves in the provision or self-management of abortion care, in order to “encourage optimization of the available health workforce, address health system shortages of specialized health-care professionals, reduce costs and improve affordability, improve equity and equality in access to health care and increase the acceptability of health services for those who need them.” The recommendations made by WHO are intended for all resource settings, refer to a range of types of health workers who can safely, effectively and satisfactorily perform some or all of the specific abortion-related tasks. It is assumed that any health worker discussed has the basic training required of that type of health worker and that they will have received the appropriate task-specific training and information prior to performing that task.

Recommendation	Individual/ Self	Community health workers	Pharmacy workers	Pharmacists	Traditional/ Complementary medicine professionals	Auxiliary nurses/ Auxiliary nurse midwives	Nurses	Midwives	Associate/ Advanced associate clinicians	Generalist/ Specialist medical practitioners
Provision of information on abortion care	NR	Recommend	Suggest (1)	Recommend	Recommend	Recommend	Recommend	Recommend	Recommend	Recommend
Provision of abortion counselling	NR	Recommend	Suggest (2)	Suggest (2)	Recommend	Recommend	Recommend	Recommend	Recommend	Recommend
Cervical priming with medication prior to surgical abortion at any gestational age	NR	Suggest (3)	Suggest (3)	Suggest (3)	Recommend	Recommend	Recommend	Recommend	Recommend	Recommend
Vacuum aspiration for induced abortion at < 14 weeks*	NR	Suggest (3)	Suggest (3)	Suggest (3)	Recommend	Recommend	Recommend	Recommend	Recommend	Recommend
Medical management of induced abortion at gestational ages < 12 weeks	Recommend	Recommend	Recommend	Recommend	Recommend	Recommend	Recommend	Recommend	Recommend	Recommend
Cervical priming with osmotic dilators prior to D&E at gestational ages ≥ 12 weeks	NR	Recommend	Recommend	Recommend	Recommend	Recommend	Recommend	Recommend	Recommend	Recommend
D&E for surgical abortion at gestational ages ≥ 14 weeks	NR	Recommend	Recommend	Recommend	Recommend	Recommend	Recommend	Recommend	Recommend	Recommend
Medical management of induced abortion at gestational ages ≥ 12 weeks	NR	Recommend	Recommend	Recommend	Recommend	Recommend	Recommend	Recommend	Recommend	Recommend

Recommendation	Individual/ Self	Community health workers	Pharmacy workers	Pharmacists	Traditional/ Complementary medicine professionals	Auxiliary nurses/ Auxiliary nurse midwives	Nurses	Midwives	Associate/ Advanced associate clinicians	Generalist/ Specialist medical practitioners
Vacuum aspiration for management of uncomplicated incomplete abortion at gestational ages < 14 weeks	NR	Recommend against	Recommend against	Recommend against	Recommend	Suggest (4)	Recommend	Recommend	Recommend	Recommend
Medical management of uncomplicated incomplete abortion with misoprostol at gestational ages < 14 weeks	NR	Recommend against	Recommend against	Recommend against	Recommend	Suggest (4)	Recommend	Recommend	Recommend	Recommend
Medical management of intrauterine fetal demise at gestational ages ≥ 14 to ≤ 28 weeks	NR	Recommend against	Recommend against	Recommend against	Suggest (6)	Suggest (6)	Suggest (6)	Suggest (6)	Suggest (6)	Recommend
Insertion and removal of intrauterine devices (IUDs)	NR	Recommend against	Recommend against	Recommend against	Suggest (5)	Suggest (7)/ Recommend	Recommend	Recommend	Recommend	Recommend
Insertion and removal of implants	NR	Suggest (7)	Recommend against	Recommend against	Suggest (5)	Suggest (8)	Recommend	Recommend	Recommend	Recommend
Administration of injectable contraceptives	Recommend	Recommend	Recommend	Recommend	Recommend	Recommend	Recommend	Recommend	Recommend	Recommend
Tubal ligation	NR	Recommend against	Recommend against	Recommend against	Recommend against	Recommend against	Suggest (7)	Suggest (7)	Recommend	Recommend
Initial management of non-life-threatening post-abortion hemorrhage or infection	NR	Recommend against	Recommend against	Recommend against	Recommend	Recommend	Recommend	Recommend	Recommend	Recommend

NR = no recommendation made

Suggest: A weak recommendation in favor of the intervention, requiring additional wording to qualify the recommendation, specifying the conditions of use

Recommend: A strong recommendation in favor of the intervention

* The provision of vacuum aspiration includes the assessment of gestational age, cervical preparation (if needed), the actual procedure, pain management including administration of a paracervical block and assessment of abortion completeness through visual inspection of products of conception.

- (1) **Condition:** In contexts where the pharmacy worker is under the direct supervision of a pharmacist and there is access or referral to appropriate health services
- (2) **Condition:** Both medical and surgical abortion counselling is provided and there is access or referral to appropriate health services should the client choose a surgical abortion method
- (3) **Condition:** Health worker ensures continuity of care from the time of cervical priming to the abortion procedure

(4) **Condition:** In contexts where established health system mechanisms involve these health workers in providing other basic emergency obstetric care

(5) **Condition:** In contexts where established health system mechanisms involve these health workers in other tasks related to maternal and reproductive health

(6) **Condition:** In contexts where access to appropriate surgical backup and proper infrastructure is available to address incomplete abortion or other complications

(7) **Condition:** In the context of rigorous research.

(8) **Condition:** In the context of targeted monitoring and evaluation

Adapted from World Health Organization. (2022). *Abortion care guideline*. Geneva: World Health Organization and World Health Organization. (2015). *Health worker roles in providing safe abortion care and post-abortion contraception*. Geneva: World Health Organization.

World Health Organization definition of health worker categories and roles

Category	Description of qualifications and tasks
Community health worker	A person who performs functions related to health-care delivery/information provision and has been trained in some way in the context of the task, but has received no formal professional or paraprofessional certificate or tertiary education degree.
Pharmacy worker	Technicians and assistants who perform a variety of tasks associated with dispensing medicinal products under the guidance of a pharmacist. They inventory, prepare and store medications and other pharmaceutical compounds and supplies, and may dispense medicines and drugs to clients and instruct on their use as prescribed by health professionals. Technicians typically receive two or three years of training in a pharmaceutical school, with an award not equivalent to a university degree. Assistants have usually also been through two or three years of secondary school, with a subsequent period of on-the-job training or apprenticeship.
Pharmacist	A health-care practitioner who dispenses medicinal products. A pharmacist can counsel on the proper use and adverse effects of drugs and medicines following prescriptions issued by medical doctors/health-care professionals. Education includes university-level training in theoretical and practical pharmacy, pharmaceutical chemistry or a related field.
Traditional and complementary medicine professionals	A professional of traditional and complementary systems of medicine (non-allopathic physician) whose training includes a four- or five-year university degree that teaches human anatomy, physiology, management of normal labor and the pharmacology of modern medicines used in obstetrics and gynecology, in addition to their systems of medicine.
Auxiliary nurse midwife and auxiliary nurse	An auxiliary nurse is someone trained in basic nursing skills, but not in nursing decision making. An auxiliary nurse midwife has basic nursing skills and some midwifery competencies but is not fully qualified as a midwife. The duration of training may vary from a few months up to three years. A period of on-the-job training may be included, and this is sometimes formalized in apprenticeships.
Nurse	A person who has been legally authorized (registered) to practice after examination by a state board of nurse examiners or similar regulatory authority. Education includes three or more years in nursing school, and leads to a university or postgraduate university degree or the equivalent.
Midwife	A person who has been registered by a state midwifery or similar regulatory authority and has been trained in the essential competencies for midwifery practice. Training typically lasts three or more years in nursing or midwifery school, and leads to a university degree or the equivalent. A registered midwife has the full range of midwifery skills, which include abortion.
Advanced associate clinician and associate clinician	A professional clinician with basic competencies to diagnose and manage common medical and surgical conditions, and also to perform some types of surgery. Training generally requires three or four years post-secondary education in an established higher education institution. The clinician is registered and their practice is regulated by a national or subnational regulatory authority.
Generalist medical practitioner	A medical doctor who holds a university-level degree in basic medical education but does not have a specialization in obstetrics and gynecology.
Specialist medical practitioner	A medical doctor with postgraduate clinical training and specialization in obstetrics and gynecology.

Adapted from World Health Organization. (2024). *Abortion care guideline, 2nd ed.*. Geneva: World Health Organization.

Ipas

Partners for
Reproductive Justice



www.ipas.org/ClinicalUpdates

www.ipas.org

ContactUs@ipas.org